


**CUMULATIVE  
SUPPLEMENT 12  
DECEMBER 2014**



**APPROVED  
DRUG PRODUCTS**

**WITH  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**34th EDITION**

**Department of Health and Human Services**

**Food and Drug Administration  
Center for Drug Evaluation and Research  
Office of Medical Products and Tobacco  
Office of Generic Drugs**

**2014**

Prepared By  
Office of Generic Drugs  
Office of Medical Products and Tobacco  
Center for Drug Evaluation and Research  
Food and Drug Administration

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**34<sup>th</sup> EDITION**

**Cumulative Supplement 12**

**December 2014**

**CONTENTS**

	<i>PAGE</i>
1.0 INTRODUCTION.....	iii
1.1 How to use the Cumulative Supplement .....	iii
1.2 Cumulative Supplement Content .....	iv
1.3 Applicant Name Changes .....	v
1.4 Levothyroxine Sodium.....	v
1.5 Availability of the Edition.....	vi
1.6 Report of Counts for the Prescription Drug Product List.....	vii
1.7 Cumulative Supplement Legend .....	viii
 DRUG PRODUCT LISTS	
Prescription Drug Product List .....	1-1
OTC Drug Product List .....	2-1
Drug Products with Approval under Section 505 of the Act	
Administered by the Center for Biologics Evaluation and Research List.....	3-1
Orphan Product Designations and Approvals List .....	4-1
Drug Products Which Must Demonstrate in vivo Bioavailability	
Only if Product Fails to Achieve Adequate Dissolution .....	5-1
 PATENT AND EXCLUSIVITY INFORMATION ADDENDUM	
A. Patent and Exclusivity Lists .....	A-1
B. Patent and Exclusivity Terms .....	B-1

**APPROVED DRUG PRODUCTS  
with  
THERAPEUTIC EQUIVALENCE EVALUATIONS**

**34<sup>th</sup> EDITION**

**CUMULATIVE SUPPLEMENT 12  
December 2014**

**1.0 INTRODUCTION**

**1.1 HOW TO USE THE CUMULATIVE SUPPLEMENT**

This Cumulative Supplement is one of a series of monthly updates to the Approved Drug Products with Therapeutic Equivalence Evaluations, 34th Edition (the List). The List is composed of four parts: approved prescription drug products with therapeutic equivalence evaluations; over-the-counter (OTC) drug products that require approved applications as a condition of marketing; drug products with approval under Section 505 of the Act administered by the Center for Biologics Evaluation and Research; and products that have never been marketed, are for exportation, are for military use, have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons.

The Cumulative Supplement provides, among other things, information on newly approved drugs and, if necessary, revised therapeutic equivalence evaluations and updated patent and exclusivity data. The Addendum contains appropriate drug patent and exclusivity information required of the Agency by the "Drug Price Competition and Patent Term Restoration Act of 1984" for the Prescription, OTC, and Drug Products with Approval under Section 505 of the Act Administered by the Center for Biologics Evaluation and Research Lists.

Because all parts of the publication are subject to changes, additions, or deletions, the List must be used in conjunction with the most current Cumulative Supplement. Users may wish to mark to the left of the ingredient(s) in the List to indicate that changes to that entry appear in the Cumulative Supplement. Drug product information is provided in each Cumulative Supplement for completeness to assist in locating the proper place in the List for the revision.

The presence of any therapeutic equivalence code indicates that the drug product is multisource; the deletion of a therapeutic equivalence code indicates that the drug product has become single source. (An infrequent exception exists when a therapeutic equivalence code is revised. In that case, the deletion of the therapeutic equivalence code is followed immediately by the addition of the revised one.)

Products that have never been marketed, are for exportation, are for military use, or have been discontinued from marketing or that have had their approvals withdrawn for other than safety or efficacy reasons, will be flagged in this Cumulative Supplement with the "@" symbol to designate their non-marketed status. All products having a "@" symbol in the 12th Cumulative Supplement of this Edition List will then be added to the "Discontinued Drug Product List" appearing in the next Edition. The current Annual Edition Section 2.1, How To Use The Drug Product Lists, describes the layout and usage of the List.

New additions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>A>**. The Patent and Exclusivity List new additions are indicated by the symbol **>A>** to the left of Patent Number or Exclusivity Code. The **>A>** symbol is then dropped in subsequent Cumulative Supplements for that item.

New deletions to the Prescription Drug Product List and OTC Drug Product List are indicated by the symbol **>D>** (DELETE) to the left of the line. The information line with the **>D>** symbol is dropped in subsequent Cumulative Supplements for that item.

The Patent and Exclusivity List is arranged in alphabetical order by active ingredient name(s) and trade name. The trade name will follow the active ingredient name separated by a dash symbol. Also shown is the application number and product number (FDA's internal file number) for reference purposes. All patents with their expiration dates are displayed for each application number. Drug substance and drug product patents are indicated as such with DS or DP in the Patent codes column. Use patents are indicated with the symbol "U" followed by a number representing a specific use. Exclusivity information for a specific drug is indicated by an abbreviation followed by the date upon which the exclusivity expires. Refer to the Exclusivity Terms, Section B, in the Patent and Exclusivity Information Addendum for an explanation of all codes and abbreviations. Refer to Section 1.3 for internet access to the most current list of Patent and Exclusivity terms.

## 1.2 CUMULATIVE SUPPLEMENT CONTENT

Since February 2005, we have been providing daily Electronic Orange Book (EOB) product information for new generic drug approvals. Daily generic updates provide the consumer with the current list of approved generic products which is important for substitution purposes. Previously, a first-time-generic product approved early in the month would not be published in the Cumulative Supplement (CS) for several weeks.

The CS monthly update publish goal is by the end of the following month's second work week (e.g., November's supplement will be updated by the end of the second full work week in December).

Currently, the monthly PDF CS includes:

- Generic product ANDA (Abbreviated New Drug Approval) approvals as of the date of publication.
- All product changes received and processed as of the date of publication.
  - Refer to CS Section 1.8 Cumulative Supplement Legend for types of changes
  - Discontinued products will be processed as of the date of publication. There will be circumstances where a product is discontinued in one month, however, it will be reported in a different month's CS. For example, the Orange Book Staff received a letter November 7 that the product has been discontinued from manufacturing and marketing. The Orange Book subsequently publishes the October CS on November 14. The product will show in the October CS that it is discontinued even though the date of discontinuance is the day that the Orange Book Staff receives notification (November 7).
- New Drug Application (NDA) approvals appear in the CS month they were approved.

- Patent information, also updated daily in the EOB, is current to the date of publication.
- Exclusivity information is updated monthly and current to the date of publication.

Every effort is made to ensure the Cumulative Supplement is current and accurate. Applicant holders are requested to inform the FDA Orange Book Staff (OBS) of any changes or corrections. The OBS can be contacted by email at [drugproducts@fda.hhs.gov](mailto:drugproducts@fda.hhs.gov).

mail to: FDA/CDER Orange Book Staff  
Office of Generic Drugs  
7620 Standish Place  
Rockville, MD 20855-2773

### 1.3 APPLICANT NAME CHANGES

It is not practical to identify in the Cumulative Supplement each and every product involved when an applicant transfers its entire line of approved drug products to another applicant, or when an applicant changes its name. Therefore, the cumulation of these transfers and name changes will be identified in this section only. Where only partial lines of approved products are transferred between applicants, each approved product involved will appear as an applicant name change entry in the Cumulative Supplement.

It is also not practical to identify each and every product involved when an applicant name is changed to meet internal publication standards (e.g., MSD or Zenith [Former Abbreviated Names] are changed, respectively to Merck Sharp Dohme or Zenith Labs [New Abbreviated Names]). When this occurs, each product involved (either currently in the Cumulative Supplement or in the following year's edition) will reflect the new abbreviated name. Consequently, it will not appear as an applicant name change entry in the Cumulative Supplement nor will the cumulation of these name changes appear in this section. The Electronic Orange Book Query, updated monthly, will contain the most current applicant holder name.

<u>FORMER APPLICANT NAME</u> <u>(FORMER ABBREVIATED NAME)</u>	<u>NEW APPLICANT NAME</u> <u>(NEW ABBREVIATED NAME)</u>
CLONMEL HEALTHCARE LTD (CLONMEL)	DAVA PHARMACEUTICALS INC (DAVA PHARMS INC)
CLONMEL HEALTHCARE (CLONMEL HLTHCARE)	DAVA PHARMACEUTICALS INC (DAVA PHARMS INC)
MARSAM PHARMACEUTICALS LLC (MARSAM PHARMS LLC)	WATSON LABORATORIES INC (WATSON LABS INC)
WATSON LABORATORIES INC (WATSON LABS)	ACTAVIS LABORATORIES INC (ACTAVIS LABS FL INC)
WEST WARD PHARMACEUTICAL CORP (WEST WARD PHARMS)	HIKMA PHARMACEUTICALS (HIKMA PHARMS)

### 1.4 LEVOTHYROXINE SODIUM

Because there are multiple reference listed drugs of levothyroxine sodium tablets and some reference listed drugs' sponsors have conducted studies to establish their drugs' therapeutic equivalence to other reference listed drugs, FDA has determined that its usual practice of assigning two or three character TE codes may be potentially confusing and inadequate for these drug products. Accordingly, FDA provides the following explanation and chart of therapeutic equivalence evaluations for levothyroxine sodium drug products.

Levothyroxine Sodium (Mylan ANDA 76187) and Levo-T (Alara NDA 21342) tablets have been determined to be therapeutically equivalent to corresponding strengths of Unithroid (Jerome Stevens NDA 021210) tablets. Levo-T (Alara NDA 021342), Levothyroxine Sodium (Mylan ANDA 76187), Unithroid (Jerome Stevens NDA 021210), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Synthroid (Abbott NDA 021402) tablets.

Levo-T (Alara NDA 021342), Unithroid (Jerome Stevens NDA 021210), Levothyroxine Sodium (Mylan ANDA 076187), and Levothyroxine Sodium (Merck KGAA ANDA 76752) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levoxyl (King Pharms NDA 021301) tablets.

Levothyroxine Sodium (Mylan ANDA 76187) tablets have been determined to be therapeutically equivalent to corresponding strengths of Levotheroid (Lloyd NDA 021116) tablets.

The chart outlines TE codes for all 0.025mg products. Other product strengths may be similar. Therapeutic equivalence has been established between products that have the same AB+number TE code. More than one TE code may apply to some products. One common TE code indicates therapeutic equivalence between products.

Trade Name	Applicant	Potency	TE Code	Appl No	Product No
UNITHROID	STEVENS J	0.025MG	AB1	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB1	76187	001
LEVOXYL	KING PHARMS	0.025MG	AB1	21301	001
SYNTHROID	ABBOTT	0.025MG	AB1	21402	001
LEVO-T	ALARA PHARM	0.025MG	AB1	21342	001
SYNTHROID	ABBOTT	0.025MG	AB2	21402	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB2	76187	001
LEVO-T	ALARA PHARM	0.025MG	AB2	21342	001
UNITHROID	STEVENS J	0.025MG	AB2	21210	001
LEVOXYL	KUNG PHARMS	0.025MG	AB3	21301	001
LEVO-T	ALARA PHARM	0.025MG	AB3	21342	001
UNITHROID	STEVENS J	0.025MG	AB3	21210	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB3	76187	001
LEVOTHROID	LLOYD	0.025MG	AB4	21116	001
LEVOTHYROXINE SODIUM	MYLAN	0.025MG	AB4	76187	001

## 1.5 AVAILABILITY OF THE EDITION

Since 1997, the Electronic Orange Book Query (EOBQ) <http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm>, has been available on the internet and has become the updated-every-month Orange Book. The Query provides searching of the approved drug list by active ingredient, proprietary name, applicant holder, applicant number or patent number. Product search categories are: prescription, over-the-counter, discontinued drugs. There are links to patent and exclusivity information that may be applicable to each product.

Commencing with the 25th edition, the Annual Edition and monthly Cumulative Supplements have been provided in downloadable Portable

Document Format (PDF) at the EOB home page by clicking on Publications. The PDF annual and cumulative supplements duplicate previous paper versions. Over time, there will be an archive for the annuals and each year's December Cumulative Supplement.

The downloaded Annual Edition and Cumulative Supplements are also available in a paper version (Approved Drug Products with Therapeutic Equivalence Evaluations, ADP) from the U.S. Government Printing Office: <http://bookstore.gpo.gov>; toll free 866-512-1800.

There are historical lists of Orange Book cumulative supplement product monthly changes at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm086229.htm>. There are ASCII text files of the Orange Book drug product, patent, and exclusivity data at <http://www.fda.gov/Drugs/InformationOnDrugs/ucm129689.htm>. The drug product text files are provided in eobzip.zip format. The files are updated concurrently with the monthly cumulative supplements. The annual Orange Book Edition Appendices A, B, and C in PDF format are updated quarterly.

Effective August 18, 2003, patent submissions for publication in the Orange Book and Docket \*95S-0117 need to be submitted on form FDA-3542 which may be downloaded from the FDA Forms List, <http://www.fda.gov/opacom/morechoices/fdaforms/default.html>.

The current listing of the Orphan Product Designations and Approvals is available at <http://www.fda.gov/orphan/designat/list.htm>.

## 1.6 REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST

### DESCRIPTION OF REPORT

This report provides summary counts derived from the product information in the Prescription Drug Product List and the current Cumulative Supplement. Products included in the counts are domestically marketed drug products approved for both safety and effectiveness under section 505 of the Federal Food, Drug, and Cosmetic Act. Excluded are approved drug products marketed by distributors; those marketed solely abroad; and those now regarded as medical devices, biologics or foods.

The baseline column (Dec 2012) refers to the products in the Prescription Drug Product List. For each three-month period, a column of quarterly data is added which incorporates counts of product activity from the previous quarter(s) with those in the baseline count.

### DEFINITIONS

#### Drug Product

For this report, a drug product is the representation in the Prescription Drug Product List of an active moiety (molecular entity and its salts, esters and derivatives) either as a single ingredient or as a combination product provided in a specific dosage form and strength for a given route of administration with approval for marketing by a firm under a particular generic or trade name.

#### New Molecular Entity

A new molecular entity is considered an active moiety that has not previously been approved (either as the parent compound or as a salt, ester or derivative of the parent compound) in the United States for use in a drug product either as a single ingredient or as part of a combination.



REPORT OF COUNTS FOR THE PRESCRIPTION DRUG PRODUCT LIST  
COUNTS CUMULATIVE BY QUARTER

<u>CATEGORIES COUNTED</u>	<u>DEC 2013</u>	<u>MAR 2014</u>	<u>JUN 2014</u>	<u>SEPT 2014</u>	<u>DEC 2014</u>
DRUG PRODUCTS LISTED	15711	15885	15823	15974	16150
SINGLE SOURCE	2517 (16.0%)	2540 (16.0%)	2516 (15.9%)	2536 (15.9%)	2572 (15.9%)
MULTISOURCE	13194 (84.0%)	13345 (84.0%)	13307 (84.1%)	13438 (84.1%)	13578 (84.1%)
THERAPEUTICALLY EQUIVALENT	13055 (83.1%)	13208 (83.1%)	13169 (83.2%)	13304 (83.3%)	13443 (83.2%)
NOT THERAPEUTICALLY EQUIVALENT	139 (0.9%)	137 (0.9%)	138 (0.9%)	134 (0.8%)	135 (.8%)
EXCEPTIONS <sup>1</sup>	78 (0.5%)	78 (0.5%)	78 (0.5%)	77 (0.5%)	77 (0.5%)
NEW MOLECULAR ENTITIES APPROVED	20	12	6	17	13
NUMBER OF APPLICANTS	866	873	889	899	927

<sup>1</sup>Amino acid-containing products of varying composition (see Introduction, page xx of the List).

## 1.7 CUMULATIVE SUPPLEMENT LEGEND

The List is sorted by Ingredient(s) and, within each grouping, by the Dosage Form; Route and then by trade name.

The individual product record contains the Therapeutic Equivalence Code, Reference Listed Drug symbol, applicant holder, strength(s), New Drug Application number, product number, and approval date. The application number preceded by "N" is a New Drug Application (NDA or innovator). The application number preceded by an "A" is an Abbreviated New Drug Application (ANDA or generic). The last two columns describe the action. The Action Month is the CS month the action occurred. The OB Action is the type of change that has occurred.

New ingredient(s), new dosage form; route(s), new trade names, and new product additions are preceded by >A> during the action month. The change month is the current CS month; the change code for new approvals is NEWA. Following months will display the same information without the >A>.

Changes to currently listed products will list two records. The deleted product record will be preceded by >D>. The product record change addition being made will be preceded by >A>. Following months will display only the >A> record without the >A>. All changes that occur to the product through the Annual year will be listed. The change month and change code will document the change.

The change code and description:

NEWA	New drug product approval usually in the supplement month.
CAHN	Applicant holder firm name has changed.
CAIN	Change. There has been a change in the Ingredient(s) name. All products will be deleted under the old name and all products will be added under the changed ingredient(s) name.
CDFR	Change. Dosage Form; Route of Administration.
CFTG	Change. A first time generic for the innovator product. A TE Code is added.
CMFD	Change. The product is moved from the Discontinued Section due to a change in marketing status.
CMS1	Change. Miscellaneous addition to list.

CMS2	Change. Miscellaneous deletion from list.
CPOT	Change. Potency amount/unit.
CRLD	Change. Reference Listed Drug.
CTEC	Change. Therapeutic Equivalence Code.
CTNA	Change. Trade Name.
DISC	Discontinued. The Rx or OTC listed product is not being marketed and will be moved to the discontinued section in the next edition.

ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE

TABLET;ORAL  
TRIUMEQ

+ VIIV HLTHCARE EQ 600MG BASE;EQ 50MG BASE;300MG N205551 001 Aug 22, 2014 Aug NEWA

ACAMPROSATE CALCIUM

TABLET, DELAYED RELEASE;ORAL  
ACAMPROSATE CALCIUM

AB MYLAN PHARMS INC 333MG A200142 001 Mar 11, 2014 Feb NEWA

ACARBOSE

TABLET;ORAL  
ACARBOSE

AB STRIDES PHARMA 25MG A090912 001 Jul 27, 2011 Aug CAHN  
AB 50MG A090912 002 Jul 27, 2011 Aug CAHN  
AB 100MG A090912 003 Jul 27, 2011 Aug CAHN

ACEBUTOLOL HYDROCHLORIDE

CAPSULE;ORAL  
ACEBUTOLOL HYDROCHLORIDE

@ WATSON LABS EQ 200MG BASE A074007 001 Oct 18, 1995 May DISC  
@ EQ 400MG BASE A074007 002 Oct 18, 1995 May DISC

ACETAMINOPHEN; BUTALBITAL

CAPSULE;ORAL  
PHRENILIN FORTE

@ VALEANT 650MG;50MG A088831 001 Jun 19, 1985 Apr DISC

TABLET;ORAL  
BUTAPAP

@ MIKART 650MG;50MG A089988 001 Oct 26, 1992 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE

CAPSULE;ORAL  
ESGIC-PLUS

@ MIKART 500MG;50MG;40MG A040085 001 Mar 28, 1996 Apr DISC

TABLET;ORAL

BUTALBITAL, ACETAMINOPHEN AND CAFFEINE

@ MIKART 750MG;50MG;40MG A040496 001 Dec 23, 2003 Apr DISC  
@ MIRROR PHARMS 325MG;50MG;40MG A040864 001 Dec 01, 2008 Mar DISC  
AA + VINTAGE PHARMS 325MG;50MG;40MG A040511 001 Aug 27, 2003 Mar CRLD  
@ 500MG;50MG;40MG A040513 001 Aug 25, 2003 Apr DISC  
@ WATSON LABS 500MG;50MG;40MG A040267 001 Jul 30, 1998 Jan DISC  
ESGIC-PLUS  
@ MIKART 500MG;50MG;40MG A089451 001 May 23, 1988 Apr DISC

ACETAMINOPHEN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE;ORAL

BUTALBITAL, ACETAMINOPHEN, CAFFEINE AND CODEINE PHOSPHATE

AB HIKMA INTL PHARMS 325MG;50MG;40MG;30MG A075618 001 Mar 23, 2001 Sep CAHN  
PHRENILIN WITH CAFFEINE AND CODEINE  
@ VALEANT 325MG;50MG;40MG;30MG A074911 001 Aug 22, 2001 Mar DISC

ACETAMINOPHEN; CAFFEINE; DIHYDROCODEINE BITARTRATE

CAPSULE;ORAL  
TREZIX

WRASER PHARMS LLC 320.5MG;30MG;16MG A204785 001 Nov 26, 2014 Nov NEWA

ACETAMINOPHEN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

HYDROCODONE BITARTRATE AND ACETAMINOPHEN

@ MALLINCKRODT 500MG/15ML;7.5MG/15ML A040418 001 Jun 27, 2001 Jan DISC  
@ MIKART 500MG/15ML;7.5MG/15ML A081051 001 Aug 28, 1992 Apr DISC  
>D> AA PAI 325MG/15ML;7.5MG/15ML A040838 001 May 10, 2013 Dec CAHN  
>A> AA PHARM ASSOC 325MG/15ML;7.5MG/15ML A040838 001 May 10, 2013 Dec CAHN  
@ 500MG/15ML;7.5MG/15ML A040182 001 Mar 13, 1998 Apr DISC  
AA VINTAGE PHARMS 325MG/15ML;7.5MG/15ML A040894 001 Jul 19, 2011 Feb CAHN  
@ 500MG/15ML;7.5MG/15ML A040520 001 Oct 30, 2003 Apr DISC

TABLET; ORAL							
ANEXSIA							
	@ MALLINCKRODT	500MG; 5MG	A 089160	001	Apr 23, 1987	Jan	DISC
	@	750MG; 10MG	A 040468	001	Oct 31, 2002	Jan	DISC
ANEXSIA 7.5/650							
	@ MALLINCKRODT	650MG; 7.5MG	A 089725	001	Sep 30, 1987	Jan	DISC
HYDROCODONE BITARTRATE AND ACETAMINOPHEN							
	@ AMNEAL PHARMS NY	500MG; 5MG	A 040729	001	Aug 25, 2006	Apr	DISC
	@	500MG; 7.5MG	A 040748	001	Aug 25, 2006	Apr	DISC
	@	500MG; 10MG	A 040813	001	Feb 23, 2007	Apr	DISC
	@	650MG; 7.5MG	A 040754	001	Aug 25, 2006	Apr	DISC
	@	650MG; 10MG	A 040757	001	Aug 25, 2006	Apr	DISC
	@	750MG; 7.5MG	A 040769	001	Aug 28, 2006	Apr	DISC
	@ CARACO	500MG; 5MG	A 090265	001	Dec 23, 2008	Apr	DISC
	@	500MG; 7.5MG	A 090265	002	Dec 23, 2008	Apr	DISC
	@	500MG; 10MG	A 090265	003	Dec 23, 2008	Apr	DISC
	@	650MG; 7.5MG	A 090380	001	Dec 23, 2008	Apr	DISC
	@	650MG; 10MG	A 090380	002	Dec 23, 2008	Apr	DISC
	@	660MG; 10MG	A 090380	003	Dec 23, 2008	Apr	DISC
	@	750MG; 7.5MG	A 090380	004	Dec 23, 2008	Apr	DISC
	@ MALLINCKRODT	500MG; 5MG	A 040084	002	Jun 01, 1995	Jan	DISC
	@	500MG; 7.5MG	A 040201	001	Feb 27, 1998	Jan	DISC
	@	500MG; 10MG	A 040201	002	Feb 27, 1998	Jan	DISC
	@	650MG; 10MG	A 040084	004	Oct 16, 1996	Jan	DISC
	@	660MG; 10MG	A 040084	003	Jul 29, 1996	Jan	DISC
	@	750MG; 7.5MG	A 040084	001	Jun 01, 1995	Jan	DISC
	@ MIKART	500MG; 7.5MG	A 089699	001	Aug 25, 1989	Apr	DISC
	@	650MG; 7.5MG	A 089689	001	Jun 29, 1988	Apr	DISC
	@	650MG; 10MG	A 081223	001	May 29, 1992	Apr	DISC
AA	SUN PHARM INDS INC	325MG; 5MG	A 090118	001	Dec 23, 2008	Jun	CAHN
AA		325MG; 7.5MG	A 090118	002	Dec 23, 2008	Jun	CAHN
AA		325MG; 10MG	A 090118	003	Dec 23, 2008	Jun	CAHN
AA	VINTAGE PHARMS	300MG; 5MG	A 090415	001	Jan 24, 2011	Feb	CAHN
AA		300MG; 7.5MG	A 090415	002	Jan 24, 2011	Feb	CAHN
AA		300MG; 10MG	A 090415	003	Jan 24, 2011	Feb	CAHN
	@	500MG; 2.5MG	A 040144	002	Apr 25, 1997	Apr	DISC
	@	500MG; 5MG	A 089971	001	Dec 02, 1988	Apr	DISC
	@	500MG; 7.5MG	A 040144	001	Feb 22, 1996	Apr	DISC
	@	500MG; 10MG	A 040356	001	May 31, 2000	Apr	DISC
	@	650MG; 7.5MG	A 040155	001	Apr 14, 1997	Jan	DISC
	@	650MG; 10MG	A 040143	001	Feb 22, 1996	Apr	DISC
	@	660MG; 10MG	A 040358	001	May 31, 2000	Apr	DISC
	@	750MG; 7.5MG	A 040157	001	Apr 12, 1996	Jan	DISC
	@ WATSON LABS	500MG; 2.5MG	A 081079	001	Aug 30, 1991	Apr	DISC
	@	500MG; 5MG	A 089883	001	Dec 01, 1988	Apr	DISC
	@	500MG; 7.5MG	A 081080	001	Aug 30, 1991	Jan	DISC
	@	650MG; 7.5MG	A 040094	001	Sep 29, 1995	Apr	DISC
	@	650MG; 10MG	A 040094	002	Sep 29, 1995	Apr	DISC
	@	660MG; 10MG	A 040094	003	Aug 08, 2000	Apr	DISC
	@	750MG; 7.5MG	A 081083	001	Aug 30, 1991	Jan	DISC
	@	750MG; 10MG	A 040094	004	Mar 22, 1999	Apr	DISC
	@ WATSON LABS FLORIDA	660MG; 10MG	A 040495	001	May 28, 2003	Apr	DISC
LORTAB							
	@ UCB INC	500MG; 5MG	A 087722	001	Jul 09, 1982	Apr	DISC
	@	500MG; 10MG	A 040100	001	Jan 26, 1996	Apr	DISC
ZYDONE							
	@ VINTAGE PHARMS LLC	400MG; 5MG	A 040288	001	Nov 27, 1998	Apr	DISC
	@	400MG; 7.5MG	A 040288	002	Nov 27, 1998	Apr	DISC
	@	400MG; 10MG	A 040288	003	Nov 27, 1998	Apr	DISC

ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

## OXYCODONE AND ACETAMINOPHEN

	@ ACTAVIS ELIZABETH	500MG; 5MG	A 040199	001	Dec 30, 1998	Aug	CAHN
	@ DURAMED PHARMS BARR	500MG; 5MG	A 040289	001	Mar 16, 1999	Apr	DISC
	@ MALLINCKRODT	500MG; 5MG	A 040257	001	Aug 04, 1998	Jan	DISC
	@ VINTAGE PHARMS	500MG; 5MG	A 040106	001	Jul 30, 1996	Apr	DISC
	@ WATSON LABS	500MG; 5MG	A 040234	001	Oct 30, 1997	Jan	DISC

## ROXILOX

	@ ROXANE	500MG; 5MG	A 040061	001	Jul 03, 1995	Apr	DISC
--	----------	------------	----------	-----	--------------	-----	------

## TYLOX

	@ JANSSEN PHARMS	500MG; 5MG	A 088790	001	Dec 12, 1984	Apr	DISC
--	------------------	------------	----------	-----	--------------	-----	------

SOLUTION; ORAL							
OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN							
>A> AA	VINTAGE PHARMS	325MG/5ML; 5MG/5ML	A203573	001	Dec 18, 2014	Dec	NEWA
TABLET; ORAL							
OXYCODONE AND ACETAMINOPHEN							
	@ ACTAVIS ELIZABETH	325MG; 5MG	A040203	001	Mar 15, 1999	Sep	CAHN
	@	325MG; 7.5MG	A040800	001	Apr 03, 2012	Sep	CAHN
	@	325MG; 10MG	A040800	002	Apr 03, 2012	Sep	CAHN
	@ ACTAVIS TOTOWA	325MG; 7.5MG	A040800	001	Apr 03, 2012	Aug	DISC
	@	325MG; 10MG	A040800	002	Apr 03, 2012	Aug	DISC
	@ AMNEAL PHARMS NY	500MG; 7.5MG	A040789	001	Nov 27, 2007	Apr	DISC
	@	650MG; 10MG	A040789	002	Nov 27, 2007	Apr	DISC
	@ COASTAL PHARMS	500MG; 7.5MG	A090177	005	Oct 20, 2008	Apr	DISC
	@	650MG; 10MG	A090177	006	Oct 20, 2008	Apr	DISC
	@ MALLINCKRODT	500MG; 7.5MG	A040550	001	Jun 30, 2004	Apr	DISC
	@	650MG; 10MG	A040550	002	Jun 30, 2004	Apr	DISC
	@ MIKART	400MG; 5MG	A040687	001	Apr 27, 2006	Apr	DISC
	@	400MG; 7.5MG	A040698	001	Apr 27, 2006	Apr	DISC
	@	400MG; 10MG	A040692	001	Apr 27, 2006	Apr	DISC
	@	500MG; 10MG	A040676	001	Apr 19, 2006	Apr	DISC
AA	RHODES PHARMS	325MG; 5MG	A201278	001	Aug 28, 2014	Aug	NEWA
AA		325MG; 7.5MG	A201278	002	Aug 28, 2014	Aug	NEWA
AA		325MG; 10MG	A201278	003	Aug 28, 2014	Aug	NEWA
AA	SUN PHARM INDS INC	325MG; 2.5MG	A090535	001	Dec 26, 2013	Jul	CAHN
AA		325MG; 5MG	A090535	002	Dec 26, 2013	Jul	CAHN
AA		325MG; 7.5MG	A090535	003	Dec 26, 2013	Jul	CAHN
AA		325MG; 10MG	A090535	004	Dec 26, 2013	Jul	CAHN
	@ WATSON LABS	500MG; 7.5MG	A040371	001	Dec 29, 2000	Jan	DISC
	@	650MG; 10MG	A040371	002	Dec 29, 2000	Jan	DISC
PERCOCET							
	@ VINTAGE PHARMS LLC	500MG; 7.5MG	A040341	001	Jul 26, 1999	Jan	DISC
	@	650MG; 10MG	A040341	002	Jul 26, 1999	Jan	DISC
TABLET, EXTENDED RELEASE; ORAL							
XARTEMIS XR							
+	MALLINCKRODT INC	325MG; 7.5MG	N204031	001	Mar 11, 2014	Mar	NEWA
<u>ACETAMINOPHEN; PENTAZOCINE HYDROCHLORIDE</u>							
TABLET; ORAL							
ACETAMINOPHEN AND PENTAZOCINE HYDROCHLORIDE							
	@ GAVIS PHARMS	650MG; EQ 25MG BASE	A076202	001	Aug 02, 2002	Apr	DISC
	@ WATSON LABS	650MG; EQ 25MG BASE	A074699	001	Mar 24, 2000	Apr	DISC
<u>ACETAMINOPHEN; TRAMADOL HYDROCHLORIDE</u>							
TABLET; ORAL							
TRAMADOL HYDROCHLORIDE AND ACETAMINOPHEN							
AB	ALLIED PHARMA INC	325MG; 37.5MG	A202076	001	Mar 30, 2012	Apr	CAHN
AB	APOTEX INC	325MG; 37.5MG	A078778	001	Apr 07, 2014	Mar	NEWA
AB	SUN PHARM INDS INC	325MG; 37.5MG	A077184	001	Dec 16, 2005	Jul	CAHN
	@ WATSON LABS	325MG; 37.5MG	A076914	001	Jul 26, 2006	May	DISC
<u>ACETAZOLAMIDE SODIUM</u>							
INJECTABLE; INJECTION							
ACETAZOLAMIDE SODIUM							
AP	EUROHLTH INTL	EQ 500MG BASE/VIAL	A040089	001	Feb 28, 1995	Aug	CAHN
ACETAZOLAMIDE SODIUM							
>A> AP	EMCURE PHARMS LTD	EQ 500MG BASE/VIAL	A202693	001	Dec 19, 2014	Dec	NEWA
<u>ACETOHEXAMIDE</u>							
TABLET; ORAL							
ACETOHEXAMIDE							
	@ WATSON LABS	250MG	A071893	001	Nov 25, 1987	May	DISC
	@	500MG	A071894	001	Nov 25, 1987	May	DISC
<u>ACETYLCYSTEINE</u>							
SOLUTION; INHALATION, ORAL							
ACETYLCYSTEINE							
AN	INNOPHARMA LICENSING	10%	A204674	001	Feb 11, 2014	Jan	NEWA
	@ ROXANE	10%	A072323	001	Apr 30, 1992	Aug	DISC
AN		10%	A072323	001	Apr 30, 1992	Jun	CAHN
	@	20%	A072324	001	Apr 30, 1992	Aug	DISC
AN		20%	A072324	001	Apr 30, 1992	Jun	CAHN

ACRIVASTINE; PSEUDOEPHEDRINE HYDROCHLORIDECAPSULE;ORAL  
SEMPREX-D

+ AUXILIUM PHARMS LLC 8MG;60MG N019806 001 Mar 25, 1994 Apr CAHN

ACYCLOVIRCAPSULE;ORAL  
ACYCLOVIR

AB CADILA PHARMS LTD 200MG A201445 001 Mar 06, 2014 Feb NEWA

ZOVIRAX

AB + DELCOR ASSET 200MG N018828 001 Jan 25, 1985 Jun CAHN

OINTMENT;TOPICAL  
ACYCLOVIR

AB AMNEAL PHARMS 5% A204605 001 Jun 18, 2014 Jun NEWA

TABLET;BUCCAL  
SITAVIG

+ INNOCUTIS HOLDINGS 50MG N203791 001 Apr 12, 2013 Apr CMFD

+ 50MG N203791 001 Apr 12, 2013 Apr CAHN

TABLET;ORAL  
ACYCLOVIR

AB ZYDUS PHARMS USA INC 400MG A204314 001 Aug 19, 2014 Aug NEWA

AB 800MG A204314 002 Aug 19, 2014 Aug NEWA

ZOVIRAX

AB DELCOR ASSET 400MG N020089 001 Apr 30, 1991 Jun CAHN

AB + 800MG N020089 002 Apr 30, 1991 Jun CAHN

ACYCLOVIR SODIUMINJECTABLE;INJECTION  
ACYCLOVIR SODIUM

+ BEDFORD EQ 1GM BASE/VIAL A074596 001 Apr 22, 1997 Feb CRLD

@ HIKMA MAPLE EQ 1GM BASE/VIAL A074913 002 Oct 15, 1997 Feb DISC

@ EQ 500MG BASE/VIAL A074913 001 Oct 15, 1997 Feb DISC

ADAPALENEGEL;TOPICAL  
ADAPALENE

AB ACTAVIS MID ATLANTIC 0.3% A201000 001 Oct 27, 2014 Oct NEWA

ADENOSINEINJECTABLE;INJECTION  
ADENOSINE

AP AGILA SPECLTS 3MG/ML A078640 001 Mar 21, 2014 Mar NEWA

AP 3MG/ML A078686 001 May 13, 2009 Feb CAHN

AP HOSPIRA INC 3MG/ML A203883 001 Mar 24, 2014 Mar NEWA

AP SAGENT STRIDES 3MG/ML A090212 001 Mar 28, 2014 Mar NEWA

SOLUTION;IV (INFUSION)  
ADENOSCAN

AP + ASTELLAS 3MG/ML N020059 001 May 18, 1995 Sep CDFR

AP + 60MG/20ML (3MG/ML) N020059 001 May 18, 1995 Sep CPOT

AP + 90MG/30ML (3MG/ML) N020059 002 May 18, 1995 Sep NEWA

ADENOSINE

AP AKORN 60MG/20ML (3MG/ML) A090450 001 Oct 02, 2014 Sep NEWA

AP 90MG/30ML (3MG/ML) A090450 002 Oct 02, 2014 Sep NEWA

AP EMCURE PHARMS LTD 60MG/20ML (3MG/ML) A202313 001 Sep 15, 2014 Sep NEWA

AP 90MG/30ML (3MG/ML) A202313 002 Sep 15, 2014 Sep NEWA

AP HOSPIRA INC 3MG/ML A203883 001 Mar 24, 2014 Sep CDFR

AP 60MG/20ML (3MG/ML) A203883 001 Mar 24, 2014 Sep CPOT

AP 90MG/30ML (3MG/ML) A203883 002 Mar 24, 2014 Sep NEWA

AP SAGENT STRIDES 3MG/ML A090212 001 Mar 28, 2014 Sep CDFR

AP 60MG/20ML (3MG/ML) A090212 001 Mar 28, 2014 Sep CPOT

AP 90MG/30ML (3MG/ML) A090212 002 Mar 28, 2014 Sep NEWA

AP TEVA PHARMS USA 3MG/ML A077425 001 Aug 29, 2013 Sep CDFR

AP 60MG/20ML (3MG/ML) A077425 001 Aug 29, 2013 Sep CPOT

AP 90MG/30ML (3MG/ML) A077425 002 Aug 29, 2013 Sep NEWA

ALBUTEROL SULFATEAEROSOL, METERED; INHALATION  
VENTOLIN HFA

BX	+	GLAXOSMITHKLINE	EQ 0.09MG BASE/INH	N020983	001	Apr 19, 2001	Sep CAHN
		SOLUTION; INHALATION					
		ACCUNEB					

AN	+	MYLAN SPECLT	EQ 0.021% BASE	N020949	002	Apr 30, 2001	May CAHN
AN	+		EQ 0.042% BASE	N020949	001	Apr 30, 2001	May CAHN

TABLET; ORAL

ALBUTEROL SULFATE

@ WATSON LABS

EQ 2MG BASE

A072764 001 Aug 28, 1991 May DISC

ALBUTEROL SULFATE; IPRATROPIUM BROMIDE

SOLUTION; INHALATION

DUONEB

AN	+	MYLAN SPECLT	EQ 0.083% BASE; 0.017%	N020950	001	Mar 21, 2001	May CAHN
----	---	--------------	------------------------	---------	-----	--------------	----------

ALCLOMETASONE DIPROPIONATE

CREAM; TOPICAL

ACLOVATE

>D>							
>D>	AB	+	FOUGERA PHARMS	0.05%	N018707	001	Dec 14, 1982
>A>		@		0.05%	N018707	001	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

>D>	AB		FOUGERA PHARMS	0.05%	A076973	001	Jul 12, 2005
>A>	AB	+		0.05%	A076973	001	Jul 12, 2005

OINTMENT; TOPICAL

ACLOVATE

>D>	AB	+	FOUGERA PHARMS	0.05%	N018702	001	Dec 14, 1982
>A>		@		0.05%	N018702	001	Dec 14, 1982

ALCLOMETASONE DIPROPIONATE

>D>	AB		FOUGERA PHARMS	0.05%	A076884	001	Jul 18, 2005
>A>	AB	+		0.05%	A076884	001	Jul 18, 2005

ALLOPURINOL

TABLET; ORAL

ALLOPURINOL

AB		SUN PHARM INDS INC	100MG	A078390	001	Aug 30, 2007	Jul CAHN
AB			300MG	A078390	002	Aug 30, 2007	Jul CAHN

ALLOPURINOL SODIUM

INJECTABLE; INJECTION

ALLOPURINOL SODIUM

AP		EUROHLTH INTL	EQ 500MG BASE/VIAL	A076870	001	Aug 26, 2004	Aug CAHN
----	--	---------------	--------------------	---------	-----	--------------	----------

ALPRAZOLAM

TABLET; ORAL

ALPRAZOLAM

AB		VINTAGE PHARMS	0.25MG	A090248	001	Sep 17, 2010	Feb CAHN
AB			0.5MG	A090248	002	Sep 17, 2010	Feb CAHN
AB			1MG	A090248	003	Sep 17, 2010	Feb CAHN
AB			2MG	A090248	004	Sep 17, 2010	Feb CAHN

TABLET, EXTENDED RELEASE; ORAL

ALPRAZOLAM

AB		ANI PHARMS INC	0.5MG	A077725	001	Jul 31, 2006	Jan CAHN
		@	0.5MG	A077979	001	Feb 28, 2007	Jan CAHN
AB			1MG	A077725	002	Jul 31, 2006	Jan CAHN
		@	1MG	A077979	002	Feb 28, 2007	Jan CAHN
AB			2MG	A077725	004	Jul 31, 2006	Jan CAHN
		@	2MG	A077979	003	Feb 28, 2007	Jan CAHN
AB			3MG	A077725	003	Jul 31, 2006	Jan CAHN
		@	3MG	A077979	004	Feb 28, 2007	Jan CAHN

TABLET, ORALLY DISINTEGRATING; ORAL

ALPRAZOLAM

AB	+	PAR PHARM	1MG	A078088	003	Jan 09, 2009	Sep CRLD
		NIRAVAM					
		@ UCB INC	0.25MG	N021726	001	Jan 19, 2005	Sep DISC
		@	0.5MG	N021726	002	Jan 19, 2005	Sep DISC
		@	1MG	N021726	003	Jan 19, 2005	Sep DISC
		@	2MG	N021726	004	Jan 19, 2005	Sep DISC

ALPROSTADIL

INJECTABLE; INJECTION  
ALPROSTADIL

AP		EUROHLTH INTL	0.5MG/ML	A074815	001	Jan 20, 1998	Aug CAHN
		EDEX					
		@ AUXILIUM PHARMS LLC	0.005MG/VIAL	N020649	001	Jun 12, 1997	Apr CAHN
AP			0.01MG/VIAL	N020649	002	Jun 12, 1997	Apr CAHN
	+		0.01MG/VIAL	N020649	005	Jul 30, 1998	Apr CAHN
AP			0.02MG/VIAL	N020649	003	Jun 12, 1997	Apr CAHN
	+		0.02MG/VIAL	N020649	006	Jul 30, 1998	Apr CAHN
AP			0.04MG/VIAL	N020649	004	Jun 12, 1997	Apr CAHN
	+		0.04MG/VIAL	N020649	007	Jul 30, 1998	Apr CAHN

AMANTADINE HYDROCHLORIDE

CAPSULE; ORAL  
AMANTADINE HYDROCHLORIDE

		@ ACTAVIS ELIZABETH	100MG	A077659	001	Feb 23, 2006	Aug CAHN
AB	+	SANDOZ	100MG	A071293	001	Feb 18, 1987	Feb CRLD
AB		USL PHARMA	100MG	A070589	001	Aug 05, 1986	Feb CRLD

AM BENONIUM CHLORIDE

TABLET; ORAL  
MYTELASE

		@ SANOFI AVENTIS US	10MG	N010155	002		Jun DISC
--	--	---------------------	------	---------	-----	--	----------

AMIFOSTINE

INJECTABLE; INJECTION  
ETHYOL

		@ CLINIGEN HLTHCARE	375MG/VIAL	N020221	002	Sep 10, 1999	Nov CAHN
AP	+		500MG/VIAL	N020221	001	Dec 08, 1995	Nov CAHN

AMIKACIN SULFATE

INJECTABLE; INJECTION  
AMIKACIN SULFATE

AP	+	EUROHLTH INTL	EQ 50MG BASE/ML	A063313	001	Apr 11, 1994	Aug CAHN
AP	+		EQ 250MG BASE/ML	A063315	001	Apr 11, 1994	Aug CAHN

AMINO ACIDS

INJECTABLE; INJECTION  
HEPATASOL 8%

		@ BAXTER HLTHCARE	8% (8GM/100ML)	A020360	001	Apr 04, 1996	Jul DISC
		RENAMIN W/O ELECTROLYTES					
		@ BAXTER HLTHCARE	6.5% (6.5GM/100ML)	N017493	007	Oct 15, 1982	Jul DISC
		TRAVASOL 10% W/O ELECTROLYTES					
		@ BAXTER HLTHCARE	10% (10GM/100ML)	N017493	006		Jul DISC
		TRAVASOL 5.5% W/O ELECTROLYTES					
		@ BAXTER HLTHCARE	5.5% (5.5GM/100ML)	N017493	004		Jul DISC
		TRAVASOL 8.5% W/O ELECTROLYTES					
		@ BAXTER HLTHCARE	8.5% (8.5GM/100ML)	N017493	005		Jul DISC

AMINO ACIDS; CALCIUM CHLORIDE; DEXTROSE; MAGNESIUM SULFATE; POTASSIUM CHLORIDE; SODIUM ACETATE; SODIUM GLYCEROPHOSPHATE; SOYBEAN OIL

EMULSION; IV (INFUSION)

KABIVEN IN PLASTIC CONTAINER

		FRESENIUS KABI USA	3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1026ML)	N200656	004	Aug 25, 2014	Aug NEWA
			3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (1540ML)	N200656	005	Aug 25, 2014	Aug NEWA
			3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2053ML)	N200656	006	Aug 25, 2014	Aug NEWA
	+		3.3%; 29MG/100ML; 9.8GM/100ML; 96MG/100ML; 174MG/100ML; 239MG/100ML; 147MG/100ML; 3.9GM/100ML (2566ML)	N200656	007	Aug 25, 2014	Aug NEWA

PERIKABIVEN IN PLASTIC CONTAINER

		FRESENIUS KABI USA	2.4%; 20MG/100ML; 6.8GM/100ML; 68MG/100ML; 124MG/100ML; 170MG/100ML; 105MG/100ML; 3.5	N200656	001	Aug 25, 2014	Aug NEWA
--	--	--------------------	---	---------	-----	--------------	----------



## EMULSION;IV (INFUSION)

## PERIKABIVEN IN PLASTIC CONTAINER

GM/100ML (1440ML)

2.4%;20MG/100ML;6.8GM/100ML;68MG/1 N200656 002 Aug 25, 2014 Aug NEWA  
00ML;124MG/100ML;170MG/100ML;105MG  
/100ML;3.5GM/100ML (1920ML)

2.4%;20MG/100ML;6.8GM/100ML;68MG/1 N200656 003 Aug 25, 2014 Aug NEWA  
00ML;124MG/100ML;170MG/100ML  
;105MG/100ML;3.5GM/100ML (2400ML)

AMINO ACIDS; MAGNESIUM CHLORIDE; POTASSIUM PHOSPHATE, DIBASIC; SODIUM ACETATE; SODIUM CHLORIDE

## INJECTABLE;INJECTION

## TRAVASOL 3.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE 3.5%;51MG/100ML;131MG/100ML;218MG/ N017493 003 Jul DISC  
100ML;35MG/100ML

## TRAVASOL 5.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE 5.5%;102MG/100ML;522MG/100ML;431MG N017493 001 Jul DISC  
/100ML;224MG/100ML

## TRAVASOL 8.5% W/ ELECTROLYTES

@ BAXTER HLTHCARE 8.5%;102MG/100ML;522MG/100ML;594MG N017493 002 Jul DISC  
/100ML;154MG/100ML

AMINOHIPPURATE SODIUM

## INJECTABLE;INJECTION

## AMINOHIPPURATE SODIUM

@ MERCK 20% N005619 001 Jun DISC

AMINOPHYLLINE

## TABLET;ORAL

## AMINOPHYLLINE

@ HIKMA INTL PHARMS 100MG A084540 001 Oct CAHN

@ 200MG A085003 001 Oct CAHN

AMIODARONE HYDROCHLORIDE

## INJECTABLE;INJECTION

## AMIODARONE HYDROCHLORIDE

@ PAR STERILE PRODUCTS 50MG/ML A076394 001 Apr 25, 2003 May CAHN

AMITRIPTYLINE HYDROCHLORIDE

## TABLET;ORAL

## AMITRIPTYLINE HYDROCHLORIDE

>A>	AMITRIPTYLINE HYDROCHLORIDE					
>A> AB	ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	Dec CTNA
>A> AB		25MG	A202446	002	Jun 04, 2014	Dec CTNA
>A> AB		50MG	A202446	003	Jun 04, 2014	Dec CTNA
>A> AB		75MG	A202446	004	Jun 04, 2014	Dec CTNA
>A> AB		100MG	A202446	005	Jun 04, 2014	Dec CTNA
>A> AB		150MG	A202446	006	Jun 04, 2014	Dec CTNA
AB	MUTUAL PHARM	10MG	A089399	002	Jul 14, 1987	Jun CMS1
AB		50MG	A089399	003	Jul 14, 1987	Jun CMS1
AB		75MG	A089399	004	Jul 14, 1987	Jun CMS1
AB		100MG	A089399	005	Jul 14, 1987	Jun CMS1
AB		100MG	A089399	006	Jul 14, 1987	Jun CMS1
AB		150MG	A089399	006	Jul 14, 1987	Jul CPOT
AB	SUN PHARM INDS INC	10MG	A040816	002	Jun 27, 2008	Jul CAHN
AB		25MG	A040816	001	Jun 27, 2008	Jul CAHN
AB		50MG	A040816	003	Jun 27, 2008	Jul CAHN
AB		75MG	A040816	004	Jun 27, 2008	Jul CAHN
AB		100MG	A040816	005	Jun 27, 2008	Jul CAHN
AB		150MG	A040816	006	Jun 27, 2008	Jul CAHN
>D>	AMITRIPTYLINE HYDROCHORIDE					
>D> AB	ACCORD HLTHCARE	10MG	A202446	001	Jun 04, 2014	Dec CTNA
AB		10MG	A202446	001	Jun 04, 2014	May NEWA
>D> AB		25MG	A202446	002	Jun 04, 2014	Dec CTNA
AB		25MG	A202446	002	Jun 04, 2014	May NEWA
>D> AB		50MG	A202446	003	Jun 04, 2014	Dec CTNA
AB		50MG	A202446	003	Jun 04, 2014	May NEWA
>D> AB		75MG	A202446	004	Jun 04, 2014	Dec CTNA
AB		75MG	A202446	004	Jun 04, 2014	May NEWA
>D> AB		100MG	A202446	005	Jun 04, 2014	Dec CTNA
AB		100MG	A202446	005	Jun 04, 2014	May NEWA
>D> AB		150MG	A202446	006	Jun 04, 2014	Dec CTNA
AB		150MG	A202446	006	Jun 04, 2014	May NEWA

AMLODIPINE BESYLATE

TABLET; ORAL

AMLODIPINE BESYLATE

	@ PURACAP PHARM	EQ 2.5MG BASE	A078131	001	Sep 04, 2007	Feb DISC
	@	EQ 5MG BASE	A078131	002	Sep 04, 2007	Feb DISC
	@	EQ 10MG BASE	A078131	003	Sep 04, 2007	Feb DISC
AB	SUN PHARM INDS INC	EQ 2.5MG BASE	A078231	001	Nov 30, 2007	Jul CAHN
AB		EQ 5MG BASE	A078231	002	Nov 30, 2007	Jul CAHN
AB		EQ 10MG BASE	A078231	003	Nov 30, 2007	Jul CAHN
AB	VIVIMED LABS	EQ 2.5MG BASE	A077516	001	Jul 11, 2007	Apr CAHN
AB		EQ 5MG BASE	A077516	002	Jul 11, 2007	Apr CAHN
AB		EQ 10MG BASE	A077516	003	Jul 11, 2007	Apr CAHN

AMLODIPINE BESYLATE; ATORVASTATIN CALCIUM

TABLET; ORAL

AMLODIPINE BESYLATE AND ATORVASTATIN CALCIUM

AB	DR REDDYS LABS LTD	EQ 2.5MG BASE;EQ 10MG BASE	A203874	001	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 20MG BASE	A203874	002	Mar 07, 2014	Feb NEWA
AB		EQ 2.5MG BASE;EQ 40MG BASE	A203874	003	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 10MG BASE	A203874	004	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 20MG BASE	A203874	005	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 40MG BASE	A203874	006	Mar 07, 2014	Feb NEWA
AB		EQ 5MG BASE;EQ 80MG BASE	A203874	007	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 10MG BASE	A203874	008	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 20MG BASE	A203874	009	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 40MG BASE	A203874	010	Mar 07, 2014	Feb NEWA
AB		EQ 10MG BASE;EQ 80MG BASE	A203874	011	Mar 07, 2014	Feb NEWA

AMLODIPINE BESYLATE; TELMISARTAN

TABLET; ORAL

TELMISARTAN AND AMLODIPINE

AB	MYLAN PHARMS INC	EQ 5MG BASE;40MG	A202516	001	Aug 26, 2014	Aug NEWA
AB		EQ 5MG BASE;80MG	A202516	003	Aug 26, 2014	Aug NEWA
AB		EQ 10MG BASE;40MG	A202516	002	Aug 26, 2014	Aug NEWA
AB		EQ 10MG BASE;80MG	A202516	004	Aug 26, 2014	Aug NEWA

AMMONIA N-13

INJECTABLE; INTRAVENOUS

AMMONIA N 13

AP	BRIGHAM WOMENS HOSP	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203783	001	Oct 30, 2014	Oct NEWA
AP	GLOBAL ISOTOPES LLC	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204465	001	Oct 23, 2014	Oct NEWA
AP	JOHNS HOPKINS UNIV	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204514	001	Aug 19, 2014	Aug NEWA
AP	MIPS CRF	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204535	001	Nov 20, 2014	Nov NEWA
	SHERTECH LABS LLC	3.75-260mCi/ML	A204366	001	Sep 19, 2014	Sep NEWA
AP	UCSF RODIOPHARM	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204496	001	Mar 28, 2014	Mar NEWA
AP	UNIV TX MD ANDERSON	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A203933	001	Jun 27, 2014	Jun NEWA
AP	WA UNIV SCH MED	30mCi-300mCi/8ML (3.75-37.5mCi/ML)	A204506	001	Feb 07, 2014	Jan NEWA
>A>	WI MEDCL CYCLOTRON	3.75-260mCi/ML	A204356	001	Dec 18, 2014	Dec NEWA

AMOXICILLIN

FOR SUSPENSION; ORAL

AMOXICILLIN

AB	AUROBINDO PHARMA LTD	125MG/5ML	A204030	001	Sep 15, 2014	Sep NEWA
AB		250MG/5ML	A204030	002	Sep 15, 2014	Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

MOXATAG

+	PRAGMA PHARMS LLC	775MG	N050813	001	Jan 23, 2008	Apr CAHN
---	-------------------	-------	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE

CAPSULE, CAPSULE, DELAYED REL PELLETS, TABLET; ORAL

LANSOPRAZOLE, AMOXICILLIN AND CLARITHROMYCIN

AB	SANDOZ	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 30MG	A202588	001	Mar 04, 2014	Feb NEWA
----	--------	--	---------	-----	--------------	----------

AMOXICILLIN; CLARITHROMYCIN; OMEPRAZOLE

CAPSULE, TABLET, CAPSULE, DELAYED RELEASE; ORAL

OMEPRAZOLE AND CLARITHROMYCIN AND AMOXICILLIN

+	GASTROENTERO	500MG, N/A, N/A; N/A, 500MG, N/A; N/A, N/A, 20MG	N050824	001	Feb 08, 2011	Mar CDFR
---	--------------	--	---------	-----	--------------	----------

AMPHETAMINE ASPARTATE; AMPHETAMINE SULFATE; DEXTROAMPHETAMINE SACCHARATE; DEXTROAMPHETAMINE SULFATE

## TABLET; ORAL

## DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE

AB	ACTAVIS ELIZABETH	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 040456	001	May 06, 2003	Sep CAHN
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 040456	002	May 06, 2003	Sep CAHN
AB		5MG; 5MG; 5MG; 5MG	A 040456	003	May 06, 2003	Sep CAHN
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 040456	004	May 06, 2003	Sep CAHN
AB	WATSON LABS	1.25MG; 1.25MG; 1.25MG; 1.25MG	A 040456	001	May 06, 2003	Apr CMFD
AB		2.5MG; 2.5MG; 2.5MG; 2.5MG	A 040456	002	May 06, 2003	Apr CMFD
AB		5MG; 5MG; 5MG; 5MG	A 040456	003	May 06, 2003	Apr CMFD
AB		7.5MG; 7.5MG; 7.5MG; 7.5MG	A 040456	004	May 06, 2003	Apr CMFD

AMPHETAMINE SULFATE

## TABLET; ORAL

## AMPHETAMINE SULFATE

	ARBOR PHARMS LLC	5MG	A 200166	001	Aug 09, 2012	Sep CAHN
+		10MG	A 200166	002	Aug 09, 2012	Sep CAHN

AMPICILLIN SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN SODIUM

AP	AGILA SPECLTS	EQ 10GM BASE/VIAL	A 202198	001	Apr 07, 2014	Mar NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A 090354	003	Dec 28, 2009	Jun CMFD
AP		EQ 2GM BASE/VIAL	A 090354	004	Dec 28, 2009	Jun CMFD
AP		EQ 250MG BASE/VIAL	A 090354	001	Dec 28, 2009	Jun CMFD
AP		EQ 500MG BASE/VIAL	A 090354	002	Dec 28, 2009	Jun CMFD
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A 062719	002	May 12, 1987	Feb CAHN
AP		EQ 2GM BASE/VIAL	A 062797	002	Jul 12, 1993	Feb CAHN
AP		EQ 10GM BASE/VIAL	A 201404	001	Dec 20, 2013	Jan CPOT
AP		EQ 125MG BASE/VIAL	A 062797	001	Jul 12, 1993	Feb CAHN
AP		EQ 250MG BASE/VIAL	A 062719	001	May 12, 1987	Feb CAHN
AP		EQ 500MG BASE/VIAL	A 062719	003	May 12, 1987	Feb CAHN
AP	STRIDES ARCOLAB LTD	EQ 1GM BASE/VIAL	A 201025	003	Apr 09, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A 201025	004	Apr 09, 2014	Mar NEWA
AP		EQ 250MG BASE/VIAL	A 201025	001	Apr 09, 2014	Mar NEWA
AP		EQ 500MG BASE/VIAL	A 201025	002	Apr 09, 2014	Mar NEWA

## POWDER; INTRAVENOUS

## AMPICILLIN SODIUM

AP	+ SANDOZ	EQ 1GM BASE/VIAL	A 062738	001	Feb 19, 1987	Sep CRLD
AP		EQ 1GM BASE/VIAL	A 062738	001	Feb 19, 1987	Sep CDFR
AP	+	EQ 2GM BASE/VIAL	A 062738	002	Feb 19, 1987	Sep CRLD
AP		EQ 2GM BASE/VIAL	A 062738	002	Feb 19, 1987	Sep CDFR

AMPICILLIN SODIUM; SULBACTAM SODIUM

## INJECTABLE; INJECTION

## AMPICILLIN AND SULBACTAM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A 201024	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A 201024	002	Apr 07, 2014	Mar NEWA
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A 202197	001	Apr 07, 2014	Mar NEWA
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A 065222	001	Nov 29, 2005	Feb CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A 065222	002	Nov 29, 2005	Feb CAHN
AP		EQ 10GM BASE/VIAL; EQ 5GM BASE/VIAL	A 065314	001	Nov 27, 2006	Feb CAHN
AP	MUSTAFA NEVZAT ILAC	EQ 1GM BASE/VIAL; EQ 500MG BASE/VIAL	A 065316	001	Jun 29, 2007	May CAHN
AP		EQ 2GM BASE/VIAL; EQ 1GM BASE/VIAL	A 065316	002	Jun 29, 2007	May CAHN

ANASTROZOLE

## TABLET; ORAL

## ANASTROZOLE

AB	CIPLA LTD	1MG	A 091164	001	Jun 28, 2010	Nov CAHN
	@ WATSON LABS	1MG	A 078984	001	Jun 28, 2010	May DISC

APREMILAST

## TABLET; ORAL

## OTEZLA

	CELGENE CORP	10MG	N 205437	001	Mar 21, 2014	Mar NEWA
		20MG	N 205437	002	Mar 21, 2014	Mar NEWA
+		30MG	N 205437	003	Mar 21, 2014	Mar NEWA

ARGATROBAN

INJECTABLE; INJECTION  
ARGATROBAN

AP	MYLAN INSTITUTIONAL	250MG/2.5ML (100MG/ML)	A202626	001	Jun 30, 2014	Jun NEWA
AP	PAR STERILE PRODUCTS	250MG/2.5ML (100MG/ML)	A091665	001	Jun 30, 2014	Jun NEWA

INJECTABLE; IV (INFUSION)

ARGATROBAN IN 0.9% SODIUM CHLORIDE

>A>	TEVA PHARMS USA	250MG/250ML (1MG/ML)	N206769	001	Dec 15, 2014	Dec NEWA
-----	-----------------	----------------------	---------	-----	--------------	----------

ARIPIPRAZOLE

FOR SUSPENSION, EXTENDED RELEASE; INTRAMUSCULAR  
ABILIFY MAINTENA KIT

	OTSUKA PHARM CO LTD	300MG	N202971	003	Sep 29, 2014	Oct NEWA
		400MG	N202971	004	Sep 29, 2014	Oct NEWA

ARMODAFINIL

TABLET; ORAL

ARMODAFINIL

	@ MYLAN PHARMS INC	50MG	A200043	001	Jun 01, 2012	Oct DISC
	@	150MG	A200043	002	Jun 01, 2012	Oct DISC
	@	250MG	A200043	003	Jun 01, 2012	Oct DISC
	@ WATSON LABS INC	100MG	A200156	002	Aug 29, 2012	Oct DISC
	@	200MG	A200156	004	Aug 29, 2012	Oct DISC
AB		200MG	A200156	004	Aug 29, 2012	May CTEC

NUVIGIL

	CEPHALON	50MG	N021875	001	Jun 15, 2007	Oct CTEC
		150MG	N021875	003	Jun 15, 2007	Oct CTEC
		200MG	N021875	005	Mar 26, 2009	Oct CTEC
AB		200MG	N021875	005	Mar 26, 2009	May CMFD
	+	250MG	N021875	004	Jun 15, 2007	Oct CTEC

ASENAPINE MALEATE

TABLET; SUBLINGUAL  
SAPHRIS

	FOREST LABS INC	EQ 5MG BASE	N022117	001	Aug 13, 2009	Feb CAHN
	+	EQ 10MG BASE	N022117	002	Aug 13, 2009	Feb CAHN

ASPIRIN; BUTALBITAL; CAFFEINE

TABLET; ORAL

BUTALBITAL, ASPIRIN AND CAFFEINE

AA	+	HIKMA INTL PHARMS	325MG; 50MG; 40MG	A086162	002	Feb 16, 1984	Aug CAHN
----	---	-------------------	-------------------	---------	-----	--------------	----------

ASPIRIN; BUTALBITAL; CAFFEINE; CODEINE PHOSPHATE

CAPSULE; ORAL

BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE

	@ WATSON LABS	325MG; 50MG; 40MG; 30MG	A074359	001	Aug 31, 1995	Mar DISC
--	---------------	-------------------------	---------	-----	--------------	----------

ASPIRIN; CAFFEINE; ORPHENADRINE CITRATE

TABLET; ORAL

ORPHENADRINE CITRATE, ASPIRIN, AND CAFFEINE

	@ STEVENS J	385MG; 30MG; 25MG	A074988	001	Apr 30, 1999	Mar DISC
	@	770MG; 60MG; 50MG	A074988	002	Apr 30, 1999	Mar DISC

ASPIRIN; CARISOPRODOL; CODEINE PHOSPHATE

TABLET; ORAL

CARISOPRODOL, ASPIRIN AND CODEINE PHOSPHATE

	@ MIRROR PHARMS	325MG; 200MG; 16MG	A040860	001	Jan 07, 2010	Mar DISC
	@ PROSAM LABS	325MG; 200MG; 16MG	A040283	001	Dec 29, 1998	Mar DISC

ASPIRIN; OXYCODONE HYDROCHLORIDE; OXYCODONE TEREPHTHALATE

TABLET; ORAL

OXYCODONE AND ASPIRIN

	@ WATSON LABS	325MG; 4.5MG; 0.38MG	A040255	001	Feb 27, 1998	May DISC
--	---------------	----------------------	---------	-----	--------------	----------

ATAZANAVIR SULFATE

CAPSULE; ORAL

ATAZANAVIR SULFATE

	TEVA PHARMS USA	EQ 100MG BASE	A091673	001	Apr 22, 2014	Aug CTEC
AB		EQ 100MG BASE	A091673	001	Apr 22, 2014	Apr NEWA
AB		EQ 150MG BASE	A091673	002	Apr 22, 2014	Apr NEWA
AB		EQ 200MG BASE	A091673	003	Apr 22, 2014	Apr NEWA

## CAPSULE;ORAL

ATAZANAVIR SULFATE							
AB		EQ 300MG BASE	A091673	004	Apr 22, 2014	Apr	NEWA
REYATAZ							
AB	BRISTOL MYERS SQUIBB	EQ 150MG BASE	N021567	002	Jun 20, 2003	Apr	CFTG
AB		EQ 200MG BASE	N021567	003	Jun 20, 2003	Apr	CFTG
AB	+	EQ 300MG BASE	N021567	004	Oct 16, 2006	Apr	CFTG
POWDER;ORAL							
REYATAZ							
+	BRISTOL MYERS SQUIBB	EQ 50MG BASE/PACKET	N206352	001	Jun 02, 2014	Jun	NEWA

ATENOLOL

## TABLET;ORAL

ATENOLOL							
AB	MYLAN	50MG	A073457	003	Jan 24, 1992	Apr	CMS1
AB	SUN PHARM INDS INC	25MG	A078210	001	Jul 10, 2007	Jul	CAHN
AB		50MG	A078210	002	Jul 10, 2007	Jul	CAHN
AB		100MG	A078210	003	Jul 10, 2007	Jul	CAHN

ATOVAQUONE

## SUSPENSION;ORAL

ATOVAQUONE							
AB	AMNEAL PHARMS	750MG/5ML	A202960	001	Mar 18, 2014	Mar	NEWA
AB	+	GLAXOSMITHKLINE LLC	N020500	001	Feb 08, 1995	Mar	CFTG

ATOVAQUONE; PROGUANIL HYDROCHLORIDE

## TABLET;ORAL

ATOVAQUONE AND PROGUANIL HYDROCHLORIDE							
AB	MYLAN PHARMS INC	62.5MG;25MG	A202362	001	May 27, 2014	May	NEWA
AB		250MG;100MG	A202362	002	May 27, 2014	May	NEWA
MALARONE PEDIATRIC							
AB	GLAXOSMITHKLINE	62.5MG;25MG	N021078	002	Jul 14, 2000	May	CTEC

ATRACURIUM BESYLATE

## INJECTABLE;INJECTION

		ATRACURIUM BESYLATE							
AP	+	EUROHLTH INTL	10MG/ML	A074901	001	Jul 18, 1997	Aug	CAHN	
		ATRACURIUM BESYLATE PRESERVATIVE FREE							
AP	+	EUROHLTH INTL	10MG/ML	A074900	001	Jul 18, 1997	Aug	CAHN	

ATROPINE SULFATE

## INJECTABLE;INTRAMUSCULAR, INTRAVENOUS, SUBCUTANEOUS

ATROPINE SULFATE ANSYR PLASTIC SYRINGE							
+	HOSPIRA	0.05MG/ML	N021146	002	Jul 09, 2001	May	CRLD
SOLUTION/DROPS;OPHTHALMIC							
ATROPINE SULFATE							
	AKORN	1%	N206289	001	Jul 18, 2014	Jul	NEWA

AZATHIOPRINE

## TABLET;ORAL

AZATHIOPRINE								
>A>	AB	AMNEAL PHARMS LLC	50MG	A074069	001	Feb 16, 1996	Dec	CAHN
>D>	AB	ROXANE	50MG	A074069	001	Feb 16, 1996	Dec	CAHN

AZATHIOPRINE SODIUM

## INJECTABLE;INJECTION

AZATHIOPRINE SODIUM							
+	EUROHLTH INTL	EQ 100MG BASE/VIAL	A074419	001	Mar 31, 1995	Aug	CAHN

AZELASTINE HYDROCHLORIDE

## SPRAY;NASAL

AZELASTINE HYDROCHLORIDE							
AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Apr	NEWA
SPRAY, METERED;NASAL							
AZELASTINE HYDROCHLORIDE							
AB	PERRIGO ISRAEL	EQ 0.1876MG BASE/SPRAY	A202743	001	May 08, 2014	Jun	CDFR
AB	ROXANE	EQ 0.125MG BASE/SPRAY	A091444	001	Oct 24, 2014	Oct	NEWA

AZILSARTAN KAMEDOXOMIL

TABLET; ORAL

EDARBI

ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL	N200796	001	Feb 25, 2011	Feb CAHN
+	EQ 80MG MEDOXOMIL	N200796	002	Feb 25, 2011	Feb CAHN

AZILSARTAN KAMEDOXOMIL; CHLORTHALIDONE

TABLET; ORAL

EDARBYCLOR

ARBOR PHARMS IRELAND	EQ 40MG MEDOXOMIL;12.5MG	N202331	001	Dec 20, 2011	Feb CAHN
+	EQ 40MG MEDOXOMIL;25MG	N202331	002	Dec 20, 2011	Feb CAHN

AZTREONAM

INJECTABLE; INJECTION

AZTREONAM

AP	EUROHLTH INTL	1GM/VIAL	A065286	001	Mar 23, 2011	Aug CAHN
AP		2GM/VIAL	A065286	002	Mar 23, 2011	Aug CAHN

BACITRACIN

INJECTABLE; INJECTION

BACITRACIN

AP	XELLIA PHARMS APS	50,000 UNITS/VIAL	A203177	001	Aug 25, 2014	Aug NEWA
	OINTMENT;OPHTHALMIC					
	BACITRACIN					
+	PERRIGO CO TENNESSEE	500 UNITS/GM	A061212	001		Feb CTEC

BACLOFEN

TABLET; ORAL

BACLOFEN

AB	SUN PHARM INDS INC	20MG	A077862	002	Aug 14, 2006	Jul CAHN
----	--------------------	------	---------	-----	--------------	----------

BECLOMETHASONE DIPROPIONATE

AEROSOL, METERED; NASAL

QNASL

>A>	TEVA BRANDED PHARM	0.04MG/ACTUATION	N202813	002	Dec 17, 2014	Dec NEWA
-----	--------------------	------------------	---------	-----	--------------	----------

BELINOSTAT

POWDER; IV (INFUSION)

BELEODAQ

+	SPECTRUM PHARMS	500MG/VIAL	N206256	001	Jul 03, 2014	Jul NEWA
---	-----------------	------------	---------	-----	--------------	----------

BENAZEPRIL HYDROCHLORIDE; HYDROCHLOROTHIAZIDE

TABLET; ORAL

BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB	APOTEX INC	5MG; 6.25MG	A078794	001	Aug 21, 2014	Aug NEWA
AB		10MG; 12.5MG	A078794	002	Aug 21, 2014	Aug NEWA
AB		20MG; 12.5MG	A078794	003	Aug 21, 2014	Aug NEWA
AB		20MG; 25MG	A078794	004	Aug 21, 2014	Aug NEWA

BENDROFLUMETHIAZIDE; NADOLOL

TABLET; ORAL

NADOLOL AND BENDROFLUMETHIAZIDE

AB	MYLAN	5MG; 40MG	A078688	001	Feb 15, 2008	Jan CTNA
AB		5MG; 80MG	A078688	002	Feb 15, 2008	Jan CTNA

BENZONATATE

CAPSULE; ORAL

BENZONATATE

AA	MIKART	150MG	A040851	002	Nov 09, 2009	Sep CTEC	
AA	SUN PHARM INDS INC	100MG	A040587	001	Mar 19, 2008	Jun CAHN	
AA		200MG	A040587	002	Mar 19, 2008	Jun CAHN	
AA	+	THE PHARMA NETWORK	100MG	A040627	001	Mar 30, 2007	Oct CRLD
AA	+		200MG	A040749	001	Jul 25, 2007	Oct CRLD
AA	+	THEPHARMANETWORK LLC	150MG	A201209	001	Sep 24, 2014	Oct CRLD
AA		150MG	A201209	001	Sep 24, 2014	Sep NEWA	
	TESSALON						
AA	PFIZER	100MG	N011210	001		Oct CRLD	
	@	200MG	N011210	003	Jun 25, 1999	Oct DISC	

BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE

GEL; TOPICAL							
ACANYA							
	+	DOW PHARM	2.5%;EQ 1.2% BASE	N050819	001	Oct 23, 2008	Nov CPOT
BENZACLIN							
AB	+	VALEANT BERMUDA	5%;EQ 1% BASE	N050756	001	Dec 21, 2000	Mar CRLD
	@		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Jul DISC
	+		5%;EQ 1% BASE	N050756	002	Apr 20, 2007	Mar CTEC
ONEXTON							
		DOW PHARM	3.75%;EQ 1.2% BASE	N050819	002	Nov 24, 2014	Nov NEWA

BEPOTASTINE BESILATE

SOLUTION/DROPS; OPHTHALMIC  
BEPREVE

+	BAUSCH AND LOMB INC	1.5%	N022288	001	Sep 08, 2009	Apr CAHN
---	---------------------	------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE

OINTMENT; TOPICAL  
CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE

>A> AB		PERRIGO ISRAEL	0.064%;0.005%	A200174	001	Dec 12, 2014	Dec NEWA
--------	--	----------------	---------------	---------	-----	--------------	----------

BETAMETHASONE DIPROPIONATE; CLOTRIMAZOLE

LOTION; TOPICAL  
LOTTRISONE

AB	+	MERCK SHARP DOHME	EQ 0.05% BASE;1%	N020010	001	Dec 08, 2000	Jan CAHN
----	---	-------------------	------------------	---------	-----	--------------	----------

BETAXOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC  
BETAXOLOL HYDROCHLORIDE

AT		IGI LABS INC	EQ 0.5% BASE	A075630	001	Apr 12, 2001	Sep CAHN
----	--	--------------	--------------	---------	-----	--------------	----------

BETHANECHOL CHLORIDE

TABLET; ORAL  
BETHANECHOL CHLORIDE

	@	ACTAVIS ELIZABETH	5MG	A040552	001	Oct 28, 2004	Jul CAHN
	@		10MG	A040553	001	Oct 28, 2004	Jul CAHN
	@		25MG	A040554	001	Oct 28, 2004	Jul CAHN
	@		50MG	A040551	001	Oct 28, 2004	Jul CAHN
AA		SUN PHARM INDS INC	5MG	A040897	001	Apr 22, 2009	Jun CAHN
AA			10MG	A040897	002	Apr 22, 2009	Jun CAHN
AA			25MG	A040897	003	Apr 22, 2009	Jun CAHN
AA			50MG	A040897	004	Apr 22, 2009	Jun CAHN
DUVOID							
	@	WELLSPRING PHARM	10MG	A086262	001		Mar DISC
	@		25MG	A086263	001		Mar DISC
	@		50MG	A085882	003		Mar DISC

BEXAROTENE

CAPSULE; ORAL  
BEXAROTENE

	@	BANNER PHARMACAPS	75MG	A203174	001	Aug 12, 2014	Aug DISC
AB			75MG	A203174	001	Aug 12, 2014	Jul NEWA
TARGRETIN							
	+	VALEANT LUXEMBOURG	75MG	N021055	001	Dec 29, 1999	Aug CTEC
AB	+		75MG	N021055	001	Dec 29, 1999	Jul CFTG

BICALUTAMIDE

TABLET; ORAL  
BICALUTAMIDE

AB		ACTAVIS ELIZABETH	50MG	A078634	001	Aug 28, 2009	Aug CAHN
AB		ACTAVIS TOTOWA	50MG	A078634	001	Aug 28, 2009	Oct CAHN
	@	ROXANE	50MG	A078285	001	Mar 24, 2011	Jun DISC

BIMATOPROST

SOLUTION/DROPS; TOPICAL  
BIMATOPROST

AT		APOTEX INC	0.03%	A201894	001	Dec 01, 2014	Nov NEWA
LATISSE							
AT	+	ALLERGAN	0.03%	N022369	001	Dec 24, 2008	Nov CFTG

BISACODYL; POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE

FOR SOLUTION, TABLET, DELAYED RELEASE;ORAL HALFLYTELY @ BRAINTREE									
		5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	N021551	003	Jul 16, 2010	Sep	DISC		
		.86GM;N/A,5.6GM							
AA	+	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	N021551	003	Jul 16, 2010	Aug	CFTG		
		.86GM;N/A,5.6GM							
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE AND BISACODYL									
	+	NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	A202217	001	Aug 20, 2014	Sep	CRLD	
			.86GM;N/A,5.6GM						
PEG-3350, SODIUM CHLORIDE, SODIUM BICARBONATE, POTASSIUM CHLORIDE, AND BISACODYL									
AA		NOVEL LABS INC	5MG,N/A;N/A,210GM;N/A,0.74GM;N/A,2	A202217	001	Aug 20, 2014	Aug	NEWA	
			.86GM;N/A,5.6GM						

BISMUTH SUBCITRATE POTASSIUM; METRONIDAZOLE; TETRACYCLINE

CAPSULE;ORAL PYLERA									
	+	FOREST LABS INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Apr	CAHN	
	+	FOREST RES INST INC	140MG;125MG;125MG	N050786	001	Sep 28, 2006	Mar	CAHN	

BISMUTH SUBSALICYLATE; METRONIDAZOLE; TETRACYCLINE HYDROCHLORIDE

TABLET, CHEWABLE, TABLET, CAPSULE;ORAL HELIDAC									
	@	PROMETHEUS LABS	262.4MG,N/A,N/A;N/A,250MG,N/A;N/A,	N050719	001	Aug 15, 1996	Aug	DISC	
			N/A,500MG						

BISOPROLOL FUMARATE; HYDROCHLOROTHIAZIDE

TABLET;ORAL BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE									
	@	WATSON LABS	2.5MG;6.25MG	A075469	001	Sep 25, 2000	May	DISC	
	@		5MG;6.25MG	A075469	002	Sep 25, 2000	May	DISC	
	@		10MG;6.25MG	A075469	003	Sep 25, 2000	May	DISC	

BLEOMYCIN SULFATE

INJECTABLE;INJECTION BLEOMYCIN SULFATE									
AP		EUROHLTH INTL	EQ 15 UNITS BASE/VIAL	A065042	002	Oct 17, 2001	Aug	CAHN	
AP			EQ 30 UNITS BASE/VIAL	A065042	001	Oct 17, 2001	Aug	CAHN	

BRIMONIDINE TARTRATE

SOLUTION/DROPS;OPHTHALMIC BRIMONIDINE TARTRATE									
AT		INDOCO REMEDIES	0.2%	A091691	001	Nov 18, 2014	Nov	NEWA	

BROMFENAC SODIUM

SOLUTION/DROPS;OPHTHALMIC BROMDAY									
AT	+	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Apr	CAHN	
AT	+	ISTA PHARMS INC	EQ 0.09% ACID	N021664	002	Oct 16, 2010	Jan	CFTG	
BROMFENAC SODIUM									
AT1		APOTEX INC	EQ 0.09% ACID	A202435	001	Jun 19, 2014	Jun	NEWA	
AT			EQ 0.09% ACID	A202620	001	Jun 23, 2014	Jun	NEWA	
AT1		COASTAL PHARMS	EQ 0.09% ACID	A201211	001	May 11, 2011	Jan	CTEC	
AT		HI-TECH PHARMACAL	EQ 0.09% ACID	A203395	001	Jan 22, 2014	Jan	NEWA	
AT1		LUITPOLD	EQ 0.09% ACID	A202030	001	Jan 09, 2013	Jan	CTEC	
XIBROM									
	@	BAUSCH AND LOMB INC	EQ 0.09% ACID	N021664	001	Mar 24, 2005	Apr	CAHN	

BROMPHENIRAMINE MALEATE; DEXTROMETHORPHAN HYDROBROMIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

SYRUP;ORAL BROMFED-DM									
AA	+	WOCKHARDT	2MG/5ML;10MG/5ML;30MG/5ML	A088811	001	Jun 07, 1985	Jun	CTEC	
BROMPHENIRAMINE MALEATE, PSEUDOEPHEDRINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE									
AA		PADDOCK LLC	2MG/5ML;10MG/5ML;30MG/5ML	A205292	001	Jul 15, 2014	Jun	NEWA	
AA		VINTAGE PHARMS	2MG/5ML;10MG/5ML;30MG/5ML	A202940	001	Jul 21, 2014	Jul	NEWA	



BUDESONIDEAEROSOL, FOAM;RECTAL  
UCERIS+ SALIX PHARMS INC 2MG/ACTUATION  
+ 2MGN205613 001 Oct 07, 2014 Nov CPOT  
N205613 001 Oct 07, 2014 Oct NEWACAPSULE;ORAL  
BUDESONIDE

AB BARR LABS DIV TEVA 3MG

A090379 001 Apr 02, 2014 Mar NEWA

SPRAY, METERED;NASAL  
BUDESONIDE

AB APOTEX INC 0.032MG/INH

A078949 001 May 12, 2014 Apr NEWA

RHINOCORT

&gt;D&gt; AB + ASTRAZENECA 0.032MG/INH

N020746 001 Oct 01, 1999 Dec CAHN

AB + 0.032MG/INH

N020746 001 Oct 01, 1999 Apr CFTG

&gt;D&gt; @ 0.064MG/INH

N020746 002 Oct 01, 1999 Dec CAHN

&gt;A&gt; AB + ASTRAZENECA PHARMS 0.032MG/INH

N020746 001 Oct 01, 1999 Dec CAHN

&gt;A&gt; @ 0.064MG/INH

N020746 002 Oct 01, 1999 Dec CAHN

SUSPENSION;INHALATION  
PULMICORT RESPULES

&gt;D&gt; AN ASTRAZENECA 0.25MG/2ML

N020929 001 Aug 08, 2000 Dec CAHN

&gt;D&gt; AN 0.5MG/2ML

N020929 002 Aug 08, 2000 Dec CAHN

&gt;D&gt; AN + 1MG/2ML

N020929 003 Aug 08, 2000 Dec CAHN

&gt;A&gt; AN ASTRAZENECA PHARMS 0.25MG/2ML

N020929 001 Aug 08, 2000 Dec CAHN

&gt;A&gt; AN 0.5MG/2ML

N020929 002 Aug 08, 2000 Dec CAHN

&gt;A&gt; AN + 1MG/2ML

N020929 003 Aug 08, 2000 Dec CAHN

TABLET, EXTENDED RELEASE;ORAL  
UCERIS

+ SALIX PHARMS INC 9MG

N203634 001 Jan 14, 2013 Feb CAHN

+ SANTARUS INC 9MG

N203634 001 Jan 14, 2013 Mar CAHN

BUPIVACAINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPIVACAINE HYDROCHLORIDE

@ HOSPIRA 0.75%

A070587 001 Mar 03, 1987 Jul DISC

BUPRENORPHINE

FILM, EXTENDED RELEASE;TRANSDERMAL

BUTRANS

PURDUE PHARMA LP 7.5MCG/HR

N021306 005 Jun 30, 2014 Jun NEWA

BUPRENORPHINE HYDROCHLORIDE

INJECTABLE;INJECTION

BUPRENORPHINE HYDROCHLORIDE

AP EUROHLTH INTL EQ 0.3MG BASE/ML

A076931 001 Mar 02, 2005 Aug CAHN

BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE

FILM;BUCCAL

BUNAVAIL

BIODELIVERY SCI INTL EQ 2.1MG BASE;EQ 0.3MG BASE

N205637 001 Jun 06, 2014 Jun NEWA

EQ 4.2MG BASE;EQ 0.7MG BASE

N205637 002 Jun 06, 2014 Jun NEWA

+ EQ 6.3MG BASE;EQ 1MG BASE

N205637 003 Jun 06, 2014 Jun NEWA

TABLET;SUBLINGUAL

BUPRENORPHINE HYDROCHLORIDE AND NALOXONE HYDROCHLORIDE

AB ROXANE EQ 2MG BASE;EQ 0.5MG BASE

A203326 001 Jun 27, 2014 Jun NEWA

AB EQ 8MG BASE;EQ 2MG BASE

A203326 002 Jun 27, 2014 Jun NEWA

AB TEVA PHARMS USA EQ 2MG BASE;EQ 0.5MG BASE

A091149 001 Sep 08, 2014 Aug NEWA

AB EQ 8MG BASE;EQ 2MG BASE

A091149 002 Sep 08, 2014 Aug NEWA

ZUBSOLV

&gt;A&gt; OREXO AB EQ 8.6MG BASE;EQ 2.1MG BASE

N204242 003 Dec 11, 2014 Dec NEWA

&gt;A&gt; EQ 11.4MG BASE;EQ 2.9MG BASE

N204242 004 Dec 11, 2014 Dec NEWA

BUPROPION HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL

BUPROPION HYDROCHLORIDE

AB1 JUBILANT GENERICS 100MG

A202774 001 Oct 11, 2013 Jul CAHN

AB1 150MG

A202774 002 Oct 11, 2013 Jul CAHN

AB2 150MG

A202775 001 Oct 11, 2013 Aug CAHN

AB1 200MG

A202774 003 Oct 11, 2013 Jul CAHN

&gt;A&gt; AB3 SUN PHARMA GLOBAL 150MG

A200695 001 Dec 18, 2014 Dec NEWA

AB1 TORRENT PHARMS LTD 100MG

A203969 001 Oct 31, 2014 Oct NEWA

AB1 150MG

A203969 002 Oct 31, 2014 Oct NEWA

TABLET, EXTENDED RELEASE;ORAL  
BUPROPION HYDROCHLORIDE

AB1		200MG	A203969	003	Oct 31, 2014	Oct NEWA
AB3	ZYDUS PHARMS USA INC	300MG	A201567	001	Jan 17, 2014	Jan NEWA

BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL  
CONTRAVE

+	TAKEDA PHARMS USA	90MG;8MG	N200063	001	Sep 10, 2014	Sep NEWA
---	-------------------	----------	---------	-----	--------------	----------

BUSPIRONE HYDROCHLORIDE

TABLET;ORAL  
BUSPIRONE HYDROCHLORIDE

>A>	AB	ACCORD HLTHCARE	5MG	A202557	001	Dec 30, 2014	Dec NEWA
>A>	AB		7.5MG	A202557	002	Dec 30, 2014	Dec NEWA
>A>	AB		10MG	A202557	003	Dec 30, 2014	Dec NEWA
>A>	AB		15MG	A202557	004	Dec 30, 2014	Dec NEWA
>A>	AB		30MG	A202557	005	Dec 30, 2014	Dec NEWA
	AB	STRIDES ARCOLAB LTD	5MG	A202330	001	Aug 25, 2014	Aug NEWA
	AB		10MG	A202330	002	Aug 25, 2014	Aug NEWA
	AB		15MG	A202330	003	Aug 25, 2014	Aug NEWA
	AB		30MG	A202330	004	Aug 25, 2014	Aug NEWA
	AB	ZYDUS PHARMS USA INC	5MG	A078888	001	Feb 07, 2014	Jan NEWA
	AB		10MG	A078888	002	Feb 07, 2014	Jan NEWA
	AB		15MG	A078888	003	Feb 07, 2014	Jan NEWA
	AB		30MG	A078888	004	Feb 07, 2014	Jan NEWA

BUTENAFINE HYDROCHLORIDE

CREAM;TOPICAL  
MENTAX-TC

@	MYLAN	1%	N021408	001	Oct 17, 2002	Jun DISC
---	-------	----	---------	-----	--------------	----------

BUTOCONAZOLE NITRATE

CREAM;VAGINAL  
GYNAZOLE-1

@	ELAN PHARMA INTL LTD	2%	N019881	001	Feb 07, 1997	Nov CAHN
@	LUMARA HEALTH INC	2%	N019881	001	Feb 07, 1997	May CAHN

BUTORPHANOL TARTRATE

INJECTABLE;INJECTION  
BUTORPHANOL TARTRATE

@	HIKMA FARMACEUTICA	2MG/ML	A078247	001	Apr 29, 2009	May DISC
---	--------------------	--------	---------	-----	--------------	----------

CAFFEINE CITRATE

SOLUTION;INTRAVENOUS  
CAFCIT

AP	+	EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	001	Sep 21, 1999	Aug CAHN
		CAFFEINE CITRATE					

AP		EXELA PHARMA SCIENCE	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077233	001	Sep 21, 2006	Feb CAHN
----	--	----------------------	------------------------------------	---------	-----	--------------	----------

SOLUTION;ORAL  
CAFCIT

AA	+	EUROHLTH INTL	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	N020793	002	Apr 12, 2000	Aug CAHN
		CAFFEINE CITRATE					

AA		EXELA PHARMA SCS LLC	EQ 30MG BASE/3ML (EQ 10MG BASE/ML)	A077304	001	Sep 21, 2006	Feb CAHN
----	--	----------------------	------------------------------------	---------	-----	--------------	----------

CAFFEINE; ERGOTAMINE TARTRATE

TABLET;ORAL  
ERGOTAMINE TARTRATE AND CAFFEINE

AA		HIKMA INTL PHARMS	100MG;1MG	A040510	001	Sep 17, 2004	Sep CAHN
----	--	-------------------	-----------	---------	-----	--------------	----------

CALCIPOTRIENE

SOLUTION;TOPICAL  
CALCIPOTRIENE

>D>		@ HI TECH PHARMA	0.005%	A077579	001	Nov 19, 2009	Dec CMFD
>A>	AT		0.005%	A077579	001	Nov 19, 2009	Dec CMFD
		@	0.005%	A077579	001	Nov 19, 2009	May DISC
AT	+	TOLMAR	0.005%	A077029	001	Nov 20, 2009	Apr CRLD

CALCITONIN SALMON

INJECTABLE;INJECTION							
MIACALCIN							
	@ SEBELA IRELAND LTD	100 IU/ML	N017808	001	Jul 03, 1986	Sep	CAHN
	+	200 IU/ML	N017808	002	Mar 29, 1991	Sep	CAHN
SPRAY, METERED;NASAL							
MIACALCIN							
AB	+	SEBELA IRELAND LTD	200 IU/SPRAY	N020313	002	Aug 17, 1995	Sep CAHN

CALCITRIOL

CAPSULE;ORAL							
CALCITRIOL							
>A> AB	STRIDES ARCOLAB LTD	0.25MCG	A091356	001	Dec 12, 2014	Dec	NEWA
>A> AB		0.5MCG	A091356	002	Dec 12, 2014	Dec	NEWA
INJECTABLE;INJECTION							
CALCITRIOL							
	@ TEVA PARENTERAL	0.002MG/ML	A075823	002	Mar 31, 2003	Feb	DISC

CALCIUM ACETATE

CAPSULE;ORAL							
CALCIUM ACETATE							
AB	AMNEAL PHARMS	EQ 169MG CALCIUM	A201658	001	Oct 06, 2014	Sep	NEWA

CALCIUM CHLORIDE; DEXTROSE; POTASSIUM CHLORIDE; SODIUM CHLORIDE

INJECTABLE;INJECTION							
DEXTROSE 5% IN RINGER'S IN PLASTIC CONTAINER							
	@ BAXTER HLTHCARE	33MG/100ML;5GM/100ML;30MG/100ML;86	N016695	001		Jul	DISC
		0MG/100ML					

CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE

TABLET;ORAL							
INVOKAMET							
	JANSSSEN PHARMS	50MG;500MG	N204353	001	Aug 08, 2014	Aug	NEWA
		50MG;1GM	N204353	002	Aug 08, 2014	Aug	NEWA
		150MG;500MG	N204353	003	Aug 08, 2014	Aug	NEWA
	+	150MG;1GM	N204353	004	Aug 08, 2014	Aug	NEWA

CAPECITABINE

TABLET;ORAL							
CAPECITABINE							
AB	MYLAN PHARMS INC	150MG	A090943	001	Aug 08, 2014	Jul	NEWA
AB		500MG	A090943	002	Aug 08, 2014	Jul	NEWA

CAPTOPRIL

TABLET;ORAL							
CAPTOPRIL							
	@ DAVA PHARMS INC	12.5MG	A074423	001	Feb 13, 1996	May	CAHN
	@	25MG	A074423	002	Feb 13, 1996	May	CAHN
	@	50MG	A074423	003	Feb 13, 1996	May	CAHN
	@	100MG	A074423	004	Feb 13, 1996	May	CAHN
	@ WATSON LABS	12.5MG	A074451	001	Feb 13, 1996	Mar	DISC
	@	25MG	A074451	002	Feb 13, 1996	Mar	DISC
	@	50MG	A074451	003	Feb 13, 1996	Mar	DISC
	@	100MG	A074451	004	Feb 13, 1996	Mar	DISC

CAPTOPRIL; HYDROCHLOROTHIAZIDE

TABLET;ORAL							
CAPOZIDE 25/15							
	@ APOTHECON	25MG;15MG	N018709	001	Oct 12, 1984	Mar	DISC
CAPOZIDE 25/25							
	@ APOTHECON	25MG;25MG	N018709	002	Oct 12, 1984	Mar	DISC
CAPOZIDE 50/15							
	@ APOTHECON	50MG;15MG	N018709	004	Oct 12, 1984	Mar	DISC
CAPOZIDE 50/25							
	@ APOTHECON	50MG;25MG	N018709	003	Oct 12, 1984	Mar	DISC
CAPTOPRIL AND HYDROCHLOROTHIAZIDE							
AB	+	MYLAN	25MG;25MG	A074896	002	Dec 29, 1997	Mar CRLD
AB	+		50MG;15MG	A074896	004	Dec 29, 1997	Mar CRLD

CARBIDOPATABLET; ORAL  
CARBIDOPA

AB	AMERIGEN PHARMS LTD	25MG	A203261	001	Mar 10, 2014	Feb NEWA
AB	+ LODOSYN					
AB	+ ATON	25MG	N017830	001		Feb CFTG

CARBIDOPA; LEVODOPATABLET, ORALLY DISINTEGRATING; ORAL  
CARBIDOPA AND LEVODOPA

	@ IMPAX LABS	10MG;100MG	A090631	001	Jun 08, 2010	Aug DISC
	@	25MG;100MG	A090631	002	Jun 08, 2010	Aug DISC
	@	25MG;250MG	A090631	003	Jun 08, 2010	Aug DISC
AB	+ MYLAN	25MG;250MG	A078893	003	Sep 18, 2008	Aug CRLD
>D> AB	SUN PHARM INDS	10MG;100MG	A078690	001	Jul 31, 2009	Dec CAHN
>D> AB		25MG;100MG	A078690	002	Jul 31, 2009	Dec CAHN
>D> AB		25MG;250MG	A078690	003	Jul 31, 2009	Dec CAHN
>A> AB	SUN PHARMA GLOBAL	10MG;100MG	A078690	001	Jul 31, 2009	Dec CAHN
>A> AB		25MG;100MG	A078690	002	Jul 31, 2009	Dec CAHN
>A> AB		25MG;250MG	A078690	003	Jul 31, 2009	Dec CAHN
	PARCOPA					
	@ UCB INC	10MG;100MG	A076699	001	Aug 27, 2004	Aug DISC
	@	25MG;100MG	A076699	002	Aug 27, 2004	Aug DISC
	@	25MG;250MG	A076699	003	Aug 27, 2004	Aug DISC

CARBINOXAMINE MALEATESOLUTION; ORAL  
CARBINOXAMINE MALEATE

AA	VINTAGE PHARMS	4MG/5ML	A040814	001	Feb 26, 2008	Feb CAHN
	TABLET; ORAL					
	CARBINOXAMINE MALEATE					
AA	MISSION PHARMACAL CO	4MG	A090756	001	May 27, 2011	Sep CAHN
AA	VINTAGE PHARMS	4MG	A040639	002	May 30, 2008	Feb CAHN

CARBOPLATININJECTABLE; INJECTION  
CARBOPLATIN

	@ BEDFORD	50MG/VIAL	A076099	001	Oct 14, 2004	May DISC
	@	150MG/VIAL	A076099	002	Oct 14, 2004	May DISC
	@	450MG/VIAL	A076099	003	Oct 14, 2004	May DISC
	@ CIPLA LTD	50MG/VIAL	A077383	001	Jan 27, 2006	May DISC
	@	150MG/VIAL	A077383	002	Jan 27, 2006	May DISC
	@	450MG/VIAL	A077383	003	Jan 27, 2006	May DISC
	@ EUROHLTH INTL	50MG/VIAL	A076099	001	Oct 14, 2004	Aug CAHN
	@	150MG/VIAL	A076099	002	Oct 14, 2004	Aug CAHN
	@	450MG/VIAL	A076099	003	Oct 14, 2004	Aug CAHN
	@ FRESENIUS KABI USA	50MG/VIAL	A076235	001	Oct 14, 2004	May DISC
	@	150MG/VIAL	A076235	002	Oct 14, 2004	May DISC
	@	450MG/VIAL	A076235	003	Oct 14, 2004	May DISC
	@ ONCO THERAPIES LTD	50MG/VIAL	A091510	001	May 29, 2012	May DISC
	@	150MG/VIAL	A091510	002	May 29, 2012	May DISC
	@	450MG/VIAL	A091510	003	May 29, 2012	May DISC
	@ SANDOZ	50MG/VIAL	A076959	001	Mar 18, 2005	May DISC
	@	150MG/VIAL	A076959	002	Mar 18, 2005	May DISC
	@	450MG/VIAL	A076959	003	Mar 18, 2005	May DISC
	@ WATSON LABS	50MG/VIAL	A076162	001	Oct 14, 2004	May DISC
	@	150MG/VIAL	A076162	002	Oct 14, 2004	May DISC
	@	450MG/VIAL	A076162	003	Oct 14, 2004	May DISC

INJECTABLE; IV (INFUSION)  
CARBOPLATIN

AP	ACTAVIS ELIZABETH	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Aug CAHN
AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Aug CAHN
AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Aug CAHN
AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Aug CAHN
AP	ACTAVIS TOTOWA	50MG/5ML (10MG/ML)	A078732	001	Feb 06, 2012	Oct CAHN
AP		150MG/15ML (10MG/ML)	A078732	002	Feb 06, 2012	Oct CAHN
AP		450MG/45ML (10MG/ML)	A078732	003	Feb 06, 2012	Oct CAHN
AP		600MG/60ML (10MG/ML)	A078732	004	Feb 06, 2012	Oct CAHN
AP	EUROHLTH INTL	50MG/5ML (10MG/ML)	A077244	001	Oct 15, 2004	Aug CAHN
AP		150MG/15ML (10MG/ML)	A077244	002	Oct 15, 2004	Aug CAHN
AP		450MG/45ML (10MG/ML)	A077244	003	Oct 15, 2004	Aug CAHN
AP		600MG/60ML (10MG/ML)	A077244	004	Jan 20, 2006	Aug CAHN

## INJECTABLE;IV (INFUSION)

## CARBOPLATIN

AP	+	PHARMACHEMIE BV	50MG/5ML (10MG/ML)	A077269	001	Oct 14, 2004	Feb CAHN
AP	+		150MG/15ML (10MG/ML)	A077269	002	Oct 14, 2004	Feb CAHN
AP	+		450MG/45ML (10MG/ML)	A077269	003	Oct 14, 2004	Feb CAHN
AP	+		600MG/60ML (10MG/ML)	A077269	004	Dec 28, 2007	Feb CAHN

CARISOPRODOL

## TABLET;ORAL

## CARISOPRODOL

	@	HIKMA INTL PHARMS	350MG	A040124	001	Jan 24, 1996	Oct CAHN
AA		NATCO PHARMA LTD	350MG	A090988	001	Oct 28, 2014	Oct NEWA
AA		ORIENT PHARMA CO LTD	350MG	A205085	001	Oct 28, 2014	Oct NEWA
AA		SCIEGEN PHARMS INC	350MG	A203374	001	Jan 27, 2014	Jan NEWA

CARVEDILOL

## TABLET;ORAL

## CARVEDILOL

AB		SUN PHARM INDS INC	3.125MG	A077346	004	Sep 05, 2007	Jul CAHN
AB			6.25MG	A077346	001	Sep 05, 2007	Jul CAHN
AB			12.5MG	A077346	002	Sep 05, 2007	Jul CAHN
AB			25MG	A077346	003	Sep 05, 2007	Jul CAHN

CEFACLOL

## FOR SUSPENSION;ORAL

## CEFACLOL

AB	+	YUNG SHIN PHARM	EQ 375MG BASE/5ML	A065412	004	Feb 17, 2012	Jan CRLD
----	---	-----------------	-------------------	---------	-----	--------------	----------

CEFADROXIL/CEFADROXIL HEMIHYDRATE

## FOR SUSPENSION;ORAL

## CEFADROXIL

## @ ANI PHARMS INC

## @

## @

## @

## @

## @

			EQ 125MG BASE/5ML	A062698	001	Mar 01, 1989	Jan CAHN
			EQ 250MG BASE/5ML	A062698	002	Mar 01, 1989	Jan CAHN
			EQ 250MG BASE/5ML	A065278	001	Jan 20, 2006	Jan CAHN
			EQ 500MG BASE/5ML	A062698	003	Mar 01, 1989	Jan CAHN
			EQ 500MG BASE/5ML	A065278	002	Jan 20, 2006	Jan CAHN

CEFAZOLIN SODIUM

## INJECTABLE;INJECTION

## CEFAZOLIN SODIUM

AP		ACS DOBFAR	EQ 20GM BASE/VIAL	A065306	002	Aug 18, 2014	Aug NEWA
	@	STERI PHARMA	EQ 1GM BASE/VIAL	A063208	001	Dec 27, 1991	Mar DISC
>D> AP			EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991	Dec DISC
>A>	@		EQ 500MG BASE/VIAL	A063216	001	Dec 27, 1991	Dec DISC

CEFTAZIDIME

## INJECTABLE;INJECTION

## FORTAZ

AP	+	COVIS INJECTABLES	1GM/VIAL	N050578	002	Jul 19, 1985	May CAHN
AP	+		2GM/VIAL	N050578	003	Jul 19, 1985	May CAHN
AP	+		6GM/VIAL	N050578	004	Jul 19, 1985	May CAHN
AP	+		500MG/VIAL	N050578	001	Jul 19, 1985	May CAHN

CEFTAZIDIME SODIUM

## INJECTABLE;INJECTION

## FORTAZ IN PLASTIC CONTAINER

## @ COVIS INJECTABLES

## +

## +

			EQ 10MG BASE/ML	N050634	001	Apr 28, 1989	Apr CAHN
			EQ 20MG BASE/ML	N050634	002	Apr 28, 1989	Apr CAHN
			EQ 40MG BASE/ML	N050634	003	Apr 28, 1989	Apr CAHN

CEFTIBUTEN DIHYDRATE

## FOR SUSPENSION;ORAL

## CEDAX

## + PERNIX THERAP

			EQ 180MG BASE/5ML	N050686	002	Dec 20, 1995	Oct CMFD
--	--	--	-------------------	---------	-----	--------------	----------

CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM

## POWDER;IV (INFUSION)

## ZERBAXA

>A>	+	CUBIST PHARMS	EQ 1GM BASE/VIAL;EQ 0.5GM BASE/VIAL	N206829	001	Dec 19, 2014	Dec NEWA
-----	---	---------------	-------------------------------------	---------	-----	--------------	----------

CEFTRIAXONE SODIUM

INJECTABLE;INJECTION  
CEFTRIAXONE

	@	AGILA SPECLTS	EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Aug DISC
AP			EQ 10GM BASE/VIAL	A091068	001	Jan 07, 2013	Feb CAHN
		SAMSON MEDCL	EQ 100GM BASE/VIAL	A090057	001	Apr 25, 2014	Apr NEWA

CEFTRIAXONE IN PLASTIC CONTAINER

+		BAXTER HLTHCARE	EQ 20MG BASE/ML	A065224	001	Aug 23, 2005	Sep CRLD
+			EQ 40MG BASE/ML	A065224	002	Aug 23, 2005	Sep CRLD

INJECTABLE;INTRAMUSCULAR, INTRAVENOUS  
CEFTRIAXONE

>D>	AP		TEVA PHARMS USA	EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	Dec DISC
>A>		@		EQ 1GM BASE/VIAL	A065227	003	Mar 15, 2007	Dec DISC
>D>	AP			EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	Dec DISC
>A>		@		EQ 2GM BASE/VIAL	A065227	004	Mar 15, 2007	Dec DISC
>D>	AP			EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	Dec DISC
>A>		@		EQ 250MG BASE/VIAL	A065227	001	Mar 15, 2007	Dec DISC
>D>	AP			EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	Dec DISC
>A>		@		EQ 500MG BASE/VIAL	A065227	002	Mar 15, 2007	Dec DISC

CEFUROXIME SODIUM

INJECTABLE;INJECTION  
CEFUROXIME SODIUM

>D>	AP		TEVA PHARMS	EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998	Dec DISC
>A>		@		EQ 7.5GM BASE/VIAL	A064191	001	Apr 16, 1998	Dec DISC

ZINACEF

AP	+		COVIS INJECTABLES	EQ 1.5GM BASE/VIAL	N050558	003	Oct 19, 1983	Apr CAHN
AP	+			EQ 7.5GM BASE/VIAL	N050558	004	Oct 23, 1986	Apr CAHN

ZINACEF IN PLASTIC CONTAINER

	@	COVIS INJECTABLES	EQ 15MG BASE/ML	N050643	001	Apr 28, 1989	May CAHN
+			EQ 30MG BASE/ML	N050643	002	Apr 28, 1989	May CAHN

CELECOXIB

CAPSULE;ORAL  
CELEBREX

AB		GD SEARLE	50MG	N020998	004	Dec 15, 2006	May CFTG
AB			100MG	N020998	001	Dec 31, 1998	May CFTG
AB			200MG	N020998	002	Dec 31, 1998	May CFTG
AB	+		400MG	N020998	003	Aug 29, 2002	May CFTG

CELECOXIB

AB		LUPIN LTD	50MG	A202240	001	Oct 29, 2014	Oct NEWA
AB		MYLAN PHARMS INC	50MG	A078857	001	May 30, 2014	May NEWA
AB		TEVA	50MG	A076898	001	May 30, 2014	May NEWA
AB			100MG	A076898	002	May 30, 2014	May NEWA
AB			200MG	A076898	003	May 30, 2014	May NEWA
AB			400MG	A076898	004	May 30, 2014	May NEWA

CEPHALEXIN

CAPSULE;ORAL  
CEPHALEXIN

	@	FACTA FARMA	EQ 250MG BASE	A062118	001		Jun DISC
	@		EQ 500MG BASE	A062118	002		Jun DISC
	@	STEVENS J	EQ 250MG BASE	A062870	001	Mar 17, 1988	Mar DISC

FOR SUSPENSION;ORAL

CEPHALEXIN

	@	FACTA FARMA	EQ 125MG BASE/5ML	A062117	002		Jun DISC
	@		EQ 250MG BASE/5ML	A062117	003		Jun DISC
	@	HIKMA PHARMS	EQ 125MG BASE/5ML	A065444	001	Aug 28, 2009	Sep DISC
	@		EQ 250MG BASE/5ML	A065444	002	Aug 28, 2009	Sep DISC
	@	RANBAXY	EQ 125MG BASE/5ML	A065081	001	Jul 27, 2001	Oct DISC
	@		EQ 250MG BASE/5ML	A065081	002	Jul 27, 2001	Oct DISC
AB	+	TEVA	EQ 250MG BASE/5ML	A062703	002	Feb 13, 1987	Sep CRLD
	@	YUNG SHIN PHARM	EQ 125MG BASE/5ML	A065336	001	Jul 25, 2007	Sep DISC
	@		EQ 250MG BASE/5ML	A065336	002	Jul 25, 2007	Sep DISC

CERITINIB

CAPSULE;ORAL  
ZYKADIA

+		NOVARTIS PHARMS CORP	150MG	N205755	001	Apr 29, 2014	Apr NEWA
---	--	----------------------	-------	---------	-----	--------------	----------

CETIRIZINE HYDROCHLORIDE

SYRUP;ORAL

CETIRIZINE HYDROCHLORIDE

AA	SUN PHARM INDS INC	5MG/5ML	A090191	001	Nov 12, 2009	Sep CAHN
----	--------------------	---------	---------	-----	--------------	----------

CEVIMELINE HYDROCHLORIDE

CAPSULE;ORAL

CEVIMELINE HYDROCHLORIDE

AB	PACK PHARMS LLC	30MG	A203775	001	Jun 04, 2014	May NEWA
----	-----------------	------	---------	-----	--------------	----------

CHLORDIAZEPOXIDE HYDROCHLORIDE

CAPSULE;ORAL

CHLORDIAZEPOXIDE HYDROCHLORIDE

@ WATSON LABS

5MG

A086383 001

May DISC

@

10MG

A086294 001

May DISC

@

25MG

A086382 001

May DISC

CHLOROPROCAINE HYDROCHLORIDE

INJECTABLE;INJECTION

CHLOROPROCAINE HYDROCHLORIDE

AP	EUROHLTH INTL	2%	A040273	001	Sep 09, 1998	Aug CAHN
----	---------------	----	---------	-----	--------------	----------

AP		3%	A040273	002	Sep 09, 1998	Aug CAHN
----	--	----	---------	-----	--------------	----------

CHLOROTHIAZIDE

TABLET;ORAL

CHLOROTHIAZIDE

@ HIKMA INTL PHARMS

250MG

A086028 001 Jul 14, 1982

Oct CAHN

@

500MG

A087736 001 Jul 14, 1982

Oct CAHN

CHLOROTHIAZIDE SODIUM

INJECTABLE;INJECTION

CHLOROTHIAZIDE SODIUM

AP	MYLAN INSTITUTIONAL	EQ 500MG BASE/VIAL	A202493	001	Jun 18, 2014	Jun NEWA
----	---------------------	--------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE MALEATE; HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	TRIS PHARMA INC	4MG/5ML;5MG/5ML;60MG/5ML	A203838	001	Nov 26, 2014	Nov NEWA
----	-----------------	--------------------------	---------	-----	--------------	----------

HYDROCODONE BITARTRATE, CHLORPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE HYDROCHLORIDE

AA	PADDOCK LLC	4MG/5ML;5MG/5ML;60MG/5ML	A204627	001	Apr 29, 2014	Apr NEWA
----	-------------	--------------------------	---------	-----	--------------	----------

ZUTRIPRO

AA	+ CYPRESS PHARM	4MG/5ML;5MG/5ML;60MG/5ML	N022439	001	Jun 08, 2011	Apr CFTG
----	-----------------	--------------------------	---------	-----	--------------	----------

CHLORPHENIRAMINE POLISTIREX; HYDROCODONE POLISTIREX

CAPSULE, EXTENDED RELEASE;ORAL

TUSSICAPS

ECR PHARMA

EQ 4MG MALEATE;EQ 5MG BITARTRATE

A077273 002 Sep 24, 2007

Jul CAHN

+

EQ 8MG MALEATE;EQ 10MG BITARTRATE

A077273 001 Sep 24, 2007

Jul CAHN

SUSPENSION, EXTENDED RELEASE;ORAL

HYDROCODONE POLISTIREX AND CHLORPHENIRAMNE POLISTIREX

AB	NEOS THERAP INC	EQ 8MG MALEATE/5ML;EQ 10MG BITARTRATE/5ML	A091671	001	Jun 29, 2012	Sep CAHN
----	-----------------	---	---------	-----	--------------	----------

CHLORPROPAMIDE

TABLET;ORAL

CHLORPROPAMIDE

@ ANI PHARMS INC

100MG

A088768 001 Oct 11, 1984

Jan CAHN

@

100MG

A088812 001 Oct 19, 1984

Jan CAHN

@

100MG

A088840 001 Oct 25, 1984

Feb CAHN

@

100MG

A088918 001 Oct 16, 1984

Jan CAHN

AB		100MG	A088921	001	Apr 12, 1985	Jan CAHN
----	--	-------	---------	-----	--------------	----------

@

100MG

A089446 001 Nov 17, 1986

Jan CAHN

@

250MG

A088813 001 Oct 19, 1984

Jan CAHN

@

250MG

A088919 001 Oct 16, 1984

Jan CAHN

AB		250MG	A088922	001	Apr 12, 1985	Jan CAHN
----	--	-------	---------	-----	--------------	----------

@

250MG

A089447 001 Nov 17, 1986

Jan CAHN

@ TEVA PHARMS USA

250MG

A087353 001

Apr CAHN

GLUCAMIDE

@ ANI PHARMS INC

250MG

A088641 001 Oct 11, 1984

Jan CAHN

@ TEVA PHARMS USA

250MG

A088641 001 Oct 11, 1984

Apr CAHN

CHLORZOXAZONE

## TABLET; ORAL

## CHLORZOXAZONE

@	ACTAVIS ELIZABETH	250MG	A088928	001	May 08, 1987	Jun	CAHN
@		500MG	A040113	001	Sep 29, 1995	Aug	CAHN
@	WATSON LABS	500MG	A040137	001	Aug 09, 1996	May	DISC
@		500MG	A081040	001	Aug 22, 1989	May	DISC

CICLOPIROX

## CREAM; TOPICAL

## CICLOPIROX

AB	TARO	0.77%	A076790	001	Apr 12, 2005	Mar	CMFD
	@	0.77%	A076790	001	Apr 12, 2005	Feb	DISC

## GEL; TOPICAL

## LOPROX

AB	+ CNTY LINE PHARMS	0.77%	N020519	001	Jul 21, 1997	Jul	CAHN
----	--------------------	-------	---------	-----	--------------	-----	------

## SHAMPOO; TOPICAL

## CICLOPIROX

AT	ACTAVIS MID ATLANTIC	1%	A090490	001	Nov 24, 2009	Aug	CAHN
----	----------------------	----	---------	-----	--------------	-----	------

CILASTATIN SODIUM; IMIPENEM

## INJECTABLE; INJECTION

## PRIMAXIN

@	MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	A062756	001	Jan 08, 1987	Sep	DISC
@		EQ 500MG BASE/VIAL; 500MG/VIAL	A062756	002	Jan 08, 1987	Sep	DISC

## POWDER; INTRAMUSCULAR

## PRIMAXIN

	MERCK	EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep	CTEC
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	N050630	001	Dec 14, 1990	Sep	CDFR
	@	EQ 750MG BASE/VIAL; 750MG/VIAL	N050630	002	Dec 14, 1990	Sep	CDFR

## POWDER; INTRAVENOUS

## IMIPENEM AND CILASTATIN

AP	ACS DOBFAR	EQ 250MG BASE/VIAL; 250MG/VIAL	A090577	001	Dec 21, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090577	002	Dec 21, 2011	Sep	CDFR
AP	HOSPIRA INC	EQ 250MG BASE/VIAL; 250MG/VIAL	A090825	001	Nov 16, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A090825	002	Nov 16, 2011	Sep	CDFR
AP		EQ 500MG BASE/VIAL; 500MG/VIAL	A091007	001	Nov 16, 2011	Sep	CDFR
	PRIMAXIN						
AP	+ MERCK	EQ 250MG BASE/VIAL; 250MG/VIAL	N050587	001	Nov 26, 1985	Sep	CDFR
AP	+	EQ 500MG BASE/VIAL; 500MG/VIAL	N050587	002	Nov 26, 1985	Sep	CDFR

CILOSTAZOL

## TABLET; ORAL

## CILOSTAZOL

@	ACTAVIS ELIZABETH	100MG	A077028	002	Nov 26, 2004	Aug	CAHN
---	-------------------	-------	---------	-----	--------------	-----	------

CIMETIDINE

## TABLET; ORAL

## CIMETIDINE

	@	CYCLE PHARMS LTD	300MG	A074361	001	Dec 23, 1994	Sep	CAHN
	@		400MG	A074361	002	Dec 23, 1994	Sep	CAHN
	@		800MG	A074371	001	Dec 23, 1994	Sep	CAHN
	@	DAVA PHARMS INC	300MG	A074340	001	Jun 23, 1995	Jul	DISC
	@		400MG	A074340	002	Jun 23, 1995	Jul	DISC
	@		800MG	A074339	001	Jun 23, 1995	Sep	DISC
	@	IVAX SUB TEVA PHARMS	200MG	A074424	001	Jul 28, 1995	Jul	DISC
	@		300MG	A074424	002	Jul 28, 1995	Jul	DISC
	@		400MG	A074424	003	Jul 28, 1995	Jul	DISC
	@		800MG	A074424	004	Jul 28, 1995	Jul	DISC
AB	+	MYLAN	800MG	A074246	004	May 17, 1994	Jul	CRLD
	@	PLIVA	200MG	A074568	001	Feb 27, 1997	Jul	DISC
	@		300MG	A074568	002	Feb 27, 1997	Jul	DISC
	@		400MG	A074568	003	Feb 27, 1997	Jul	DISC

CIMETIDINE HYDROCHLORIDE

## SOLUTION; ORAL

## CIMETIDINE HYDROCHLORIDE

AA	ANI PHARMS INC	EQ 300MG BASE/5ML	A074610	001	Sep 26, 1996	Jan	CAHN	
	@	EQ 300MG BASE/5ML	A074859	001	Jul 09, 1998	Feb	CAHN	
	@	EQ 300MG BASE/5ML	A075110	001	Jun 18, 1998	Jan	CAHN	
	@	CYCLE PHARMS LTD	EQ 300MG BASE/5ML	A074541	001	Aug 05, 1997	Sep	CAHN



CIPROFLOXACINFOR SUSPENSION; ORAL  
CIPRO

AB	BAYER HLTHCARE	250MG/5ML	N020780	001	Sep 26, 1997	Feb CFTG
AB	+ CIPROFLOXACIN	500MG/5ML	N020780	002	Sep 26, 1997	Feb CFTG
AB	LUPIN LTD	250MG/5ML	A200563	001	Mar 05, 2014	Feb NEWA
AB		500MG/5ML	A200563	002	Mar 05, 2014	Feb NEWA

CIPROFLOXACIN HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
CIPROFLOXACIN HYDROCHLORIDE

AT	IGI LABS INC	EQ 0.3% BASE	A076754	001	Jun 09, 2004	Sep CAHN
AT	WATSON LABS INC	EQ 0.3% BASE	A076673	001	Jan 21, 2005	Apr CAHN

CISPLATININJECTABLE; INJECTION  
CISPLATIN

AP	EUROHLTH INTL	1MG/ML	A075036	001	Nov 07, 2000	Aug CAHN
AP	PHARMACHEMIE BV	1MG/ML	A074656	001	May 16, 2000	Feb CAHN

CITALOPRAM HYDROBROMIDETABLET; ORAL  
CITALOPRAM HYDROBROMIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A077032	001	Nov 12, 2004	Jul CAHN
AB		EQ 20MG BASE	A077032	002	Nov 12, 2004	Jul CAHN
AB		EQ 40MG BASE	A077032	003	Nov 12, 2004	Jul CAHN
	@ WATSON LABS	EQ 10MG BASE	A077034	001	Jun 30, 2005	May DISC
	@	EQ 20MG BASE	A077034	002	Jun 30, 2005	May DISC
	@	EQ 40MG BASE	A077034	003	Jun 30, 2005	May DISC

CLADRIBINEINJECTABLE; INJECTION  
CLADRIBINE

AP	EUROHLTH INTL	1MG/ML	A075405	001	Feb 28, 2000	Aug CAHN
----	---------------	--------	---------	-----	--------------	----------

CLINDAMYCIN PALMITATE HYDROCHLORIDEFOR SOLUTION; ORAL  
CLINDAMYCIN PALMITATE HYDROCHLORIDE

AA	AMNEAL PHARMS	EQ 75MG BASE/5ML	A203513	001	Mar 13, 2014	Feb NEWA
----	---------------	------------------	---------	-----	--------------	----------

CLINDAMYCIN PHOSPHATECREAM; VAGINAL  
CLINDESSE+ ELAN PHARMA INTL LTD EQ 2% BASE  
+ LUMARA HEALTH INC EQ 2% BASE

N050793	001	Nov 30, 2004	Nov CAHN
N050793	001	Nov 30, 2004	May CAHN

INJECTABLE; INJECTION  
CLINDAMYCIN PHOSPHATE

>A> AP	SAGENT PHARMS	EQ 150MG BASE/ML	A090108	001	Sep 30, 2011	Dec CAHN
>D> AP	SAGENT STRIDES	EQ 150MG BASE/ML	A090108	001	Sep 30, 2011	Dec CAHN

SOLUTION; TOPICAL  
CLINDAMYCIN PHOSPHATE

AB	ACTAVIS MID ATLANTIC	EQ 1% BASE	A062811	001	Sep 01, 1988	Apr CMFD
AT	G AND W LABS INC	EQ 1% BASE	A062811	001	Sep 01, 1988	Jun CTEC
AB		EQ 1% BASE	A062811	001	Sep 01, 1988	May CAHN
	@ VINTAGE PHARMS	EQ 1% BASE	A062930	001	Jun 28, 1989	Feb CAHN

CLOBETASOL PROPIONATEAEROSOL, FOAM; TOPICAL  
OLUX

AB1	+ DELCOR ASSET	0.05%	N021142	001	May 26, 2000	Jun CAHN
-----	----------------	-------	---------	-----	--------------	----------

CREAM; TOPICAL  
CLOBETASOL PROPIONATE

>D>	@ G AND W LABS INC	0.05%	A074139	001	Aug 03, 1994	Dec CMFD
>A> AB1		0.05%	A074139	001	Aug 03, 1994	Dec CMFD

CLONAZEPAMTABLET; ORAL  
CLONAZEPAM

AB	SUN PHARM INDS INC	0.5MG	A075423	001	Apr 27, 2001	Jul CAHN
AB		1MG	A075423	002	Apr 27, 2001	Jul CAHN
AB		2MG	A075423	003	Apr 27, 2001	Jul CAHN

TABLET, ORALLY DISINTEGRATING; ORAL  
CLONAZEPAM

AB	SUN PHARM INDS INC	0.125MG	A078654	001	Aug 27, 2014	Aug NEWA
AB		0.25MG	A078654	002	Aug 27, 2014	Aug NEWA
AB		0.5MG	A078654	003	Aug 27, 2014	Aug NEWA
AB		1MG	A078654	004	Aug 27, 2014	Aug NEWA
AB		2MG	A078654	005	Aug 27, 2014	Aug NEWA

CLONIDINEFILM, EXTENDED RELEASE; TRANSDERMAL  
CLONIDINE

AB	WATSON LABS INC	0.1MG/24HR	A090873	001	May 06, 2014	Apr NEWA
AB		0.2MG/24HR	A090873	002	May 06, 2014	Apr NEWA
AB		0.3MG/24HR	A090873	003	May 06, 2014	Apr NEWA

CLONIDINE HYDROCHLORIDEINJECTABLE; INJECTION  
CLONIDINE HYDROCHLORIDE

AP	ZYDUS PHARMS USA INC	1MG/10ML (0.1MG/ML)	A202601	001	Feb 20, 2014	Feb NEWA
AP		5MG/10ML (0.5MG/ML)	A202601	002	Feb 20, 2014	Feb NEWA

TABLET; ORAL

CLONIDINE HYDROCHLORIDE

AB	CARACO	0.1MG	A090329	001	Jul 03, 2014	Jun NEWA
AB		0.2MG	A090329	002	Jul 03, 2014	Jun NEWA
AB		0.3MG	A090329	003	Jul 03, 2014	Jun NEWA
AB	SUN PHARM INDS INC	0.1MG	A090329	001	Jul 03, 2014	Jul CAHN
AB		0.2MG	A090329	002	Jul 03, 2014	Jul CAHN
AB		0.3MG	A090329	003	Jul 03, 2014	Jul CAHN
	@ WATSON LABS	0.3MG	A070963	001	Jul 08, 1986	May DISC

TABLET, EXTENDED RELEASE; ORAL

CLONIDINE HYDROCHLORIDE

AB	ANCHEN PHARMS	0.1MG	A202983	001	Apr 02, 2014	Mar NEWA
AB		0.2MG	A202983	002	Apr 02, 2014	Mar NEWA

CLOPIDOGRELTABLET; ORAL  
CLOPIDOGREL

AB	AMNEAL PHARMS	75MG	A203751	001	Apr 11, 2014	Mar NEWA
----	---------------	------	---------	-----	--------------	----------

CLOPIDOGREL BISULFATE

TABLET; ORAL

CLOPIDOGREL BISULFATE

AB	ACTAVIS ELIZABETH	EQ 75MG BASE	A090307	001	May 28, 2013	Aug CAHN
AB	ACTAVIS TOTOWA	EQ 75MG BASE	A090307	001	May 28, 2013	Oct CAHN
AB	APOTEX INC	EQ 300MG BASE	A076274	002	Mar 04, 2014	Feb NEWA
AB	MACLEODS PHARMS LTD	EQ 75MG BASE	A202928	001	Feb 10, 2014	Jan NEWA
AB	SCIEGEN PHARMS INC	EQ 75MG BASE	A204165	001	Sep 15, 2014	Sep NEWA
AB		EQ 300MG BASE	A204165	002	Sep 15, 2014	Sep NEWA

CLORAZEPATE DIPOTASSIUM

TABLET; ORAL

CLORAZEPATE DIPOTASSIUM

@ WATSON LABS

3.75MG

A071852	001	Feb 09, 1988	May DISC
---------	-----	--------------	----------

@

7.5MG

A071853	001	Feb 09, 1988	May DISC
---------	-----	--------------	----------

@

15MG

A071854	001	Feb 09, 1988	May DISC
---------	-----	--------------	----------

CLOZAPINE

TABLET; ORAL

CLOZAPINE

AB	IVAX SUB TEVA PHARMS	12.5MG	A074949	003	Jul 31, 2003	Mar CTEC
AB		200MG	A076809	001	Dec 16, 2005	Mar CTEC
AB	MYLAN	12.5MG	A075417	003	Apr 15, 2010	Mar NEWA
AB		50MG	A075417	004	Apr 15, 2010	Mar NEWA
AB		200MG	A075417	005	Apr 15, 2010	Mar NEWA
AB	SUN PHARM INDS INC	25MG	A075713	001	Nov 15, 2002	Jul CAHN

TABLET;ORAL									
CLOZAPINE									
AB		50MG	A075713	003	Aug 19, 2005	Jul	CAHN		
AB		100MG	A075713	002	Nov 15, 2002	Jul	CAHN		
<u>COBICISTAT</u>									
TABLET;ORAL									
TYBOST									
+	GILEAD SCIENCES INC	150MG	N203094	001	Sep 24, 2014	Sep	NEWA		
<u>CODEINE PHOSPHATE; PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE, PHENYLEPHRINE HYDROCHLORIDE W/CODEINE PHOSPHATE									
>A> AA	HI-TECH PHARMA CO	10MG/5ML;5MG/5ML;6.25MG/5ML	A040674	001	Dec 23, 2014	Dec	NEWA		
<u>CODEINE PHOSPHATE; PROMETHAZINE HYDROCHLORIDE</u>									
SYRUP;ORAL									
PROMETHAZINE HYDROCHLORIDE AND CODEINE PHOSPHATE									
AA	SUN PHARM INDS INC	10MG/5ML;6.25MG/5ML	A090180	001	Mar 17, 2010	Sep	CAHN		
<u>CODEINE SULFATE</u>									
TABLET;ORAL									
CODEINE SULFATE									
AB	LANNETT HOLDINGS INC	15MG	A203046	001	Jun 13, 2014	Jun	NEWA		
AB		30MG	A203046	002	Jun 13, 2014	Jun	NEWA		
AB		60MG	A203046	003	Jun 13, 2014	Jun	NEWA		
AB	ROXANE	15MG	N022402	001	Jul 16, 2009	Jun	CFTG		
AB		30MG	N022402	002	Jul 16, 2009	Jun	CFTG		
AB	+	60MG	N022402	003	Jul 16, 2009	Jun	CFTG		
<u>COLCHICINE</u>									
CAPSULE;ORAL									
MITIGARE									
	HIKMA PHARMS LLC	0.6MG	N204820	001	Sep 26, 2014	Sep	NEWA		
<u>COLISTIMETHATE SODIUM</u>									
INJECTABLE;INJECTION									
COLISTIMETHATE SODIUM									
AP	SAGENT PHARMS	EQ 150MG BASE/VIAL	A201365	001	Feb 19, 2014	Feb	NEWA		
COLY-MYCIN M									
AP	+	PAR STERILE PRODUCTS	EQ 150MG BASE/VIAL	N050108	002		Apr	CAHN	
<u>COLISTIN SULFATE; HYDROCORTISONE ACETATE; NEOMYCIN SULFATE; THONZONIUM BROMIDE</u>									
SUSPENSION/DROPS;OTIC									
COLY-MYCIN S									
+	PAR STERILE PRODUCTS	EQ 3MG BASE/ML;10MG/ML;EQ 3.3MG BASE/ML;0.5MG/ML	N050356	001		Apr	CAHN		
<u>CONIVAPTAN HYDROCHLORIDE</u>									
INJECTABLE;IV (INFUSION)									
VAPRISOL									
	CUMBERLAND PHARMS	20MG/4ML (5MG/ML)	N021697	001	Dec 29, 2005	Feb	CAHN		
	VAPRISOL IN 5% DEXTROSE	IN PLASTIC CONTAINER							
+	CUMBERLAND PHARMS	20MG/100ML (0.2MG/ML)	N021697	002	Oct 08, 2008	Feb	CAHN		
<u>CORTISONE ACETATE</u>									
TABLET;ORAL									
CORTISONE ACETATE									
+	HIKMA INTL PHARMS	25MG	A080776	002		Sep	CAHN		
<u>COSYNTROPIN</u>									
SOLUTION;INTRAVENOUS									
COSYNTROPIN									
	@ SANDOZ	0.25MG/ML (0.25MG/ML)	N022028	001	Feb 21, 2008	Sep	DISC		
<u>CROMOLYN SODIUM</u>									
SOLUTION;INHALATION									
CROMOLYN SODIUM									
AN	MYLAN SPECLT	10MG/ML	A074209	001	Apr 26, 1994	May	CAHN		
	@ WATSON LABS	10MG/ML	A076469	001	Jun 17, 2005	May	DISC		

SOLUTION/DROPS;OPHTHALMIC							
CROMOLYN SODIUM							
AT	+	AKORN	4%	A074706	001	Apr 29, 1998	Jun CRLD
OPTICROM							
	@	ALLERGAN	4%	N018155	001	Oct 03, 1984	Jun DISC
<u>CYCLOPHOSPHAMIDE</u>							
INJECTABLE;INJECTION							
CYCLOPHOSPHAMIDE							
AP		JIANGSU HENGRUI MED	1GM/VIAL	A204555	002	Oct 31, 2014	Oct NEWA
AP			2GM/VIAL	A204555	003	Oct 31, 2014	Oct NEWA
AP			500MG/VIAL	A204555	001	Oct 31, 2014	Oct NEWA
NEOSAR							
	@	BEDFORD	1GM/VIAL	A087442	004	Jul 08, 1983	Sep CAHN
	@		2GM/VIAL	A087442	005	Mar 30, 1989	Sep CAHN
	@		100MG/VIAL	A087442	001	Feb 16, 1982	Sep CAHN
	@		200MG/VIAL	A087442	002	Feb 16, 1982	Sep CAHN
	@		500MG/VIAL	A087442	003	Feb 16, 1982	Sep CAHN
<u>CYCLOSPORINE</u>							
INJECTABLE;INJECTION							
CYCLOSPORINE							
AP		EUROHLTH INTL	50MG/ML	A065004	001	Oct 29, 1999	Aug CAHN
<u>CYSTEAMINE BITARTRATE</u>							
CAPSULE, DELAYED RELEASE;ORAL							
PROCYSBI							
		RAPTOR INC	EQ 25MG BASE	N203389	001	Apr 30, 2013	Aug CAHN
	+		EQ 75MG BASE	N203389	002	Apr 30, 2013	Aug CAHN
<u>CYTARABINE</u>							
INJECTABLE;INJECTION							
CYTARABINE							
AP		EUROHLTH INTL	1GM/VIAL	A074245	001	Aug 31, 1994	Aug CAHN
AP			2GM/VIAL	A074245	002	Aug 31, 1994	Aug CAHN
AP			100MG/VIAL	A071471	001	Aug 02, 1989	Aug CAHN
AP			500MG/VIAL	A071472	001	Aug 02, 1989	Aug CAHN
<u>DACARBAZINE</u>							
INJECTABLE;INJECTION							
DACARBAZINE							
AP		EUROHLTH INTL	200MG/VIAL	A075812	001	Jun 15, 2001	Aug CAHN
AP			500MG/VIAL	A075812	002	Oct 31, 2002	Aug CAHN
<u>DACTINOMYCIN</u>							
INJECTABLE;INJECTION							
DACTINOMYCIN							
AP		EUROHLTH INTL	0.5MG/VIAL	A090304	001	Mar 16, 2010	Aug CAHN
<u>DALBAVANCIN HYDROCHLORIDE</u>							
INJECTABLE;IV (INFUSION)							
DALVANCE							
	+	DURATA THERAPS INTL	EQ 500MG BASE/VIAL	N021883	001	May 23, 2014	May NEWA
<u>DANAPAROID SODIUM</u>							
INJECTABLE;INJECTION							
ORGARAN							
	@	AGI	750 UNITS/0.6ML	N020430	001	Dec 24, 1996	Nov CAHN
<u>DANTROLENE SODIUM</u>							
CAPSULE;ORAL							
DANTRIUM							
AB		PAR STERILE PRODUCTS	25MG	N017443	001		Mar CAHN
AB			50MG	N017443	003		Mar CAHN
AB	+		100MG	N017443	002		Mar CAHN
FOR SUSPENSION;INTRAVENOUS							
RYANODEX							
		EAGLE PHARMS	250MG/VIAL	N205579	001	Jul 22, 2014	Jul NEWA
INJECTABLE;INJECTION							
DANTRIUM							
AP	+	PAR STERILE PRODUCTS	20MG/VIAL	N018264	001		Apr CAHN

INJECTABLE; INJECTION								
REVONTO								
AP	US WORLDMEDS	20MG/VIAL	A078378	001	Jul 24, 2007	Mar	CTNA	
<u>DAPAGLIFLOZIN</u>								
TABLET; ORAL								
FARXIGA								
	ASTRAZENECA AB	5MG	N202293	001	Jan 08, 2014	Feb	CAHN	
+		10MG	N202293	002	Jan 08, 2014	Feb	CAHN	
	BRISTOL MYERS SQUIBB	5MG	N202293	001	Jan 08, 2014	Jan	NEWA	
+		10MG	N202293	002	Jan 08, 2014	Jan	NEWA	
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE</u>								
TABLET, EXTENDED RELEASE; ORAL								
XIGDUO XR								
	ASTRAZENECA AB	5MG; 1GM	N205649	002	Oct 29, 2014	Oct	NEWA	
		5MG; 500MG	N205649	001	Oct 29, 2014	Oct	NEWA	
+		10MG; 1GM	N205649	004	Oct 29, 2014	Oct	NEWA	
		10MG; 500MG	N205649	003	Oct 29, 2014	Oct	NEWA	
<u>DAPTOMYCIN</u>								
INJECTABLE; IV (INFUSION)								
CUBICIN								
AP	+ CUBIST	500MG/VIAL	N021572	002	Sep 12, 2003	Sep	CFTG	
DAPTOMYCIN								
AP	HOSPIRA INC	500MG/VIAL	A202857	001	Sep 12, 2014	Sep	NEWA	
>A>	<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVIR; RITONAVIR</u>							
>A>	TABLET, TABLET; ORAL							
>A>	VIEKIRA PAK (COPACKAGED)							
>A>	+	ABBVIE INC	EQ 250MG BASE, N/A, N/A, N/A; N/A, 12.5MG, 75MG, 50MG	N206619	001	Dec 19, 2014	Dec	NEWA
<u>DAUNORUBICIN HYDROCHLORIDE</u>								
INJECTABLE; INJECTION								
CERUBIDINE								
AP	+ EUROHLTH INTL	EQ 20MG BASE/VIAL	A064103	001	Feb 03, 1995	Aug	CAHN	
DAUNORUBICIN HYDROCHLORIDE								
AP	+ EUROHLTH INTL	EQ 5MG BASE/ML	N050731	001	Jan 30, 1998	Aug	CAHN	
<u>DECITABINE</u>								
INJECTABLE; INTRAVENOUS								
DECITABINE								
AP	SANDOZ	50MG/VIAL	A202969	001	Aug 28, 2014	Aug	NEWA	
POWDER; INTRAVENOUS								
DECITABINE								
+	SUN PHARMA GLOBAL	50MG/VIAL	N205582	001	Jan 28, 2014	Jan	NEWA	
<u>DEFEROXAMINE MESYLATE</u>								
INJECTABLE; INJECTION								
DEFEROXAMINE MESYLATE								
AP	EUROHLTH INTL	2GM/VIAL	A078086	002	May 30, 2007	Aug	CAHN	
AP		500MG/VIAL	A078086	001	May 30, 2007	Aug	CAHN	
	@ WATSON LABS	2GM/VIAL	A076806	002	Mar 31, 2006	May	DISC	
	@	500MG/VIAL	A076806	001	Mar 31, 2006	May	DISC	
<u>DESIPRAMINE HYDROCHLORIDE</u>								
TABLET; ORAL								
DESIPRAMINE HYDROCHLORIDE								
AB	ACTAVIS ELIZABETH	10MG	A074430	001	Feb 09, 1996	Aug	CAHN	
AB		25MG	A071601	001	Jun 05, 1987	Aug	CAHN	
AB		50MG	A071588	001	Jun 05, 1987	Aug	CAHN	
AB		75MG	A071602	001	Oct 05, 1987	Aug	CAHN	
AB		100MG	A071766	001	Oct 05, 1987	Aug	CAHN	
AB		150MG	A074430	002	Feb 09, 1996	Aug	CAHN	
AB	ACTAVIS TOTOWA	10MG	A074430	001	Feb 09, 1996	Oct	CAHN	
AB		25MG	A071601	001	Jun 05, 1987	Oct	CAHN	
AB		50MG	A071588	001	Jun 05, 1987	Oct	CAHN	
AB		75MG	A071602	001	Oct 05, 1987	Oct	CAHN	
AB		100MG	A071766	001	Oct 05, 1987	Oct	CAHN	
AB		150MG	A074430	002	Feb 09, 1996	Oct	CAHN	
	@ ANI PHARMS INC	25MG	A071800	001	Dec 08, 1987	Jan	CAHN	

TABLET;ORAL					
DESIPRAMINE HYDROCHLORIDE					
	@	50MG	A071801	001	Dec 08, 1987 Jan CAHN
	@	75MG	A071802	001	Dec 08, 1987 Jan CAHN
	@	100MG	A071803	001	May 29, 1997 Feb CAHN
	@	150MG	A071804	001	May 29, 1997 Feb CAHN
<u>DESLORATADINE</u>					
SOLUTION;ORAL					
CLARINEX					
	+	MERCK SHARP DOHME 0.5MG/ML	N021300	001	Sep 01, 2004 May CDFR
<u>DESMOPRESSIN ACETATE</u>					
INJECTABLE;INJECTION					
DDAVP					
AP	+	FERRING PHARMS INC 0.004MG/ML	N018938	001	Mar 30, 1984 Oct CAHN
	@	0.015MG/ML	N018938	002	Apr 25, 1995 Oct CAHN
SOLUTION;NASAL					
DDAVP					
AB	+	FERRING PHARMS INC 0.01%	N017922	001	Oct CAHN
SPRAY, METERED;NASAL					
DDAVP					
	@	FERRING PHARMS INC 0.01MG/SPRAY	N017922	002	Feb 06, 1989 Oct CAHN
DDAVP (NEEDS NO REFRIGERATION)					
AB	+	FERRING PHARMS INC 0.01MG/SPRAY	N017922	003	Aug 07, 1996 Oct CAHN
DESMOPRESSIN ACETATE (NEEDS NO REFRIGERATION)					
AB		SUN PHARMA GLOBAL 0.01MG/SPRAY	A078271	001	Dec 23, 2013 Jan CMS2
TABLET;ORAL					
DESMOPRESSIN ACETATE					
AB		MYLAN PHARMS INC 0.1MG	A200653	001	Jun 27, 2014 Jun NEWA
AB		0.2MG	A200653	002	Jun 27, 2014 Jun NEWA
<u>DESOGESTREL; ETHINYL ESTRADIOL</u>					
TABLET;ORAL-28					
KARIVA					
	+	BARR 0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002 Oct CTEC
AB	+	0.15MG,N/A;0.02MG,0.01MG	A075863	001	Apr 05, 2002 Sep CRLD
MIRCETTE					
	@	TEVA BRANDED PHARM 0.15MG,N/A;0.02MG,0.01MG	N020713	001	Apr 22, 1998 Sep DISC
<u>DESONIDE</u>					
AEROSOL, FOAM;TOPICAL					
VERDESO					
	+	AQUA PHARMS 0.05%	N021978	001	Sep 19, 2006 May CAHN
LOTION;TOPICAL					
DESONIDE					
AB		TARO 0.05%	A202161	001	Oct 31, 2014 Oct NEWA
<u>DESOXIMETASONE</u>					
OINTMENT;TOPICAL					
DESOXIMETASONE					
AB		VERSAPHARM INC 0.25%	A201005	001	Apr 24, 2014 Apr NEWA
<u>DESVENLAFAXINE</u>					
TABLET, EXTENDED RELEASE;ORAL					
DESVENLAFAXINE					
BC		SUN PHARMA GLOBAL 50MG	N205583	001	Jan 28, 2014 Jan NEWA
BC	+	100MG	N205583	002	Jan 28, 2014 Jan NEWA
<u>DESVENLAFAXINE FUMARATE</u>					
TABLET, EXTENDED RELEASE;ORAL					
DESVENLAFAXINE					
	+	SUN PHARMA GLOBAL EQ 50MG BASE	N205583	001	Jan 28, 2014 Jun CTNA
	+	EQ 100MG BASE	N205583	002	Jan 28, 2014 Jun CTNA
	@	TEVA PHARMS USA EQ 50MG BASE	N205208	001	Oct 11, 2013 Jun DISC
	+	EQ 50MG BASE	N205208	001	Oct 11, 2013 Jun CTNA
	@	EQ 100MG BASE	N205208	002	Oct 11, 2013 Jun DISC
	+	EQ 100MG BASE	N205208	002	Oct 11, 2013 Jun CTNA
DESVENLAFAXINE FUMARATE					
	+	SUN PHARMA GLOBAL EQ 50MG BASE	N205583	001	Jan 28, 2014 Feb CTEC
	+	EQ 100MG BASE	N205583	002	Jan 28, 2014 Feb CTEC

DESVENLAFAXINE SUCCINATE

TABLET, EXTENDED RELEASE;ORAL  
PRISTIQ

WYETH PHARMS INC EQ 25MG BASE N021992 003 Aug 20, 2014 Oct NEWA

DEXCHLORPHENIRAMINE MALEATE

TABLET;ORAL  
DEXCHLORPHENIRAMINE MALEATE  
@ ANI PHARMS INC 2MG

A088682 001 Jan 17, 1986 Jan CAHN

DEXLANSOPRAZOLE

CAPSULE, DELAYED RELEASE;ORAL  
DEXILANT

TAKEDA PHARMS USA 30MG  
+ 60MG

N022287 001 Jan 30, 2009 Jun CAHN  
N022287 002 Jan 30, 2009 Jun CAHN

DEXMEDETOMIDINE HYDROCHLORIDE

INJECTABLE;INJECTION  
DEXMEDETOMIDINE HYDROCHLORIDE

AP AKORN INC EQ 200MCG BASE/2ML (EQ 100MCG  
BASE/ML)

A202585 001 Nov 24, 2014 Nov NEWA

AP MYLAN INSTITUTIONAL EQ 200MCG BASE/2ML (EQ 100MCG  
BASE/ML)

A202881 001 Aug 18, 2014 Aug NEWA

AP PAR STERILE PRODUCTS EQ 200MCG BASE/2ML (EQ 100MCG  
BASE/ML)

A203972 001 Aug 18, 2014 Aug NEWA

PRECEDEX  
AP + HOSPIRA EQ 200MCG BASE/2ML (EQ 100MCG  
BASE/ML)

N021038 001 Dec 17, 1999 Aug CFTG

DEXMETHYLPHENIDATE HYDROCHLORIDE

CAPSULE, EXTENDED RELEASE;ORAL  
DEXMETHYLPHENIDATE HYDROCHLORIDE

AB TEVA PHARMS USA 15MG

A078908 004 May 19, 2014 May NEWA

AB 30MG

A202731 003 May 19, 2014 May NEWA

AB WATSON LABS INC 15MG

A079108 003 May 19, 2014 May NEWA

DEXRAZOXANE HYDROCHLORIDE

INJECTABLE;INJECTION  
DEXRAZOXANE HYDROCHLORIDE

AP EUROHLTH INTL EQ 250MG BASE/VIAL

A076068 001 Sep 28, 2004 Aug CAHN

AP EQ 500MG BASE/VIAL

A076068 002 Sep 28, 2004 Aug CAHN

DEXTROAMPHETAMINE SULFATE

TABLET;ORAL  
DEXTROAMPHETAMINE SULFATE

AA COREPHARMA 5MG

A090652 001 Mar 07, 2014 Feb NEWA

AA 10MG

A090652 002 Mar 07, 2014 Feb NEWA

DEXTROMETHORPHAN HYDROBROMIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP;ORAL  
PROMETH W/ DEXTROMETHORPHAN

@ ACTAVIS MID ATLANTIC 15MG/5ML;6.25MG/5ML

A088762 001 Oct 31, 1984 Sep DISC

PROMETHAZINE DM

AA + VINTAGE 15MG/5ML;6.25MG/5ML

A040649 001 Feb 14, 2006 Sep CRLD

PROMETHAZINE HYDROCHLORIDE AND DEXTROMETHORPHAN HYDROBROMIDE

@ AMNEAL PHARMS 15MG/5ML;6.25MG/5ML

A090575 001 Feb 08, 2011 Sep DISC

@ TRIS PHARMA INC 15MG/5ML;6.25MG/5ML

A091687 001 Jun 28, 2012 Sep DISC

DIAZEPAM

CONCENTRATE;ORAL  
DIAZEPAM

AA LANNETT HOLDINGS INC 5MG/ML

A204433 001 Apr 14, 2014 Mar NEWA

DIAZEPAM INTENSOL

AA + ROXANE 5MG/ML

A071415 001 Apr 03, 1987 Mar CFTG

GEL;RECTAL  
DIASTAT

VALEANT PHARMS NORTH 2.5MG/0.5ML (5MG/ML)

N020648 001 Jul 29, 1997 Nov CAHN

@ 5MG/ML (5MG/ML)

N020648 002 Jul 29, 1997 Nov CAHN

@ 10MG/2ML (5MG/ML)

N020648 003 Jul 29, 1997 Nov CAHN

@ 15MG/3ML (5MG/ML)

N020648 004 Jul 29, 1997 Nov CAHN

@ 20MG/4ML (5MG/ML)

N020648 005 Jul 29, 1997 Nov CAHN

GEL;RECTAL									
DIASTAT ACUDIAL									
	VALEANT PHARMS NORTH	10MG/2ML (5MG/ML)		N020648	007	Sep 15, 2005		Nov	CAHN
+		20MG/4ML (5MG/ML)		N020648	006	Sep 15, 2005		Nov	CAHN
TABLET;ORAL									
DIAZEPAM									
	@ DAVA PHARMS INC	2MG		A070226	001	Sep 26, 1985		Mar	DISC
<u>DICLOFENAC POTASSIUM</u>									
FOR SOLUTION;ORAL									
CAMBIA									
+	DEPOMED INC	50MG		N022165	001	Jun 17, 2009		Jan	CAHN
<u>DICLOFENAC SODIUM</u>									
>A>	SOLUTION;INTRAVENOUS								
>A>	DYLOJECT								
>A>	+	JAVELIN PHARMS INC	37.5MG/ML (37.5MG/ML)	N022396	001	Dec 23, 2014		Dec	NEWA
SOLUTION;TOPICAL									
DICLOFENAC SODIUM									
AT	APOTEX INC	1.5%		A202027	001	May 27, 2014		May	NEWA
AT	PADDOCK LLC	1.5%		A202393	001	Nov 24, 2014		Nov	NEWA
AT	TARO	1.5%		A203818	001	Nov 26, 2014		Nov	NEWA
AT	WATSON LABS INC	1.5%		A202852	001	Nov 24, 2014		Nov	NEWA
PENNSAID									
>A>	+	HORIZON PHARMA	2%	N204623	001	Jan 16, 2014		Dec	CAHN
>D>	AT	+	MALLINCKRODT	N020947	001	Nov 04, 2009		Dec	CAHN
	AT	+		N020947	001	Nov 04, 2009		May	CFTG
>D>	+	MALLINCKRODT INC	2%	N204623	001	Jan 16, 2014		Dec	CAHN
			2%	N204623	001	Jan 16, 2014		Jan	NEWA
>A>	AT	+	NUVO RES INC	N020947	001	Nov 04, 2009		Dec	CAHN
<u>DICLOFENAC SODIUM; MISOPROSTOL</u>									
TABLET, DELAYED RELEASE;ORAL									
DICLOFENAC SODIUM AND MISOPROSTOL									
AB	EAGLE PHARMS	50MG;0.2MG		A200540	001	Mar 14, 2014		Mar	NEWA
AB		75MG;0.2MG		A200540	002	Mar 14, 2014		Mar	NEWA
<u>DICYCLOMINE HYDROCHLORIDE</u>									
CAPSULE;ORAL									
BENTYL									
AB	+	FOREST LABS INC	10MG	N007409	003	Oct 15, 1984		Apr	CAHN
INJECTABLE;INJECTION									
BENTYL									
AP	+	FOREST LABS INC	10MG/ML	N008370	001	Oct 15, 1984		Apr	CAHN
BENTYL PRESERVATIVE FREE									
AP	+	FOREST LABS INC	10MG/ML	N008370	002	Oct 15, 1984		Apr	CAHN
DICYCLOMINE HYDROCHLORIDE (PRESERVATIVE-FREE)									
AP	EUROHLTH INTL	10MG/ML		A040465	001	Jun 30, 2003		Aug	CAHN
TABLET;ORAL									
BENTYL									
AB	+	FOREST LABS INC	20MG	N007409	001	Oct 15, 1984		Apr	CAHN
<u>DIGOXIN</u>									
INJECTABLE;INJECTION									
LANOXIN									
AP	+	COVIS INJECTABLES	0.25MG/ML	N009330	002			Apr	CAHN
LANOXIN PEDIATRIC									
+	COVIS INJECTABLES	0.1MG/ML		N009330	004			Apr	CAHN
TABLET;ORAL									
DIGOXIN									
AB	HIKMA INTL PHARMS	0.125MG		A077002	002	Oct 30, 2007		Sep	CAHN
AB		0.25MG		A077002	001	Oct 30, 2007		Sep	CAHN
	MYLAN PHARMS INC	0.125MG		A040282	001	Dec 23, 1999		Sep	CMFD
		0.25MG		A040282	002	Dec 23, 1999		Sep	CMFD
	@ SUN PHARM INDS INC	0.125MG		A076363	001	Jan 31, 2003		Jul	CAHN
	@	0.25MG		A076363	002	Jan 31, 2003		Jul	CAHN
LANOXIN									
	COVIS PHARMA	0.0625MG		N020405	001	Sep 30, 1997		Jan	CMFD
		0.1875MG		N020405	003	Sep 30, 1997		Jan	CMFD



DILTIAZEM HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
DILTIAZEM HYDROCHLORIDE

AB3	ACTAVIS ELIZABETH	360MG	A202463	001	Dec 07, 2012	Sep CAHN
	@ NESHER PHARMS	120MG	A076563	002	Sep 12, 2006	Mar DISC
	@	180MG	A076563	003	Sep 12, 2006	Mar DISC
	@	240MG	A076563	004	Sep 12, 2006	Mar DISC
	@	300MG	A076563	005	Sep 12, 2006	Mar DISC
	@	360MG	A076563	006	Sep 12, 2006	Mar DISC
	@	420MG	A076563	001	Sep 12, 2006	Mar DISC
INJECTABLE;INJECTION						
DILTIAZEM HYDROCHLORIDE						
	@ AGILA SPECLTS	5MG/ML	A075375	001	Sep 30, 1999	Feb CAHN

DIPHENHYDRAMINE HYDROCHLORIDEINJECTABLE;INJECTION  
DIPHENHYDRAMINE HYDROCHLORIDE PRESERVATIVE FREE

	@ INTL MEDICATION	50MG/ML	A084094	001		Jun DISC
--	-------------------	---------	---------	-----	--	----------

DIPIVEFRIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
AKPRO

	@ AKORN	0.1%	A074382	001	Sep 29, 1995	Jun DISC
DIPIVEFRIN HYDROCHLORIDE						
	@ FALCON PHARMS	0.1%	A073636	001	Jun 30, 1994	Jun DISC
PROPINE						
	@ ALLERGAN	0.1%	N018239	001		Jun DISC

DIPYRIDAMOLE

TABLET;ORAL

DIPYRIDAMOLE

	@ GLENMARK GENERICS	25MG	A088999	001	Feb 05, 1991	Mar DISC
	@	50MG	A089000	001	Feb 05, 1991	Mar DISC
	@	75MG	A089001	001	Feb 05, 1991	Mar DISC
	@ WATSON LABS	50MG	A087160	001	Jun 07, 1996	May DISC

DISULFIRAM

TABLET;ORAL

DISULFIRAM

AB	ROXANE	250MG	A202652	001	Feb 05, 2014	Jan NEWA
AB		500MG	A202652	002	Feb 05, 2014	Jan NEWA

DIVALPROEX SODIUMTABLET, EXTENDED RELEASE;ORAL  
DIVALPROEX SODIUM

AB	AUROBINDO PHARMA LTD	EQ 250MG VALPROIC ACID	A202419	001	Jun 02, 2014	May NEWA
AB		EQ 500MG VALPROIC ACID	A202419	002	Jun 02, 2014	May NEWA

DOBUTAMINE HYDROCHLORIDE

INJECTABLE;INJECTION

DOBUTAMINE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 12.5MG BASE/ML	A074277	001	Oct 31, 1994	Aug CAHN
	@ WATSON LABS	EQ 12.5MG BASE/ML	A074114	001	Nov 30, 1993	May DISC

DOCETAXEL

INJECTABLE;INJECTION

DOCETAXEL

		ACCORD HLTHCARE	20MG/0.5ML (40MG/ML)	N201195	001	Jun 08, 2011	Jul CTEC
			80MG/2ML (40MG/ML)	N201195	002	Jun 08, 2011	Jul CTEC
AP	+		160MG/8ML (20MG/ML)	N201195	005	Apr 20, 2012	Aug CRLD
AP		DR REDDYS LABS LTD	20MG/ML (20MG/ML)	A204193	001	Nov 05, 2014	Oct NEWA
AP			80MG/4ML (20MG/ML)	A204193	002	Nov 05, 2014	Oct NEWA
		PFIZER LABS	20MG/2ML (10MG/ML)	N202356	001	Mar 13, 2014	Mar NEWA
			80MG/8ML (10MG/ML)	N202356	002	Mar 13, 2014	Mar NEWA
			130MG/13ML (10MG/ML)	N202356	003	Mar 13, 2014	Mar NEWA
			200MG/20ML (10MG/ML)	N202356	004	Mar 13, 2014	Mar NEWA

DONEPEZIL HYDROCHLORIDE

TABLET; ORAL

DONEPEZIL HYDROCHLORIDE

AB	JUBILANT GENERICS	5MG	A090768	001	May 31, 2011	Jul CAHN
AB		10MG	A090768	002	May 31, 2011	Jul CAHN
AB	MACLEODS PHARMS LTD	23MG	A202631	001	Jan 22, 2014	Jan NEWA
AB	SCIEGEN PHARMS INC	5MG	A203907	001	Oct 29, 2014	Oct NEWA
AB		10MG	A203907	002	Oct 29, 2014	Oct NEWA
AB	TWI PHARMS INC	23MG	A203104	001	Oct 29, 2014	Oct NEWA

DONEPEZIL HYDROCHLORIDE; MEMANTINE HYDROCHLORIDE

&gt;A&gt; CAPSULE, EXTENDED RELEASE; ORAL

&gt;A&gt; NAMZARIC

>A>	FOREST LABS INC	10MG; 14MG	N206439	001	Dec 23, 2014	Dec NEWA
>A>	+	10MG; 28MG	N206439	002	Dec 23, 2014	Dec NEWA

DORZOLAMIDE HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE

AT	WATSON LABS INC	EQ 2% BASE	A202053	001	Sep 11, 2014	Sep NEWA
----	-----------------	------------	---------	-----	--------------	----------

DORZOLAMIDE HYDROCHLORIDE; TIMOLOL MALEATE

SOLUTION/DROPS; OPHTHALMIC

DORZOLAMIDE HYDROCHLORIDE AND TIMOLOL MALEATE

AT	AKORN INC	EQ 2% BASE; EQ 0.5% BASE	A203058	001	Sep 22, 2014	Sep NEWA
>A> AT	LANNETT HOLDINGS INC	EQ 2% BASE; EQ 0.5% BASE	A201998	001	Dec 17, 2014	Dec NEWA
AT	WATSON LABS INC	EQ 2% BASE; EQ 0.5% BASE	A202054	001	Sep 03, 2014	Aug NEWA

DOXAPRAM HYDROCHLORIDE

INJECTABLE; INJECTION

DOXAPRAM HYDROCHLORIDE

@ WATSON LABS	20MG/ML	A073529	001	Jan 30, 1992	May DISC
---------------	---------	---------	-----	--------------	----------

DOXAZOSIN MESYLATE

TABLET; ORAL

DOXAZOSIN MESYLATE

AB	ACCORD HLTHCARE	EQ 1MG BASE	A202824	001	Jun 11, 2014	May NEWA
AB		EQ 2MG BASE	A202824	002	Jun 11, 2014	May NEWA
AB		EQ 4MG BASE	A202824	003	Jun 11, 2014	May NEWA
AB		EQ 8MG BASE	A202824	004	Jun 11, 2014	May NEWA

DOXERCALCIFEROL

INJECTABLE; INJECTION

DOXERCALCIFEROL

AP	SANDOZ	4MCG/2ML (2MCG/ML)	A091333	001	May 05, 2014	Apr NEWA
AP		4MCG/2ML (2MCG/ML)	A200926	001	Feb 04, 2014	Jan NEWA

DOXORUBICIN HYDROCHLORIDE

INJECTABLE; INJECTION

DOXORUBICIN HYDROCHLORIDE

AP	ACTAVIS INC	2MG/ML	A203622	001	Jun 27, 2014	Jun NEWA
AP	+	EUROHLTH INTL	A062975	001	Mar 17, 1989	Aug CAHN
AP	+	10MG/VIAL	A062921	001	Mar 17, 1989	Aug CAHN
AP	+	20MG/VIAL	A062921	002	Mar 17, 1989	Aug CAHN
AP	+	50MG/VIAL	A062921	003	Mar 17, 1989	Aug CAHN
AP	+	200MG/100ML	A064097	001	Sep 13, 1994	Aug CAHN
AP	PHARMACHEMIE BV	2MG/ML	A063336	001	Feb 28, 1995	Feb CAHN
AP		10MG/VIAL	A063097	001	May 21, 1990	Feb CAHN
AP		20MG/VIAL	A063097	002	May 21, 1990	Feb CAHN
AP		50MG/VIAL	A063097	003	May 21, 1990	Feb CAHN
AP		200MG/100ML	A063336	004	Feb 28, 1995	Feb CAHN

DOXYCYCLINE

CAPSULE; ORAL

DOXYCYCLINE

AB	LUPIN LTD	EQ 50MG BASE	A204234	001	Mar 05, 2014	Feb NEWA
AB		EQ 75MG BASE	A204234	002	Mar 05, 2014	Feb NEWA
AB		EQ 100MG BASE	A204234	003	Mar 05, 2014	Feb NEWA
	@ WATSON LABS	EQ 50MG BASE	A065041	001	Apr 28, 2000	May DISC
	@	EQ 100MG BASE	A065041	002	Apr 28, 2000	May DISC

CAPSULE;ORAL  
ORACEA

	+	GALDERMA LABS LP	40MG	N050805	001	May 26, 2006	Jul CTEC
--	---	------------------	------	---------	-----	--------------	----------

DOXYCYCLINE HYCLATE

## CAPSULE;ORAL

## DOXYCYCLINE HYCLATE

	+	HIKMA INTL PHARMS	EQ 20MG BASE	A065103	001	May 13, 2005	Sep CAHN
AB			EQ 50MG BASE	A062396	002	Nov 07, 1984	Sep CAHN
AB			EQ 100MG BASE	A062396	001	May 07, 1984	Sep CAHN
AB		MYLAN	EQ 50MG BASE	A062337	001	Mar 29, 1982	Jul CMFD
AB			EQ 100MG BASE	A062337	002	Mar 29, 1982	Jul CMFD

## INJECTABLE;INJECTION

## DOXYCYCLINE

AP	+	EUROHLTH INTL	EQ 100MG BASE/VIAL	A062569	001	Mar 09, 1988	Aug CAHN
	@		EQ 200MG BASE/VIAL	A062569	002	Mar 09, 1988	Aug CAHN

## TABLET;ORAL

## ACTICLATE

		AQUA PHARMS LLC	EQ 75MG BASE	N205931	001	Jul 25, 2014	Jul NEWA
	+		EQ 150MG BASE	N205931	002	Jul 25, 2014	Nov CRLD
			EQ 150MG BASE	N205931	002	Jul 25, 2014	Jul NEWA

## DOXYCYCLINE HYCLATE

AB	+	HIKMA INTL PHARMS	EQ 100MG BASE	A065095	001	Jul 02, 2003	Sep CAHN
AB	+	LANNETT	EQ 20MG BASE	A065277	001	Nov 10, 2005	Oct CRLD
AB		MYLAN	EQ 100MG BASE	A062432	001	Feb 15, 1983	Jul CMFD

## PERIOSTAT

## @ GALDERMA LABS LP

			EQ 20MG BASE	N050783	001	Feb 02, 2001	Oct DISC
--	--	--	--------------	---------	-----	--------------	----------

## TABLET, DELAYED RELEASE;ORAL

## DORYX

AB		MAYNE PHARMA	EQ 150MG BASE	N050795	003	Jun 20, 2008	Feb CRLD
	+		EQ 200MG BASE	N050795	005	Apr 11, 2013	Feb CRLD

## DOXTERIC

>A>		MAYNE PHARMA	EQ 50MG BASE	N050795	006	Dec 19, 2014	Dec NEWA
-----	--	--------------	--------------	---------	-----	--------------	----------

DRONABINOL

## CAPSULE;ORAL

## DRONABINOL

AB		AKORN INC	2.5MG	A079217	001	Jun 20, 2014	Jun NEWA
AB			5MG	A079217	002	Jun 20, 2014	Jun NEWA
AB			10MG	A079217	003	Jun 20, 2014	Jun NEWA

DROSPIRENONE; ETHINYL ESTRADIOL

## TABLET;ORAL

## NIKKI

AB		LUPIN LTD	3MG;0.02MG	A201661	001	May 27, 2014	May NEWA
----	--	-----------	------------	---------	-----	--------------	----------

## TABLET;ORAL-28

## YAELA

AB		NOVAST LABS LTD	3MG;0.03MG	A202015	001	Nov 19, 2014	Nov NEWA
----	--	-----------------	------------	---------	-----	--------------	----------

DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM

## TABLET;ORAL

## BEYAZ

		BAYER HLTHCARE	3MG,N/A;0.02MG,N/A;0.451MG,0.451MG	N022532	001	Sep 24, 2010	Jul CRLD
--	--	----------------	------------------------------------	---------	-----	--------------	----------

## SAFYRAL

	+	BAYER HLTHCARE	3MG,N/A;0.03MG,N/A;0.451MG,0.451MG	N022574	001	Dec 16, 2010	Jul CRLD
--	---	----------------	------------------------------------	---------	-----	--------------	----------

DROXIDOPA

## CAPSULE;ORAL

## NORTHERA

		CHELSEA THERAPS INC	100MG	N203202	001	Feb 18, 2014	Feb NEWA
			200MG	N203202	002	Feb 18, 2014	Feb NEWA
	+		300MG	N203202	003	Feb 18, 2014	Feb NEWA
		LUNDBECK NA LTD	100MG	N203202	001	Feb 18, 2014	Jun CAHN
			200MG	N203202	002	Feb 18, 2014	Jun CAHN
	+		300MG	N203202	003	Feb 18, 2014	Jun CAHN

DULOXETINE HYDROCHLORIDECAPSULE, DELAYED REL PELLETS;ORAL  
DULOXETINE HYDROCHLORIDE

AB	ALEMBIC PHARMS LTD	EQ 20MG BASE	A202949	001	Jun 09, 2014	May NEWA
AB		EQ 30MG BASE	A202949	002	Jun 09, 2014	May NEWA
AB		EQ 60MG BASE	A202949	003	Jun 09, 2014	May NEWA
AB	APOTEX INC	EQ 20MG BASE	A202045	001	Jun 11, 2014	May NEWA
AB		EQ 30MG BASE	A202045	002	Jun 11, 2014	May NEWA
AB		EQ 60MG BASE	A202045	003	Jun 11, 2014	May NEWA
AB	BRECKENRIDGE PHARM	EQ 20MG BASE	A203088	001	Jun 11, 2014	May NEWA
AB		EQ 30MG BASE	A203088	002	Jun 11, 2014	May NEWA
AB		EQ 60MG BASE	A203088	003	Jun 11, 2014	May NEWA

DUTASTERIDE; TAMSULOSIN HYDROCHLORIDE

CAPSULE;ORAL

DUTASTERIDE AND TAMSULOSIN HYDROCHLORIDE

AB	ANCHEN PHARMS	0.5MG;0.4MG	A202509	001	Feb 26, 2014	Feb NEWA
	JALYN					
AB	+ GLAXOSMITHKLINE	0.5MG;0.4MG	N022460	001	Jun 14, 2010	Feb CFTG

ECONAZOLE NITRATEAEROSOL, FOAM;TOPICAL  
ECOZA

	+ VELDANA MEDICAL SA	1%	N205175	001	Oct 24, 2013	Feb CAHN
	CREAM;TOPICAL					
	SPECTAZOLE					
	@ MERZ PHARMS LLC	1%	N018751	001	Dec 23, 1982	Jan CAHN

EFINACONAZOLESOLUTION;TOPICAL  
JUBLIA

	+ DOW PHARM	10%	N203567	001	Jun 06, 2014	Jun NEWA
--	-------------	-----	---------	-----	--------------	----------

ELIGLUSTAT TARTRATE

CAPSULE;ORAL

CERDELGA

	+ GENZYME CORP	EQ 84MG BASE	N205494	001	Aug 19, 2014	Aug NEWA
--	----------------	--------------	---------	-----	--------------	----------

ELVITEGRAVIR

TABLET;ORAL

VITEKTA

	GILEAD SCIENCES INC	85MG	N203093	001	Sep 24, 2014	Sep NEWA
	+	150MG	N203093	002	Sep 24, 2014	Sep NEWA

EMPAGLIFLOZIN

TABLET;ORAL

JARDIANCE

	BOEHRINGER INGELHEIM	10MG	N204629	001	Aug 01, 2014	Aug NEWA
	+	25MG	N204629	002	Aug 01, 2014	Aug NEWA

ENALAPRIL MALEATE

TABLET;ORAL

ENALAPRIL MALEATE

	@ WATSON LABS	2.5MG	A075501	001	Aug 22, 2000	May DISC
	@	5MG	A075501	002	Aug 22, 2000	May DISC
	@	10MG	A075501	003	Aug 22, 2000	May DISC
	@	20MG	A075501	004	Aug 22, 2000	May DISC

ENOXAPARIN SODIUM

INJECTABLE;SUBCUTANEOUS

ENOXAPARIN SODIUM (PRESERVATIVE FREE)

AP	TEVA	30MG/0.3ML (100MG/ML)	A076726	001	Jun 23, 2014	Jun NEWA
AP		40MG/0.4ML (100MG/ML)	A076726	002	Jun 23, 2014	Jun NEWA
AP		60MG/0.6ML (100MG/ML)	A076726	003	Jun 23, 2014	Jun NEWA
AP		80MG/0.8ML (100MG/ML)	A076726	004	Jun 23, 2014	Jun NEWA
AP		100MG/ML (100MG/ML)	A076726	005	Jun 23, 2014	Jun NEWA
AP		120MG/0.8ML (150MG/ML)	A076726	006	Jun 23, 2014	Jun NEWA
AP		150MG/ML (150MG/ML)	A076726	007	Jun 23, 2014	Jun NEWA

ENTECAVIRTABLET; ORAL  
BARACLUDE

AB	BRISTOL MYERS SQUIBB	0.5MG	N021797	001	Mar 29, 2005	Aug CFTG
AB	+	1MG	N021797	002	Mar 29, 2005	Aug CFTG
	ENTECAVIR					
AB	TEVA PHARMS USA	0.5MG	A202122	001	Aug 26, 2014	Aug NEWA
AB		1MG	A202122	002	Aug 26, 2014	Aug NEWA

EPINASTINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
EPINASTINE HYDROCHLORIDE

AT	GAVIS PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Sep CAHN
AT	TESA PHARMS LLC	0.05%	A090951	001	Oct 31, 2011	Jul CAHN

EPINEPHRINEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS  
ADRENALIN

+	PAR STERILE PRODUCTS	1MG/ML	N204200	001	Dec 07, 2012	Apr CAHN
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS ADRENALIN					
+	PAR STERILE PRODUCTS	30MG/30ML (1MG/ML)	N204640	001	Dec 18, 2013	Apr CAHN

EPINEPHRINE HYDROCHLORIDEINJECTABLE; INTRAMUSCULAR, INTRAOCULAR, SUBCUTANEOUS  
ADRENALIN

+	PAR STERILE PRODUCTS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N204200	001	Dec 07, 2012	Jul CAIN
	INJECTABLE; INTRAMUSCULAR, SUBCUTANEOUS ADRENALIN					
+	PAR STERILE PRODUCTS	EQ 30MG BASE/30ML (EQ 1MG BASE/ML)	N204640	001	Dec 18, 2013	Jul CAIN
	SOLUTION; IV (INFUSION) EPINEPHRINE					
	BELCHER PHARMS LLC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	N205029	001	Jul 29, 2014	Jul NEWA

EPIRUBICIN HYDROCHLORIDEINJECTABLE; INJECTION  
EPIRUBICIN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Aug CAHN
AP		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Aug CAHN
AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Aug CAHN
AP	ACTAVIS TOTOWA	10MG/5ML (2MG/ML)	A065445	001	Sep 18, 2008	Oct CAHN
AP		50MG/25ML (2MG/ML)	A065445	002	Sep 18, 2008	Oct CAHN
AP		200MG/100ML (2MG/ML)	A065445	003	Sep 18, 2008	Oct CAHN
	@ EBEWE PHARMA	50MG/25ML (2MG/ML)	A065339	001	Dec 22, 2009	Nov DISC
	@	200MG/100ML (2MG/ML)	A065339	002	Dec 22, 2009	Nov DISC
AP	EUROHLTH INTL	50MG/25ML (2MG/ML)	A065289	001	Jun 27, 2007	Aug CAHN
AP		200MG/100ML (2MG/ML)	A065289	002	Jun 27, 2007	Aug CAHN
	@ HOSPIRA	50MG/25ML (2MG/ML)	A065343	002	Apr 19, 2007	May DISC
	@ MUSTAFA NEVSAT	50MG/25ML (2MG/ML)	A090266	001	Apr 15, 2011	Mar DISC
	@	200MG/100ML (2MG/ML)	A090266	002	Apr 15, 2011	Mar DISC
	INJECTABLE; IV (INFUSION) EPIRUBICIN HYDROCHLORIDE					
	@ HOSPIRA	50MG/VIAL	N050807	001	Sep 15, 2006	Jun DISC

ERGOALCIFEROLCAPSULE; ORAL  
ERGOALCIFEROL

AA	STRIDES PHARMA	50,000 IU	A090455	001	Aug 03, 2010	Aug CAHN
----	----------------	-----------	---------	-----	--------------	----------

ERGOLOID MESYLATESTABLET; SUBLINGUAL  
ERGOLOID MESYLATES

@	WATSON LABS	0.5MG	A087233	001		May DISC
---	-------------	-------	---------	-----	--	----------

ERLOTINIB HYDROCHLORIDETABLET; ORAL  
ERLOTINIB HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 25MG BASE	A091002	001	Jun 11, 2014	May NEWA
AB		EQ 100MG BASE	A091002	002	Jun 11, 2014	May NEWA
AB		EQ 150MG BASE	A091002	003	Jun 11, 2014	May NEWA

TABLET;ORAL							
TARCEVA							
AB	OSI PHARMS	EQ 25MG BASE	N021743	001	Nov 18, 2004	May	CFTG
AB		EQ 100MG BASE	N021743	002	Nov 18, 2004	May	CFTG
AB	+	EQ 150MG BASE	N021743	003	Nov 18, 2004	May	CFTG
<u>ERYTHROMYCIN</u>							
CAPSULE, DELAYED REL PELLETS;ORAL							
ERYTHROMYCIN							
AB	ARBOR PHARMS LLC	250MG	A062746	001	Dec 22, 1986	Sep	CAHN
SWAB;TOPICAL							
ERYTHROMYCIN							
	@ FOUGERA PHARMS	2%	A065320	001	Jul 25, 2006	May	DISC
TABLET;ORAL							
ERYTHROMYCIN							
	ARBOR PHARMS LLC	250MG	A061621	001		Sep	CAHN
+		500MG	A061621	002		Sep	CAHN
TABLET, COATED PARTICLES;ORAL							
PCE							
	ARBOR PHARMS LLC	333MG	N050611	001	Sep 09, 1986	Sep	CAHN
+		500MG	N050611	002	Aug 22, 1990	Sep	CAHN
TABLET, DELAYED RELEASE;ORAL							
ERY-TAB							
	ARBOR PHARMS LLC	333MG	A062298	003	Mar 29, 1982	Sep	CRLD
+		500MG	A062298	002		Sep	CRLD
<u>ERYTHROMYCIN ETHYLSUCCINATE</u>							
GRANULE;ORAL							
E.E.S.							
AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	001		Sep	CAHN
ERYPED							
AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	N050207	003	Mar 30, 1987	Sep	CAHN
+		EQ 400MG BASE/5ML	N050207	002		Sep	CAHN
SUSPENSION;ORAL							
E.E.S. 200							
AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A061639	001		Sep	CAHN
E.E.S. 400							
AB	+	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A061639	002	Sep	CAHN
PEDIAMYCIN							
AB	ARBOR PHARMS LLC	EQ 200MG BASE/5ML	A062304	001		Sep	CAHN
PEDIAMYCIN 400							
AB	ARBOR PHARMS LLC	EQ 400MG BASE/5ML	A062304	002		Sep	CAHN
TABLET;ORAL							
E.E.S. 400							
	@ ARBOR PHARMS LLC	EQ 400MG BASE	A061905	001		Sep	CAHN
BX	+	EQ 400MG BASE	A061905	002	Aug 12, 1982	Sep	CAHN
ERYTHROMYCIN ETHYLSUCCINATE							
BX	+	ARBOR PHARMS LLC	EQ 400MG BASE	A061904	001	Sep	CAHN
<u>ERYTHROMYCIN LACTOBIONATE</u>							
INJECTABLE;INJECTION							
ERYTHROCIN							
+	HOSPIRA	EQ 1GM BASE/VIAL	A062638	002	Oct 31, 1986	May	CTEC
<u>ERYTHROMYCIN STEARATE</u>							
TABLET;ORAL							
ERYTHROCIN STEARATE							
	@ ARBOR PHARMS LLC	EQ 125MG BASE	A060359	002		Sep	CAHN
+		EQ 250MG BASE	A060359	001		Sep	CAHN
	@	EQ 500MG BASE	A060359	003		Sep	CAHN
ERYTHROMYCIN STEARATE							
	@ ANI PHARMS INC	EQ 250MG BASE	A061461	001		Feb	CAHN
	@	EQ 250MG BASE	A061591	001		Jan	CAHN
	@	EQ 500MG BASE	A061461	002		Feb	CAHN
<u>ESCITALOPRAM OXALATE</u>							
TABLET;ORAL							
ESCITALOPRAM OXALATE							
AB	JUBILANT GENERICS	EQ 5MG BASE	A202280	001	Sep 12, 2012	Aug	CAHN
AB		EQ 10MG BASE	A202280	002	Sep 12, 2012	Aug	CAHN
AB		EQ 20MG BASE	A202280	003	Sep 12, 2012	Aug	CAHN

## TABLET;ORAL

## ESCITALOPRAM OXALATE

AB	TEVA PHARMS USA	EQ 5MG BASE	A076765	001	Mar 14, 2012	Feb CAHN
AB		EQ 10MG BASE	A076765	002	Mar 14, 2012	Feb CAHN
AB		EQ 20MG BASE	A076765	003	Mar 14, 2012	Feb CAHN

ESMOLOL HYDROCHLORIDE

## INJECTABLE;INJECTION

## ESMOLOL HYDROCHLORIDE

AP	EUROHLTH INTL	10MG/ML	A076323	001	Aug 10, 2004	Aug CAHN
----	---------------	---------	---------	-----	--------------	----------

ESOMEPRAZOLE MAGNESIUM

## CAPSULE, DELAYED REL PELLETS;ORAL

## NEXIUM

>D>	ASTRAZENECA	EQ 20MG BASE	N021153	001	Feb 20, 2001	Dec CAHN
>D>	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Dec CAHN
>A>	ASTRAZENECA PHARMS	EQ 20MG BASE	N021153	001	Feb 20, 2001	Dec CAHN
>A>	+	EQ 40MG BASE	N021153	002	Feb 20, 2001	Dec CAHN

## FOR SUSPENSION, DELAYED RELEASE;ORAL

## NEXIUM

>D>	ASTRAZENECA	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011	Dec CAHN
>D>		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011	Dec CAHN
>D>		EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Dec CAHN
>D>		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Dec CAHN
>D>	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Dec CAHN
>A>	ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N021957	003	Dec 15, 2011	Dec CAHN
>A>		EQ 5MG BASE/PACKET	N021957	004	Dec 15, 2011	Dec CAHN
>A>		EQ 10MG BASE/PACKET	N022101	001	Feb 27, 2008	Dec CAHN
>A>		EQ 20MG BASE/PACKET	N021957	001	Oct 20, 2006	Dec CAHN
>A>	+	EQ 40MG BASE/PACKET	N021957	002	Oct 20, 2006	Dec CAHN

ESOMEPRAZOLE SODIUM

## INJECTABLE;INTRAVENOUS

## NEXIUM IV

>D>	AP	+	ASTRAZENECA	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Dec CAHN
>D>	AP	+		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Dec CAHN
>A>	AP	+	ASTRAZENECA PHARMS	EQ 20MG BASE/VIAL	N021689	001	Mar 31, 2005	Dec CAHN
>A>	AP	+		EQ 40MG BASE/VIAL	N021689	002	Mar 31, 2005	Dec CAHN

ESTRADIOL

## FILM, EXTENDED RELEASE;TRANSDERMAL

## ESTRADIOL

>A>	AB1	MYLAN TECHNOLOGIES	0.025MG/24HR	A201675	001	Dec 19, 2014	Dec NEWA
>A>	AB1		0.0375MG/24HR	A201675	002	Dec 19, 2014	Dec NEWA
>A>	AB1		0.05MG/24HR	A201675	003	Dec 19, 2014	Dec NEWA
>A>	AB1		0.075MG/24HR	A201675	004	Dec 19, 2014	Dec NEWA
>A>	AB1		0.1MG/24HR	A201675	005	Dec 19, 2014	Dec NEWA

## VIVELLE-DOT

>D>	BX	NOVARTIS	0.025MG/24HR	N020538	009	May 03, 2002	Dec CTEC
>A>	AB1		0.025MG/24HR	N020538	009	May 03, 2002	Dec CTEC
>D>	BX		0.0375MG/24HR	N020538	005	Jan 08, 1999	Dec CTEC
>A>	AB1		0.0375MG/24HR	N020538	005	Jan 08, 1999	Dec CTEC
>D>	BX		0.075MG/24HR	N020538	007	Jan 08, 1999	Dec CTEC
>A>	AB1		0.075MG/24HR	N020538	007	Jan 08, 1999	Dec CTEC

## GEL;TOPICAL

## ESTROGEL

## @ ASCEND THERAPS US

## GEL;TRANSDERMAL

## DIVIGEL

## VERTICAL PHARMS LLC

	0.1% (0.25GM/PACKET)	N022038	001	Jun 04, 2007	Apr CAHN
	0.1% (0.5GM/PACKET)	N022038	002	Jun 04, 2007	Apr CAHN
+	0.1% (1GM/PACKET)	N022038	003	Jun 04, 2007	Apr CAHN

## GEL, METERED;TRANSDERMAL

## ESTROGEL

## + ASCEND THERAPS US

## SPRAY;TRANSDERMAL

## EVAMIST

+	ELAN PHARMA INTL LTD	1.53MG/SPRAY	N022014	001	Jul 27, 2007	Nov CAHN
+	LUMARA HEALTH INC	1.53MG/SPRAY	N022014	001	Jul 27, 2007	May CAHN

## TABLET; ORAL

## ESTRADIOL

@ LANNETT HOLDINGS INC 0.5MG  
 @ 1MG  
 @ 2MG

A040138 001 Jan 30, 1998 Nov CAHN  
 A040138 002 Jan 30, 1998 Nov CAHN  
 A040138 003 Jan 30, 1998 Nov CAHN

ESTRADIOL CYPIONATE

## INJECTABLE; INJECTION

## DEPO-ESTRADIOL

+ PHARMACIA AND UPJOHN 5MG/ML  
 ESTRADIOL CYPIONATE  
 @ WATSON LABS 5MG/ML

A085470 003 May CTEC  
 A085620 001 May DISC

ESTRADIOL VALERATE

## INJECTABLE; INJECTION

## DELESTROGEN

+ PAR STERILE PRODUCTS 10MG/ML  
 AO + 10MG/ML  
 AO + 20MG/ML  
 AO + 40MG/ML

N009402 002 Nov CTEC  
 N009402 002 Apr CAHN  
 N009402 004 Apr CAHN  
 N009402 003 Apr CAHN

## ESTRADIOL VALERATE

@ SANDOZ 10MG/ML  
 @ 20MG/ML  
 @ 40MG/ML

A040628 001 Oct 04, 2007 Nov DISC  
 A040628 002 Oct 04, 2007 Nov DISC  
 A040628 003 Oct 04, 2007 Nov DISC

ESTRADIOL; NORETHINDRONE ACETATE

## FILM, EXTENDED RELEASE; TRANSDERMAL

## COMBIPATCH

>D> NOVARTIS 0.05MG/24HR; 0.14MG/24HR  
 >D> + 0.05MG/24HR; 0.25MG/24HR  
 >A> NOVEN PHARMS INC 0.05MG/24HR; 0.14MG/24HR  
 >A> + 0.05MG/24HR; 0.25MG/24HR

N020870 001 Aug 07, 1998 Dec CAHN  
 N020870 002 Aug 07, 1998 Dec CAHN  
 N020870 001 Aug 07, 1998 Dec CAHN  
 N020870 002 Aug 07, 1998 Dec CAHN

## TABLET; ORAL

## ACTIVELLA

AB AMNEAL PHARMS LLC 0.5MG; 0.1MG  
 AB + 1MG; 0.5MG

N020907 002 Dec 28, 2006 Jun CAHN  
 N020907 001 Nov 18, 1998 Jun CAHN

ESTRADIOL; NORGESTIMATE

## TABLET; ORAL

## ESTRADIOL AND NORGESTIMATE

+ BARR 1MG, 1MG; N/A, 0.09MG  
 AB + 1MG, 1MG; N/A, 0.09MG  
 PREFEST  
 @ TEVA WOMENS 1MG, 1MG; N/A, 0.09MG

A076812 001 Apr 29, 2005 Oct CTEC  
 A076812 001 Apr 29, 2005 Sep CRLD  
 N021040 001 Oct 22, 1999 Sep DISC

ESTROPIPATE

## TABLET; ORAL

## ESTROPIPATE

@ WATSON LABS 6MG  
 OGEN 5  
 PHARMACIA AND UPJOHN 6MG  
 ORTHO-EST  
 @ SUN PHARM INDS INC 0.75MG  
 @ 1.5MG

A081216 001 Sep 23, 1993 May DISC  
 A083220 004 May CTEC  
 A089567 001 Feb 27, 1991 Jun CAHN  
 A089582 001 Jul 17, 1991 Jun CAHN

ESZOPICLONE

## TABLET; ORAL

## ESZOPICLONE

AB DR REDDYS LABS LTD 1MG  
 AB 2MG  
 AB 3MG  
 AB GLENMARK GENERICS 1MG  
 AB 2MG  
 AB 3MG  
 AB LUPIN LTD 1MG  
 AB 2MG  
 AB 3MG  
 AB ORCHID HLTHCARE 1MG  
 AB 2MG  
 AB 3MG  
 AB ROXANE 1MG  
 AB 2MG

A091024 001 Apr 15, 2014 Mar NEWA  
 A091024 002 Apr 15, 2014 Mar NEWA  
 A091024 003 Apr 15, 2014 Mar NEWA  
 A091166 001 Apr 15, 2014 Mar NEWA  
 A091166 002 Apr 15, 2014 Mar NEWA  
 A091166 003 Apr 15, 2014 Mar NEWA  
 A091124 001 Sep 13, 2011 Mar CMFD  
 A091124 002 Sep 13, 2011 Mar CMFD  
 A091124 003 Sep 13, 2011 Mar CMFD  
 A091113 001 Jun 10, 2014 May NEWA  
 A091113 002 Jun 10, 2014 May NEWA  
 A091113 003 Jun 10, 2014 May NEWA  
 A091153 001 Apr 15, 2014 Mar NEWA  
 A091153 002 Apr 15, 2014 Mar NEWA



TABLET;ORAL  
ESZOPICLONE

AB		3MG	A091153	003	Apr 15, 2014	Mar NEWA
AB	TEVA	1MG	A091169	001	May 23, 2011	Jan CMFD
AB		2MG	A091169	002	May 23, 2011	Jan CMFD
AB		3MG	A091169	003	May 23, 2011	Jan CMFD

ETHAMBUTOL HYDROCHLORIDE

TABLET;ORAL  
ETHAMBUTOL HYDROCHLORIDE

>D>	@ HIKMA INTL PHARMS	100MG	A075095	001	Nov 30, 1999	Dec CAHN
	@	100MG	A075095	001	Nov 30, 1999	Oct CAHN
>D>	@	400MG	A075095	002	Nov 30, 1999	Dec CAHN
	@	400MG	A075095	002	Nov 30, 1999	Oct CAHN
>A>	@ VERSAPHARM INC	100MG	A075095	001	Nov 30, 1999	Dec CAHN
>A>	@	400MG	A075095	002	Nov 30, 1999	Dec CAHN

ETHINYL ESTRADIOL; ETONOGESTREL

RING;VAGINAL  
NUVARING

+	ORGANON USA INC	0.015MG/24HR;0.12MG/24HR	N021187	001	Oct 03, 2001	Apr CPOT
---	-----------------	--------------------------	---------	-----	--------------	----------

ETHINYL ESTRADIOL; LEVONORGESTREL

TABLET;ORAL  
SETLAKIN

AB	NOVAST LABS LTD	0.03MG;0.15MG	A090716	001	Sep 15, 2014	Sep NEWA
----	-----------------	---------------	---------	-----	--------------	----------

TABLET;ORAL-28

LEVONORGESTREL AND ETHINYL ESTRADIOL

AB2	FAMY CARE LTD	0.02MG;0.1MG	A202247	001	Dec 08, 2014	Nov NEWA
AB1	HAUPT PHARMA	0.02MG;0.1MG	A201108	001	Feb 05, 2014	Jan NEWA
AB		0.03MG;0.15MG	A201095	001	Dec 08, 2014	Nov NEWA

ETHINYL ESTRADIOL; NORELGESTROMIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
ORTHO EVRA

AB	+	JANSSEN PHARMS	0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar CFTG
	+		0.035MG/24HR;0.15MG/24HR	N021180	001	Nov 20, 2001	Mar CPOT
AB		MYLAN TECHNOLOGIES	0.035MG/24HR;0.15MG/24HR	A200910	001	Apr 16, 2014	Mar NEWA

ETHINYL ESTRADIOL; NORETHINDRONE

TABLET;ORAL-21  
NORETHIN 1/35E-21

@ WATSON LABS 0.035MG;1MG

A071480 001 Apr 12, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON LABS 0.035MG;0.4MG

A078379 001 Feb 23, 2010 May DISC

@ 0.035MG;1MG

A070685 001 Jan 29, 1987 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (10/11)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG

A071043 001 Apr 01, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG

A071041 001 Sep 24, 1991 May DISC

TABLET;ORAL-28

NORETHIN 1/35E-28

@ WATSON LABS 0.035MG;1MG

A071481 001 Apr 12, 1988 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL

@ WATSON LABS 0.035MG,0.035MG,0.035MG;0.5MG,0.75MG,1MG

A076393 001 Feb 04, 2010 May DISC

NORETHINDRONE AND ETHINYL ESTRADIOL (7/14)

@ WATSON LABS 0.035MG,0.035MG;0.5MG,1MG

A071042 001 Sep 24, 1991 May DISC

TABLET, CHEWABLE;ORAL

NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE

AB		FAMY CARE LTD	0.025MG;0.8MG	A203371	001	Apr 23, 2014	Apr NEWA
AB	+	WARNER CHILCOTT	0.025MG;0.8MG	N022573	001	Dec 22, 2010	Apr CFTG

ETHINYL ESTRADIOL; NORETHINDRONE ACETATE

TABLET;ORAL  
GILDESS 24 FE

AB	VINTAGE PHARMS	0.02MG;1MG	A090293	001	Dec 01, 2014	Nov NEWA
	NORETHINDRONE ACETATE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE					
AB	BARR LABS INC	0.02MG;1MG	A090938	001	Dec 01, 2014	Nov NEWA
AB	FAMY CARE LTD	0.02MG;1MG	A202742	001	Oct 30, 2014	Oct NEWA

## TABLET;ORAL-21

	GILDESS 1.5/30						
AB	VINTAGE PHARMS LLC	0.03MG;1.5MG	A077075	002	Jul 24, 2012	Mar	NEWA
	GILDESS 1/20						
AB	VINTAGE PHARMS LLC	0.02MG;1MG	A077077	002	Jul 24, 2012	Mar	NEWA
	LARIN 1.5/30						
AB	NOVAST LABS LTD	0.03MG;1.5MG	A202996	001	Mar 20, 2014	Mar	NEWA
	LOESTRIN 21 1.5/30						
AB	WARNER CHILCOTT LLC	0.03MG;1.5MG	N017875	001		Oct	CMFD
	@	0.03MG;1.5MG	N017875	001		May	DISC
	LOESTRIN 21 1/20						
AB	WARNER CHILCOTT LLC	0.02MG;1MG	N017876	001		Oct	CMFD
	@	0.02MG;1MG	N017876	001		May	DISC
	TABLET;ORAL-28						
	LOESTRIN FE 1.5/30						
AB	+ WARNER CHILCOTT LLC	0.03MG;1.5MG	N017355	001		Oct	CMFD
	@	0.03MG;1.5MG	N017355	001		May	DISC
	LOESTRIN FE 1/20						
AB	WARNER CHILCOTT	0.02MG;1MG	N017354	001		Oct	CMFD
	@	0.02MG;1MG	N017354	001		May	DISC
	MICROGESTIN FE 1.5/30						
AB	WATSON LABS	0.03MG;1.5MG	A075548	001	Feb 05, 2001	Oct	CRLD
AB	+	0.03MG;1.5MG	A075548	001	Feb 05, 2001	May	CRLD

ETHINYL ESTRADIOL; NORGESTIMATE

## TABLET;ORAL-28

## NORGESTIMATE AND ETHINYL ESTRADIOL

@	WATSON LABS	0.025MG,0.025MG,0.025MG;0.18MG,0.2	A090479	001	Mar 09, 2011	May	DISC
		15MG,0.25MG					
@		0.035MG,0.035MG,0.035MG;0.18MG,0.2	A076626	001	Aug 17, 2006	May	DISC
		15MG,0.25MG					
@		0.035MG;0.25MG	A076627	001	Aug 17, 2006	May	DISC

ETHINYL ESTRADIOL; NORGESTREL

## TABLET;ORAL-21

## LOW-OGESTREL-21

@	WATSON LABS	0.03MG;0.3MG	A075288	001	Jul 28, 1999	May	DISC
---	-------------	--------------	---------	-----	--------------	-----	------

## TABLET;ORAL-28

## LOW-OGESTREL-28

@	WATSON LABS	0.03MG;0.3MG	A075288	002	Jul 28, 1999	May	DISC
---	-------------	--------------	---------	-----	--------------	-----	------

ETHIODIZED OIL

## OIL;INTRALYMPHATIC, INTRAUTERINE

## ETHIODOL

+	GUERBET	99%	N009190	001		Apr	CMFD
	LIPIODOL						
+	GUERBET	99%	N009190	001		Apr	CTNA

ETODOLAC

## CAPSULE;ORAL

## ETODOLAC

>D>	@	ANI PHARMS INC	200MG	A074899	001	Jul 08, 1997	Feb	CAHN
>A>	AB	@	200MG	A075126	001	Sep 16, 1999	Dec	CMFD
		@	200MG	A075126	001	Sep 16, 1999	Dec	CMFD
		@	200MG	A075126	001	Sep 16, 1999	Jan	CAHN
		@	300MG	A074899	002	Jul 08, 1997	Feb	CAHN
	AB		300MG	A075126	002	Sep 16, 1999	Jan	CAHN

## TABLET, EXTENDED RELEASE;ORAL

## ETODOLAC

AB	ZYDUS PHARMS USA INC	400MG	A091134	001	Jan 23, 2014	May	NEWA
AB		500MG	A091134	002	Jan 23, 2014	May	NEWA
AB		600MG	A091134	003	Jan 23, 2014	May	NEWA

ETOMIDATE

## INJECTABLE;INJECTION

## ETOMIDATE

AP	AGILA SPECLTS	2MG/ML	A078289	001	Jan 02, 2009	Feb	CAHN
AP	EMCURE PHARMS LTD	2MG/ML	A204618	001	Aug 13, 2014	Aug	NEWA
AP	PAR STERILE PRODUCTS	2MG/ML	A091297	001	Jun 20, 2012	Jul	CAHN
AP	ZYDUS PHARMS USA INC	2MG/ML	A202360	001	Jul 18, 2014	Jul	NEWA

ETOPOSIDE

CAPSULE;ORAL							
VEPESID							
	@ DAVA PHARMS INC	50MG	N019557	001	Dec 30, 1986	Sep	CAHN
	@	100MG	N019557	002	Dec 30, 1986	Sep	CAHN
INJECTABLE;INJECTION							
ETOPOSIDE							
AP	EUROHLTH INTL	20MG/ML	A074290	001	Jul 17, 1995	Aug	CAHN
	@ PHARMACHEMIE BV	20MG/ML	A074227	001	Feb 22, 1996	Feb	CAHN
	@ TEVA PHARMS USA	20MG/ML	A074284	001	Feb 10, 1994	May	DISC

EXEMESTANE

TABLET;ORAL							
EXEMESTANE							
AB	ALVOGEN INC	25MG	A200898	001	Jul 28, 2014	Aug	CAHN
AB	EIRGEN PHARMA LTD	25MG	A200898	001	Jul 28, 2014	Jul	NEWA

EXENATIDE SYNTHETIC

FOR SUSPENSION, EXTENDED RELEASE;SUBCUTANEOUS							
BYDUREON							
+	ASTRAZENECA AB	2MG/VIAL	N022200	001	Jan 27, 2012	Jun	CAHN
INJECTABLE;SUBCUTANEOUS							
BYETTA							
+	ASTRAZENECA AB	300MCG/1.2ML (250MCG/ML)	N021773	001	Apr 28, 2005	Mar	CAHN
+		600MCG/2.4ML (250MCG/ML)	N021773	002	Apr 28, 2005	Mar	CAHN

FAMCICLOVIR

TABLET;ORAL							
FAMCICLOVIR							
AB	HETERO LABS LTD V	125MG	A202438	001	Sep 10, 2014	Sep	NEWA
AB		250MG	A202438	002	Sep 10, 2014	Sep	NEWA
AB		500MG	A202438	003	Sep 10, 2014	Sep	NEWA

FAMOTIDINE

FOR SUSPENSION;ORAL							
FAMOTIDINE							
AB	HI-TECH PHARMA CO	40MG/5ML	A201995	001	May 30, 2014	May	NEWA
INJECTABLE;INJECTION							
FAMOTIDINE PRESERVATIVE FREE							
AP	BEDFORD LABS	10MG/ML	A075825	001	Apr 17, 2001	Feb	CAHN

FELODIPINE

TABLET, EXTENDED RELEASE;ORAL							
FELODIPINE							
	@ WOCKHARDT LTD	2.5MG	A091484	001	Aug 15, 2012	Nov	DISC
	@	5MG	A091484	002	Aug 15, 2012	Nov	DISC
	@	10MG	A091484	003	Aug 15, 2012	Nov	DISC

FENOFIBRATE

CAPSULE;ORAL							
FENOFIBRATE							
AB	RANBAXY LABS LTD	43MG	A201748	001	Oct 31, 2014	Oct	NEWA
AB		130MG	A201748	002	Oct 31, 2014	Oct	NEWA
TABLET;ORAL							
FENOGLIDE							
	SANTARUS INC	40MG	N022118	001	Aug 10, 2007	Feb	CAHN
+		120MG	N022118	002	Aug 10, 2007	Feb	CAHN
TRIGLIDE							
	@ SKYEPHARMA AG	50MG	N021350	001	May 07, 2005	May	DISC

FENOLDOPAM MESYLATE

INJECTABLE;INJECTION							
FENOLDOPAM MESYLATE							
AP	EUROHLTH INTL	EQ 10MG BASE/ML	A076582	001	Oct 12, 2004	Aug	CAHN

FENTANYL

FILM, EXTENDED RELEASE;TRANSDERMAL

FENTANYL-100

@ NOVEN 100MCG/HR

A077775 004 Oct 16, 2009 Apr DISC

FENTANYL-25

@ NOVEN 25MCG/HR

A077775 001 Oct 16, 2009 Apr DISC

FENTANYL-37

&gt;A&gt; MYLAN TECHNOLOGIES 37.5MCG/HR

A076258 006 Dec 29, 2014 Dec NEWA

FENTANYL-50

@ NOVEN 50MCG/HR

A077775 002 Oct 16, 2009 Apr DISC

FENTANYL-62

&gt;A&gt; MYLAN TECHNOLOGIES 62.5MCG/HR

A076258 007 Dec 29, 2014 Dec NEWA

FENTANYL-75

@ NOVEN 75MCG/HR

A077775 003 Oct 16, 2009 Apr DISC

FENTANYL-87

&gt;A&gt; MYLAN TECHNOLOGIES 87.5MCG/HR

A076258 008 Dec 29, 2014 Dec NEWA

FENTANYL CITRATE

TABLET;BUCCAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 May DISC

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 May DISC

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 May DISC

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 May DISC

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 May DISC

TABLET;BUCCAL, SUBLINGUAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 Jun CDFR

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 Jun CDFR

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 Jun CDFR

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 Jun CDFR

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 Jun CDFR

FENTORA

CEPHALON EQ 0.1MG BASE

N021947 001 Sep 25, 2006 Jun CTEC

EQ 0.2MG BASE

N021947 002 Sep 25, 2006 Jun CTEC

+ EQ 0.4MG BASE

N021947 003 Sep 25, 2006 Jun CTEC

EQ 0.6MG BASE

N021947 004 Sep 25, 2006 Jun CTEC

EQ 0.8MG BASE

N021947 005 Sep 25, 2006 Jun CTEC

TABLET;SUBLINGUAL

FENTANYL CITRATE

@ WATSON LABS EQ 0.1MG BASE

A079075 001 Jan 07, 2011 May CDFR

@ EQ 0.2MG BASE

A079075 002 Jan 07, 2011 May CDFR

@ EQ 0.4MG BASE

A079075 003 Jan 07, 2011 May CDFR

@ EQ 0.6MG BASE

A079075 004 Jan 07, 2011 May CDFR

@ EQ 0.8MG BASE

A079075 005 Jan 07, 2011 May CDFR

FERRIC CITRATE

TABLET;ORAL

FERRIC CITRATE

+ KERYX BIOPHARMS EQ 210MG IRON

N205874 001 Sep 05, 2014 Sep NEWA

FIDAXOMICIN

TABLET;ORAL

DIFICID

+ CUBIST PHARMS 200MG

N201699 001 May 27, 2011 Jul CAHN

>A> FINAFLOXACIN

&gt;A&gt; SUSPENSION/DROPS;OTIC

&gt;A&gt; XTORO

&gt;A&gt; + ALCON RES LTD 0.3%

N206307 001 Dec 17, 2014 Dec NEWA

FINASTERIDE

TABLET;ORAL

FINASTERIDE

AB ACTAVIS ELIZABETH 1MG

A078371 001 Nov 05, 2013 Aug CAHN

AB 5MG

A077914 001 Mar 28, 2007 Aug CAHN

AB ACTAVIS TOTOWA 1MG

A078371 001 Nov 05, 2013 Oct CAHN

AB 5MG

A077914 001 Mar 28, 2007 Oct CAHN

AB CIPLA LTD 1MG

A077335 001 Nov 20, 2014 Nov NEWA

FLECAINIDE ACETATE

TABLET; ORAL

TAMBOCOR

@ CNTY LINE PHARMS	50MG	N018830	004	Aug 23, 1988	Jul CAHN
@	100MG	N018830	001	Oct 31, 1985	Jul CAHN
@	150MG	N018830	003	Jun 03, 1988	Jul CAHN
@	200MG	N018830	002	Oct 31, 1985	Jul CAHN

FLORBETABEN F-18

SOLUTION; INTRAVENOUS

NEURACEQ

+ PIRAMAL IMAGING	30ML (1.4-135mCi/ML)	N204677	001	Mar 19, 2014	Mar NEWA
-------------------	----------------------	---------	-----	--------------	----------

FLOXURIDINE

INJECTABLE; INJECTION

FLOXURIDINE

AP + EUROHLTH INTL	500MG/VIAL	A075387	001	Apr 16, 2000	Aug CAHN
--------------------	------------	---------	-----	--------------	----------

FLUCONAZOLE

INJECTABLE; INJECTION

FLUCONAZOLE IN SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER

@ TEVA PHARMS	200MG/100ML (2MG/ML)	A076837	001	Jan 13, 2005	Apr DISC
@	400MG/200ML (2MG/ML)	A076837	002	Jan 13, 2005	Apr DISC

TABLET; ORAL

FLUCONAZOLE

AB DR REDDYS LABS INC	50MG	A076658	001	Jul 29, 2004	Nov CTEC
AB	100MG	A076658	002	Jul 29, 2004	Nov CTEC
AB	150MG	A076658	003	Jul 29, 2004	Nov CTEC
AB	200MG	A076658	004	Jul 29, 2004	Nov CTEC

FLUDARABINE PHOSPHATE

INJECTABLE; INJECTION

FLUDARABINE PHOSPHATE

AP ACTAVIS ELIZABETH	50MG/VIAL	A078610	001	Feb 11, 2009	Aug CAHN
AP ACTAVIS TOTOWA	50MG/VIAL	A078610	001	Feb 11, 2009	Oct CAHN
AP MUSTAFA NEVZAT ILAC	50MG/2ML (25MG/ML)	A090724	001	Sep 27, 2010	May CAHN

FLUDEOXYGLUCOSE F-18

INJECTABLE; INTRAVENOUS

FLUDEOXYGLUCOSE F18

AP BRIGHAM WOMENS	20-300mCi/ML	A203816	001	Oct 30, 2014	Oct NEWA
AP CHILDRENS HOSP MI	20-300mCi/ML	A204385	001	Oct 29, 2014	Oct NEWA
AP CPDC	20-300mCi/ML	A204525	001	Oct 29, 2014	Oct NEWA
AP ESSENTIAL ISOTOPES	20-300mCi/ML	A203946	001	Feb 05, 2014	Jan NEWA
>D> AP + FEINSTEIN	20-300mCi/ML	N021870	002	Nov 21, 2008	Dec CPOT
>A> AP +	20-400mCi/ML	N021870	002	Nov 21, 2008	Dec CPOT
AP GLOBAL ISOTOPES LLC	20-300mCi/ML	A204463	001	Oct 21, 2014	Oct NEWA
AP HOT SHOTS NM LLC	4-500mCi/ML	A203937	001	Oct 30, 2014	Oct NEWA
AP LANTHEUS MEDICAL	20-200mCi/ML	A203664	001	Feb 04, 2014	Jan NEWA
AP MA GENERAL HOSP	20-300mCi/ML	A204333	001	Sep 25, 2014	Sep NEWA
>D> MCPRF	20-240mCi/ML	A203612	001	Aug 05, 2013	Dec CTEC
>A> AP	20-240mCi/ML	A203612	001	Aug 05, 2013	Dec CTEC
>A> AP NCM USA BRONX LLC	20-300mCi/ML	A204512	001	Jan 07, 2015	Dec NEWA
>A> AP SHERTECH LABS LLC	20-300mCi/ML	A204264	001	Dec 18, 2014	Dec NEWA
AP TRUSTEES UNIV PA	20-200mCi/ML	A203801	001	Oct 29, 2014	Oct NEWA
AP UCSF RODIOPHARM	20-300mCi/ML	A203902	001	May 09, 2014	Apr NEWA
AP UIHC PET IMAGING	20-300mCi/ML	A203990	001	Aug 06, 2014	Jul NEWA
@ WEILL MEDCL COLL	10-100mCi/ML	N021768	001	Aug 05, 2004	Feb DISC
AP WUSM CYCLOTRON	20-300mCi/ML	A203935	001	Feb 05, 2014	Jan NEWA

FLUDROCORTISONE ACETATE

TABLET; ORAL

FLUDROCORTISONE ACETATE

AB HIKMA PHARMS	0.1MG	A091302	001	Jul 22, 2011	Jan CAHN
-----------------	-------	---------	-----	--------------	----------

FLUNISOLIDE

AEROSOL, METERED; INHALATION

AEROSPAN HFA

+ MEDA PHARMS INC	0.078MG/INH	N021247	001	Jan 27, 2006	Aug CPOT
+ EQ 78MG BASE/INH		N021247	001	Jan 27, 2006	Mar CAHN

FLUOCINOLONE ACETONIDEIMPLANT;INTRAVITREAL  
ILUVIEN

+	ALIMERA SCIENCES INC	0.19MG	N201923	001	Sep 26, 2014	Sep NEWA
---	----------------------	--------	---------	-----	--------------	----------

FLUOCINOLONE ACETONIDE; NEOMYCIN SULFATECREAM;TOPICAL  
NEO-SYNALAR

+	MEDIMETRIKS PHARMS	0.025%;EQ 3.5MG BASE/GM	A060700	001		Apr CMFD
---	--------------------	-------------------------	---------	-----	--	----------

FLUOCINONIDECREAM;TOPICAL  
FLUOCINONIDE

AB	FOUGERA PHARMS INC	0.1%	A200735	001	Jul 14, 2014	Jun NEWA
AB	GLENMARK GENERICS	0.1%	A091282	001	Jul 14, 2014	Jun NEWA
AB	TARO	0.1%	A200734	001	Jul 14, 2014	Jun NEWA

SOLUTION;TOPICAL  
FLUOCINONIDE

AT	G AND W LABS INC	0.05%	A071535	001	Dec 02, 1988	May CAHN
	LIDEX					
AT	CNTY LINE PHARMS	0.05%	N018849	001	Apr 06, 1984	Apr CMFD

FLUOROURACILINJECTABLE;INJECTION  
FLUOROURACIL

>D> AP	EBEWE PHARMA	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008	Dec DISC
>A>	@	500MG/10ML (50MG/ML)	A040772	001	Aug 11, 2008	Dec DISC

FLUOXETINE HYDROCHLORIDE

CAPSULE;ORAL

FLUOXETINE HYDROCHLORIDE

AB2	ANI PHARMS INC	EQ 10MG BASE	A076287	001	May 20, 2008	Jan CAHN
AB2		EQ 20MG BASE	A076287	002	May 20, 2008	Jan CAHN

TABLET;ORAL  
SARAFEM

AB1	WARNER CHILCOTT LLC	EQ 10MG BASE	N021860	001	May 19, 2006	Jan CFTG
AB1		EQ 15MG BASE	N021860	002	May 19, 2006	Jan CFTG
AB1	+	EQ 20MG BASE	N021860	003	May 19, 2006	Jan CFTG
	SELFEMRA					
AB1	TEVA PHARMS USA	EQ 10MG BASE	A200151	001	Feb 03, 2014	Jan NEWA
AB1		EQ 15MG BASE	A200151	002	Feb 03, 2014	Jan NEWA
AB1		EQ 20MG BASE	A200151	003	Feb 03, 2014	Jan NEWA

FLUPHENAZINE DECANOATE

INJECTABLE;INJECTION

FLUPHENAZINE DECANOATE

AO	EUROHLTH INTL	25MG/ML	A074531	001	Aug 30, 1996	Aug CAHN
AO	PAR STERILE PRODUCTS	25MG/ML	A203732	001	Jul 03, 2014	Jun NEWA

FLUPHENAZINE HYDROCHLORIDE

ELIXIR;ORAL

FLUPHENAZINE HYDROCHLORIDE

@	ANI PHARMS INC	2.5MG/5ML	A081310	001	Apr 29, 1993	Feb CAHN
---	----------------	-----------	---------	-----	--------------	----------

FLURANDRENOLIDE

TAPE;TOPICAL

CORDRAN

+	WATSON LABS INC	0.004MG/SQ CM	N016455	001		Sep CAHN
---	-----------------	---------------	---------	-----	--	----------

FLURAZEPAM HYDROCHLORIDE

CAPSULE;ORAL

FLURAZEPAM HYDROCHLORIDE

	MYLAN PHARMS INC	15MG	A070345	002	Nov 27, 1985	May CTEC
+		30MG	A070345	001	Nov 27, 1985	May CTEC
@	WATSON LABS	15MG	A071205	001	Nov 25, 1986	May DISC
@		30MG	A071068	001	Nov 25, 1986	May DISC
@		30MG	A072369	001	Mar 30, 1989	May DISC

FLURBIPROFEN

TABLET; ORAL

FLURBIPROFEN

AB	SUN PHARM INDS INC	50MG	A075058	001	Apr 27, 2001	Jul	CAHN
AB		100MG	A075058	002	Apr 27, 2001	Jul	CAHN

FLUTICASONE FUROATE

POWDER; INHALATION

ARNUITY ELLIPTA

	GLAXOSMITHKLINE	0.1MG/INH	N205625	001	Aug 20, 2014	Aug	NEWA
+		0.2MG/INH	N205625	002	Aug 20, 2014	Aug	NEWA

FLUVOXAMINE MALEATE

CAPSULE, EXTENDED RELEASE; ORAL

FLUVOXAMINE MALEATE

AB	TORRENT PHARMS LTD	100MG	A203240	001	Oct 31, 2014	Oct	NEWA
AB		150MG	A203240	002	Oct 31, 2014	Oct	NEWA

TABLET; ORAL

FLUVOXAMINE MALEATE

@ SUN PHARM INDS INC

@

@

25MG

50MG

100MG

A075900	001	Feb 23, 2006	Jul	CAHN
A075900	002	Feb 23, 2006	Jul	CAHN
A075900	003	Feb 23, 2006	Jul	CAHN

FOLIC ACID

TABLET; ORAL

FOLIC ACID

AA	CADILA PHARMS LTD	1 MG	A202437	001	Jan 27, 2014	Jan	NEWA
>D> AA	JUBILANT CADISTA	1MG	A040514	001	Jun 14, 2005	Dec	DISC
>A>	@	1MG	A040514	001	Jun 14, 2005	Dec	DISC

FOLLITROPIN ALFA/BETA

INJECTABLE; SUBCUTANEOUS

GONAL-F RFF REDI-JECT

+	EMD SERONO	300 IU/0.5ML	N021684	001	May 25, 2004	May	CTNA
+		450 IU/0.75ML	N021684	002	May 25, 2004	May	CTNA
+		900 IU/1.5ML	N021684	003	May 25, 2004	May	CTNA

FOMEPIZOLE

INJECTABLE; INJECTION

FOMEPIZOLE

@ MYLAN INSTITUTIONAL

1.5GM/1.5ML (1GM/ML)

A079033	001	Apr 07, 2009	Jun	DISC
---------	-----	--------------	-----	------

FONDAPARINUX SODIUM

INJECTABLE; SUBCUTANEOUS

ARIXTRA

AP	+	AGI	2.5MG/0.5ML	N021345	001	Dec 07, 2001	May	CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	May	CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	May	CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	May	CAHN
AP	+	MYLAN IRELAND LTD	2.5MG/0.5ML	N021345	001	Dec 07, 2001	Oct	CAHN
AP	+		5MG/0.4ML	N021345	002	May 28, 2004	Oct	CAHN
AP	+		7.5MG/0.6ML	N021345	003	May 28, 2004	Oct	CAHN
AP	+		10MG/0.8ML	N021345	004	May 28, 2004	Oct	CAHN

FOSINOPRIL SODIUM

TABLET; ORAL

FOSINOPRIL SODIUM

@ WATSON LABS

@

@

10MG

20MG

40MG

A077531	001	Aug 31, 2006	May	DISC
A077531	002	Aug 31, 2006	May	DISC
A077531	003	Aug 31, 2006	May	DISC

FOSINOPRIL SODIUM; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	EMCURE PHARMS INDIA	10MG;12.5MG	A079025	001	Sep 17, 2010	Feb	CAIN
AB	+	20MG;12.5MG	A079025	002	Sep 17, 2010	Feb	CAIN

FOSINOPRIL; HYDROCHLOROTHIAZIDE

TABLET; ORAL

FOSINOPRIL SODIUM AND HYDROCHLOROTHIAZIDE

AB	+	EMCURE PHARMS INDIA	20MG;12.5MG	A079025	002	Sep 17, 2010	Jan CRLD
----	---	---------------------	-------------	---------	-----	--------------	----------

FOSPHENYTOIN SODIUM

INJECTABLE; INJECTION

CEREBYX

AP		PARKE DAVIS	EQ 50MG PHENYTOIN NA/ML	N020450	001	Aug 05, 1996	Feb CMFD
		FOSPHENYTOIN SODIUM					
AP		AGILA SPECLTS	EQ 50MG PHENYTOIN NA/ML	A078736	001	Jun 08, 2010	Feb CAHN
AP		AMNEAL PHARMS CO	EQ 50MG PHENYTOIN NA/ML	A078476	001	Mar 18, 2008	Jun CAHN

FROVATRIPTAN SUCCINATE

TABLET; ORAL

FROVA

AB	+	ENDO PHARMS	EQ 2.5MG BASE	N021006	001	Nov 08, 2001	Aug CFTG
		FROVATRIPTAN SUCCINATE					
AB		MYLAN PHARMS INC	EQ 2.5MG BASE	A202931	001	Aug 28, 2014	Aug NEWA

FUROSEMIDE

INJECTABLE; INJECTION

FUROSEMIDE

AP		CLARIS LIFESCIENCES	10MG/ML	A202747	001	Jan 27, 2014	Jan NEWA
AP		EMCURE PHARMS LTD	10MG/ML	A203428	001	Aug 26, 2014	Aug NEWA

TABLET; ORAL

FUROSEMIDE

AB		CARACO	20MG	A091258	001	Apr 01, 2014	Mar NEWA
AB			40MG	A091258	002	Apr 01, 2014	Mar NEWA
AB			80MG	A091258	003	Apr 01, 2014	Mar NEWA
AB		SUN PHARM INDS INC	20MG	A091258	001	Apr 01, 2014	Jul CAHN
AB			40MG	A091258	002	Apr 01, 2014	Jul CAHN
AB			80MG	A091258	003	Apr 01, 2014	Jul CAHN
	@	WATSON LABS	20MG	A070412	001	Feb 26, 1986	May DISC
	@		20MG	A070449	001	Nov 22, 1985	May DISC
	@		20MG	A071379	001	Jan 02, 1987	May DISC
	@		40MG	A070450	001	Nov 22, 1985	May DISC
	@		80MG	A070528	001	Jan 07, 1986	May DISC
	@		80MG	A071594	001	Feb 09, 1988	May DISC

GABAPENTIN

CAPSULE; ORAL

GABAPENTIN

	@	WATSON LABS	100MG	A075485	003	May 11, 2007	May DISC
	@		300MG	A075485	002	May 11, 2007	May DISC
	@		400MG	A075485	001	May 11, 2007	May DISC

TABLET; ORAL

GABAPENTIN

AB		ACI HEALTHCARE LTD	600MG	A203244	002	Jul 12, 2013	Feb CAHN
AB			800MG	A203244	001	Jul 12, 2013	Feb CAHN

GALANTAMINE HYDROBROMIDE

TABLET; ORAL

GALANTAMINE HYDROBROMIDE

	@	YABAO PHARM	EQ 4MG BASE	A077604	001	Feb 06, 2009	May CAHN
	@		EQ 8MG BASE	A077604	002	Feb 06, 2009	May CAHN
	@		EQ 12MG BASE	A077604	003	Feb 06, 2009	May CAHN

GANCICLOVIR SODIUM

INJECTABLE; INJECTION

GANCICLOVIR SODIUM

	@	EUROHLTH INTL	EQ 500MG BASE/VIAL	A076222	001	Jul 16, 2003	Aug CAHN
--	---	---------------	--------------------	---------	-----	--------------	----------

GATIFLOXACIN

SOLUTION/DROPS; OPHTHALMIC

GATIFLOXACIN

AT		HI-TECH PHARMA CO	0.5%	A203189	001	Sep 03, 2014	Aug NEWA
		ZYMAR					
	+	ALLERGAN	0.3%	N021493	001	Mar 28, 2003	Sep CTEC



GEMCITABINE HYDROCHLORIDE

INJECTABLE; INJECTION

GEMCITABINE HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Aug CAHN
AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Aug CAHN
AP	ACTAVIS TOTOWA	EQ 1GM BASE/VIAL	A079160	002	Jul 25, 2011	Oct CAHN
AP		EQ 200MG BASE/VIAL	A079160	001	Jul 25, 2011	Oct CAHN

GEMFIBROZIL

TABLET; ORAL

GEMFIBROZIL

AB	SUN PHARM INDS INC	600MG	A079239	001	Dec 29, 2008	Jun CAHN
	@ WATSON LABS	600MG	A074442	001	Apr 28, 1995	May DISC

GENTAMICIN SULFATE

CREAM; TOPICAL

GENTAMICIN SULFATE

>D>	@ BAUSCH AND LOMB	EQ 0.1% BASE	A064056	001	Apr 29, 1994	Dec CAHN
>A>	@ G AND W LABS INC	EQ 0.1% BASE	A064056	001	Apr 29, 1994	Dec CAHN

OINTMENT; TOPICAL

GENTAMICIN SULFATE

>D>	@ BAUSCH AND LOMB	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Dec CAHN
>A>	@ G AND W LABS INC	EQ 0.1% BASE	A064054	001	Apr 29, 1994	Dec CAHN

SOLUTION/DROPS; OPHTHALMIC

GENTAMICIN SULFATE

>A> AT	ALCON RES LTD	EQ 0.3% BASE	A062196	001		Dec CAHN
>D> AT	FALCON PHARMS	EQ 0.3% BASE	A062196	001		Dec CAHN

GLATIRAMER ACETATE

INJECTABLE; SUBCUTANEOUS

COPAXONE

+	TEVA PHARMS USA	40MG/ML	N020622	003	Jan 28, 2014	Jan NEWA
---	-----------------	---------	---------	-----	--------------	----------

GLIMEPIRIDE

TABLET; ORAL

GLIMEPIRIDE

@ WATSON LABS

1MG

A077280 001 Feb 03, 2006 May DISC

@

2MG

A077280 002 Feb 03, 2006 May DISC

@

4MG

A077280 003 Feb 03, 2006 May DISC

GLIPIZIDE

TABLET; ORAL

GLIPIZIDE

AB	SUN PHARM INDS INC	5MG	A077820	001	Jul 11, 2006	Jul CAHN
AB		10MG	A077820	002	Jul 11, 2006	Jul CAHN
	@ WATSON LABS	5MG	A074370	001	Nov 22, 1994	May DISC
	@	10MG	A074370	002	Nov 22, 1994	May DISC

GLIPIZIDE; METFORMIN HYDROCHLORIDE

TABLET; ORAL

GLIPIZIDE AND METFORMIN HYDROCHLORIDE

AB	SUN PHARM INDS INC	2.5MG; 250MG	A077620	001	Jan 11, 2008	Jul CAHN
AB		2.5MG; 500MG	A077620	002	Jan 11, 2008	Jul CAHN
AB		5MG; 500MG	A077620	003	Jan 11, 2008	Jul CAHN

GLYBURIDE

TABLET; ORAL

GLYBURIDE

@ ACTAVIS ELIZABETH

1.5MG

A075947 001 Nov 14, 2002 Aug CAHN

@

3MG

A075947 002 Nov 14, 2002 Aug CAHN

@

6MG

A075947 003 Nov 14, 2002 Aug CAHN

GLYCOPYRROLATE

TABLET; ORAL

GLYCOPYRROLATE

AA	STASON PHARMS	1MG	A091182	001	Feb 03, 2014	Jan NEWA
AA		2MG	A091182	002	Feb 03, 2014	Jan NEWA
AA	VINTAGE PHARMS	1MG	A090020	001	Oct 19, 2011	Feb CAHN
AA		2MG	A090020	002	Oct 19, 2011	Feb CAHN

GRANISETRON HYDROCHLORIDE

INJECTABLE;INJECTION

GRANISETRON HYDROCHLORIDE

AP	BANNER PHARMACAPS	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078863	001	Jun 30, 2008	Aug CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078880	001	Jun 30, 2008	Sep CAHN
	@ SANDOZ	EQ 0.1MG BASE/ML (EQ 0.1MG BASE/ML)	A078808	001	Apr 29, 2008	Jun CAHN
AP	SANDOZ INC	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078835	001	Jun 30, 2008	Jun CAHN
AP		EQ 4MG BASE/4ML (EQ 1MG BASE/ML)	A078835	002	Jun 30, 2008	Jun CAHN
	GRANISETRON HYDROCHLORIDE PRESERVATIVE FREE					
AP	BANNER PHARMACAPS	EQ 1MG BASE/ML (EQ 1MG BASE/ML)	A078863	002	Jun 30, 2008	Aug CAHN
	SOLUTION;ORAL					
	GRANISOL					
	@ PEDIATRX	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul DISC
	+	EQ 2MG BASE/10ML	A078334	001	Feb 28, 2008	Jul CTNA

GRISEOFULVIN, MICROSIZE

SUSPENSION;ORAL

GRIFULVIN V

	@ VALEANT LUXEMBOURG	125MG/5ML	A062483	001	Jan 26, 1984	Oct DISC
	GRISEOFULVIN					
AB	+ ACTAVIS MID ATLANTIC	125MG/5ML	A065394	001	Jul 06, 2007	Oct CRLD

GRISEOFULVIN, ULTRAMICROSIZE

TABLET;ORAL

GRIS-PEG

AB	VALEANT PHARMS INC	125MG	N050475	001		Sep CAHN
AB	+	250MG	N050475	002		Sep CAHN

GUAIFENESIN; HYDROCODONE BITARTRATE

SOLUTION;ORAL

OBREDON

	+	SOVEREIGN PHARMS	200MG/5ML;2.5MG/5ML	N205474	001	Nov 14, 2014	Nov NEWA
--	---	------------------	---------------------	---------	-----	--------------	----------

GUANABENZ ACETATE

TABLET;ORAL

GUANABENZ ACETATE

	ANI PHARMS INC	EQ 4MG BASE	A074149	001	Apr 07, 1995	Jan CAHN
	@	EQ 4MG BASE	A074267	001	Jun 01, 1994	Mar CAHN
	+	EQ 8MG BASE	A074149	002	Apr 07, 1995	Jan CAHN
	@	EQ 8MG BASE	A074267	002	Jun 01, 1994	Mar CAHN

HALOBETASOL PROPIONATE

OINTMENT;TOPICAL

HALOBETASOL PROPIONATE

AB	TARO	0.05%	A076994	001	Dec 16, 2004	Apr CMFD
----	------	-------	---------	-----	--------------	----------

HALOPERIDOL DECANOATE

INJECTABLE;INJECTION

HALOPERIDOL DECANOATE

AO	AGILA SPECLTS	EQ 50MG BASE/ML	A075440	001	Feb 28, 2000	Feb CMFD
AO		EQ 100MG BASE/ML	A075440	002	Feb 28, 2000	Feb CMFD
AO	EUROHLTH INTL	EQ 50MG BASE/ML	A074811	001	Jan 30, 1998	Aug CAHN
AO		EQ 100MG BASE/ML	A075305	001	Sep 28, 1998	Aug CAHN

HALOPERIDOL LACTATE

INJECTABLE;INJECTION

HALOPERIDOL

AP	EUROHLTH INTL	EQ 5MG BASE/ML	A075858	001	Jun 18, 2001	Aug CAHN
----	---------------	----------------	---------	-----	--------------	----------

HEPARIN SODIUM

INJECTABLE;INJECTION

HEPARIN SODIUM

	+	FRESENIUS KABI USA	10,000 UNITS/ML	N017029	020	Mar 31, 2011	Mar NEWA
	+	HOSPIRA	5,000 UNITS/ML	A088100	001	Apr 28, 1983	Mar CRLD
	+	PFIZER	1,000 UNITS/ML	N201370	001	Jul 21, 2011	Mar CRLD
	+		5,000 UNITS/ML	N201370	002	Jul 21, 2011	Mar CRLD
	+		10,000 UNITS/ML	N201370	003	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW	1,000 UNITS/ML	A202957	001	Jun 12, 2014	Jun NEWA
AP			5,000 UNITS/ML	A202733	001	Jun 12, 2014	Jun NEWA

## INJECTABLE; INJECTION

## HEPARIN SODIUM

AP		5,000 UNITS/ML	A202957	002	Jun 12, 2014	Jun NEWA
AP		10,000 UNITS/ML	A203198	001	Jun 12, 2014	Jun NEWA
AP		20,000 UNITS/ML	A203198	002	Jun 12, 2014	Jun NEWA
HEPARIN SODIUM IN PLASTIC CONTAINER						
AP	+	FRESENIUS KABI USA 1,000 UNITS/ML	N017029	013	Dec 05, 1985	Jun CTEC
	+	1,000 UNITS/ML	N017029	013	Dec 05, 1985	Mar CTEC
AP	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985	Jun CTEC
	+	10,000 UNITS/ML	N017029	015	Dec 05, 1985	Mar CTEC
AP	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Jun CTEC
	+	20,000 UNITS/ML	N017029	016	Dec 05, 1985	Mar CTEC
HEPARIN SODIUM PRESERVATIVE FREE						
	+	FRESENIUS KABI USA 10,000 UNITS/ML	N017029	019	Nov 22, 2010	Mar NEWA
	+	HOSPIRA 10,000 UNITS/ML	A089522	001	May 04, 1987	Mar CTEC
	+	PFIZER 1,000 UNITS/ML	N201370	004	Jul 21, 2011	Mar CRLD
AP		SHENZHEN TECHDOW 1,000 UNITS/ML	A202732	001	Jun 12, 2014	Jun NEWA

HOMATROPINE METHYLBROMIDE; HYDROCODONE BITARTRATE

## TABLET; ORAL

## HOMATROPINE METHYLBROMIDE AND HYDROCODONE BITARTRATE

@	ACTAVIS ELIZABETH	1.5MG; 5MG	A040295	001	Dec 01, 2000	Aug CAHN
---	-------------------	------------	---------	-----	--------------	----------

HYDRALAZINE HYDROCHLORIDE

## TABLET; ORAL

## HYDRALAZINE HYDROCHLORIDE

	@	ACTAVIS ELIZABETH 25MG	A088560	001	Oct 04, 1984	Aug CAHN
	@	50MG	A088649	001	Oct 18, 1984	Aug CAHN
AA		CADILA PHARMS LTD 25MG	A203845	001	Sep 18, 2014	Sep NEWA
AA		50MG	A203845	002	Sep 18, 2014	Sep NEWA
AA		100MG	A203845	003	Sep 18, 2014	Sep NEWA
AA		STRIDES PHARMA 25MG	A200770	001	May 03, 2013	Aug CAHN
AA		50MG	A200770	002	May 03, 2013	Aug CAHN
AA		100MG	A200770	003	May 03, 2013	Aug CAHN
	@	WATSON LABS 25MG	A084504	001		May DISC
	@	50MG	A084503	001		May DISC

HYDRALAZINE HYDROCHLORIDE; ISOSORBIDE DINITRATE

## TABLET; ORAL

## BIDIL

+	ARBOR PHARMS LLC	37.5MG; 20MG	N020727	001	Jun 23, 2005	Sep CAHN
---	------------------	--------------	---------	-----	--------------	----------

HYDROCHLOROTHIAZIDE

## CAPSULE; ORAL

## HYDROCHLOROTHIAZIDE

AB		CARACO 12.5MG	A090651	001	Apr 07, 2014	Mar NEWA
	@	HIKMA INTL PHARMS 12.5MG	A077885	001	Nov 26, 2007	Sep CAHN
AB		SUN PHARM INDS INC 12.5MG	A090651	001	Apr 07, 2014	Jul CAHN

## TABLET; ORAL

## HYDROCHLOROTHIAZIDE

AB		SCIEGEN PHARMS INC 25MG	A203018	001	Jul 23, 2014	Jul NEWA
AB		50MG	A203018	002	Jul 23, 2014	Jul NEWA
AB		SUN PHARM INDS INC 12.5MG	A040857	001	May 30, 2008	Jul CAHN
AB		25MG	A040810	001	Mar 27, 2007	Jul CAHN
AB		50MG	A040810	002	Mar 27, 2007	Jul CAHN

HYDROCHLOROTHIAZIDE; IRBESARTAN

## TABLET; ORAL

## IRBESARTAN AND HYDROCHLOROTHIAZIDE

AB		PRINSTON INC 12.5MG; 150MG	A203072	001	May 09, 2014	Apr NEWA
AB		12.5MG; 300MG	A203072	002	May 09, 2014	Apr NEWA

HYDROCHLOROTHIAZIDE; LISINAPRIL

## TABLET; ORAL

## LISINAPRIL AND HYDROCHLOROTHIAZIDE

AB		HIKMA INTL PHARMS 12.5MG; 10MG	A076265	001	Jul 08, 2002	Sep CAHN
AB		12.5MG; 20MG	A076265	002	Jul 08, 2002	Sep CAHN
AB		25MG; 20MG	A076265	003	Jul 08, 2002	Sep CAHN

HYDROCHLOROTHIAZIDE; LOSARTAN POTASSIUM

TABLET; ORAL

LOSARTAN POTASSIUM AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 12.5MG; 50MG  
 @ 12.5MG; 100MG  
 @ 25MG; 100MG

A200180 001 Jan 12, 2011 May DISC  
 A200180 002 Jan 12, 2011 May DISC  
 A200180 003 Jan 12, 2011 May DISC

HYDROCHLOROTHIAZIDE; METHYLDOPA

TABLET; ORAL

METHYLDOPA AND HYDROCHLOROTHIAZIDE

MYLAN 15MG; 250MG

A070265 002 Jan 23, 1986 Mar CMS1

HYDROCHLOROTHIAZIDE; METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL

DUTOPROL

COVIS PHARMA SARL 12.5MG; EQ 25MG TARTRATE  
 12.5MG; EQ 50MG TARTRATE  
 + 12.5MG; EQ 100MG TARTRATE

N021956 001 Aug 28, 2006 Jun CAHN  
 N021956 002 Aug 28, 2006 Jun CAHN  
 N021956 003 Aug 28, 2006 Jun CAHN

HYDROCHLOROTHIAZIDE; MOEXIPRIL HYDROCHLORIDE

TABLET; ORAL

MOEXIPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB HERITAGE PHARMS INC 12.5MG; 7.5MG  
 AB 12.5MG; 15MG  
 AB 25MG; 15MG  
 AB INDICUS PHARMA 12.5MG; 7.5MG  
 AB 12.5MG; 15MG  
 AB 25MG; 15MG

A202150 001 Mar 07, 2014 Apr CAHN  
 A202150 002 Mar 07, 2014 Apr CAHN  
 A202150 003 Mar 07, 2014 Apr CAHN  
 A202150 001 Mar 07, 2014 Feb NEWA  
 A202150 002 Mar 07, 2014 Feb NEWA  
 A202150 003 Mar 07, 2014 Feb NEWA

HYDROCHLOROTHIAZIDE; PROPRANOLOL HYDROCHLORIDE

TABLET; ORAL

PROPRANOLOL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE

AB MYLAN 25MG; 40MG

A070947 002 Mar 04, 1987 Mar CMS1

HYDROCHLOROTHIAZIDE; SPIRONOLACTONE

TABLET; ORAL

SPIRONOLACTONE AND HYDROCHLOROTHIAZIDE

@ WATSON LABS 25MG; 25MG

A087398 001 May DISC

HYDROCHLOROTHIAZIDE; TELMISARTAN

TABLET; ORAL

MICARDIS HCT

AB BOEHRINGER INGELHEIM 12.5MG; 40MG  
 AB 12.5MG; 80MG  
 AB + 25MG; 80MG

N021162 001 Nov 17, 2000 Feb CFTG  
 N021162 002 Nov 17, 2000 Feb CFTG  
 N021162 003 Apr 19, 2004 Feb CFTG

TELMISARTAN AND HYDROCHLOROTHIAZIDE

AB ALEMBIC PHARMS LTD 12.5MG; 40MG  
 AB 12.5MG; 80MG  
 AB 25MG; 80MG  
 AB LUPIN LTD 12.5MG; 40MG  
 AB 12.5MG; 80MG  
 AB 25MG; 80MG  
 AB MYLAN PHARMS INC 12.5MG; 40MG  
 AB 12.5MG; 80MG  
 AB 25MG; 80MG  
 AB TORRENT PHARMS LTD 12.5MG; 40MG  
 AB 12.5MG; 80MG  
 AB 25MG; 80MG

A203010 001 Feb 25, 2014 Feb NEWA  
 A203010 002 Feb 25, 2014 Feb NEWA  
 A203010 003 Feb 25, 2014 Feb NEWA  
 A091351 001 Aug 07, 2014 Jul NEWA  
 A091351 002 Aug 07, 2014 Jul NEWA  
 A091351 003 Aug 07, 2014 Jul NEWA  
 A091648 001 Feb 25, 2014 Feb NEWA  
 A091648 002 Feb 25, 2014 Feb NEWA  
 A091648 003 Feb 25, 2014 Feb NEWA  
 A201192 001 Feb 25, 2014 Feb NEWA  
 A201192 002 Feb 25, 2014 Feb NEWA  
 A201192 003 Feb 25, 2014 Feb NEWA

HYDROCODONE BITARTRATE

TABLET, EXTENDED RELEASE; ORAL

HYSINGLA

PURDUE PHARMA LP 20MG  
 30MG  
 40MG  
 60MG  
 80MG  
 100MG  
 120MG

N206627 001 Nov 20, 2014 Nov NEWA  
 N206627 002 Nov 20, 2014 Nov NEWA  
 N206627 003 Nov 20, 2014 Nov NEWA  
 N206627 004 Nov 20, 2014 Nov NEWA  
 N206627 005 Nov 20, 2014 Nov NEWA  
 N206627 006 Nov 20, 2014 Nov NEWA  
 N206627 007 Nov 20, 2014 Nov NEWA

HYDROCODONE BITARTRATE; PSEUDOEPHEDRINE HYDROCHLORIDE

SOLUTION;ORAL							
HYDROCODONE BITARTRATE AND PSEUDOEPHEDRINE HYDROCHLORIDE							
AA	PADDOCK LLC	5MG/5ML;60MG/5ML	A204658	001	Apr 29, 2014	Apr	NEWA
AA	TRIS PHARMA INC	5MG/5ML;60MG/5ML	A203839	001	Oct 28, 2014	Oct	NEWA
REZIRA							
AA	+ CYPRESS PHARM	5MG/5ML;60MG/5ML	N022442	001	Jun 08, 2011	Apr	CFTG

HYDROCORTISONE

CREAM; TOPICAL					
HYDROCORTISONE					
@ TARO	1%	A086155	001		Mar DISC
LOTION; TOPICAL					
ALA-CORT					
@ CROWN LABS	1%	A083201	001		Mar DISC
NUTRACORT					
@ DOW PHARM	1%	A080443	003		Mar DISC
TABLET; ORAL					
HYDROCORTISONE					
@ HIKMA INTL PHARMS	20MG	A083365	001		Sep CAHN

HYDROCORTISONE ACETATE; PRAMOXINE HYDROCHLORIDE

AEROSOL, METERED;TOPICAL						
HYDROCORTISONE ACETATE 1% AND PRAMOXINE HYDROCHLORIDE 1%						
@ VINTAGE PHARMS		1%;1%		A089440	001	May 17, 1988 Feb CAHN

HYDROCORTISONE BUTYRATE

CREAM; TOPICAL						
HYDROCORTISONE BUTYRATE						
AB2	GLENMARK GENERICS	0.1%	A202145	001	Sep 27, 2013	Aug CTEC
AB1	TARO PHARM INDS	0.1%	A076654	001	Aug 03, 2005	Aug CTEC
LOCOID						
AB1	+ PRECISION DERMAT	0.1%	N018514	001	Mar 31, 1982	Aug CTEC
LOCOID LIPOCREAM						
AB2	+ PRECISION DERMAT	0.1%	N020769	001	Sep 08, 1997	Aug CTEC

HYDROMORPHONE HYDROCHLORIDE

TABLET, EXTENDED RELEASE;ORAL							
EXALGO							
AB	MALLINCKRODT INC	8MG	N021217	001	Mar 01, 2010	Apr	CFTG
AB		12MG	N021217	002	Mar 01, 2010	Apr	CFTG
AB		16MG	N021217	003	Mar 01, 2010	Apr	CFTG
HYDROMORPHONE HYDROCHLORIDE							
AB	ACTAVIS LABS FL INC	8MG	A202144	001	May 12, 2014	Apr	NEWA
AB		12MG	A202144	002	May 12, 2014	Apr	NEWA
AB		16MG	A202144	003	May 12, 2014	Apr	NEWA

HYDROXYCHLOROQUINE SULFATE

TABLET; ORAL					
HYDROXYCHLOROQUINE SULFATE					
@ WATSON LABS	200MG	A040133	001	Nov 30, 1995	May DISC

HYDROXYPROGESTERONE CAPROATE

SOLUTION; INTRAMUSCULAR						
MAKENA						
+	LUMARA HEALTH INC	1250MG/5ML (250MG/ML)	N021945	001	Feb 03, 2011	May CAHN

HYDROXYZINE HYDROCHLORIDE

TABLET; ORAL						
HYDROXYZINE HYDROCHLORIDE						
	@ ACTAVIS ELIZABETH	10MG	A089071	001	Jul 22, 1986	Aug CAHN
	@	25MG	A089072	001	Jul 22, 1986	Aug CAHN
	@	50MG	A089073	001	Jul 22, 1986	Aug CAHN
AB	EMCURE PHARMS USA	10MG	A204279	001	Aug 20, 2014	Aug NEWA
AB		25MG	A204279	002	Aug 20, 2014	Aug NEWA
AB		50MG	A204279	003	Aug 20, 2014	Aug NEWA
AB	SUN PHARM INDS INC	10MG	A040899	001	Jun 10, 2008	Jun CAHN
AB		25MG	A040899	002	Jun 10, 2008	Jun CAHN
AB		50MG	A040899	003	Jun 10, 2008	Jun CAHN
	@ WATSON LABS	10MG	A081149	001	Mar 18, 1994	May DISC
	@	25MG	A081150	001	Mar 18, 1994	May DISC

TABLET;ORAL							
HYDROXYZINE HYDROCHLORIDE							
	@	50MG		A081151	001	Mar 18, 1994	May DISC
<u>HYDROXYZINE PAMOATE</u>							
CAPSULE;ORAL							
HYDROXYZINE PAMOATE							
AB	EMCURE PHARMS USA	EQ 25MG HYDROCHLORIDE		A201507	001	Jun 03, 2013	Jun CPOT
AB		EQ 50MG HYDROCHLORIDE		A201507	002	Jun 03, 2013	Jun CPOT
	@ WATSON LABS	EQ 25MG HYDROCHLORIDE		A081165	001	Jul 31, 1991	May DISC
<u>IBANDRONATE SODIUM</u>							
INJECTABLE;INTRAVENOUS							
BONIVA							
AP	+ ROCHE	EQ 3MG BASE/3ML		N021858	001	Jan 06, 2006	Feb CFTG
IBANDRONATE SODIUM							
AP	AGILA SPECLTS	EQ 3MG BASE/3ML		A202671	001	Sep 02, 2014	Aug NEWA
AP	EMCURE PHARMS LTD	EQ 3MG BASE/3ML		A203987	001	Sep 02, 2014	Aug NEWA
AP	SAGENT PHARMS	EQ 3MG BASE/3ML		A202235	001	Sep 02, 2014	Aug NEWA
AP	SUN PHARM INDS LTD	EQ 3MG BASE/3ML		A090853	001	Feb 14, 2014	Feb NEWA
<u>IBUPROFEN</u>							
TABLET;ORAL							
IBUPROFEN							
	@ WATSON LABS	400MG		A070436	001	Aug 21, 1985	May DISC
	@	600MG		A070437	001	Aug 21, 1985	May DISC
<u>IDARUBICIN HYDROCHLORIDE</u>							
INJECTABLE;INJECTION							
IDARUBICIN HYDROCHLORIDE							
AP	EUROHLTH INTL	1MG/ML		A065275	001	Dec 14, 2006	Aug CAHN
AP		1MG/ML		A065288	001	May 15, 2007	Aug CAHN
	@ SANDOZ	1MG/ML		A091293	001	Mar 29, 2011	Nov DISC
<u>IDELALISIB</u>							
TABLET;ORAL							
ZYDELIG							
	GILEAD SCIENCES INC	100MG		N205858	001	Jul 23, 2014	Jul NEWA
	+	150MG		N205858	002	Jul 23, 2014	Jul NEWA
<u>IFOSEFAMIDE</u>							
INJECTABLE;INJECTION							
IFOSEFAMIDE							
AP	EUROHLTH INTL	1GM/20ML (50MG/ML)		A076619	001	Jun 29, 2011	Aug CAHN
AP		3GM/60ML (50MG/ML)		A076619	002	Jun 29, 2011	Aug CAHN
<u>IMIQUIMOD</u>							
CREAM;TOPICAL							
IMIQUIMOD							
AB	STRIDES ARCOLAB LTD	5%		A202002	001	Jun 24, 2014	Jun NEWA
AB	STRIDES PHARMA	5%		A202002	001	Jun 24, 2014	Aug CAHN
<u>INAMRINONE LACTATE</u>							
INJECTABLE;INJECTION							
AMRINONE LACTATE							
	+ EUROHLTH INTL	EQ 5MG BASE/ML		A075513	001	May 09, 2000	Aug CAHN
<u>INDAPAMIDE</u>							
TABLET;ORAL							
INDAPAMIDE							
	@ AMERIGEN PHARMS LTD	1.25MG		A075201	001	Dec 04, 1998	Jul CAHN
	@	2.5MG		A075201	002	Dec 04, 1998	Jul CAHN
	@ WATSON LABS	1.25MG		A074585	001	Sep 26, 1996	May DISC
	@	2.5MG		A074585	002	Sep 26, 1996	May DISC
<u>INDOMETHACIN</u>							
CAPSULE;ORAL							
INDOCIN							
	@ IROKO PHARMS LLC	25MG		N016059	001		May CAHN
	@	50MG		N016059	002		May CAHN

	CAPSULE;ORAL								
	INDOMETHACIN								
	@ CYCLE PHARMS LTD	25MG	A070353	001	Jun 18, 1985	Sep	CAHN		
	@	50MG	A070354	001	Jun 18, 1985	Sep	CAHN		
AB	SUN PHARM INDS INC	25MG	A091401	001	Mar 28, 2013	Jun	CAHN		
AB		50MG	A091401	002	Mar 28, 2013	Jun	CAHN		
	TIVORBEX								
	IROKO PHARMS LLC	20MG	N204768	001	Feb 24, 2014	Feb	NEWA		
	+	40MG	N204768	002	Feb 24, 2014	Feb	NEWA		
	CAPSULE, EXTENDED RELEASE;ORAL								
	INDOMETHACIN								
AB	MYLAN PHARMS INC	75MG	A202139	001	Mar 20, 2014	Mar	NEWA		
	SUSPENSION;ORAL								
	INDOMETHACIN								
	@ CYCLE PHARMS LTD	25MG/5ML	A071412	001	Mar 18, 1987	Sep	CAHN		
	<u>INDOMETHACIN SODIUM</u>								
	INJECTABLE;INJECTION								
	INDOMETHACIN SODIUM								
AP	EUROHLTH INTL	EQ 1MG BASE/VIAL	A078713	001	Jul 16, 2008	Aug	CAHN		
	<u>INSULIN ASPART RECOMBINANT</u>								
	INJECTABLE;SUBCUTANEOUS								
	NOVOLOG FLEXTOUCH								
	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N020986	005	Oct 31, 2013	Feb	NEWA	
	<u>INSULIN DETEMIR RECOMBINANT</u>								
	INJECTABLE;SUBCUTANEOUS								
	LEVEMIR FLEXTOUCH								
	+	NOVO NORDISK INC	300 UNITS/3ML (100 UNITS/ML)	N021536	005	Oct 31, 2013	Feb	NEWA	
	<u>INSULIN RECOMBINANT HUMAN</u>								
	POWDER;INHALATION								
	AFREZZA								
	MANNKIND	4 UNITS/INH	N022472	001	Jun 27, 2014	Jun	NEWA		
	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Jun	NEWA		
	SANOFI AVENTIS	4 UNITS/INH	N022472	001	Jun 27, 2014	Nov	CAHN		
	+	8 UNITS/INH	N022472	002	Jun 27, 2014	Nov	CAHN		
	<u>IPRATROPIUM BROMIDE</u>								
	SOLUTION;INHALATION								
	IPRATROPIUM BROMIDE								
AN	+	MYLAN SPECLT	0.02%	A074755	001	Jan 10, 1997	Mar	CAHN	
	SPRAY, METERED;NASAL								
	IPRATROPIUM BROMIDE								
AB	MYLAN SPECLT	0.021MG/SPRAY	A075552	001	Mar 31, 2003	May	CAHN		
AB		0.042MG/SPRAY	A075553	001	Mar 31, 2003	May	CAHN		
	<u>IRINOTECAN HYDROCHLORIDE</u>								
	INJECTABLE;INJECTION								
	IRINOTECAN HYDROCHLORIDE								
AP	ACTAVIS ELIZABETH	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Aug	CAHN		
AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Aug	CAHN		
AP	ACTAVIS TOTOWA	40MG/2ML (20MG/ML)	A078589	001	Feb 27, 2008	Oct	CAHN		
AP		100MG/5ML (20MG/ML)	A078589	002	Feb 27, 2008	Oct	CAHN		
AP	MUSTAFA NEVZAT ILAC	40MG/2ML (20MG/ML)	A090393	002	May 13, 2011	May	CAHN		
AP		100MG/5ML (20MG/ML)	A090393	003	May 13, 2011	May	CAHN		
	<u>ISOFLURANE</u>								
	LIQUID;INHALATION								
	ISOFLURANE								
AN	PIRAMAL ENT	99.9%	A074502	001	Jun 27, 1995	Feb	CAHN		
	<u>ISONIAZID</u>								
	TABLET;ORAL								
	ISONIAZID								
	@ HIKMA INTL PHARMS	100MG	A080212	001		Sep	CAHN		
	@	300MG	A087425	001		Sep	CAHN		
AA	THEPHARMANETWORK LLC	100MG	A202610	001	Oct 29, 2014	Oct	NEWA		
AA		300MG	A202610	002	Oct 29, 2014	Oct	NEWA		

ISONIAZID; RIFAMPIN

CAPSULE; ORAL

RIFAMPIN AND ISONIAZID

@ HIKMA INTL PHARMS

150MG; 300MG

A065221 001 Jul 29, 2005 Sep CAHN

ISOSORBIDE DINITRATE

CAPSULE, EXTENDED RELEASE; ORAL

DILATRATE-SR

+ AUXILIUM PHARMS LLC

40MG

N019790 001 Sep 02, 1988 Apr CAHN

TABLET; ORAL

ISORDIL

&gt;D&gt; AB VALEANT BERMUDA 10MG

N012093 002 Jul 29, 1988 Dec DISC

&gt;A&gt; @ 10MG

N012093 002 Jul 29, 1988 Dec DISC

&gt;D&gt; AB 20MG

N012093 006 Jul 29, 1988 Dec DISC

&gt;A&gt; @ 20MG

N012093 006 Jul 29, 1988 Dec DISC

&gt;D&gt; AB + 30MG

N012093 005 Jul 29, 1988 Dec DISC

&gt;A&gt; @ 30MG

N012093 005 Jul 29, 1988 Dec DISC

ISOSORBIDE DINITRATE

AB HIKMA INTL PHARMS 5MG

A086067 001 Oct 29, 1987 Jul CAHN

AB 10MG

A086066 001 Oct 29, 1987 Jul CAHN

AB 20MG

A088088 001 Nov 02, 1987 Jul CAHN

AB 30MG

A040591 001 Jan 10, 2007 Jul CAHN

&gt;D&gt; AB PAR PHARM 30MG

A087946 001 Jan 12, 1988 Dec CRLD

&gt;A&gt; AB + 30MG

A087946 001 Jan 12, 1988 Dec CRLD

TABLET; SUBLINGUAL

ISOSORBIDE DINITRATE

@ HIKMA INTL PHARMS 2.5MG

A086054 001 Oct 29, 1987 Jul CAHN

@ 5MG

A086055 001 Nov 02, 1987 Jul CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE DINITRATE

AB + SUN PHARM INDS INC 40MG

A040009 001 Dec 30, 1998 Jul CAHN

ISOSORBIDE MONONITRATE

TABLET; ORAL

ISOSORBIDE MONONITRATE

AB ANI PHARMS INC 20MG

A075147 001 Nov 27, 1998 Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

ISOSORBIDE MONONITRATE

@ ACTAVIS ELIZABETH 30MG

A075306 001 Dec 31, 1998 May DISC

@ 60MG

A075306 002 Dec 31, 1998 May DISC

ISOSULFAN BLUE

INJECTABLE; INJECTION

ISOSULFAN BLUE

+ MYLAN INSTITUTIONAL 1%

A090874 001 Jul 20, 2010 Sep CRLD

ISRADIPINE

CAPSULE; ORAL

ISRADIPINE

AB MIKAH PHARMA 2.5MG

A077169 001 Apr 24, 2006 May CMFD

@ 2.5MG

A077169 001 Apr 24, 2006 Feb DISC

AB 5MG

A077169 002 Apr 24, 2006 May CMFD

@ 5MG

A077169 002 Apr 24, 2006 Feb DISC

AB WATSON LABS 2.5MG

A077317 001 Jan 05, 2006 May CTEC

2.5MG

A077317 001 Jan 05, 2006 Feb CTEC

AB + 5MG

A077317 002 Jan 05, 2006 May CTEC

+ 5MG

A077317 002 Jan 05, 2006 Feb CTEC

IVERMECTIN

&gt;A&gt; CREAM; TOPICAL

&gt;A&gt; SOOLANTRA

&gt;A&gt; + GALDERMA LABS LP 1%

N206255 001 Dec 19, 2014 Dec NEWA

TABLET; ORAL

IVERMECTIN

AB EDENBRIDGE PHARMS 3MG

A204154 001 Oct 24, 2014 Oct NEWA

STROMECTOL

AB + MERCK SHARP DOHME 3MG

N050742 002 Oct 08, 1998 Oct CFTG



KETAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
KETALAR

AP	+	PAR STERILE PRODUCTS	EQ 10MG BASE/ML	N016812	001		Apr	CAHN
AP	+		EQ 50MG BASE/ML	N016812	002		Apr	CAHN
AP	+		EQ 100MG BASE/ML	N016812	003		Apr	CAHN

KETAMINE HYDROCHLORIDE

AP		EUROHLTH INTL	EQ 50MG BASE/ML	A074524	001	Mar 22, 1996	Aug	CAHN
AP			EQ 100MG BASE/ML	A074524	002	Mar 22, 1996	Aug	CAHN

KETOCONAZOLEAEROSOL, FOAM; TOPICAL  
EXTINA

AT	+	DELCOR ASSET CORP	2%	N021738	001	Jun 12, 2007	Jun	CAHN
----	---	-------------------	----	---------	-----	--------------	-----	------

TABLET; ORAL

KETOCONAZOLE

		@ APOTEX	200MG	A075912	001	Jan 10, 2002	Oct	DISC
		@ MUTUAL PHARMA	200MG	A075314	001	Jun 15, 1999	Oct	DISC
		@ PLIVA	200MG	A075362	001	Jun 15, 1999	Oct	DISC
AB	+	TEVA	200MG	A075273	001	Jun 15, 1999	Oct	CRLD
		NIZORAL						
		@ JANSSEN PHARMS	200MG	N018533	001		Oct	DISC
AB	+		200MG	N018533	001		Mar	CAHN

KETOROLAC TROMETHAMINE

INJECTABLE; INJECTION

KETOROLAC TROMETHAMINE

AP		AGILA SPECLTS	15MG/ML	A201155	001	Aug 04, 2014	Jul	NEWA
AP			30MG/ML	A201155	002	Aug 04, 2014	Jul	NEWA
		@ HIKMA MAPLE	15MG/ML	A075299	001	Nov 03, 1999	Jun	DISC
		@	15MG/ML	A075772	001	Jul 21, 2004	Jun	DISC
		@	30MG/ML	A075299	002	Nov 03, 1999	Jun	DISC
		@	30MG/ML	A075772	002	Jul 21, 2004	Jun	DISC
AP	+	HOSPIRA	15MG/ML	A074802	001	Jun 05, 1997	Jul	CRLD
AP	+		30MG/ML	A074802	002	Jun 05, 1997	Jul	CRLD
		@ SANDOZ	15MG/ML	A076271	001	Oct 06, 2004	Jul	DISC
		@ SUN PHARMA GLOBAL	15MG/ML	A078737	001	Oct 06, 2008	Jul	DISC
		@	30MG/ML	A078737	002	Oct 06, 2008	Jul	DISC
		@ WOCKHARDT	30MG/ML	A077943	001	Mar 27, 2007	Jun	DISC

SOLUTION/DROPS; OPHTHALMIC

ACUVAIL

AT	+	ALLERGAN	0.45%	N022427	001	Jul 22, 2009	Jan	CFTG
		KETOROLAC TROMETHAMINE						
		@ AKORN	0.45%	A203376	001	Feb 10, 2014	Feb	DISC
AT			0.45%	A203376	001	Feb 10, 2014	Jan	NEWA

TABLET; ORAL

KETOROLAC TROMETHAMINE

		@ CYCLE PHARMS LTD	10MG	A074790	001	Jun 26, 1997	Sep	CAHN
--	--	--------------------	------	---------	-----	--------------	-----	------

KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IRRIGATION

OMIDRIA

	+	OMEROS	EQ 2.88MG BASE/ML; EQ 10.16MG BASE/ML	N205388	001	May 30, 2014	Jun	CPOT
	+		EQ 4.24MG BASE/ML; EQ 12.4MG BASE/ML	N205388	001	May 30, 2014	May	NEWA

LABETALOL HYDROCHLORIDE

INJECTABLE; INJECTION

LABETALOL HYDROCHLORIDE

AP		EUROHLTH INTL	5MG/ML	A075303	001	May 28, 1999	Aug	CAHN
----	--	---------------	--------	---------	-----	--------------	-----	------

TABLET; ORAL

TRANDATE

AB		CNTY LINE PHARMS	100MG	N018716	001	May 24, 1985	Nov	CAHN
AB			200MG	N018716	002	Aug 01, 1984	Nov	CAHN
AB			300MG	N018716	003	Aug 01, 1984	Nov	CAHN
		@	400MG	N018716	004	Aug 01, 1984	Nov	CAHN
AB		PROMETHEUS LABS	100MG	N018716	001	May 24, 1985	Oct	CMFD
AB			200MG	N018716	002	Aug 01, 1984	Oct	CMFD
AB			300MG	N018716	003	Aug 01, 1984	Oct	CMFD

LAMIVUDINESOLUTION;ORAL  
EPIVIR

AA	+	VIIV HLTHCARE	10MG/ML	N020596	001	Nov 17, 1995	Oct CFTG
----	---	---------------	---------	---------	-----	--------------	----------

AA		SILARX PHARMS INC	10MG/ML	A203564	001	Oct 31, 2014	Oct NEWA
----	--	-------------------	---------	---------	-----	--------------	----------

TABLET;ORAL  
LAMIVUDINE

>A>	AB	LUPIN LTD	150MG	A205217	001	Dec 18, 2014	Dec NEWA
>A>	AB		300MG	A205217	002	Dec 18, 2014	Dec NEWA
>A>	AB	MYLAN PHARMS INC	100MG	A204002	001	Dec 31, 2014	Dec NEWA

LAMIVUDINE; ZIDOVUDINE

TABLET;ORAL

LAMIVUDINE AND ZIDOVUDINE

AB		HETERO LABS LTD V	150MG;300MG	A203259	001	Feb 03, 2014	Jan NEWA
AB		MYLAN PHARMS INC	150MG;300MG	A204005	001	Aug 28, 2014	Aug NEWA

LAMOTRIGINE

TABLET;ORAL

LAMOTRIGINE

	@	ACTAVIS ELIZABETH	25MG	A078669	001	Apr 08, 2011	Aug CAHN
	@		100MG	A078669	002	Apr 08, 2011	Aug CAHN
	@		150MG	A078669	003	Apr 08, 2011	Aug CAHN
	@		200MG	A078669	004	Apr 08, 2011	Aug CAHN
	@	ACTAVIS TOTOWA	25MG	A078669	001	Apr 08, 2011	Oct CAHN
	@		25MG	A078669	001	Apr 08, 2011	May DISC
	@		100MG	A078669	002	Apr 08, 2011	Oct CAHN
	@		100MG	A078669	002	Apr 08, 2011	May DISC
	@		150MG	A078669	003	Apr 08, 2011	Oct CAHN
	@		150MG	A078669	003	Apr 08, 2011	May DISC
	@		200MG	A078669	004	Apr 08, 2011	Oct CAHN
	@		200MG	A078669	004	Apr 08, 2011	May DISC
	@	PHARMASCIENCE INC	25MG	A078310	001	Feb 04, 2009	Jul DISC
BX			25MG	A078310	001	Feb 04, 2009	Jul CAHN
	@		100MG	A078310	002	Feb 04, 2009	Jul DISC
BX			100MG	A078310	002	Feb 04, 2009	Jul CAHN
	@		150MG	A078310	003	Feb 04, 2009	Jul DISC
BX			150MG	A078310	003	Feb 04, 2009	Jul CAHN
	@		200MG	A078310	004	Feb 04, 2009	Jul DISC
BX			200MG	A078310	004	Feb 04, 2009	Jul CAHN

TABLET, CHEWABLE;ORAL  
LAMOTRIGINE

AB		ALEMBIC PHARMS LTD	5MG	A201168	001	Jun 12, 2014	May NEWA
AB			25MG	A201168	002	Jun 12, 2014	May NEWA
AB		JUBILANT GENERICS	5MG	A200220	001	Feb 28, 2011	Jul CAHN
AB			25MG	A200220	002	Feb 28, 2011	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
LAMOTRIGINE

AB		IMPAX LABS INC	25MG	A200828	001	Jul 15, 2013	Jul CAHN
AB			50MG	A200828	002	Jul 15, 2013	Jul CAHN
AB			100MG	A200828	003	Jul 15, 2013	Jul CAHN
AB			200MG	A200828	004	Jul 15, 2013	Jul CAHN

LANREOTIDE ACETATE>D> INJECTABLE;SUBCUTANEOUS  
>D> SOMATULINE DEPOT

>D>	+	IPSEN PHARMA	EQ 60MG BASE	N022074	001	Aug 30, 2007	Dec CDFR
>D>	+		EQ 90MG BASE	N022074	002	Aug 30, 2007	Dec CDFR
>D>	+		EQ 120MG BASE	N022074	003	Aug 30, 2007	Dec CDFR

>A> SOLUTION;SUBCUTANEOUS  
>A> SOMATULINE DEPOT

>A>	+	IPSEN PHARMA	EQ 60MG BASE/0.2ML (EQ 60MG BASE/0.2ML)	N022074	001	Aug 30, 2007	Dec CDFR
>A>	+		EQ 90MG BASE/0.3ML (EQ 90MG BASE/0.3ML)	N022074	002	Aug 30, 2007	Dec CDFR
>A>	+		EQ 120MG BASE/0.5ML (EQ 120MG BASE/0.5ML)	N022074	003	Aug 30, 2007	Dec CDFR

LANSOPRAZOLE

TABLET, DELAYED RELEASE, ORALLY DISINTEGRATING;ORAL  
LANSOPRAZOLE

@ ANI PHARMS INC	15MG	A078730	001	Oct 15, 2010	Jan CAHN
@	30MG	A078730	002	Oct 15, 2010	Jan CAHN

LANTHANUM CARBONATE

POWDER;ORAL  
FOSRENOL

+ SHIRE DEV LLC	EQ 1GM BASE	N204734	002	Sep 24, 2014	Sep NEWA
	EQ 750MG BASE	N204734	001	Sep 24, 2014	Sep NEWA

LEDIPASVIR; SOFOSBUVIR

TABLET;ORAL  
HARVONI

+ GILEAD SCIENCES INC	90MG;400MG	N205834	001	Oct 10, 2014	Sep NEWA
-----------------------	------------	---------	-----	--------------	----------

LEFLUNOMIDE

TABLET;ORAL  
LEFLUNOMIDE

@ SANDOZ	10MG	A077087	001	Sep 13, 2005	Nov DISC
@	20MG	A077087	002	Sep 13, 2005	Nov DISC

LETROZOLE

TABLET;ORAL  
LETROZOLE

@ ACTAVIS ELIZABETH	2.5MG	A090292	001	Jul 13, 2011	Aug CAHN
@ ACTAVIS TOTOWA	2.5MG	A090292	001	Jul 13, 2011	Oct CAHN
@	2.5MG	A090292	001	Jul 13, 2011	May DISC
@ IMPAX LABS	2.5MG	A091638	001	Jun 03, 2011	Oct DISC
AB LANNETT HOLDINGS INC	2.5MG	A202048	001	Oct 29, 2014	Oct NEWA

LEUCOVORIN CALCIUM

INJECTABLE;INJECTION  
LEUCOVORIN CALCIUM

AP + EUROHLTH INTL	EQ 50MG BASE/VIAL	A089384	001	Sep 14, 1987	Aug CAHN
AP +	EQ 100MG BASE/VIAL	A089717	001	Mar 28, 1988	Aug CAHN
	LEUCOVORIN CALCIUM PRESERVATIVE FREE				
+ EUROHLTH INTL	EQ 10MG BASE/ML	A040347	001	Apr 25, 2000	Aug CAHN
AP +	EQ 200MG BASE/VIAL	A040056	001	May 23, 1995	Aug CAHN
AP +	EQ 350MG BASE/VIAL	A040335	001	Apr 20, 2000	Aug CAHN

LEUPROLIDE ACETATE

INJECTABLE;INJECTION  
LUPRON DEPOT

+ ABBVIE ENDOCRINE INC	3.75MG	N020011	002	Oct 26, 1995	May NEWA
------------------------	--------	---------	-----	--------------	----------

LEVALBUTEROL HYDROCHLORIDE

SOLUTION;INHALATION  
LEVALBUTEROL HYDROCHLORIDE

AN MYLAN SPECLT	EQ 0.0103% BASE	A077800	001	Mar 15, 2013	May CAHN
AN	EQ 0.021% BASE	A077800	002	Mar 15, 2013	May CAHN
AN	EQ 0.042% BASE	A077800	003	Mar 15, 2013	May CAHN
AN TEVA PARENTERAL	EQ 0.25% BASE	A200875	001	Sep 11, 2014	Sep NEWA
AN WATSON LABS INC	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	Jun CMFD
@	EQ 0.0103% BASE	A077756	003	Apr 09, 2008	May DISC
AN	EQ 0.021% BASE	A077756	001	Apr 09, 2008	Jun CMFD
@	EQ 0.021% BASE	A077756	001	Apr 09, 2008	May DISC
AN	EQ 0.042% BASE	A077756	002	Apr 09, 2008	Jun CMFD
@	EQ 0.042% BASE	A077756	002	Apr 09, 2008	May DISC
	XOPENEX				
AN + OAK PHARMS INC	EQ 0.0103% BASE	N020837	003	Jan 30, 2002	Oct CAHN
AN +	EQ 0.021% BASE	N020837	001	Mar 25, 1999	Oct CAHN
AN +	EQ 0.042% BASE	N020837	002	Mar 25, 1999	Oct CAHN
AN +	EQ 0.25% BASE	N020837	004	Jul 18, 2003	Oct CAHN

LEVETIRACETAM

## TABLET; ORAL

## LEVETIRACETAM

	@ SANDOZ	1GM	A077324	004	Jan 15, 2009	Jun	DISC
	@	250MG	A077324	001	Jan 15, 2009	Jun	DISC
	@	500MG	A077324	002	Jan 15, 2009	Jun	DISC
	@	750MG	A077324	003	Jan 15, 2009	Jun	DISC
AB	VINTAGE PHARMS	250MG	A077319	001	Mar 20, 2009	Feb	CAHN
AB		500MG	A077319	002	Mar 20, 2009	Feb	CAHN
AB		750MG	A077319	003	Mar 20, 2009	Feb	CAHN
	@ WATSON LABS INC	1GM	A078797	001	Jan 15, 2009	May	DISC
	@	250MG	A078797	002	Jan 15, 2009	Oct	DISC
	@	500MG	A078797	003	Jan 15, 2009	Oct	DISC
	@	750MG	A078797	004	Jan 15, 2009	Oct	DISC

## TABLET, EXTENDED RELEASE; ORAL

## LEVETIRACETAM

AB	VINTAGE PHARMS	500MG	A201464	001	May 25, 2012	Feb	CAHN
AB		750MG	A201464	002	May 25, 2012	Feb	CAHN

LEVOBUNOLOL HYDROCHLORIDE

## SOLUTION/DROPS; OPHTHALMIC

## LEVOBUNOLOL HYDROCHLORIDE

>A>	AT	ALCON RES LTD	0.5%	A074850	001	Oct 28, 1996	Dec	CAHN
>D>	AT	FALCON PHARMS	0.5%	A074850	001	Oct 28, 1996	Dec	CAHN

LEVOCARNITINE

## INJECTABLE; INJECTION

## LEVOCARNITINE

AP	EUROHLTH INTL	200MG/ML	A075567	001	Mar 29, 2001	Aug	CAHN
----	---------------	----------	---------	-----	--------------	-----	------

LEVOCETIRIZINE DIHYDROCHLORIDE

## SOLUTION; ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

AA	APOTEX INC	2.5MG/5ML	A202915	001	Aug 21, 2014	Aug	NEWA
AA	L FERRIGO CO	2.5MG/5ML	A091263	001	Nov 07, 2011	Jan	CAHN

## TABLET; ORAL

## LEVOCETIRIZINE DIHYDROCHLORIDE

	@ SANDOZ	5MG	A090486	001	Mar 26, 2013	May	DISC
AB	SCIEGEN PHARMS INC	5MG	A203646	001	Sep 09, 2014	Aug	NEWA

LEVOFLOXACIN

## SOLUTION/DROPS; OPHTHALMIC

## IQUIX

## @ SANTEN

1.5%

N021571 001 Mar 01, 2004 Jun DISC

## LEVOFLOXACIN

AT	WATSON LABS INC	0.5%	A076826	001	Feb 10, 2011	May	CAHN
----	-----------------	------	---------	-----	--------------	-----	------

## TABLET; ORAL

## LEVOFLOXACIN

>A>	AB	HETERO LABS LTD V	250MG	A202801	001	Jan 08, 2015	Dec	NEWA
>A>	AB		500MG	A202801	002	Jan 08, 2015	Dec	NEWA
>A>	AB		750MG	A202801	003	Jan 08, 2015	Dec	NEWA
	@	WATSON LABS INC	250MG	A201484	001	Nov 22, 2013	Oct	DISC
	@		500MG	A201484	002	Nov 22, 2013	Oct	DISC
	@		750MG	A201484	003	Nov 22, 2013	Oct	DISC

LEVONORGESTREL

## TABLET; ORAL

## LEVONORGESTREL

## @ LUPIN LTD

0.75MG

A091328 001 Jan 23, 2013 Sep DISC

## @ WATSON LABS

0.75MG

A078666 001 Jun 24, 2009 Aug DISC

LEVORPHANOL TARTRATE

## TABLET; ORAL

## LEVORPHANOL TARTRATE

+	ROXANE	2MG	A074278	001	Mar 31, 2000	Feb	CRLD
---	--------	-----	---------	-----	--------------	-----	------

LIDOCAINE HYDROCHLORIDE

INJECTABLE; INJECTION							
LIDOCAINE HYDROCHLORIDE							
AP	AGILA SPECLTS	2%	A202242	001	Apr 11, 2014	Mar	NEWA
LIDOPEN							
	@ MERIDIAN MEDCL TECHN	10%	N017549	001		Mar	DISC
XYLOCAINE PRESERVATIVE FREE							
	@ FRESENIUS KABI USA	10%	N016801	003		Jun	DISC
+		10%	N016801	003		Mar	CTEC
JELLY; TOPICAL							
ANESTACON							
	@ BANNER PHARMACAPS	2%	A080429	001		Jun	CAHN
	@ DSM PHARMS INC	2%	A080429	001		Jan	CAHN
GLYDO							
AT	SAGENT PHARMS	2%	A201094	001	Apr 28, 2014	Apr	NEWA
LIDOCAINE HYDROCHLORIDE							
AT	WATSON LABS INC	2%	A040837	001	Mar 23, 2011	May	CAHN
SOLUTION; TOPICAL							
LIDOCAINE HYDROCHLORIDE							
AT	IGI LABS INC	4%	A204494	001	Mar 12, 2014	Feb	NEWA
SYSTEM; INTRADERMAL							
ZINGO							
	POWDER PHARMS	0.5MG	N022114	001	Aug 16, 2007	Mar	CMFD

LIDOCAINE; PRILOCAINE

CREAM; TOPICAL							
EMLA							
AB	+ WATSON LABS INC	2.5%; 2.5%	N019941	001	Dec 30, 1992	May	CAHN

LIOTHYRONINE SODIUM

INJECTABLE; INJECTION							
TRIOSTAT							
AP	+ PAR STERILE PRODUCTS	EQ 0.01MG BASE/ML	N020105	001	Dec 31, 1991	Apr	CAHN

LIRAGLUTIDE RECOMBINANT

>A>	SOLUTION; SUBCUTANEOUS						
>A>	SAXENDA						
>A>	+ NOVO NORDISK INC	18MG/3ML (6MG/ML)	N206321	001	Dec 23, 2014	Dec	NEWA

LISDEXAMFETAMINE DIMESYLATE

CAPSULE; ORAL							
VYVANSE							
	SHIRE DEVELOPMENT	10MG	N021977	007	Oct 30, 2014	Oct	NEWA

LISINOPRIL

TABLET; ORAL							
LISINOPRIL							
AB	HIKMA INTL PHARMS	2.5MG	A076063	001	Jul 01, 2002	Jul	CAHN
AB		5MG	A076063	002	Jul 01, 2002	Jul	CAHN
AB		10MG	A076063	003	Jul 01, 2002	Jul	CAHN
AB		20MG	A076063	004	Jul 01, 2002	Jul	CAHN
AB		30MG	A076063	006	Jun 27, 2003	Jul	CAHN
AB		40MG	A076063	005	Jul 01, 2002	Jul	CAHN

LITHIUM CARBONATE

CAPSULE; ORAL							
LITHIUM CARBONATE							
AB	HIKMA INTL PHARMS	150MG	A076243	002	Feb 24, 2003	Sep	CAHN
AB		300MG	A076243	001	Jun 27, 2002	Sep	CAHN
TABLET; ORAL							
LITHIUM CARBONATE							
	@ HIKMA INTL PHARMS	300MG	A078715	001	Dec 28, 2010	Sep	CAHN
TABLET, EXTENDED RELEASE; ORAL							
LITHIUM CARBONATE							
AB	HIKMA INTL PHARMS	450MG	A076490	001	Jun 17, 2003	Sep	CAHN
LITHOBID							
AB	+ ANI PHARMS INC	300MG	N018027	001		Jun	CAHN

LOMUSTINECAPSULE; ORAL  
GLEOSTINE

CORDEN PHARMA	10MG	N017588	001		Aug	CTNA
	40MG	N017588	002		Aug	CTNA
+	100MG	N017588	003		Aug	CTNA

LORAZEPAMINJECTABLE; INJECTION  
ATIVAN

AP	+	HIKMA MAPLE	2MG/ML	N018140	001		Jun	CAHN
AP	+		4MG/ML	N018140	002		Jun	CAHN

TABLET; ORAL  
LORAZEPAM

@ WATSON LABS	1MG	A071118	001	Jul 24, 1986	May	DISC
---------------	-----	---------	-----	--------------	-----	------

LOSARTAN POTASSIUMTABLET; ORAL  
LOSARTAN POTASSIUM

@ WATSON LABS	25MG	A091129	001	Oct 06, 2010	Oct	DISC
@	50MG	A091129	002	Oct 06, 2010	Oct	DISC
@	100MG	A091129	003	Oct 06, 2010	Oct	DISC

LOTEPREDNOL ETABONATEGEL; OPHTHALMIC  
LOTEMAX

+	BAUSCH AND LOMB INC	0.5%	N202872	001	Sep 28, 2012	Feb	CAHN
---	---------------------	------	---------	-----	--------------	-----	------

LUBIPROSTONECAPSULE; ORAL  
AMITIZA

SUCAMPO PHARMA LLC	8MCG	N021908	002	Apr 29, 2008	Aug	CAHN
+	24MCG	N021908	001	Jan 31, 2006	Aug	CAHN

LULICONAZOLECREAM; TOPICAL  
LUZU

+	MEDICIS	1%	N204153	001	Nov 14, 2013	Jan	CRLD
---	---------	----	---------	-----	--------------	-----	------

MAFENIDE ACETATEFOR SOLUTION; TOPICAL  
MAFENIDE ACETATE

AT		PAR FORM	5%	A201511	001	Feb 12, 2013	Aug	CTEC
----	--	----------	----	---------	-----	--------------	-----	------

AT	+	MYLAN INSTITUTIONAL	5%	N019832	003	Jun 05, 1998	Aug	CTEC
----	---	---------------------	----	---------	-----	--------------	-----	------

MAGNESIUM SULFATEINJECTABLE; INJECTION  
MAGNESIUM SULFATE

>A>	AP	EXELA PHARMA SCS LLC	500MG/ML	A206039	001	Dec 18, 2014	Dec	NEWA
	AP	+	HOSPIRA	A075151	001	Apr 25, 2000	Jun	CRLD

MALATHIONLOTION; TOPICAL  
MALATHION

@ MYLAN PHARMS INC	0.5%	A078743	001	Mar 06, 2009	Mar	DISC
--------------------	------	---------	-----	--------------	-----	------

MANNITOLPOWDER; INHALATION  
ARIDOL KIT

@ PHARMAXIS LTD	N/A, 5MG, 10MG, 20MG, 40MG	N022368	001	Oct 05, 2010	Sep	DISC
-----------------	----------------------------	---------	-----	--------------	-----	------

MEBENDAZOLETABLET, CHEWABLE; ORAL  
MEBENDAZOLE

+	AMEDRA PHARMS LLC	100MG	A073580	001	Jan 04, 1995	Jun	CAHN
---	-------------------	-------	---------	-----	--------------	-----	------

MECHLORETHAMINE HYDROCHLORIDEGEL; TOPICAL  
VALCHLOR

+ ACTELION PHARMS LTD EQ 0.016% BASE N202317 001 Aug 23, 2013 Jun CPOT

MECLIZINE HYDROCHLORIDETABLET; ORAL  
ANTIVERT

@ CITRON PHARMA LLC	12.5MG	N010721	006		Oct	DISC
@	25MG	N010721	004		Oct	DISC
@	50MG	N010721	001	Jan 20, 1982	Oct	DISC
MECLIZINE HYDROCHLORIDE						
@ AMNEAL PHARMS	50MG	A201451	003	Feb 23, 2011	Oct	DISC
@ MYLAN PHARMS INC	50MG	A202640	003	Sep 17, 2012	Oct	DISC
@ PAR PHARM	50MG	A089674	001	Mar 31, 1988	Oct	DISC
@ WATSON LABS	25MG	A085740	001		May	DISC

MEDROXYPROGESTERONE ACETATETABLET; ORAL  
MEDROXYPROGESTERONE ACETATE

@ USL PHARMA 10MG A088484 001 Jul 26, 1984 Mar DISC

MEFENAMIC ACIDCAPSULE; ORAL  
MEFENAMIC ACID

AB VINTAGE PHARMS LLC 250MG A091608 001 Jun 02, 2014 May NEWA

MEGESTROL ACETATESUSPENSION; ORAL  
MEGACE ES

AB + PAR PHARM 125MG/ML N021778 001 Jul 05, 2005 Aug CFTG

AB	MEGESTROL ACETATE					
AB	TWI PHARMS INC	125MG/ML	A203139	001	Aug 27, 2014	Aug NEWA

MELOXICAMTABLET; ORAL  
MELOXICAM

AB	STRIDES PHARMA	7.5MG	A077928	001	May 13, 2009	Aug CAHN
AB		15MG	A077928	002	May 13, 2009	Aug CAHN
AB	SUN PHARM INDS INC	7.5MG	A077937	001	Jul 19, 2006	Jul CAHN
AB		15MG	A077937	002	Jul 19, 2006	Jul CAHN
	@ YABAO PHARM	7.5MG	A077933	001	Jul 19, 2006	May CAHN
	@	15MG	A077933	002	Jul 19, 2006	May CAHN

MELPHALAN HYDROCHLORIDEINJECTABLE; INJECTION  
MELPHALAN HYDROCHLORIDE

AP EUROHLTH INTL EQ 50MG BASE/VIAL A090303 001 Oct 28, 2010 Aug CAHN

MEMANTINE HYDROCHLORIDETABLET; ORAL  
MEMANTINE HYDROCHLORIDE

AB	@ DR REDDYS LABS LTD	5MG	A090048	001	Apr 14, 2010	Jul DISC
AB		5MG	A090048	001	Apr 14, 2010	Jun CMFD
	@	10MG	A090048	002	Apr 14, 2010	Jul DISC
AB		10MG	A090048	002	Apr 14, 2010	Jun CMFD
NAMENDA						
AB	FOREST LABS	5MG	N021487	001	Oct 16, 2003	Sep CMFD
	@	5MG	N021487	001	Oct 16, 2003	Aug DISC
		5MG	N021487	001	Oct 16, 2003	Jul CTEC
AB		5MG	N021487	001	Oct 16, 2003	Jun CTEC
AB	+	10MG	N021487	002	Oct 16, 2003	Sep CMFD
	@	10MG	N021487	002	Oct 16, 2003	Aug DISC
	+	10MG	N021487	002	Oct 16, 2003	Jul CTEC
AB	+	10MG	N021487	002	Oct 16, 2003	Jun CTEC

MEPERIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPERIDINE HYDROCHLORIDE

@ WATSON LABS 50MG/ML

A073444 001 Mar 17, 1992 May DISC

@ 100MG/ML

A073445 001 Mar 17, 1992 May DISC

MEPERIDINE HYDROCHLORIDE PRESERVATIVE FREE

@ INTL MEDICATION 10MG/ML

A081309 001 Aug 30, 1993 Mar DISC

@ WATSON LABS 10MG/ML

A073443 001 Mar 17, 1992 May DISC

TABLET; ORAL

MEPERIDINE HYDROCHLORIDE

AA SUN PHARM INDS INC 50MG

A040446 001 Aug 08, 2002 Jul CAHN

AA 100MG

A040446 002 Aug 08, 2002 Jul CAHN

@ WATSON LABS 50MG

A040186 001 Jun 30, 1997 May DISC

@ 100MG

A040186 002 Jun 30, 1997 May DISC

MEPIVACAINE HYDROCHLORIDE

INJECTABLE; INJECTION

MEPIVACAINE HYDROCHLORIDE

@ WATSON LABS 1%

A088769 001 Nov 20, 1984 May DISC

@ 2%

A088770 001 Nov 20, 1984 May DISC

MERCAPTOPURINE

SUSPENSION; ORAL

PURIXAN

+ NOVA LABS LTD 20MG/ML

N205919 001 Apr 28, 2014 Apr NEWA

TABLET; ORAL

MERCAPTOPURINE

AB + ROXANE 50MG

A040528 001 Feb 13, 2004 Nov CRLD

PURINETHOL

@ TEVA 50MG

N009053 002 Nov DISC

MESALAMINE

SUPPOSITORY; RECTAL

CANASA

+ FOREST LABS INC 1GM

N021252 002 Nov 05, 2004 Apr CAHN

@ 500MG

N021252 001 Jan 05, 2001 Apr CAHN

MESNA

INJECTABLE; INTRAVENOUS

MESNA

AP AGILA SPECLTS 100MG/ML

A203364 001 Jul 18, 2014 Jul NEWA

AP EUROHLTH INTL 100MG/ML

A075739 001 Jan 09, 2004 Aug CAHN

METAPROTERENOL SULFATE

SOLUTION; INHALATION

METAPROTERENOL SULFATE

AN + MYLAN SPECLT 0.4%

A071786 001 Aug 05, 1988 May CAHN

AN + 0.6%

A070804 001 Aug 17, 1987 May CAHN

METFORMIN HYDROCHLORIDE

TABLET; ORAL

METFORMIN HYDROCHLORIDE

AB ATLAS PHARMS LLC 1GM

A076033 003 Jan 24, 2002 May CAHN

AB 500MG

A076033 001 Jan 24, 2002 May CAHN

AB 850MG

A076033 002 Jan 24, 2002 May CAHN

AB SUN PHARM INDS INC 1GM

A075967 003 Jan 29, 2002 Jul CAHN

AB 500MG

A075967 001 Jan 29, 2002 Jul CAHN

AB 850MG

A075967 002 Jan 29, 2002 Jul CAHN

@ WATSON LABS 1GM

A075979 003 Jan 24, 2002 May DISC

@ 500MG

A075979 001 Jan 24, 2002 May DISC

@ 850MG

A075979 002 Jan 24, 2002 May DISC

AB ZYDUS HLTHCARE 1GM

A203686 003 Aug 28, 2014 Aug NEWA

AB 500MG

A203686 001 Aug 28, 2014 Aug NEWA

AB 850MG

A203686 002 Aug 28, 2014 Aug NEWA

TABLET, EXTENDED RELEASE; ORAL

GLUMETZA

+ SALIX PHARMS INC 1GM

N021748 002 Jun 03, 2005 Feb CTEC

500MG

N021748 001 Jun 03, 2005 Feb CTEC

+ SANTARUS INC 1GM

N021748 002 Jun 03, 2005 Mar CAHN

500MG

N021748 001 Jun 03, 2005 Mar CAHN



METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE

AB	TEVA PHARMS USA	500MG;EQ 15MG BASE	A091155	001	Mar 10, 2014	Feb NEWA
AB		850MG;EQ 15MG BASE	A091155	002	Mar 10, 2014	Feb NEWA

METFORMIN HYDROCHLORIDE; ROSIGLITAZONE MALEATE

TABLET; ORAL

AVANDAMET

AB	SB PHARMCO	1GM;EQ 2MG BASE	N021410	004	Aug 25, 2003	Apr CFTG
AB	+	1GM;EQ 4MG BASE	N021410	005	Aug 25, 2003	Apr CFTG
AB		500MG;EQ 2MG BASE	N021410	002	Oct 10, 2002	Apr CFTG
AB		500MG;EQ 4MG BASE	N021410	003	Oct 10, 2002	Apr CFTG

ROSIGLITAZONE MALEATE AND METFORMIN HYDROCHLORIDE

AB	TEVA	1GM;EQ 4MG BASE	A077337	004	May 07, 2014	Apr NEWA
AB		1GM;EQ 2MG BASE	A077337	003	May 07, 2014	Apr NEWA
AB		500MG;EQ 2MG BASE	A077337	001	May 07, 2014	Apr NEWA
AB		500MG;EQ 4MG BASE	A077337	002	May 07, 2014	Apr NEWA

METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

KOMBIGLYZE XR

	ASTRAZENECA AB	1GM;EQ 2.5MG BASE	N200678	003	Nov 05, 2010	Apr CAHN
+		1GM;EQ 5MG BASE	N200678	002	Nov 05, 2010	Apr CAHN
		500MG;EQ 5MG BASE	N200678	001	Nov 05, 2010	Apr CAHN

METHAZOLAMIDE

TABLET; ORAL

METHAZOLAMIDE

AB	ANI PHARMS INC	25MG	A040001	001	Jun 30, 1993	Jan CAHN
AB		50MG	A040001	002	Jun 30, 1993	Jan CAHN

METHIMAZOLE

TABLET; ORAL

METHIMAZOLE

AB	SUN PHARM INDS INC	5MG	A040870	001	Sep 25, 2007	Jul CAHN
AB		10MG	A040870	002	Sep 25, 2007	Jul CAHN
AB	VINTAGE PHARMS	5MG	A202068	001	Mar 07, 2012	Feb CAHN
AB		10MG	A202068	002	Mar 07, 2012	Feb CAHN

METHOCARBAMOL

SOLUTION; IM-IV

METHOCARBAMOL

AP	MYLAN INSTITUTIONAL	1GM/10ML (100MG/ML)	A204404	001	Dec 05, 2014	Nov NEWA
AP	+	ROBAXIN				
AP	+	HIKMA MAPLE	1GM/10ML (100MG/ML)	N011790	001	Nov CFTG

TABLET; ORAL

METHOCARBAMOL

AA	HIKMA INTL PHARMS	500MG	A085159	001		Jul CAHN
AA		750MG	A085123	001		Jul CAHN
	@ WATSON LABS	500MG	A085180	001		May DISC
	@	750MG	A085192	001		May DISC
	ROBAXIN					
AA	+	AUXILIUM PHARMS LLC	500MG	N011011	004	Apr CAHN
		ROBAXIN-750				
AA	+	AUXILIUM PHARMS LLC	750MG	N011011	006	Apr CAHN

METHOHEXITAL SODIUM

INJECTABLE; INJECTION

BREVITAL SODIUM

+	PAR STERILE PRODUCTS	2.5GM/VIAL	N011559	002		Apr CAHN
@		5GM/VIAL	N011559	003		Apr CAHN
+		200MG/VIAL	N011559	004	Dec 21, 2012	Apr CAHN
+		500MG/VIAL	N011559	001		Apr CAHN

METHOTREXATE

SOLUTION; SUBCUTANEOUS

OTREXUP

>D>	ANTARES PHARMA INC	7.5MG/0.4ML	N204824	005	Nov 07, 2014	Dec CPOT
>A>		7.5MG/0.4ML (7.5MG/0.4ML)	N204824	005	Nov 07, 2014	Dec CPOT
		7.5MG/0.4ML	N204824	005	Nov 07, 2014	Nov NEWA

SOLUTION; SUBCUTANEOUS  
OTREXUP

>D>		10MG/0.4ML	N204824	001	Oct 11, 2013	Dec CPOT
>A>		10MG/0.4ML (10MG/0.4ML)	N204824	001	Oct 11, 2013	Dec CPOT
>D>		15MG/0.4ML	N204824	002	Oct 11, 2013	Dec CPOT
>A>		15MG/0.4ML (15MG/0.4ML)	N204824	002	Oct 11, 2013	Dec CPOT
>D>		20MG/0.4ML	N204824	003	Oct 11, 2013	Dec CPOT
>A>		20MG/0.4ML (20MG/0.4ML)	N204824	003	Oct 11, 2013	Dec CPOT
>D>	+	25MG/0.4ML	N204824	004	Oct 11, 2013	Dec CPOT
>A>	+	25MG/0.4ML (25MG/0.4ML)	N204824	004	Oct 11, 2013	Dec CPOT

## RASUVO

>D>	MEDAC PHARMA INC	7.5MG/0.15ML	N205776	001	Jul 10, 2014	Dec CPOT
>A>		7.5MG/0.15ML (7.5MG/0.15ML)	N205776	001	Jul 10, 2014	Dec CPOT
		7.5MG/0.15ML	N205776	001	Jul 10, 2014	Jul NEWA
>D>		10MG/0.20ML	N205776	002	Jul 10, 2014	Dec CPOT
>A>		10MG/0.20ML (10MG/0.20ML)	N205776	002	Jul 10, 2014	Dec CPOT
		10MG/0.20ML	N205776	002	Jul 10, 2014	Jul NEWA
>D>		12.5MG/0.25ML	N205776	003	Jul 10, 2014	Dec CPOT
>A>		12.5MG/0.25ML (12.5MG/0.25ML)	N205776	003	Jul 10, 2014	Dec CPOT
		12.5MG/0.25ML	N205776	003	Jul 10, 2014	Jul NEWA
>D>		15MG/0.30ML	N205776	004	Jul 10, 2014	Dec CPOT
>A>		15MG/0.30ML (15MG/0.30ML)	N205776	004	Jul 10, 2014	Dec CPOT
		15MG/0.30ML	N205776	004	Jul 10, 2014	Jul NEWA
>D>		17.5MG/0.35ML	N205776	005	Jul 10, 2014	Dec CPOT
>A>		17.5MG/0.35ML (17.5MG/0.35ML)	N205776	005	Jul 10, 2014	Dec CPOT
		17.5MG/0.35ML	N205776	005	Jul 10, 2014	Jul NEWA
>D>		20MG/0.4ML	N205776	006	Jul 10, 2014	Dec CPOT
>A>		20MG/0.4ML (20MG/0.4ML)	N205776	006	Jul 10, 2014	Dec CPOT
		20MG/0.4ML	N205776	006	Jul 10, 2014	Jul NEWA
>D>		22.5MG/0.45ML	N205776	007	Jul 10, 2014	Dec CPOT
>A>		22.5MG/0.45ML (22.5MG/0.45ML)	N205776	007	Jul 10, 2014	Dec CPOT
		22.5MG/0.45ML	N205776	007	Jul 10, 2014	Jul NEWA
>D>		25MG/0.5ML	N205776	008	Jul 10, 2014	Dec CPOT
>A>		25MG/0.5ML (25MG/0.5ML)	N205776	008	Jul 10, 2014	Dec CPOT
		25MG/0.5ML	N205776	008	Jul 10, 2014	Jul NEWA
>D>		27.5MG/0.55ML	N205776	009	Jul 10, 2014	Dec CPOT
>A>		27.5MG/0.55ML (27.5MG/0.55ML)	N205776	009	Jul 10, 2014	Dec CPOT
		27.5MG/0.55ML	N205776	009	Jul 10, 2014	Jul NEWA
>D>		30MG/0.6ML	N205776	010	Jul 10, 2014	Dec CPOT
>A>		30MG/0.6ML (30MG/0.6ML)	N205776	010	Jul 10, 2014	Dec CPOT
		30MG/0.6ML	N205776	010	Jul 10, 2014	Jul NEWA

METHOTREXATE SODIUMINJECTABLE; INJECTION  
METHOTREXATE SODIUM

AP	+	EUROHLTH INTL	EQ 100MG BASE/4ML (EQ 25MG BASE/ML)	A089341	001	Sep 16, 1986	Aug CAHN
	+		EQ 200MG BASE/8ML (EQ 25MG BASE/ML)	A089342	001	Sep 16, 1986	Aug CAHN
			METHOTREXATE SODIUM PRESERVATIVE FREE				
	+	EUROHLTH INTL	EQ 1GM BASE/VIAL	A040632	001	Aug 12, 2005	Aug CAHN
AP	+		EQ 50MG BASE/2ML (EQ 25MG BASE/ML)	A089340	001	Sep 16, 1986	Aug CAHN
AP	+		EQ 250MG BASE/10ML (EQ 25MG BASE/ML)	A089343	001	Sep 16, 1986	Aug CAHN

METHOXSALENCAPSULE; ORAL  
METHOXSALEN

AB		STRIDES ARCOLAB LTD	10MG	A202687	001	Jun 05, 2014	May NEWA
AB		STRIDES PHARMA	10MG	A202687	001	Jun 05, 2014	Aug CAHN
			OXSORALEN-ULTRA				
AB	+	DOW PHARM	10MG	N019600	001	Oct 30, 1986	May CTEC

METHSCOPOLAMINE BROMIDETABLET; ORAL  
METHSCOPOLAMINE BROMIDE

AA		VINTAGE PHARMS	2.5MG	A040624	001	Dec 28, 2006	Feb CAHN
AA			5MG	A040624	002	Dec 28, 2006	Feb CAHN

METHYLDOPATABLET; ORAL  
METHYLDOPA

AB	MYLAN	250MG	A070076	002	Apr 18, 1985	Apr CMS1
----	-------	-------	---------	-----	--------------	----------

METHYLERGONOVINE MALEATEINJECTABLE; INJECTION  
METHERGINE

AP	+ EDISON THERAPS LLC	0.2MG/ML	N006035	004		Feb CAHN
----	----------------------	----------	---------	-----	--	----------

TABLET; ORAL  
METHERGINE

AB	+ EDISON THERAPS LLC	0.2MG	N006035	003		Feb CAHN
----	----------------------	-------	---------	-----	--	----------

METHYLNALTREXONE BROMIDEINJECTABLE; SUBCUTANEOUS  
RELISTOR

>D>	SALIX PHARMS	8MG/0.4ML	N021964	002	Sep 27, 2010	Dec CPOT
>A>		8MG/0.4ML (8MG/0.4ML)	N021964	002	Sep 27, 2010	Dec CPOT

METHYLPHENIDATE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
METHYLPHENIDATE HYDROCHLORIDE

AB1	BARR LABS INC	10MG	A079031	004	Oct 15, 2014	Oct NEWA
-----	---------------	------	---------	-----	--------------	----------

RITALIN LA

AB1	NOVARTIS	10MG	N021284	004	Apr 10, 2004	Oct CTEC
		60MG	N021284	005	Oct 27, 2014	Oct NEWA

SOLUTION; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AA	SUN PHARM INDS INC	5MG/5ML	A201466	001	Nov 12, 2013	Sep CAHN
AA		10MG/5ML	A201466	002	Nov 12, 2013	Sep CAHN

TABLET; ORAL

METHYLPHENIDATE HYDROCHLORIDE

AB	COREPHARMA	5MG	A091159	001	Mar 12, 2014	Feb NEWA
AB		10MG	A091159	002	Mar 12, 2014	Feb NEWA
AB		20MG	A091159	003	Mar 12, 2014	Feb NEWA
AB	SUN PHARM INDS INC	5MG	A090710	001	Mar 15, 2012	Jun CAHN
AB		10MG	A090710	002	Mar 15, 2012	Jun CAHN
AB		20MG	A090710	003	Mar 15, 2012	Jun CAHN
AB	VINTAGE PHARMS	5MG	A202892	001	Sep 23, 2014	Sep NEWA
AB		10MG	A202892	002	Sep 23, 2014	Sep NEWA
AB		20MG	A202892	003	Sep 23, 2014	Sep NEWA

TABLET, EXTENDED RELEASE; ORAL

CONCERTA

JANSSEN PHARMS

18MG

27MG

36MG

+

54MG

METHYLPHENIDATE HYDROCHLORIDE

BX	KUDCO IRELAND	18MG	A091695	001	Jul 09, 2013	Oct CTEC
BX		27MG	A091695	002	Jul 09, 2013	Oct CTEC
BX		36MG	A091695	003	Sep 23, 2013	Oct CTEC
BX		54MG	A091695	004	Sep 23, 2013	Oct CTEC
BX	MALLINCKRODT INC	27MG	A202608	001	Dec 28, 2012	Oct CTEC
BX		36MG	A202608	002	Dec 28, 2012	Oct CTEC
BX		54MG	A202608	003	Dec 28, 2012	Oct CTEC
	@ WATSON LABS	20MG	A040410	001	Feb 09, 2001	May DISC

METIPRANOLOL HYDROCHLORIDE

SOLUTION/DROPS; OPHTHALMIC

METIPRANOLOL

>A>	AT	ALCON RES LTD	0.3%	A075720	001	Aug 06, 2001	Dec CAHN
>D>	AT	FALCON PHARMS	0.3%	A075720	001	Aug 06, 2001	Dec CAHN

METOCLOPRAMIDE HYDROCHLORIDETABLET, ORALLY DISINTEGRATING; ORAL  
METOCLOPRAMIDE HYDROCHLORIDE

AB	NOVEL LABS INC	EQ 5MG BASE	A202191	001	Aug 15, 2014	Aug NEWA
		EQ 10MG BASE	A202191	002	Aug 15, 2014	Aug NEWA

METOZOLV ODT

AB	+ SALIX PHARMS	EQ 5MG BASE	N022246	001	Sep 04, 2009	Aug CFTG
----	----------------	-------------	---------	-----	--------------	----------

METOPROLOL SUCCINATE

TABLET, EXTENDED RELEASE; ORAL  
METOPROLOL SUCCINATE

AB	REDDYS	EQ 100MG TARTRATE	A078889	001	Aug 15, 2012	Aug CPOT
AB		EQ 200MG TARTRATE	A078889	002	Aug 15, 2012	Aug CPOT
	TOPROL-XL					
>D> AB	ASTRAZENECA	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Dec CAHN
>D> AB	+	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Dec CAHN
>D> AB		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Dec CAHN
>D> AB	+	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Dec CAHN
>A> AB	ASTRAZENECA PHARMS	EQ 25MG TARTRATE	N019962	004	Feb 05, 2001	Dec CAHN
>A> AB	+	EQ 50MG TARTRATE	N019962	001	Jan 10, 1992	Dec CAHN
>A> AB		EQ 100MG TARTRATE	N019962	002	Jan 10, 1992	Dec CAHN
>A> AB	+	EQ 200MG TARTRATE	N019962	003	Jan 10, 1992	Dec CAHN

METOPROLOL TARTRATE

INJECTABLE; INJECTION  
METOPROLOL TARTRATE

AP	GLAND PHARMA LTD	1MG/ML	A204205	001	Aug 27, 2014	Aug NEWA
	TABLET; ORAL					
	METOPROLOL TARTRATE					
AB	RUBICON RES PVT LTD	25MG	A200981	001	Oct 28, 2014	Oct NEWA
AB		50MG	A200981	002	Oct 28, 2014	Oct NEWA
AB		100MG	A200981	003	Oct 28, 2014	Oct NEWA
AB	SUN PHARM INDS INC	25MG	A076670	001	Jan 15, 2004	Jul CAHN
AB		50MG	A074644	001	Dec 10, 1996	Jul CAHN
AB		100MG	A074644	002	Dec 10, 1996	Jul CAHN

METRONIDAZOLE

GEL; VAGINAL

METRONIDAZOLE

	VALEANT PHARM NORTH	1.3%	N205223	001	Mar 24, 2014	Mar NEWA
+	WATSON LABS INC	1.3%	N205223	001	Mar 24, 2014	Sep CRLD
		1.3%	N205223	001	Mar 24, 2014	Jun CAHN

TABLET; ORAL

METRONIDAZOLE

AB	UNICHEM LABS LTD	250MG	A203458	001	Jan 22, 2014	Jan NEWA
AB		500MG	A203458	002	Jan 22, 2014	Jan NEWA
	@ VIVIMED LABS	250MG	A070040	001	Jan 29, 1985	Apr CAHN
	@	500MG	A070039	001	Jan 29, 1985	Apr CAHN
	@ WATSON LABS	250MG	N018764	001	Sep 17, 1982	May DISC
	@	500MG	N018764	002	Dec 20, 1982	May DISC
AB	WATSON LABS INC	500MG	A070044	001	Feb 08, 1985	Mar CAHN

MICONAZOLE

TABLET; BUCCAL

ORAVIG

+	BIOALLIANCE PHARMA	50MG	N022404	001	Apr 16, 2010	Apr CAHN
---	--------------------	------	---------	-----	--------------	----------

MICONAZOLE NITRATE

SUPPOSITORY; VAGINAL

MONISTAT 3

AB	+	MEDTECH PRODUCTS	200MG	N018888	001	Aug 15, 1984	Oct CAHN
----	---	------------------	-------	---------	-----	--------------	----------

MICONAZOLE NITRATE; PETROLATUM, WHITE; ZINC OXIDE

OINTMENT; TOPICAL

VUSION

+	DELCOR ASSET	0.25%; 81.35%; 15%	N021026	001	Feb 16, 2006	Jun CAHN
---	--------------	--------------------	---------	-----	--------------	----------

MIDAZOLAM HYDROCHLORIDE

INJECTABLE; INJECTION

MIDAZOLAM HYDROCHLORIDE

AP	BEDFORD LABS	EQ 1MG BASE/ML	A075421	002	Jun 20, 2000	Apr CAHN
AP		EQ 5MG BASE/ML	A075421	001	Jun 20, 2000	Apr CAHN
	MIDAZOLAM HYDROCHLORIDE	PRESERVATIVE FREE				
AP	BD RX	EQ 1MG BASE/ML	A203460	001	Aug 22, 2014	Aug NEWA
AP		EQ 5MG BASE/ML	A203460	002	Aug 22, 2014	Aug NEWA

MILRINONE LACTATE

INJECTABLE;INJECTION  
MILRINONE LACTATE

AP	HOSPIRA INC	EQ 1MG BASE/ML	A203280	001	Sep 03, 2014	Aug NEWA
----	-------------	----------------	---------	-----	--------------	----------

MILTEFOSINE

CAPSULE;ORAL  
IMPAVIDO

+	KNIGHT THERAPS	50MG	N204684	001	Mar 19, 2014	Sep CRLD
		50MG	N204684	001	Mar 19, 2014	Sep CAHN
	PALADIN THERAP	50MG	N204684	001	Mar 19, 2014	Mar NEWA

MINOCYCLINE HYDROCHLORIDE

CAPSULE;ORAL  
DYNACIN

	@ CNTY LINE PHARMS	EQ 50MG BASE	A063066	001	Aug 14, 1990	Aug CAHN
AB		EQ 75MG BASE	A063067	002	Sep 15, 1999	Jul CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	Jul CAHN
AB	MEDICIS	EQ 75MG BASE	A063067	002	Sep 15, 1999	May CAHN
AB		EQ 100MG BASE	A063067	001	Jul 31, 1990	May CAHN
	MINOCYCLINE HYDROCHLORIDE					
AB	SUN PHARM INDS INC	EQ 50MG BASE	A090867	001	May 13, 2013	Jul CAHN
AB		EQ 75MG BASE	A090867	002	May 13, 2013	Jul CAHN
AB		EQ 100MG BASE	A090867	003	May 13, 2013	Jul CAHN

TABLET, EXTENDED RELEASE;ORAL  
MINOCYCLINE HYDROCHLORIDE

AB	MYLAN PHARMS INC	EQ 80MG BASE	A203443	002	Aug 22, 2014	Aug NEWA
AB		EQ 105MG BASE	A203443	003	Aug 22, 2014	Aug NEWA
AB	RANBAXY LABS LTD	EQ 45MG BASE	A091118	001	Sep 25, 2014	Sep NEWA
AB		EQ 80MG BASE	A091118	004	Sep 25, 2014	Sep NEWA
AB		EQ 90MG BASE	A091118	005	Sep 25, 2014	Sep NEWA
AB		EQ 105MG BASE	A091118	006	Sep 25, 2014	Sep NEWA
AB		EQ 135MG BASE	A091118	008	Sep 25, 2014	Sep NEWA
	SOLODYN					
AB	+ MEDICIS	EQ 80MG BASE	N050808	007	Aug 27, 2010	Aug CTEC
AB		EQ 105MG BASE	N050808	006	Aug 27, 2010	Aug CTEC

MIRTAZAPINE

TABLET;ORAL  
MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076241	001	Jun 25, 2003	Aug CAHN
	@	30MG	A076241	002	Jun 25, 2003	Aug CAHN
	@	45MG	A076241	003	Jun 25, 2003	Aug CAHN
AB	SUN PHARM INDS INC	7.5MG	A076541	004	Apr 22, 2004	Jul CAHN
AB		15MG	A076541	001	Apr 22, 2004	Jul CAHN
AB		30MG	A076541	002	Apr 22, 2004	Jul CAHN
AB		45MG	A076541	003	Apr 22, 2004	Jul CAHN

TABLET, ORALLY DISINTEGRATING;ORAL  
MIRTAZAPINE

	@ ACTAVIS ELIZABETH	15MG	A076689	001	Aug 31, 2005	Jun CAHN
	@	30MG	A076689	002	Aug 31, 2005	Jun CAHN
	@	45MG	A076689	003	Aug 31, 2005	Jun CAHN

MITOXANTRONE HYDROCHLORIDE

INJECTABLE;INJECTION  
MITOXANTRONE HYDROCHLORIDE

AP	EUROHLTH INTL	EQ 20MG BASE/10ML (EQ 2MG BASE/ML)	A076611	001	Apr 11, 2006	Aug CAHN
AP		EQ 25MG BASE/12.5ML (EQ 2MG BASE/ML)	A076611	002	Apr 11, 2006	Aug CAHN
AP		EQ 30MG BASE/15ML (EQ 2MG BASE/ML)	A076611	003	Apr 11, 2006	Aug CAHN

MIVACURIUM CHLORIDE

INJECTABLE;INJECTION  
MIVACURIUM CHLORIDE

	@ AGILA SPECLTS	EQ 2MG BASE/ML	A078562	001	Apr 30, 2009	Feb CAHN
--	-----------------	----------------	---------	-----	--------------	----------

MODAFINILTABLET; ORAL  
MODAFINIL

AB	APOTEX INC	100MG	A077667	001	Feb 03, 2014	Jan NEWA
AB		200MG	A077667	002	Feb 03, 2014	Jan NEWA

MOMETASONE FUROATEAEROSOL, METERED; INHALATION  
ASMANEX HFA

	MERCK SHARP DOHME	0.10MG/INH	N205641	001	Apr 25, 2014	Apr NEWA
+		0.20MG/INH	N205641	002	Apr 25, 2014	Apr NEWA

POWDER; INHALATION

ASMANEX TWISTHALER

	MERCK SHARP DOHME	0.11MG/INH	N021067	002	Feb 01, 2008	Mar CAHN
+		0.22MG/INH	N021067	001	Mar 30, 2005	Mar CAHN

MOMETASONE FUROATE MONOHYDRATESPRAY, METERED; NASAL  
NASONEX

+	MERCK SHARP DOHME	EQ 0.05MG BASE/SPRAY	N020762	001	Oct 01, 1997	May CAHN
---	-------------------	----------------------	---------	-----	--------------	----------

MONTELUKAST SODIUM

TABLET; ORAL

MONTELUKAST SODIUM

AB	HETERO LABS LTD V	EQ 10MG BASE	A202843	001	Sep 10, 2014	Sep NEWA
AB	MACLEODS PHARMS LTD	EQ 10MG BASE	A203366	001	Sep 11, 2014	Sep NEWA
AB	UNIMARK REMEDIES LTD	EQ 10MG BASE	A202859	001	Oct 30, 2014	Oct NEWA

TABLET, CHEWABLE; ORAL

MONTELUKAST SODIUM

AB	UNIMARK REMEDIES LTD	EQ 4MG BASE	A203037	001	Oct 30, 2014	Oct NEWA
AB		EQ 5MG BASE	A203037	002	Oct 30, 2014	Oct NEWA

MORPHINE SULFATECAPSULE, EXTENDED RELEASE; ORAL  
AVINZA

AB2	KING PHARMS LLC	30MG	N021260	001	Mar 20, 2002	Mar CAHN
AB2		45MG	N021260	005	Dec 18, 2008	Mar CAHN
AB2		60MG	N021260	002	Mar 20, 2002	Mar CAHN
AB2		75MG	N021260	006	Dec 18, 2008	Mar CAHN
AB2		90MG	N021260	003	Mar 20, 2002	Mar CAHN
AB2	+	120MG	N021260	004	Mar 20, 2002	Mar CAHN

MORPHINE SULFATE

>A>	AB1	TEVA PHARMS USA	20MG	A202718	001	Dec 29, 2014	Dec NEWA
>A>	AB1		30MG	A202718	002	Dec 29, 2014	Dec NEWA
>A>	AB1		50MG	A202718	003	Dec 29, 2014	Dec NEWA
>A>	AB1		60MG	A202718	004	Dec 29, 2014	Dec NEWA
>A>	AB1		80MG	A202718	005	Dec 29, 2014	Dec NEWA
>A>	AB1		100MG	A202718	006	Dec 29, 2014	Dec NEWA

INJECTABLE; INJECTION

MORPHINE SULFATE

@	WATSON LABS	0.5MG/ML	A073373	001	Sep 30, 1991	May DISC
@		0.5MG/ML	A073375	001	Sep 30, 1991	May DISC
@		1MG/ML	A073374	001	Sep 30, 1991	May DISC
@		1MG/ML	A073376	001	Sep 30, 1991	May DISC

SOLUTION; ORAL

MORPHINE SULFATE

AA	CARACO	10MG/5ML	A201011	001	Feb 05, 2014	Jan NEWA
AA		20MG/5ML	A201011	002	Feb 05, 2014	Jan NEWA
AA	SUN PHARM INDS INC	10MG/5ML	A201011	001	Feb 05, 2014	Sep CAHN
AA		20MG/5ML	A201011	002	Feb 05, 2014	Sep CAHN

MORPHINE SULFATE; NALTREXONE HYDROCHLORIDECAPSULE, EXTENDED RELEASE; ORAL  
EMBEDA

	ALPHARMA PHARMS	20MG; 0.8MG	N022321	001	Aug 13, 2009	Mar CAHN
		30MG; 1.2MG	N022321	002	Aug 13, 2009	Mar CAHN
		50MG; 2MG	N022321	003	Aug 13, 2009	Mar CAHN
+		60MG; 2.4MG	N022321	004	Aug 13, 2009	Mar CAHN
		80MG; 3.2MG	N022321	005	Aug 13, 2009	Mar CAHN
		100MG; 4MG	N022321	006	Aug 13, 2009	Mar CAHN

MOXIFLOXACIN HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
MOXIFLOXACIN HYDROCHLORIDE

AT	LUPIN LTD	EQ 0.5% BASE	A202867	001	Sep 04, 2014	Aug NEWA
	VIGAMOX					
AT	+ ALCON PHARMS LTD	EQ 0.5% BASE	N021598	001	Apr 15, 2003	Aug CFTG
	TABLET;ORAL					
	AVELOX					
AB	+ BAYER HLTHCARE	EQ 400MG BASE	N021085	001	Dec 10, 1999	Feb CFTG
	MOXIFLOXACIN HYDROCHLORIDE					
AB	AUROBINDO PHARMA LTD	EQ 400MG BASE	A202632	001	Mar 04, 2014	Feb NEWA
AB	DR REDDYS LABS LTD	EQ 400MG BASE	A076938	001	Mar 04, 2014	Feb NEWA
AB	TEVA PHARMS USA	EQ 400MG BASE	A077437	001	Feb 18, 2014	Feb NEWA
AB	TORRENT PHARMS LTD	EQ 400MG BASE	A200160	001	Apr 03, 2014	Mar NEWA

MYCOPHENOLATE MOFETILCAPSULE;ORAL  
MYCOPHENOLATE MOFETIL

>A>	AB	CADISTA PHARMS	250MG	A090762	001	Dec 15, 2014	Dec NEWA
	AB	STRIDES PHARMA	250MG	A090055	001	Jun 10, 2010	Aug CAHN
		SUSPENSION;ORAL					
		CELLCEPT					
	AB	+ ROCHE PALO	200MG/ML	N050759	001	Oct 01, 1998	Nov CFTG
		MYCOPHENOLATE MOFETIL					
	AB	ALKEM LABS LTD	200MG/ML	A203005	001	Nov 14, 2014	Nov NEWA
		TABLET;ORAL					
		MYCOPHENOLATE MOFETIL					
>A>	AB	CADISTA PHARMS	500MG	A090661	001	Dec 15, 2014	Dec NEWA
	AB	STRIDES PHARMA	500MG	A090456	001	Jun 10, 2010	Aug CAHN

MYCOPHENOLIC ACIDTABLET, DELAYED RELEASE;ORAL  
MYCOPHENOLIC ACID

AB	APOTEX INC	360MG	A091558	002	Aug 19, 2014	Aug NEWA
AB	TEVA PHARMS USA	180MG	A202720	001	Oct 30, 2014	Oct NEWA
AB		360MG	A202720	002	Oct 30, 2014	Oct NEWA

NAFCILLIN SODIUMINJECTABLE;INJECTION  
NAFCILLIN SODIUM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A200002	001	Apr 07, 2014	Mar NEWA
AP		EQ 2GM BASE/VIAL	A200002	002	Apr 07, 2014	Mar NEWA
AP	ANTIBIOTICE	EQ 1GM BASE/VIAL	A090560	001	Oct 03, 2011	Jan CPOT
AP		EQ 2GM BASE/VIAL	A090560	002	Oct 03, 2011	Jan CPOT
AP	ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A090002	001	Jun 30, 2011	Feb CAHN
AP		EQ 2GM BASE/VIAL	A090002	002	Jun 30, 2011	Feb CAHN
AP		EQ 10GM BASE/VIAL	A090005	001	Apr 20, 2011	Feb CAHN

NALOXEGOL OXALATETABLET;ORAL  
MOVANTIK

	ASTRAZENECA PHARMS	EQ 12.5MG BASE	N204760	001	Sep 16, 2014	Sep NEWA
+		EQ 25MG BASE	N204760	002	Sep 16, 2014	Sep NEWA

NALOXONE HYDROCHLORIDEINJECTABLE;INJECTION  
NALOXONE HYDROCHLORIDE

AP	MYLAN INSTITUTIONAL	0.4MG/ML	A204997	001	Mar 06, 2014	Feb NEWA
	SOLUTION;INTRAMUSCULAR, SUBCUTANEOUS					
	EVZIO					
+	KALEO INC	0.4MG/0.4ML	N205787	001	Apr 03, 2014	Apr NEWA

NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDETABLET, EXTENDED RELEASE;ORAL  
TARGINIQ

@	PURDUE PHARMA LP	5MG;10MG	N205777	001	Jul 23, 2014	Jul DISC
@		10MG;20MG	N205777	002	Jul 23, 2014	Jul DISC
@		20MG;40MG	N205777	003	Jul 23, 2014	Jul DISC

NANDROLONE DECANOATEINJECTABLE; INJECTION  
DECA-DURABOLIN

>A>	@ AGI	50MG/ML	N013132	001	Jun 12, 1986	Dec CAHN
>A>	@	100MG/ML	N013132	002	Jun 12, 1986	Dec CAHN
>A>	@	200MG/ML	N013132	003	Jun 12, 1986	Dec CAHN
>D>	@ ORGANON USA INC	50MG/ML	N013132	001	Jun 12, 1986	Dec CAHN
>D>	@	100MG/ML	N013132	002	Jun 12, 1986	Dec CAHN
>D>	@	200MG/ML	N013132	003	Jun 12, 1986	Dec CAHN

NAPHAZOLINE HYDROCHLORIDESOLUTION/DROPS; OPHTHALMIC  
ALBALON

@ ALLERGAN 0.1%

A080248 001 Jun DISC

NAPHAZOLINE HYDROCHLORIDE

+ AKORN INC 0.1%

A083590 001 Jun CRLD

NAPROXEN

TABLET; ORAL

NAPROXEN

	@ DAVA PHARMS INC	250MG	A074410	001	Apr 28, 1995	Feb DISC
	@	375MG	A074410	002	Apr 28, 1995	Feb DISC
	@	500MG	A074410	003	Apr 28, 1995	Feb DISC
AB	HIKMA INTL PHARMS	250MG	A076494	001	Jan 14, 2004	Sep CAHN
AB		375MG	A076494	002	Jan 14, 2004	Sep CAHN
AB		500MG	A076494	003	Jan 14, 2004	Sep CAHN
	@ WATSON LABS	250MG	A074457	001	May 31, 1995	May DISC
	@	375MG	A074457	002	May 31, 1995	May DISC
	@	500MG	A074457	003	May 31, 1995	May DISC

NAPROXEN SODIUM

TABLET; ORAL

NAPROXEN SODIUM

@ WATSON LABS EQ 250MG BASE

A074455 001 May 31, 1995 May DISC

@ EQ 500MG BASE

A074455 002 May 31, 1995 May DISC

TABLET, EXTENDED RELEASE; ORAL

NAPRELAN

AB	ALMATICA PHARMA INC	EQ 375MG BASE	N020353	001	Jan 05, 1996	Aug CTEC
AB		EQ 500MG BASE	N020353	002	Jan 05, 1996	Aug CTEC
	NAPROXEN SODIUM					
AB	ACTAVIS LABS FL INC	EQ 375MG BASE	A075416	002	Apr 23, 2003	Aug CMFD
AB		EQ 500MG BASE	A075416	001	Aug 27, 2002	Aug CMFD

NAPROXEN SODIUM; SUMATRIPTAN SUCCINATE

TABLET; ORAL

TREXIMET

+ PERNIX IRELAND LTD 500MG; EQ 85MG BASE

N021926 001 Apr 15, 2008 Nov CAHN

NARATRIPTAN HYDROCHLORIDE

TABLET; ORAL

NARATRIPTAN

AB	APOTEX CORP	EQ 1MG BASE	A091373	001	Apr 22, 2011	Jan CAIN
AB		EQ 2.5MG BASE	A091373	002	Apr 22, 2011	Jan CAIN
AB	SUN PHARM INDS LTD	EQ 2.5MG BASE	A091552	001	Feb 14, 2011	Jan CAIN

NETUPITANT; PALONOSETRON HYDROCHLORIDE

CAPSULE; ORAL

AKYNZEO

+ HELSINN HLTHCARE 300MG; EQ 0.5MG BASE

N205718 001 Oct 10, 2014 Sep NEWA

NEVIRAPINE

TABLET; ORAL

NEVIRAPINE

AB	STRIDES ARCOLAB LTD	200MG	A078195	001	May 22, 2012	Jan CAHN
AB	STRIDES PHARMA	200MG	A078195	001	May 22, 2012	Aug CAHN

TABLET, EXTENDED RELEASE; ORAL

NEVIRAPINE

AB	APOTEX INC	400MG	A205258	001	Apr 03, 2014	Mar NEWA
AB	MYLAN PHARMS INC	400MG	A205651	001	Oct 27, 2014	Oct NEWA
AB	SANDOZ	400MG	A203411	001	Apr 03, 2014	Mar NEWA



TABLET, EXTENDED RELEASE;ORAL  
VIRAMUNE XR

AB	+	BOEHRINGER INGELHEIM	400MG	N201152	001	Mar 25, 2011	Mar CFTG
----	---	----------------------	-------	---------	-----	--------------	----------

NIACIN

TABLET, EXTENDED RELEASE;ORAL  
NIACIN

AB		LUPIN LTD	1GM	A090446	001	Mar 20, 2014	Mar NEWA
AB			500MG	A090860	001	Mar 20, 2014	Mar NEWA
AB			750MG	A090892	001	Mar 20, 2014	Mar NEWA
AB		SUN PHARMA GLOBAL	1GM	A200484	002	Apr 23, 2014	Apr NEWA
AB			500MG	A200484	001	Apr 23, 2014	Apr NEWA
AB			750MG	A201273	001	Apr 23, 2014	Apr NEWA

NICARDIPINE HYDROCHLORIDE

CAPSULE;ORAL  
CARDENE

AB		CHIESI USA INC	20MG	N019488	001	Dec 21, 1988	Apr CAHN
AB	+		30MG	N019488	002	Dec 21, 1988	Apr CAHN
		NICARDIPINE HYDROCHLORIDE					
AB		ANI PHARMS INC	20MG	A074439	001	Dec 10, 1996	Jan CAHN
AB			20MG	A074540	001	Oct 28, 1996	Jan CAHN
AB			30MG	A074439	002	Dec 10, 1996	Jan CAHN
AB			30MG	A074540	002	Oct 28, 1996	Jan CAHN
		@ WATSON LABS	20MG	A074670	001	Oct 28, 1996	May DISC
		@	30MG	A074670	002	Oct 28, 1996	May DISC

>D> CAPSULE, EXTENDED RELEASE;ORAL

>D> CARDENE SR

>D>	+	CHIESI USA INC	30MG	N020005	001	Feb 21, 1992	Dec DISC
>A>	@		30MG	N020005	001	Feb 21, 1992	Dec DISC
	+		30MG	N020005	001	Feb 21, 1992	Apr CAHN
	@		45MG	N020005	002	Feb 21, 1992	Apr CAHN
>D>	+		60MG	N020005	003	Feb 21, 1992	Dec DISC
>A>	@		60MG	N020005	003	Feb 21, 1992	Dec DISC
	+		60MG	N020005	003	Feb 21, 1992	Apr CAHN

INJECTABLE;INJECTION  
CARDENE

AP	+	CHIESI USA INC	25MG/10ML (2.5MG/ML)	N019734	001	Jan 30, 1992	Apr CAHN
		NICARDIPINE HYDROCHLORIDE					
AP		LUITPOLD	25MG/10ML (2.5MG/ML)	A090534	001	Nov 17, 2009	Jan CAHN
		INJECTABLE;INTRAVENOUS					
		CARDENE IN 0.83% SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	004	Nov 07, 2008	Apr CAHN
		CARDENE IN 0.86% SODIUM CHLORIDE IN PLASTIC CONTAINER					
	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	003	Jul 31, 2008	Apr CAHN
		CARDENE IN 4.8% DEXTROSE IN PLASTIC CONTAINER					
	+	CHIESI USA INC	20MG/200ML (0.1MG/ML)	N019734	002	Jul 31, 2008	Apr CAHN
		CARDENE IN 5.0% DEXTROSE IN PLASTIC CONTAINER					
	+	CHIESI USA INC	40MG/200ML (0.2MG/ML)	N019734	005	Nov 07, 2008	Apr CAHN

NIFEDIPINE

TABLET, EXTENDED RELEASE;ORAL  
NIFEDIPINE

AB2		TWI PHARMS INC	30MG	A203126	001	Apr 03, 2014	Mar NEWA
AB2			60MG	A203126	002	Apr 03, 2014	Mar NEWA
AB2			90MG	A203126	003	Apr 03, 2014	Mar NEWA

NIMODIPINE

CAPSULE;ORAL  
NIMODIPINE

AB		THEPHARMANETWORK LLC	30MG	A090103	001	Apr 07, 2014	Mar NEWA
		SOLUTION;ORAL					
		NYMALIZE					
	+	ARBOR PHARMS LLC	60MG/20ML	N203340	001	May 10, 2013	Sep CAHN

NINTEDANIB

CAPSULE;ORAL  
OFEV

		BOEHRINGER INGELHEIM	100MG	N205832	001	Oct 15, 2014	Oct NEWA
	+		150MG	N205832	002	Oct 15, 2014	Oct NEWA

NITROFURANTOINSUSPENSION;ORAL  
NITROFURANTOIN

AB	NOVEL LABS INC	25MG/5ML	A201693	001	Sep 08, 2014	Aug NEWA
AB	SUN PHARM INDS INC	25MG/5ML	A201355	001	Aug 14, 2013	Sep CAHN

NITROGLYCERINFILM, EXTENDED RELEASE;TRANSDERMAL  
MINITRAN

AB1	VALEANT PHARM NORTH	0.1MG/HR	A089771	001	Aug 30, 1996	Aug CAHN
AB1		0.6MG/HR	A089774	001	Aug 30, 1996	Aug CAHN

NITROGLYCERIN

@ KREMERS URBAN PHARMS 0.2MG/HR  
@ 0.4MG/HR

A075115	001	Aug 10, 2004	May DISC
A075115	002	Aug 10, 2004	May DISC

OINTMENT;INTRA-ANAL  
RECTIV

+	FOREST LABS INC	0.4%	N021359	001	Jun 21, 2011	Apr CAHN
---	-----------------	------	---------	-----	--------------	----------

NIZATIDINECAPSULE;ORAL  
NIZATIDINE

	@ ANI PHARMS INC	150MG	A075461	001	Jul 08, 2002	Jan CAHN
AB		150MG	A075668	001	Sep 12, 2002	Jan CAHN
	@	300MG	A075461	002	Jul 08, 2002	Jan CAHN
AB		300MG	A075668	002	Sep 12, 2002	Jan CAHN

NORFLOXACINTABLET;ORAL  
NOROXIN

@	MERCK	400MG	N019384	002	Oct 31, 1986	Jul DISC
---	-------	-------	---------	-----	--------------	----------

NORTRIPTYLINE HYDROCHLORIDESOLUTION;ORAL  
NORTRIPTYLINE HYDROCHLORIDE

AA	+	PHARM ASSOC	EQ 10MG BASE/5ML	A075606	001	Aug 28, 2000	Apr CRLD
----	---	-------------	------------------	---------	-----	--------------	----------

NYSTATINCREAM;TOPICAL  
MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/GM	A060575	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

NYSTATIN

@	G AND W LABS INC	100,000 UNITS/GM	A061966	001		Oct CAHN
---	------------------	------------------	---------	-----	--	----------

OINTMENT;TOPICAL

MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/GM	A060571	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

SUSPENSION;ORAL

MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS/ML	A061533	001		Jul CAHN
---	-------------------	------------------	---------	-----	--	----------

TABLET;ORAL

MYCOSTATIN

@	DELCOR ASSET CORP	500,000 UNITS	A060574	001		Jul CAHN
---	-------------------	---------------	---------	-----	--	----------

TABLET;VAGINAL

MYCOSTATIN

@	DELCOR ASSET CORP	100,000 UNITS	A060577	001		Jul CAHN
---	-------------------	---------------	---------	-----	--	----------

NYSTATIN; TRIAMCINOLONE ACETONIDECREAM;TOPICAL  
MYCOLOG-II

@	DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060576	002	May 01, 1985	Sep CAHN
---	-------------------	-----------------------	---------	-----	--------------	----------

@ 100,000 UNITS/GM;0.1%

A062606	001	May 15, 1985	Sep CAHN
---------	-----	--------------	----------

OINTMENT;TOPICAL

MYCOLOG-II

@	DELCOR ASSET CORP	100,000 UNITS/GM;0.1%	A060572	001	Jun 28, 1985	Sep CAHN
---	-------------------	-----------------------	---------	-----	--------------	----------

OCTREOTIDE ACETATEINJECTABLE;INJECTION  
OCTREOTIDE ACETATE

AP	+	EUROHLTH INTL	EQ 0.2MG BASE/ML	A076330	001	Apr 08, 2005	Aug CAHN
AP	+		EQ 1MG BASE/ML	A076330	002	Apr 08, 2005	Aug CAHN

## INJECTABLE;INJECTION

## OCTREOTIDE ACETATE (PRESERVATIVE FREE)

AP	+	EUROHLTH INTL	EQ 0.05MG BASE/ML	A076313	001	Mar 28, 2005	Aug CAHN
AP	+		EQ 0.1MG BASE/ML	A076313	003	Mar 28, 2005	Aug CAHN
AP	+		EQ 0.5MG BASE/ML	A076313	002	Mar 28, 2005	Aug CAHN

OFLOXACIN

## TABLET;ORAL

## OFLOXACIN

AB		CADILA PHARMS LTD	200MG	A091656	001	Sep 18, 2014	Sep NEWA
AB			300MG	A091656	002	Sep 18, 2014	Sep NEWA
AB			400MG	A091656	003	Sep 18, 2014	Sep NEWA

OLANZAPINE

## TABLET;ORAL

## OLANZAPINE

AB		MACLEODS PHARMS LTD	2.5MG	A202862	001	Aug 15, 2014	Aug NEWA
AB			5MG	A202862	002	Aug 15, 2014	Aug NEWA
AB			7.5MG	A202862	003	Aug 15, 2014	Aug NEWA
AB			10MG	A202862	004	Aug 15, 2014	Aug NEWA
AB			15MG	A202862	005	Aug 15, 2014	Aug NEWA
AB			20MG	A202862	006	Aug 15, 2014	Aug NEWA

## TABLET, ORALLY DISINTEGRATING;ORAL

## OLANZAPINE

AB		AUROBINDO PHARMA LTD	5MG	A203708	001	May 15, 2014	Apr NEWA
AB			10MG	A203708	002	May 15, 2014	Apr NEWA
AB			15MG	A203708	003	May 15, 2014	Apr NEWA
AB			20MG	A203708	004	May 15, 2014	Apr NEWA
AB		JUBILANT GENERICS	5MG	A200221	001	Sep 12, 2012	Jul CAHN
AB			10MG	A200221	002	Sep 12, 2012	Jul CAHN
AB			15MG	A200221	003	Sep 12, 2012	Jul CAHN
AB			20MG	A200221	004	Sep 12, 2012	Jul CAHN
AB		MYLAN PHARMS INC	5MG	A202285	001	May 12, 2014	Apr NEWA
AB			10MG	A202285	002	May 12, 2014	Apr NEWA
AB			15MG	A202285	003	May 12, 2014	Apr NEWA
AB			20MG	A202285	004	May 12, 2014	Apr NEWA

>A> OLAPARIB

## &gt;A&gt; CAPSULE;ORAL

## &gt;A&gt; OLAPARIB

>A>		ASTRAZENECA PHARMS	50MG	N206162	001	Dec 19, 2014	Dec NEWA
-----	--	--------------------	------	---------	-----	--------------	----------

OLODATEROL HYDROCHLORIDE

## SPRAY, METERED;INHALATION

## STRIVERDI RESPIMAT

+		BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N203108	001	Jul 31, 2014	Sep CPOT
+			EQ 2.5MG BASE/INH	N203108	001	Jul 31, 2014	Jul NEWA

OLOPATADINE HYDROCHLORIDE

## SPRAY, METERED;NASAL

## OLOPATADINE HYDROCHLORIDE

AB		APOTEX INC	0.665MG/SPRAY	A091572	001	Oct 08, 2014	Sep NEWA
AB	+	ALCON PHARMS LTD	0.665MG/SPRAY	N021861	001	Apr 15, 2008	Sep CFTG

OMEGA-3-ACID ETHYL ESTERS

## CAPSULE;ORAL

## LOVAZA

AB	+	SMITHKLINE BEECHAM	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N021654	001	Nov 10, 2004	Mar CFTG
----	---	--------------------	--	---------	-----	--------------	----------

## OMEGA-3-ACID ETHYL ESTERS

AB		APOTEX INC	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A090973	001	Sep 30, 2014	Sep NEWA
----	--	------------	--	---------	-----	--------------	----------

AB		TEVA PHARMS USA	1GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	A091028	001	Apr 07, 2014	Mar NEWA
----	--	-----------------	--	---------	-----	--------------	----------

## OMTRYG

+		TRYGG	1.2GM CONTAINS AT LEAST 900MG OF THE ETHYL ESTERS OF OMEGA-3 FATTY ACIDS	N204977	001	Apr 23, 2014	Apr NEWA
---	--	-------	--	---------	-----	--------------	----------

OMEGA-3-CARBOXYLIC ACIDS

CAPSULE;ORAL

EPANOVA

+	ASTRAZENECA PHARMS	1GM CONTAINS AT LEAST 850MG OF POLYUNSATURATED FATTY ACIDS	N205060	001	May 05, 2014	May NEWA
---	--------------------	--	---------	-----	--------------	----------

OMEPRAZOLE

CAPSULE, DELAYED REL PELLETS;ORAL

OMEPRAZOLE

AB	GLENMARK GENERICS	10MG	A091672	001	Oct 31, 2014	Oct NEWA
AB		20MG	A091672	002	Oct 31, 2014	Oct NEWA
AB		40MG	A091672	003	Oct 31, 2014	Oct NEWA

PRILOSEC

>D>	AB	ASTRAZENECA	10MG	N019810	003	Oct 05, 1995	Dec CAHN
>D>	AB	+	20MG	N019810	001	Sep 14, 1989	Dec CAHN
>D>	AB	+	40MG	N019810	002	Jan 15, 1998	Dec CAHN
>A>	AB	ASTRAZENECA PHARMS	10MG	N019810	003	Oct 05, 1995	Dec CAHN
>A>	AB	+	20MG	N019810	001	Sep 14, 1989	Dec CAHN
>A>	AB	+	40MG	N019810	002	Jan 15, 1998	Dec CAHN

OMEPRAZOLE MAGNESIUM

FOR SUSPENSION, DELAYED RELEASE;ORAL

PRILOSEC

>D>		ASTRAZENECA	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Dec CAHN
>D>		+	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Dec CAHN
>A>		ASTRAZENECA PHARMS	EQ 2.5MG BASE/PACKET	N022056	001	Mar 20, 2008	Dec CAHN
>A>		+	EQ 10MG BASE/PACKET	N022056	002	Mar 20, 2008	Dec CAHN

OMEPRAZOLE; SODIUM BICARBONATE

CAPSULE;ORAL

ZEGERID

AB	SANTARUS INC	20MG;1.1GM	N021849	001	Feb 27, 2006	Feb CAHN
AB	+	40MG;1.1GM	N021849	002	Feb 27, 2006	Feb CAHN

FOR SUSPENSION;ORAL

OMEPRAZOLE AND SODIUM BICARBONATE

@ PAR PHARM

@

ZEGERID

		20MG/PACKET;1.68GM/PACKET	A079182	001	Apr 19, 2013	Jun DISC
		40MG/PACKET;1.68GM/PACKET	A079182	002	Apr 19, 2013	Jun DISC
AB	SANTARUS INC	20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Jun CTEC
		20MG/PACKET;1.68GM/PACKET	N021636	001	Jun 15, 2004	Feb CAHN
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Jun CTEC
	+	40MG/PACKET;1.68GM/PACKET	N021636	002	Dec 21, 2004	Feb CAHN

ONDANSETRON

FILM;ORAL

ZUPLENZ

	GALENA BIOPHARMA INC	4MG	N022524	001	Jul 02, 2010	Aug CAHN
	+	8MG	N022524	002	Jul 02, 2010	Aug CAHN

ONDANSETRON HYDROCHLORIDE

INJECTABLE;INJECTION

ONDANSETRON HYDROCHLORIDE

@ LANNETT

AP	QILU PHARM CO LTD	EQ 2MG BASE/ML	A090116	001	Apr 14, 2010	Jan DISC
		EQ 2MG BASE/ML	A203711	001	Sep 08, 2014	Aug NEWA

TABLET;ORAL

ONDANSETRON HYDROCHLORIDE

AB	IPCA LABS LTD	EQ 4MG BASE	A203761	001	Jan 23, 2014	Jan NEWA
AB		EQ 8MG BASE	A203761	002	Jan 23, 2014	Jan NEWA

ORITAVANCIN DIPHOSPHATE

POWDER;IV (INFUSION)

ORBACTIV

+	MEDICINES CO	EQ 400MG BASE/VIAL	N206334	001	Aug 06, 2014	Aug NEWA
---	--------------	--------------------	---------	-----	--------------	----------

ORPHENADRINE CITRATE

INJECTABLE;INJECTION

ORPHENADRINE CITRATE

AP	EUROHLTH INTL	30MG/ML	A040463	001	Mar 04, 2003	Aug CAHN
	@ WATSON LABS	30MG/ML	A087062	001		May DISC

OXACILLIN SODIUM

## INJECTABLE; INJECTION

## OXACILLIN SODIUM

AP	AGILA SPECLTS	EQ 1GM BASE/VIAL	A091486	001	Aug 25, 2014	Aug NEWA
AP		EQ 2GM BASE/VIAL	A091486	002	Aug 25, 2014	Aug NEWA
	@ ISTITUTO BIO ITA SPA	EQ 1GM BASE/VIAL	A062798	001	Dec 11, 1995	Feb CAHN
	@	EQ 2GM BASE/VIAL	A062798	002	Dec 11, 1995	Feb CAHN
	@	EQ 125MG BASE/VIAL	A062798	003	Dec 11, 1995	Feb CAHN
	@	EQ 250MG BASE/VIAL	A062798	004	Dec 11, 1995	Feb CAHN
	@	EQ 500MG BASE/VIAL	A062798	005	Dec 11, 1995	Feb CAHN
	POWDER; INTRAVENOUS					
	OXACILLIN SODIUM					
AP	+ SANDOZ	EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986	Sep CRLD
AP		EQ 1GM BASE/VIAL	A062737	001	Dec 23, 1986	Sep CDFR
AP	+	EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986	Sep CRLD
AP		EQ 2GM BASE/VIAL	A062737	002	Dec 23, 1986	Sep CDFR

OXALIPLATIN

## INJECTABLE; IV (INFUSION)

## OXALIPLATIN

AP	ACTAVIS ELIZABETH	50MG/VIAL	A078803	001	Aug 08, 2012	Aug CAHN
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Aug CAHN
AP	ACTAVIS TOTOWA	50MG/VIAL	A078803	001	Aug 08, 2012	Oct CAHN
AP		100MG/VIAL	A078803	002	Aug 08, 2012	Oct CAHN
AP	JIANGSU HENGRUI MED	50MG/10ML (5MG/ML)	A203869	001	Jun 18, 2014	Jun NEWA
AP		100MG/20ML (5MG/ML)	A203869	002	Jun 18, 2014	Jun NEWA
AP	SUN PHARMA GLOBAL	50MG/10ML (5MG/ML)	A202922	001	Apr 08, 2014	Mar NEWA
AP		100MG/20ML (5MG/ML)	A202922	002	Apr 08, 2014	Mar NEWA

OXANDROLONE

## TABLET; ORAL

## OXANDRIN

AB	CREALTA PHARMS LLC	2.5MG	N013718	001		Jan CAHN
AB	+	10MG	N013718	002	Nov 05, 2001	Jan CAHN

OXAPROZIN

## TABLET; ORAL

## OXAPROZIN

AB	SUN PHARM INDS INC	600MG	A075844	001	Jan 03, 2002	Jul CAHN
	@ WATSON LABS	600MG	A075848	001	Feb 09, 2001	May DISC

OXAZEPAM

## CAPSULE; ORAL

## OXAZEPAM

	@ IVAX SUB TEVA PHARMS	10MG	A070943	001	Aug 03, 1987	Apr DISC
	@	15MG	A070944	001	Aug 03, 1987	Apr DISC
	@	30MG	A070945	001	Aug 03, 1987	Apr DISC
	@ WATSON LABS	10MG	A072952	001	Sep 28, 1990	May DISC
	@	15MG	A072953	001	Sep 28, 1990	May DISC
	@	30MG	A072954	001	Sep 28, 1990	May DISC

OXCARBAZEPINE

## TABLET; ORAL

## OXCARBAZEPINE

	@ ANI PHARMS INC	150MG	A078005	001	Dec 11, 2007	Jan CAHN
	@	300MG	A078005	002	Dec 11, 2007	Jan CAHN
	@	600MG	A078005	003	Dec 11, 2007	Jan CAHN

OXYBUTYNIN

## FILM, EXTENDED RELEASE; TRANSDERMAL

## OXYBUTYNIN

AB	BARR LABS DIV TEVA	3.9MG/24HR	A090526	001	Mar 04, 2014	Feb NEWA
	OXYTROL					
AB	+ WATSON LABS (UTAH)	3.9MG/24HR	N021351	002	Feb 26, 2003	Feb CFTG

OXYCODONE HYDROCHLORIDE

## CAPSULE; ORAL

## OXYCODONE HYDROCHLORIDE

AB	LANNETT HOLDINGS INC	5MG	A203823	001	Aug 01, 2014	Jul NEWA
----	----------------------	-----	---------	-----	--------------	----------

## SOLUTION;ORAL

## OXYCODONE HYDROCHLORIDE

AA	COASTAL PHARMS	100MG/5ML	A204092	001	Jun 05, 2014	May NEWA
AA	LANNETT HOLDINGS INC	100MG/5ML	A204085	001	Sep 09, 2014	Aug NEWA
AA	LEHIGH VALLEY	5MG/5ML	N200535	002	Aug 22, 2013	Jun NEWA

## TABLET;ORAL

## OXECTA

	ACURA PHARMS INC	5MG	N202080	001	Jun 17, 2011	May CAHN
		7.5MG	N202080	002	Jun 17, 2011	May CAHN

## OXYCODONE HYDROCHLORIDE

AB	ACTAVIS ELIZABETH	15MG	A076636	001	Feb 06, 2004	Jul CAHN
AB		30MG	A076636	002	Feb 06, 2004	Jul CAHN
AB	AMNEAL PHARMS	5MG	A203638	001	Jun 03, 2014	May NEWA
AB		10MG	A203638	002	Jun 03, 2014	May NEWA
AB		15MG	A203638	003	Jun 03, 2014	May NEWA
AB		20MG	A203638	004	Jun 03, 2014	May NEWA
AB		30MG	A203638	005	Jun 03, 2014	May NEWA

OXYMORPHONE HYDROCHLORIDE

## TABLET;ORAL

## OXYMORPHONE HYDROCHLORIDE

>A>	AB	COREPHARMA	5MG	A201187	001	Dec 15, 2014	Dec NEWA
>A>	AB		10MG	A201187	002	Dec 15, 2014	Dec NEWA

## TABLET, EXTENDED RELEASE;ORAL

## OXYMORPHONE HYDROCHLORIDE

AB	MALLINCKRODT INC	5MG	A202946	001	Jun 27, 2014	Jun NEWA
AB		7.5MG	A202946	002	Jun 27, 2014	Jun NEWA
AB		10MG	A202946	003	Jun 27, 2014	Jun NEWA
AB		15MG	A202946	004	Jun 27, 2014	Jun NEWA
AB		20MG	A202946	005	Jun 27, 2014	Jun NEWA
AB		30MG	A202946	006	Jun 27, 2014	Jun NEWA
AB		40MG	A202946	007	Jun 27, 2014	Jun NEWA
AB	PAR PHARM	5MG	A200792	001	Oct 24, 2014	Oct NEWA
AB		7.5MG	A200792	002	Oct 24, 2014	Oct NEWA
AB		10MG	A200792	003	Oct 24, 2014	Oct NEWA
AB		15MG	A200792	004	Oct 24, 2014	Oct NEWA
AB		20MG	A200792	005	Oct 24, 2014	Oct NEWA
AB		30MG	A200792	006	Oct 24, 2014	Oct NEWA
AB		40MG	A200792	007	Oct 24, 2014	Oct NEWA

OXYTOCIN

## INJECTABLE;INJECTION

## OXYTOCIN

AP	+	HIKMA MAPLE	10USP UNITS/ML (10USP UNITS/ML)	N018243	001		May CAHN
AP	+		100USP UNITS/10ML (10USP UNITS/ML)	N018243	002	Jan 10, 2007	May CAHN
AP		SAGENT PHARMS	10USP UNITS/ML (10USP UNITS/ML)	A091676	001	Oct 29, 2014	Oct NEWA
AP			100USP UNITS/10ML (10USP UNITS/ML)	A091676	002	Oct 29, 2014	Oct NEWA

## PITOCIN

AP	+	PAR STERILE PRODUCTS	10USP UNITS/ML (10USP UNITS/ML)	N018261	001		Apr CAHN
AP			100USP UNITS/10ML (10USP UNITS/ML)	N018261	002	Jul 27, 2007	Apr CAHN
			500USP UNITS/50ML (10USP UNITS/ML)	N018261	003	Sep 05, 2012	Apr CAHN

## SOLUTION;NASAL

## SYNTOCINON

	@	RETROPHIN INC	40USP UNITS/ML	N012285	001		Feb CAHN
--	---	---------------	----------------	---------	-----	--	----------

PACLITAXEL

## INJECTABLE;INJECTION

## PACLITAXEL

AP		ACTAVIS ELIZABETH	6MG/ML	A090130	001	Dec 09, 2009	Aug CAHN
AP		ACTAVIS TOTOWA	6MG/ML	A090130	001	Dec 09, 2009	Oct CAHN
AP		EUROHLTH INTL	6MG/ML	A075190	001	Jan 28, 2002	Aug CAHN
	@	MYLAN	6MG/ML	A075278	001	Jan 25, 2002	Jun DISC

PAMIDRONATE DISODIUM

## INJECTABLE;INJECTION

## PAMIDRONATE DISODIUM

AP		EUROHLTH INTL	30MG/VIAL	A075290	001	Apr 30, 2001	Aug CAHN
AP	+		30MG/10ML (3MG/ML)	N021113	001	Mar 04, 2002	Aug CAHN
AP			90MG/VIAL	A075290	003	Apr 30, 2001	Aug CAHN
AP	+		90MG/10ML (9MG/ML)	N021113	002	Mar 04, 2002	Aug CAHN
	@	MN PHARMS	30MG/VIAL	A078300	001	Mar 10, 2009	Jan DISC
	@		90MG/VIAL	A078300	002	Mar 10, 2009	Jan DISC

PANCRELIPASE (AMYLASE;LIPASE;PROTEASE)

## CAPSULE, DELAYED RELEASE;ORAL

## PANCREAZE

JANSSEN PHARMS	10,850USP UNITS;2,600USP UNITS;6,200USP UNITS	N022523	005	Mar 07, 2014	Jun NEWA
----------------	---	---------	-----	--------------	----------

## ULTRESA

FOREST LABS INC	27,600USP UNITS;13,800USP UNITS;27,600USP UNITS	N022222	001	Mar 01, 2012	May CAHN
-----------------	---	---------	-----	--------------	----------

	41,400USP UNITS;20,700USP UNITS;41,400USP UNITS	N022222	002	Mar 01, 2012	May CAHN
--	---	---------	-----	--------------	----------

+

	46,000USP UNITS;23,000USP UNITS;46,000USP UNITS	N022222	003	Mar 01, 2012	May CAHN
--	---	---------	-----	--------------	----------

## ZENPEP

APTALIS PHARMA US	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Mar NEWA
-------------------	---	---------	-----	--------------	----------

FOREST LABS INC	218,000USP UNITS; 40,00USP UNITS; 136,000 USP UNITS	N022210	007	Mar 25, 2014	Apr CAHN
-----------------	---	---------	-----	--------------	----------

	16,000USP UNITS;3,000USP UNITS;10,000USP UNITS	N022210	005	Jun 15, 2011	Apr CAHN
--	--	---------	-----	--------------	----------

	55,000USP UNITS;10,000USP UNITS;34,000USP UNITS	N022210	002	Aug 27, 2009	Apr CAHN
--	---	---------	-----	--------------	----------

	82,000USP UNITS;15,000USP UNITS;51,000USP UNITS	N022210	003	Aug 27, 2009	Apr CAHN
--	---	---------	-----	--------------	----------

	27,000USP UNITS;5,000USP UNITS;17,000USP UNITS	N022210	001	Aug 27, 2009	Apr CAHN
--	--	---------	-----	--------------	----------

	109,000USP UNITS;20,000USP UNITS;68,000USP UNITS	N022210	004	Aug 27, 2009	Apr CAHN
--	--	---------	-----	--------------	----------

+

	136,000USP UNITS;25,000USP UNITS;85,000USP UNITS	N022210	006	Jul 13, 2011	Apr CAHN
--	--	---------	-----	--------------	----------

## TABLET;ORAL

## VIOKACE

FOREST LABS INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Apr CAHN
-----------------	---	---------	-----	--------------	----------

+

	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Apr CAHN
--	---	---------	-----	--------------	----------

FOREST RES INST INC	39,150USP UNITS;10,440USP UNITS;39,150USP UNITS	N022542	001	Mar 01, 2012	Mar CAHN
---------------------	---	---------	-----	--------------	----------

+

	78,300USP UNITS;20,880USP UNITS;78,300USP UNITS	N022542	002	Mar 01, 2012	Mar CAHN
--	---	---------	-----	--------------	----------

PANTOPRAZOLE SODIUM

## TABLET, DELAYED RELEASE;ORAL

## PANTOPRAZOLE SODIUM

AB	ACTAVIS ELIZABETH	EQ 20MG BASE	A090797	001	Feb 07, 2011	Aug CAHN
----	-------------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Aug CAHN
----	--	--------------	---------	-----	--------------	----------

AB	ACTAVIS TOTOWA	EQ 20MG BASE	A090797	001	Feb 07, 2011	Oct CAHN
----	----------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A090797	002	Feb 07, 2011	Oct CAHN
----	--	--------------	---------	-----	--------------	----------

AB	HETERO LABS LTD V	EQ 20MG BASE	A202882	001	Sep 10, 2014	Aug NEWA
----	-------------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A202882	002	Sep 10, 2014	Aug NEWA
----	--	--------------	---------	-----	--------------	----------

AB	JUBILANT GENERICS	EQ 20MG BASE	A090901	001	Aug 30, 2011	Jul CAHN
----	-------------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A090901	002	Aug 30, 2011	Jul CAHN
----	--	--------------	---------	-----	--------------	----------

AB	ORCHID HLTHCARE	EQ 20MG BASE	A202052	001	Dec 02, 2014	Nov NEWA
----	-----------------	--------------	---------	-----	--------------	----------

AB		EQ 40MG BASE	A202052	002	Dec 02, 2014	Nov NEWA
----	--	--------------	---------	-----	--------------	----------

AB	PERRIGO R AND D	EQ 20MG BASE	A203024	001	May 07, 2014	Apr NEWA
----	-----------------	--------------	---------	-----	--------------	----------

PARICALCITOL

## CAPSULE;ORAL

## PARICALCITOL

AB	ANCHEN PHARMS	1MCG	A202124	001	Jun 24, 2014	Jun NEWA
----	---------------	------	---------	-----	--------------	----------

AB		2MCG	A202124	002	Jun 24, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		4MCG	A202124	003	Jun 24, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	BANNER PHARMACAPS	1MCG	A202539	001	Mar 27, 2014	Mar NEWA
----	-------------------	------	---------	-----	--------------	----------

AB		2MCG	A202539	002	Mar 27, 2014	Mar NEWA
----	--	------	---------	-----	--------------	----------

AB		4MCG	A202539	003	Mar 27, 2014	Mar NEWA
----	--	------	---------	-----	--------------	----------

AB	DR REDDYS LABS LTD	1MCG	A091412	001	Jun 24, 2014	Jun NEWA
----	--------------------	------	---------	-----	--------------	----------

AB		2MCG	A091412	002	Jun 24, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		4MCG	A091412	003	Jun 24, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	RISING PHARMS INC	1MCG	A202124	001	Jun 24, 2014	Sep CAHN
----	-------------------	------	---------	-----	--------------	----------

AB		2MCG	A202124	002	Jun 24, 2014	Sep CAHN
----	--	------	---------	-----	--------------	----------

AB		4MCG	A202124	003	Jun 24, 2014	Sep CAHN
----	--	------	---------	-----	--------------	----------

## INJECTABLE;INJECTION

## PARICALCITOL

HOSPIRA INC	0.002MG/ML	N201657	001	Oct 21, 2014	Oct NEWA
-------------	------------	---------	-----	--------------	----------

	0.005MG/ML	N201657	002	Oct 21, 2014	Oct NEWA
--	------------	---------	-----	--------------	----------

	0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	Oct NEWA
--	-------------------------	---------	-----	--------------	----------

SOLUTION; INTRAVENOUS  
PARICALCITOL

AP	HIKMA PHARMS	0.002MG/ML (0.002MG/ML)	N205917	001	Nov 18, 2014	Nov NEWA
AP		0.005MG/ML (0.005MG/ML)	N205917	002	Nov 18, 2014	Nov NEWA
AP		0.01MG/2ML (0.005MG/ML)	N205917	003	Nov 18, 2014	Nov NEWA
AP	HOSPIRA INC	0.002MG/ML (0.002MG/ML)	N201657	001	Oct 21, 2014	Nov CDFR
AP		0.005MG/ML (0.005MG/ML)	N201657	002	Oct 21, 2014	Nov CDFR
AP		0.01MG/2ML (0.005MG/ML)	N201657	003	Oct 21, 2014	Nov CDFR
AP	SANDOZ CANADA INC	0.002MG/ML (0.002MG/ML)	A091108	001	Jul 27, 2011	Nov CDFR
AP		0.005MG/ML (0.005MG/ML)	A091108	002	Jul 27, 2011	Nov CDFR
AP		0.01MG/2ML (0.005MG/ML)	A091108	003	Jul 27, 2011	Nov NEWA
	ZEMPLAR					
AP	+ ABBVIE	0.002MG/ML (0.002MG/ML)	N020819	002	Feb 01, 2000	Nov CDFR
AP	+	0.005MG/ML (0.005MG/ML)	N020819	001	Apr 17, 1998	Nov CDFR
AP	+	0.01MG/2ML (0.005MG/ML)	N020819	003	Feb 01, 2000	Nov NEWA

PAROMOMYCIN SULFATE

CAPSULE; ORAL  
PAROMOMYCIN SULFATE

AA	+ SUN PHARM INDS INC	EQ 250MG BASE	A064171	001	Jun 30, 1997	Jul CAHN
----	----------------------	---------------	---------	-----	--------------	----------

PAROXETINE HYDROCHLORIDE

CAPSULE; ORAL  
PAXIL

@	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020885	001	Oct 09, 1998	Feb CAHN
@		EQ 20MG BASE	N020885	002	Oct 09, 1998	Feb CAHN
@		EQ 30MG BASE	N020885	003	Oct 09, 1998	Feb CAHN
@		EQ 40MG BASE	N020885	004	Oct 09, 1998	Feb CAHN

SUSPENSION; ORAL

PAXIL

AB	+ APOTEX TECHNOLOGIES	EQ 10MG BASE/5ML	N020710	001	Jun 25, 1997	Feb CAHN
----	-----------------------	------------------	---------	-----	--------------	----------

TABLET; ORAL

PAROXETINE

AB	PRINSTON INC	EQ 10MG BASE	A203854	001	Oct 31, 2014	Oct NEWA
AB		EQ 20MG BASE	A203854	002	Oct 31, 2014	Oct NEWA
AB		EQ 30MG BASE	A203854	003	Oct 31, 2014	Oct NEWA
AB		EQ 40MG BASE	A203854	004	Oct 31, 2014	Oct NEWA

PAROXETINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 10MG BASE	A078194	001	Jun 29, 2007	Jul CAHN
AB		EQ 20MG BASE	A078194	002	Jun 29, 2007	Jul CAHN
AB		EQ 30MG BASE	A078194	003	Jun 29, 2007	Jul CAHN
AB		EQ 40MG BASE	A078194	004	Jun 29, 2007	Jul CAHN

PAXIL

AB	APOTEX TECHNOLOGIES	EQ 10MG BASE	N020031	001	Dec 29, 1992	Jan CAHN
AB		EQ 20MG BASE	N020031	002	Dec 29, 1992	Jan CAHN
AB		EQ 30MG BASE	N020031	003	Dec 29, 1992	Jan CAHN
AB	+	EQ 40MG BASE	N020031	005	Dec 29, 1992	Jan CAHN
	@	EQ 50MG BASE	N020031	004	Dec 29, 1992	Jan CAHN

TABLET, EXTENDED RELEASE; ORAL

PAXIL CR

AB	APOTEX TECHNOLOGIES	EQ 12.5MG BASE	N020936	001	Feb 16, 1999	Feb CAHN
AB		EQ 25MG BASE	N020936	002	Feb 16, 1999	Feb CAHN
AB	+	EQ 37.5MG BASE	N020936	003	Dec 06, 2000	Feb CAHN

>A> PASIREOTIDE PAMOATE

>A> POWDER; INTRAMUSCULAR  
>A> SIGNIFOR LAR

>A>	NOVARTIS PHARMS CORP	EQ 20MG BASE/VIAL	N203255	001	Dec 15, 2014	Dec NEWA
>A>		EQ 40MG BASE/VIAL	N203255	002	Dec 15, 2014	Dec NEWA
>A>	+	EQ 60MG BASE/VIAL	N203255	003	Dec 15, 2014	Dec NEWA

PEGVISOMANT

INJECTABLE; SUBCUTANEOUS  
SOMAVERT

+	PHARMACIA AND UPJOHN	25MG/VIAL	N021106	004	Jul 31, 2014	Jul NEWA
+		30MG/VIAL	N021106	005	Jul 31, 2014	Jul NEWA



PEMIROLAST POTASSIUMSOLUTION/DROPS;OPHTHALMIC  
ALAMAST

@ SANTEN	0.1%	N021079	001	Sep 24, 1999	Jun DISC
----------	------	---------	-----	--------------	----------

PEMOLINE

TABLET;ORAL

PEMOLINE

@ ACTAVIS ELIZABETH	18.75MG	A075595	001	Feb 28, 2000	Aug CAHN
@	37.5MG	A075595	002	Feb 28, 2000	Aug CAHN
@	75MG	A075595	003	Feb 28, 2000	Aug CAHN

TABLET, CHEWABLE;ORAL

PEMOLINE

@ ACTAVIS ELIZABETH	37.5MG	A075678	001	Jul 26, 2000	Aug CAHN
---------------------	--------	---------	-----	--------------	----------

PENBUTOLOL SULFATE

TABLET;ORAL

LEVATOL

@ AUXILIUM PHARMS LLC	10MG	N018976	001	Dec 30, 1987	Apr CAHN
@	20MG	N018976	004	Jan 05, 1989	Sep DISC
+	20MG	N018976	004	Jan 05, 1989	Apr CAHN

PENICILLIN G POTASSIUM

INJECTABLE;INJECTION

PENICILLIN G POTASSIUM

AP	ISTITUTO BIO ITA SPA	5,000,000 UNITS/VIAL	A065448	001	Aug 18, 2009	Feb CAHN
AP		20,000,000 UNITS/VIAL	A065448	002	Aug 18, 2009	Feb CAHN

PENTAMIDINE ISETHIONATE

INJECTABLE;INJECTION

PENTAM

+	FRESENIUS KABI USA	300MG/VIAL	N019264	001	Oct 16, 1984	May CTEC
	PENTAMIDINE ISETHIONATE					
@	WATSON LABS	300MG/VIAL	A074303	001	Aug 17, 1995	May DISC

PENTOSTATIN

INJECTABLE;INJECTION

PENTOSTATIN

AP	EUROHLTH INTL	10MG/VIAL	A077841	001	Aug 07, 2007	Aug CAHN
AP	MYLAN INSTITUTIONAL	10MG/VIAL	A203554	001	Sep 19, 2014	Sep NEWA

PENTOXIFYLLINE

TABLET, EXTENDED RELEASE;ORAL

PENTOXIFYLLINE

AB	VALEANT BERMUDA	400MG	A075028	001	Jul 20, 1998	Sep CAHN
	@ WATSON LABS	400MG	A075107	001	Sep 04, 1998	May DISC
	TRENTAL					
	@ SANOFI AVENTIS US	400MG	N018631	001	Aug 30, 1984	Jun DISC

>A> PERAMIVIR

SOLUTION;IV (INFUSION)

RAPIVAB

>A>	+	BIOCRIST	200MG/20ML (10MG/ML)	N206426	001	Dec 19, 2014	Dec NEWA
-----	---	----------	----------------------	---------	-----	--------------	----------

PERINDOPRIL ERBUMINE

TABLET;ORAL

ACEON

AB	SYMPLMED PHARMS LLC	2MG	N020184	001	Dec 30, 1993	Jul CAHN
AB		4MG	N020184	002	Dec 30, 1993	Jul CAHN
AB	+	8MG	N020184	003	Dec 30, 1993	Jul CAHN
	PERINDOPRIL ERBUMINE					
AB	ANI PHARMS INC	2MG	A078138	001	Nov 10, 2009	Jan CAHN
AB		4MG	A078138	002	Nov 10, 2009	Jan CAHN
AB		8MG	A078138	003	Nov 10, 2009	Jan CAHN

PERPHENAZINE

TABLET; ORAL

PERPHENAZINE

@ ANI PHARMS INC	8MG	A089456	001	Sep 10, 1987	Apr CAHN
@ TEVA PHARMS USA	4MG	A089708	001	Sep 10, 1987	Apr CAHN
@	16MG	A089457	001	Sep 10, 1987	Apr CAHN

PHENDIMETRAZINE TARTRATE

TABLET; ORAL

PHENDIMETRAZINE TARTRATE

AA	ELITE LABS INC	35MG	A040762	001	Jan 28, 2008	Apr CAHN
----	----------------	------	---------	-----	--------------	----------

PHENOXYBENZAMINE HYDROCHLORIDE

CAPSULE; ORAL

DIBENZYLINE

AB	+ COVIS PHARMA SARL	10MG	N008708	001		Nov CAHN
----	---------------------	------	---------	-----	--	----------

PHENTERMINE HYDROCHLORIDE

CAPSULE; ORAL

PHENTERMINE HYDROCHLORIDE

AA	INVAGEN PHARMS	15MG	A202858	001	Feb 14, 2014	Feb NEWA
AA		30MG	A202858	002	Feb 14, 2014	Feb NEWA
AA		30MG	A204414	001	May 05, 2014	Apr NEWA
AA		37.5MG	A202846	001	Feb 05, 2014	Jan NEWA
AA	KEN LIFESCIENCE	15MG	A205019	001	Dec 05, 2014	Nov NEWA
AA		30MG	A205019	002	Dec 05, 2014	Nov NEWA
AA		37.5MG	A205017	001	Sep 25, 2014	Sep NEWA

TABLET; ORAL

PHENTERMINE HYDROCHLORIDE

AA	AUROLIFE PHARMA LLC	37.5MG	A203068	001	Aug 06, 2014	Jul NEWA
AA	INVAGEN PHARMS	37.5MG	A202942	001	Feb 05, 2014	Jan NEWA
AA	KEN LIFESCIENCE	37.5MG	A205008	001	Sep 25, 2014	Sep NEWA
AA	MIKAH PHARMA	37.5MG	A040190	001	May 30, 1997	May CMFD
AA	SUN PHARM INDS INC	37.5MG	A040790	001	Aug 21, 2007	Jul CAHN

PHENTOLAMINE MESYLATE

INJECTABLE; INJECTION

PHENTOLAMINE MESYLATE

AP	EUROHLTH INTL	5MG/VIAL	A040235	001	Mar 11, 1998	Aug CAHN
----	---------------	----------	---------	-----	--------------	----------

PHENYLEPHRINE HYDROCHLORIDE

SOLUTION; IV (INFUSION)

VAZCULEP

	ECLAT PHARMS LLC	10MG/ML (10MG/ML)	N204300	001	Jun 27, 2014	Jun NEWA
		50MG/5ML (10MG/ML)	N204300	002	Jun 27, 2014	Jun NEWA
+		100MG/10ML (10MG/ML)	N204300	003	Jun 27, 2014	Jun NEWA

PHENYLEPHRINE HYDROCHLORIDE; PROMETHAZINE HYDROCHLORIDE

SYRUP; ORAL

PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE

>A> AA	HI-TECH PHARMACAL	5MG/5ML; 6.25MG/5ML	A040675	001	Dec 23, 2014	Dec NEWA
--------	-------------------	---------------------	---------	-----	--------------	----------

PHENYTOIN

TABLET, CHEWABLE; ORAL

PHENYTOIN

AB	COREPHARMA	50MG	A040884	001	Nov 28, 2014	Nov NEWA
AB	TARO	50MG	A200565	001	Apr 17, 2014	Apr NEWA

PHENYTOIN SODIUM

CAPSULE; ORAL

EXTENDED PHENYTOIN SODIUM

@ ANI PHARMS INC	100MG EXTENDED	A040435	001	Jun 20, 2003	Apr CAHN
@	100MG EXTENDED	A089441	001	Dec 18, 1986	Jan CAHN
PROMPT PHENYTOIN SODIUM					
@ ANI PHARMS INC	100MG PROMPT	A080259	001		Jan CAHN

PINDOLOL

TABLET; ORAL

PINDOLOL

AB	MUTUAL PHARM	5MG	A074063	001	Jan 27, 1994	Feb CMFD
AB		10MG	A074063	002	Jan 27, 1994	Feb CMFD
AB	MYLAN PHARMS INC	5MG	A074019	001	Sep 03, 1992	Feb CTEC
AB	+	10MG	A074019	002	Sep 03, 1992	Feb CTEC

PIOGLITAZONE HYDROCHLORIDE

TABLET; ORAL

PIOGLITAZONE HYDROCHLORIDE

>A>	AB	BRECKENRIDGE PHARM	EQ 15MG BASE	A078472	001	Feb 13, 2013	Dec CAHN
>A>	AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Dec CAHN
>A>	AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Dec CAHN
	AB	LUPIN LTD	EQ 15MG BASE	A204133	001	Apr 07, 2014	Mar NEWA
	AB		EQ 30MG BASE	A204133	002	Apr 07, 2014	Mar NEWA
	AB		EQ 45MG BASE	A204133	003	Apr 07, 2014	Mar NEWA
>D>	AB	SYNTHON PHARMS	EQ 15MG BASE	A078472	001	Feb 13, 2013	Dec CAHN
>D>	AB		EQ 30MG BASE	A078472	002	Feb 13, 2013	Dec CAHN
>D>	AB		EQ 45MG BASE	A078472	003	Feb 13, 2013	Dec CAHN

PIPERACILLIN SODIUM

INJECTABLE; INJECTION

PIPERACILLIN

+	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL	A065114	001	Nov 14, 2003	Feb CAHN
+		EQ 3GM BASE/VIAL	A065114	002	Nov 14, 2003	Feb CAHN
+		EQ 4GM BASE/VIAL	A065114	003	Nov 14, 2003	Feb CAHN
+		EQ 40GM BASE/VIAL	A065157	001	Jul 12, 2004	Feb CAHN

PIPERACILLIN SODIUM; TAZOBACTAM SODIUM

INJECTABLE; INJECTION

PIPERACILLIN AND TAZOBACTAM

AP	AGILA SPECLTS	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065458	001	Aug 15, 2014	Aug NEWA
AP		EQ 3MG BASE/VIAL; EQ 375MG BASE/VIAL	A065458	002	Aug 15, 2014	Aug NEWA
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065458	003	Aug 15, 2014	Aug NEWA
AP	ISTITUTO BIO ITA SPA	EQ 2GM BASE/VIAL; EQ 250MG BASE/VIAL	A065523	001	May 31, 2011	Feb CAHN
AP		EQ 3GM BASE/VIAL; EQ 375MG BASE/VIAL	A065523	002	May 31, 2011	Feb CAHN
AP		EQ 4GM BASE/VIAL; EQ 500MG BASE/VIAL	A065523	003	May 31, 2011	Feb CAHN
AP		EQ 36GM BASE/VIAL; EQ 4.5GM BASE/VIAL	A090498	001	May 31, 2011	Feb CAHN

INJECTABLE; IV (INFUSION)

PIPERACILLIN AND TAZOBACTAM

SANDOZ

EQ 12GM BASE/VIAL; EQ 1.5GM BASE/VIAL

A203557 001 Oct 29, 2014 Oct NEWA

PIRBUTEROL ACETATE

AEROSOL, METERED; INHALATION

MAXAIR

@	VALEANT PHARM NORTH	EQ 0.2MG BASE/INH	N019009	001	Dec 30, 1986	Jul CAHN
---	---------------------	-------------------	---------	-----	--------------	----------

PIRFENIDONE

CAPSULE; ORAL

ESBRIET

+	INTERMUNE INC	267MG	N022535	001	Oct 15, 2014	Oct NEWA
---	---------------	-------	---------	-----	--------------	----------

PIROXICAM

CAPSULE; ORAL

PIROXICAM

@	CYCLE PHARMS LTD	10MG	A073651	001	Feb 26, 1993	Sep CAHN
@		20MG	A073651	002	Feb 26, 1993	Sep CAHN
@	WATSON LABS	10MG	A074287	001	May 16, 1996	May DISC
@		10MG	A074460	001	Sep 29, 1995	May DISC
@		20MG	A074287	002	May 16, 1996	May DISC
@		20MG	A074460	002	Sep 29, 1995	May DISC

POLYETHYLENE GLYCOL 3350; POTASSIUM CHLORIDE; SODIUM BICARBONATE; SODIUM CHLORIDE; SODIUM SULFATE ANHYDROUS

FOR SUSPENSION;ORAL

CO-LAV

@ VINTAGE PHARMS	240GM/BOT;2.98GM/BOT;6.72GM/BOT;5.84GM/BOT;22.72GM/BOT	A 073428	001	Jan 28, 1992	Feb CAHN
------------------	--	----------	-----	--------------	----------

GO-EVAC

@ VINTAGE PHARMS	236GM/BOT;2.97GM/BOT;6.74GM/BOT;5.86GM/BOT;22.74GM/BOT	A 073433	001	Apr 28, 1992	Feb CAHN
------------------	--	----------	-----	--------------	----------

PORACTANT ALFASUSPENSION;INTRATRACHEAL  
CUROSURF

+ CHIESI USA INC	80MG/ML	N 020744	001	Nov 18, 1999	Apr CAHN
------------------	---------	----------	-----	--------------	----------

PORFIMER SODIUMINJECTABLE;INJECTION  
PHOTOFRIN

CONCORDIA LABS INC	75MG/VIAL	N 020451	001	Dec 27, 1995	Nov CAHN
--------------------	-----------	----------	-----	--------------	----------

POSACONAZOLESOLUTION;IV (INFUSION)  
NOXAFIL

+ MERCK SHARP DOHME	300MG/16.7ML (18MG/ML)	N 205596	001	Mar 13, 2014	Mar NEWA
---------------------	------------------------	----------	-----	--------------	----------

POTASSIUM CHLORIDEINJECTABLE;INJECTION  
POTASSIUM CHLORIDE

@ INTL MEDICATION	2MEQ/ML	A 083163	001		Mar DISC
-------------------	---------	----------	-----	--	----------

&gt;A&gt; SOLUTION;ORAL

&gt;A&gt; POTASSIUM CHLORIDE

>A> PHARMA-MED INC	20MEQ/15ML	N 206814	001	Dec 22, 2014	Dec NEWA
--------------------	------------	----------	-----	--------------	----------

>A> +	40MEQ/15ML	N 206814	002	Dec 22, 2014	Dec NEWA
-------	------------	----------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

K-TAB

BC	ABBVIE	8MEQ	N 018279	002	Aug 01, 1988	Nov CMFD
----	--------	------	----------	-----	--------------	----------

BC	+	20MEQ	N 018279	003	Nov 25, 2013	Nov CRLD
----	---	-------	----------	-----	--------------	----------

KLOR-CON

AB2	UPSHER-SMITH LABS	8MEQ	N 019123	001	Apr 17, 1986	Aug CTEC
-----	-------------------	------	----------	-----	--------------	----------

AB2	+	10MEQ	N 019123	002	Apr 17, 1986	Aug CTEC
-----	---	-------	----------	-----	--------------	----------

KLOR-CON M10

AB1	UPSHER SMITH LABS	10MEQ	A 074726	002	Aug 09, 2000	Aug CTEC
-----	-------------------	-------	----------	-----	--------------	----------

KLOR-CON M20

AB1	+	UPSHER SMITH LABS	20MEQ	A 074726	001	Nov 20, 1998	Aug CTEC
-----	---	-------------------	-------	----------	-----	--------------	----------

POTASSIUM CHLORIDE

AB1	ACTAVIS LABS FL INC	10MEQ	A 075604	001	Apr 10, 2002	Aug CTEC
-----	---------------------	-------	----------	-----	--------------	----------

AB1		20MEQ	A 075604	002	Apr 10, 2002	Aug CTEC
-----	--	-------	----------	-----	--------------	----------

AB1	EURAND	20MEQ	A 076368	001	Aug 18, 2004	Aug CTEC
-----	--------	-------	----------	-----	--------------	----------

AB2	MYLAN PHARMS INC	8.0MEQ	A 204662	001	Aug 21, 2014	Aug NEWA
-----	------------------	--------	----------	-----	--------------	----------

AB2		10.0MEQ	A 204662	002	Aug 21, 2014	Aug NEWA
-----	--	---------	----------	-----	--------------	----------

POTASSIUM CITRATE

FOR SOLUTION;ORAL

POTASSIUM CITRATE

@ UT SW MEDCTR	10MEQ/PACKET	N 019647	002	Oct 13, 1988	Jul CAHN
----------------	--------------	----------	-----	--------------	----------

@ 20MEQ/PACKET

N 019647	001	Oct 13, 1988	Jul CAHN
----------	-----	--------------	----------

TABLET, EXTENDED RELEASE;ORAL

POTASSIUM CITRATE

AB	ZYDUS PHARMS USA INC	5MEQ	A 203546	001	Aug 06, 2014	Jul NEWA
----	----------------------	------	----------	-----	--------------	----------

AB		10MEQ	A 203546	002	Aug 06, 2014	Jul NEWA
----	--	-------	----------	-----	--------------	----------

AB		15MEQ	A 203546	003	Aug 06, 2014	Jul NEWA
----	--	-------	----------	-----	--------------	----------

UROCIT-K

AB	+	MISSION PHARMA	15MEQ	N 019071	003	Dec 30, 2009	Jul CTEC
----	---	----------------	-------	----------	-----	--------------	----------

PRAMIPEXOLE DIHYDROCHLORIDE

TABLET;ORAL

PRAMIPEXOLE DIHYDROCHLORIDE

AB	SCIEGEN PHARMS INC	0.125MG	A 203855	001	Oct 28, 2014	Oct NEWA
----	--------------------	---------	----------	-----	--------------	----------

AB		0.25MG	A 203855	002	Oct 28, 2014	Oct NEWA
----	--	--------	----------	-----	--------------	----------

AB		0.5MG	A 203855	003	Oct 28, 2014	Oct NEWA
----	--	-------	----------	-----	--------------	----------

AB		0.75MG	A 203855	004	Oct 28, 2014	Oct NEWA
----	--	--------	----------	-----	--------------	----------

## TABLET;ORAL

## PRAMIPEXOLE DIHYDROCHLORIDE

AB		1MG	A203855	005	Oct 28, 2014	Oct NEWA
AB		1.5MG	A203855	006	Oct 28, 2014	Oct NEWA
AB	STRIDES ARCOLAB LTD	0.125MG	A202702	001	Jun 03, 2014	May NEWA
AB		0.25MG	A202702	002	Jun 03, 2014	May NEWA
AB		0.5MG	A202702	003	Jun 03, 2014	May NEWA
AB		0.75MG	A202702	004	Jun 03, 2014	May NEWA
AB		1MG	A202702	005	Jun 03, 2014	May NEWA
AB		1.5MG	A202702	006	Jun 03, 2014	May NEWA
AB	STRIDES PHARMA	0.125MG	A202702	001	Jun 03, 2014	Aug CAHN
AB		0.25MG	A202702	002	Jun 03, 2014	Aug CAHN
AB		0.5MG	A202702	003	Jun 03, 2014	Aug CAHN
AB		0.75MG	A202702	004	Jun 03, 2014	Aug CAHN
AB		1MG	A202702	005	Jun 03, 2014	Aug CAHN
AB		1.5MG	A202702	006	Jun 03, 2014	Aug CAHN
AB	@ WATSON LABS	0.125MG	A078551	001	Oct 08, 2010	Oct DISC
AB	@	0.25MG	A078551	002	Oct 08, 2010	Oct DISC
AB	@	0.5MG	A078551	003	Oct 08, 2010	Oct DISC
AB	@	1MG	A078551	004	Oct 08, 2010	Oct DISC
AB	@	1.5MG	A078551	005	Oct 08, 2010	Oct DISC

## TABLET, DELAYED RELEASE;ORAL

## PRAMIPEXOLE DIHYDROCHLORIDE

AB	SANDOZ	0.375MG	A202353	001	Dec 04, 2014	Nov NEWA
AB		0.75MG	A202353	002	Dec 04, 2014	Nov NEWA
AB		1.5MG	A202353	003	Dec 04, 2014	Nov NEWA
AB		3MG	A202353	004	Dec 04, 2014	Nov NEWA
AB		4.5MG	A202353	005	Dec 04, 2014	Nov NEWA

## TABLET, EXTENDED RELEASE;ORAL

## MIRAPEX ER

AB	+ BOEHRINGER INGELHEIM	0.375MG	N022421	001	Feb 19, 2010	Jan CFTG
AB		0.75MG	N022421	002	Feb 19, 2010	Jan CFTG
AB		1.5MG	N022421	003	Feb 19, 2010	Jan CFTG
AB		2.25MG	N022421	006	Jun 17, 2011	Jan CFTG
AB		3MG	N022421	004	Feb 19, 2010	Jan CFTG
AB		3.75MG	N022421	007	Jun 17, 2011	Jan CFTG
AB		4.5MG	N022421	005	Feb 19, 2010	Jan CFTG

## PRAMIPEXOLE DIHYDROCHLORIDE

AB	ANCHEN PHARMS	0.375MG	A202206	001	Feb 06, 2014	Jan NEWA
AB		0.75MG	A202206	002	Feb 06, 2014	Jan NEWA
AB		1.5MG	A202206	003	Feb 06, 2014	Jan NEWA
AB		2.25MG	A202206	004	Feb 06, 2014	Jan NEWA
AB		3MG	A202206	005	Feb 06, 2014	Jan NEWA
AB		3.75MG	A202206	006	Feb 06, 2014	Jan NEWA
AB		4.5MG	A202206	007	Feb 06, 2014	Jan NEWA

PRAMLINTIDE ACETATE

## INJECTABLE;SUBCUTANEOUS

## SYMPLIN

	ASTRAZENECA AB	EQ 1.5MG BASE/1.5ML (EQ 1MG BASE/ML)	N021332	002	Sep 25, 2007	Feb CAHN
+		EQ 2.7MG BASE/2.7ML (EQ 1MG BASE/ML)	N021332	003	Sep 25, 2007	Feb CAHN
@		EQ 3MG BASE/5ML (EQ 600MCG BASE/ML)	N021332	001	Mar 16, 2005	Feb CAHN

PRAVASTATIN SODIUM

## TABLET;ORAL

## PRAVACHOL

	@ BRISTOL MYERS SQUIBB	10MG	N019898	002	Oct 31, 1991	Oct DISC
AB	SANDOZ	10MG	A076397	003	Oct 23, 2006	Apr CMFD
AB		20MG	A076397	002	Oct 23, 2006	Apr CMFD
AB		40MG	A076397	001	Oct 23, 2006	Apr CMFD
AB		80MG	A077491	001	Feb 11, 2008	Aug CMFD

PREDNISOLONE SODIUM PHOSPHATE

## SOLUTION;ORAL

## PREDNISOLONE SODIUM PHOSPHATE

	@ MEDICIS PHARMS	EQ 15MG BASE/5ML	A075250	001	Jul 12, 2002	Nov CAHN
--	------------------	------------------	---------	-----	--------------	----------

PREDNISOLONE SODIUM PHOSPHATE; SULFACETAMIDE SODIUM

SOLUTION/DROPS;OPHTHALMIC

SULFACETAMIDE SODIUM AND PREDNISOLONE SODIUM PHOSPHATE

AT	+	BAUSCH AND LOMB	EQ 0.23% PHOSPHATE;10%	A074449	001	Dec 29, 1995	Feb CRLD
		VASOCIDIN					
	@	NOVARTIS	EQ 0.23% PHOSPHATE;10%	N018988	001	Aug 26, 1988	Feb DISC

PRIMAQUINE PHOSPHATE

TABLET;ORAL

PRIMAQUINE

AB	+	SANOFI AVENTIS US	EQ 15MG BASE	N008316	001		Jan CFTG
		PRIMAQUINE PHOSPHATE					
AB		ALVOGEN INC	EQ 15MG BASE	A203924	001	Feb 03, 2014	Jan NEWA
AB		BAYSHORE PHARMS LLC	EQ 15MG BASE	A204476	001	Feb 25, 2014	Feb NEWA

PROCAINAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

PROCAINAMIDE HYDROCHLORIDE

+	HOSPIRA	100MG/ML	A089069	001	Feb 12, 1986	Jul CTEC
+		500MG/ML	A089070	001	Feb 12, 1986	Jul CTEC
@	INTL MEDICATION	100MG/ML	A088636	001	Jul 31, 1984	Jul DISC
@		500MG/ML	A088637	001	Jul 31, 1984	Jul DISC

TABLET, EXTENDED RELEASE;ORAL

PROCAINAMIDE HYDROCHLORIDE

@	ANI PHARMS INC	1GM	A040111	001	Dec 13, 1996	Jan CAHN
@		250MG	A088958	001	Dec 02, 1985	Jan CAHN
@		500MG	A088959	001	Dec 02, 1985	Jan CAHN
@		500MG	A088974	001	Jul 22, 1985	Mar CAHN
@		750MG	A089438	001	Mar 23, 1987	Jan CAHN

PROMETHAZINE HYDROCHLORIDE

INJECTABLE;INJECTION

PROMETHAZINE HYDROCHLORIDE

AP	+	HIKMA MAPLE	25MG/ML	A083312	001		Oct CRLD
AP	+		50MG/ML	A083312	002		Oct CRLD
	@	HOSPIRA	25MG/ML	A040372	001	Jun 08, 2000	Oct DISC
	@	LUITPOLD	25MG/ML	A040515	001	Mar 19, 2003	Sep DISC
	@	TEVA PHARMS USA	25MG/ML	A040454	001	Aug 22, 2002	Oct DISC
	@		50MG/ML	A040454	002	Aug 22, 2002	Oct DISC
	@	WOCKHARDT	25MG/ML	A040785	001	Sep 26, 2008	Oct DISC
	@		50MG/ML	A040785	002	Sep 26, 2008	Oct DISC

SUPPOSITORY;RECTAL

PHENERGAN

@	DELCOR ASSET CORP	50MG	N011689	001		Apr CAHN
---	-------------------	------	---------	-----	--	----------

SYRUP;ORAL

PROMETHAZINE HYDROCHLORIDE

AA		SUN PHARM INDS INC	6.25MG/5ML	A040891	001	Mar 13, 2009	Sep CAHN
----	--	--------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

PHENERGAN

@	DELCOR ASSET CORP	12.5MG	N007935	002		Jul CAHN
@		12.5MG	N007935	002		Apr CAHN
@		25MG	N007935	003		Jul CAHN
@		25MG	N007935	003		Apr CAHN
@		50MG	N007935	004		Jul CAHN
@		50MG	N007935	004		Apr CAHN
@	SHIONOGI INC	12.5MG	N007935	002		May CAHN
@		25MG	N007935	003		May CAHN
@		50MG	N007935	004		May CAHN

PROMETHAZINE HYDROCHLORIDE

AB		SANDOZ	25MG	A084176	003		Apr CMS1
AB		SUN PHARM INDS INC	12.5MG	A040863	001	Dec 30, 2008	Jun CAHN
AB			25MG	A040863	002	Dec 30, 2008	Jun CAHN
AB			50MG	A040863	003	Dec 30, 2008	Jun CAHN

PROPAFENONE HYDROCHLORIDE

TABLET;ORAL

PROPAFENONE HYDROCHLORIDE

AB		ANI PHARMS INC	150MG	A076550	001	Apr 23, 2004	Jan CAHN
AB			225MG	A076550	002	Apr 23, 2004	Jan CAHN
AB			300MG	A076550	003	Apr 23, 2004	Jan CAHN

PROPARACAINE HYDROCHLORIDESOLUTION/DROPS;OPHTHALMIC  
ALCAINE

AT	+	ALCON	0.5%	A080027	001		Jun	CRLD
		OPHTHAINE						
	@	APOTHECON	0.5%	N008883	001		Jun	DISC
		OPHTHETIC						
	@	ALLERGAN	0.5%	N012583	001		Jun	DISC

PROPOFOLINJECTABLE;INJECTION  
PROPOFOL

@	EUROHLTH INTL	10MG/ML	A074848	001	Apr 19, 2005	Aug	CAHN
---	---------------	---------	---------	-----	--------------	-----	------

PROPOXYPHENE HYDROCHLORIDECAPSULE;ORAL  
PROPOXYPHENE HYDROCHLORIDE

@	MUTUAL PHARM	65MG	A083186	001		Aug	DISC
---	--------------	------	---------	-----	--	-----	------

PROPRANOLOL HYDROCHLORIDECAPSULE, EXTENDED RELEASE;ORAL  
INDERAL LA

>D>	AB	AKRIMAX PHARMS	60MG	N018553	004	Mar 18, 1987	Dec	CAHN
>D>	AB		80MG	N018553	002	Apr 19, 1983	Dec	CAHN
>D>	AB		120MG	N018553	003	Apr 19, 1983	Dec	CAHN
>D>	AB	+	160MG	N018553	001	Apr 19, 1983	Dec	CAHN
>A>	AB	CRANFORD PHARMS LLC	60MG	N018553	004	Mar 18, 1987	Dec	CAHN
>A>	AB		80MG	N018553	002	Apr 19, 1983	Dec	CAHN
>A>	AB		120MG	N018553	003	Apr 19, 1983	Dec	CAHN
>A>	AB	+	160MG	N018553	001	Apr 19, 1983	Dec	CAHN
		PROPRANOLOL HYDROCHLORIDE						
AB		NORTEC DEV ASSOC	60MG	A078065	001	Jan 26, 2007	Sep	CAHN
AB			80MG	A078065	002	Jan 26, 2007	Sep	CAHN
AB			120MG	A078065	003	Jan 26, 2007	Sep	CAHN
AB			160MG	A078065	004	Jan 26, 2007	Sep	CAHN
		SOLUTION;ORAL						
		HEMANGEOL						
+		PIERRE FABRE DERMA	4.28MG/ML	N205410	001	Mar 14, 2014	Mar	NEWA
		TABLET;ORAL						
		INDERAL						
	@	WYETH PHARMS INC	40MG	N016418	002		Jan	DISC
	@		60MG	N016418	009	Oct 18, 1982	Jan	DISC
		PROPRANOLOL HYDROCHLORIDE						
	@	ANI PHARMS INC	90MG	A071977	001	Apr 06, 1988	Jan	CAHN

PROPYLTHIOURACILTABLET;ORAL  
PROPYLTHIOURACIL

@	ANI PHARMS INC	50MG	A080215	001		Jan	CAHN
---	----------------	------	---------	-----	--	-----	------

PYRIDOSTIGMINE BROMIDESYRUP;ORAL  
MESTINON

+	VALEANT PHARM NORTH	60MG/5ML	N015193	001		Aug	CAHN
---	---------------------	----------	---------	-----	--	-----	------

QUETIAPINE FUMARATETABLET;ORAL  
QUETIAPINE FUMARATE

AB		ALEMBIC PHARMS LTD	EQ 25MG BASE	A203390	001	Oct 28, 2014	Oct	NEWA
AB			EQ 50MG BASE	A203390	002	Oct 28, 2014	Oct	NEWA
AB			EQ 100MG BASE	A203390	003	Oct 28, 2014	Oct	NEWA
AB			EQ 200MG BASE	A203390	004	Oct 28, 2014	Oct	NEWA
AB			EQ 300MG BASE	A203390	005	Oct 28, 2014	Oct	NEWA
AB			EQ 400MG BASE	A203390	006	Oct 28, 2014	Oct	NEWA
AB		JUBILANT GENERICS	EQ 25MG BASE	A203150	001	Nov 26, 2013	Jul	CAHN

QUINAPRIL HYDROCHLORIDE

TABLET; ORAL

QUINAPRIL HYDROCHLORIDE

@ ACTAVIS ELIZABETH EQ 5MG BASE  
 @ EQ 10MG BASE  
 @ EQ 20MG BASE  
 @ EQ 40MG BASE

A076459 001 Dec 22, 2004 Aug CAHN  
 A076459 002 Dec 22, 2004 Aug CAHN  
 A076459 003 Dec 22, 2004 Aug CAHN  
 A076459 004 Dec 22, 2004 Aug CAHN

QUINIDINE GLUCONATE

TABLET, EXTENDED RELEASE; ORAL

QUINIDINE GLUCONATE

@ WATSON LABS 324MG

A087810 001 Sep 29, 1982 May DISC

RALOXIFENE HYDROCHLORIDE

TABLET; ORAL

EVISTA

AB + LILLY 60MG

N020815 001 Dec 09, 1997 Feb CFTG

RALOXIFENE HYDROCHLORIDE

AB INVAGEN PHARMS 60MG

A090842 001 Sep 24, 2014 Sep NEWA

AB TEVA PHARMS USA 60MG

A078193 001 Mar 04, 2014 Feb NEWA

RAMIPRIL

CAPSULE; ORAL

RAMIPRIL

AB ACCORD HLTHCARE INC 1.25MG

A202392 001 Apr 15, 2014 Mar NEWA

AB 2.5MG

A202392 002 Apr 15, 2014 Mar NEWA

AB 5MG

A202392 003 Apr 15, 2014 Mar NEWA

AB 10MG

A202392 004 Apr 15, 2014 Mar NEWA

RANITIDINE HYDROCHLORIDE

INJECTABLE; INJECTION

RANITIDINE HYDROCHLORIDE

AP EUROHLTH INTL EQ 25MG BASE/ML

A074777 001 Mar 02, 2005 Aug CAHN

AP EQ 25MG BASE/ML

A077458 001 Feb 16, 2006 Aug CAHN

ZANTAC

AP + COVIS INJECTABLES EQ 25MG BASE/ML

N019090 001 Oct 19, 1984 Apr CAHN

ZANTAC IN PLASTIC CONTAINER

@ COVIS INJECTABLES EQ 1MG BASE/ML

N019593 002 Sep 27, 1991 Apr CAHN

@ EQ 50MG BASE/100ML

N019593 001 Dec 17, 1986 Apr CAHN

TABLET; ORAL

RANITIDINE HYDROCHLORIDE

@ WOCKHARDT EQ 150MG BASE

A078701 001 Nov 12, 2009 Oct DISC

@ EQ 300MG BASE

A078701 002 Dec 11, 2009 Oct DISC

TABLET, EFFERVESCENT; ORAL

ZANTAC 25

@ GLAXO GRP LTD EQ 25MG BASE

N020251 003 Apr 01, 2004 Feb DISC

RASAGILINE MESYLATE

TABLET; ORAL

RASAGILINE MESYLATE

@ WATSON LABS INC EQ 0.5MG BASE

A201823 001 Jul 01, 2013 May DISC

@ EQ 1MG BASE

A201823 002 Jul 01, 2013 May DISC

REPAGLINIDE

TABLET; ORAL

REPAGLINIDE

AB ACTAVIS ELIZABETH 0.5MG

A090008 001 Jan 22, 2014 Aug CAHN

AB 1MG

A090008 002 Jan 22, 2014 Aug CAHN

AB 2MG

A090008 003 Jan 22, 2014 Aug CAHN

AB ACTAVIS TOTOWA 0.5MG

A090008 001 Jan 22, 2014 Oct CAHN

AB 0.5MG

A090008 001 Jan 22, 2014 Jan NEWA

AB 1MG

A090008 002 Jan 22, 2014 Oct CAHN

AB 1MG

A090008 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090008 003 Jan 22, 2014 Oct CAHN

AB 2MG

A090008 003 Jan 22, 2014 Jan NEWA

AB AUROBINDO PHARMA LTD 0.5MG

A203820 001 Jan 22, 2014 Jan NEWA

AB 1MG

A203820 002 Jan 22, 2014 Jan NEWA

AB 2MG

A203820 003 Jan 22, 2014 Jan NEWA

AB MYLAN PHARMS INC 1MG

A090252 002 Jan 22, 2014 Jan NEWA

AB 2MG

A090252 003 Jan 22, 2014 Jan NEWA

AB PADDOCK LLC 1MG

A201189 002 Jan 22, 2014 Jan NEWA



TABLET;ORAL  
REPAGLINIDE

AB		2MG	A201189	003	Jan 22, 2014	Jan NEWA
AB	SANDOZ	1MG	A078555	002	Jan 22, 2014	Jan NEWA
AB		2MG	A078555	003	Jan 22, 2014	Jan NEWA
AB	SUN PHARM INDS INC	1MG	A077571	002	Jul 11, 2013	Jul CAHN
AB		2MG	A077571	003	Jul 11, 2013	Jul CAHN

RESERPINE

TABLET;ORAL  
RESERPINE

@	CYCLE PHARMS LTD	0.1MG	N009859	001		Nov CAHN
@		0.25MG	N009859	002		Nov CAHN

RIBAVIRIN

TABLET;ORAL  
RIBAVIRIN

AB	SANDOZ	200MG	A202546	001	Aug 12, 2014	Aug NEWA
AB		400MG	A202546	002	Aug 12, 2014	Aug NEWA
AB		500MG	A202546	003	Aug 12, 2014	Aug NEWA
AB		600MG	A202546	004	Aug 12, 2014	Aug NEWA
AB	ZYDUS PHARMS USA	500MG	A077094	004	Apr 18, 2008	Aug CTEC

RIFABUTIN

CAPSULE;ORAL  
MYCOBUTIN

AB	+ PHARMACIA AND UPJOHN	150MG	N050689	001	Dec 23, 1992	Feb CFTG
AB	RIFABUTIN					
AB	LUPIN LTD	150MG	A090033	001	Feb 24, 2014	Feb NEWA

RIFAMPIN

INJECTABLE;INJECTION  
RIFAMPIN

AP	EMCURE PHARMS LTD	600MG/VIAL	A204101	001	Aug 18, 2014	Aug NEWA
AP	FRESENIUS KABI USA	600MG/VIAL	A091181	001	Aug 21, 2014	Aug NEWA

RIMANTADINE HYDROCHLORIDE

TABLET;ORAL  
RIMANTADINE HYDROCHLORIDE

@	ACTAVIS ELIZABETH	100MG	A076375	001	Jan 14, 2003	Aug CAHN
---	-------------------	-------	---------	-----	--------------	----------

RISEDRONATE SODIUM

TABLET;ORAL  
ACTONEL

AB	+ WARNER CHILCOTT LLC	150MG	N020835	005	Apr 22, 2008	May CTEC
	RISEDRONATE SODIUM					
AB	APOTEX INC	75MG	A090877	002	Jun 10, 2014	May NEWA
AB		150MG	A090877	003	Jun 10, 2014	May NEWA
AB	MYLAN PHARMS INC	75MG	A200477	004	Jun 10, 2014	May NEWA
AB		150MG	A200477	005	Jun 10, 2014	May NEWA
AB	SUN PHARMA GLOBAL	75MG	A090886	004	Jun 10, 2014	May NEWA
AB		150MG	A090886	005	Jun 10, 2014	May NEWA
AB	TEVA PHARMS USA	150MG	A079215	001	Jun 13, 2014	Jun NEWA

RISPERIDONE

SOLUTION;ORAL  
RISPERIDONE

AA	ANI PHARMS INC	1MG/ML	A076440	001	Jan 30, 2009	Jan CAHN
>A> AA	SILARX PHARMS INC	1MG/ML	A202386	001	Jan 12, 2015	Dec NEWA

TABLET;ORAL  
RISPERIDONE

AB	CARACO	0.25MG	A078036	001	Mar 10, 2014	Feb NEWA
AB		0.5MG	A078036	002	Mar 10, 2014	Feb NEWA
AB		1MG	A078036	003	Mar 10, 2014	Feb NEWA
AB		2MG	A078036	004	Mar 10, 2014	Feb NEWA
AB		3MG	A078036	005	Mar 10, 2014	Feb NEWA
AB		4MG	A078036	006	Mar 10, 2014	Feb NEWA
AB	SUN PHARM INDS INC	0.25MG	A078036	001	Mar 10, 2014	Jul CAHN
AB		0.5MG	A078036	002	Mar 10, 2014	Jul CAHN
AB		1MG	A078036	003	Mar 10, 2014	Jul CAHN
AB		2MG	A078036	004	Mar 10, 2014	Jul CAHN
AB		3MG	A078036	005	Mar 10, 2014	Jul CAHN

TABLET;ORAL  
RISPERIDONE

AB		4MG	A078036	006	Mar 10, 2014	Jul CAHN
	@ WATSON LABS	0.25MG	A077860	001	Dec 05, 2008	Oct DISC
	@	0.5MG	A077860	002	Dec 05, 2008	Oct DISC
	@	1MG	A077860	003	Dec 05, 2008	Oct DISC
	@	2MG	A077860	004	Dec 05, 2008	Oct DISC
	@	3MG	A077860	005	Dec 05, 2008	Oct DISC
	@	4MG	A077860	006	Dec 05, 2008	Oct DISC
	@ WEST WARD PHARMS	0.25MG	A078740	001	May 29, 2009	Sep DISC
	@	0.5MG	A078740	002	May 29, 2009	Sep DISC
	@	1MG	A078740	003	May 29, 2009	Sep DISC
	@	2MG	A078740	004	May 29, 2009	Sep DISC
	@	3MG	A078740	005	May 29, 2009	Sep DISC
	@	4MG	A078740	006	May 29, 2009	Sep DISC

TABLET, ORALLY DISINTEGRATING;ORAL  
RISPERIDONE

AB	JUBILANT GENERICS	0.5MG	A090839	001	Nov 04, 2011	Jul CAHN
AB		1MG	A090839	002	Nov 04, 2011	Jul CAHN
AB		2MG	A090839	003	Nov 04, 2011	Jul CAHN
AB		3MG	A090839	004	Nov 04, 2011	Jul CAHN
AB		4MG	A090839	005	Nov 04, 2011	Jul CAHN

RITONAVIR

TABLET;ORAL  
NORVIR

>D>	+	ABBVIE	100MG	N022417	001	Feb 10, 2010	Dec CFTG
>A>	AB	+	100MG	N022417	001	Feb 10, 2010	Dec CFTG

RIVASTIGMINE TARTRATE

CAPSULE;ORAL  
RIVASTIGMINE TARTRATE

AB	MACLEODS PHARMS LTD	EQ 1.5MG BASE	A203148	001	Aug 22, 2014	Aug NEWA
AB		EQ 3MG BASE	A203148	002	Aug 22, 2014	Aug NEWA
AB		EQ 4.5MG BASE	A203148	003	Aug 22, 2014	Aug NEWA
AB		EQ 6MG BASE	A203148	004	Aug 22, 2014	Aug NEWA

SOLUTION;ORAL  
EXELON

@	NOVARTIS	EQ 2MG BASE/ML	N021025	001	Apr 21, 2000	Jun DISC
---	----------	----------------	---------	-----	--------------	----------

RIZATRIPTAN BENZOATE

TABLET;ORAL  
RIZATRIPTAN BENZOATE

>A>	AB	JUBILANT GENERICS	EQ 5MG BASE	A203252	001	Dec 31, 2014	Dec NEWA
>A>	AB		EQ 10MG BASE	A203252	002	Dec 31, 2014	Dec NEWA
	AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203147	001	Feb 11, 2014	Jan NEWA
	AB		EQ 10MG BASE	A203147	002	Feb 11, 2014	Jan NEWA

TABLET, ORALLY DISINTEGRATING;ORAL  
RIZATRIPTAN BENZOATE

AB	MACLEODS PHARMS LTD	EQ 5MG BASE	A203146	001	Sep 19, 2014	Sep NEWA
AB		EQ 10MG BASE	A203146	002	Sep 19, 2014	Sep NEWA

ROCURONIUM BROMIDE

INJECTABLE;INJECTION  
ROCURONIUM BROMIDE

>D>	AP	+	MYLAN INSTITUTIONAL	50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Dec CRLD
>A>	AP			50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Dec CRLD
	AP	+		50MG/5ML (10MG/ML)	A079199	001	Nov 26, 2008	Sep CRLD
>D>	AP	+		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Dec CRLD
>A>	AP			100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Dec CRLD
	AP	+		100MG/10ML (10MG/ML)	A079199	002	Nov 26, 2008	Sep CRLD
>D>	AP		SANDOZ	50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Dec CRLD
>A>	AP	+		50MG/5ML (10MG/ML)	A079195	001	Dec 05, 2008	Dec CRLD
>D>	AP			100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Dec CRLD
>A>	AP	+		100MG/10ML (10MG/ML)	A079195	002	Dec 05, 2008	Dec CRLD
			ZEMURON					
	@	ORGANON USA INC		50MG/5ML (10MG/ML)	N020214	001	Mar 17, 1994	Sep DISC
	@			100MG/10ML (10MG/ML)	N020214	003	Mar 17, 1994	Sep DISC

ROPIVACAINE HYDROCHLORIDEINJECTABLE; INJECTION  
NAROPIN

AP	FRESENIUS KABI USA	2MG/ML	N020533	001	Sep 24, 1996	Sep CTEC
AP		5MG/ML	N020533	003	Sep 24, 1996	Jul CFTG
AP		7.5MG/ML	N020533	004	Sep 24, 1996	Sep CTEC
AP	+	10MG/ML	N020533	005	Sep 24, 1996	Jul CFTG

ROPIVACAINE HYDROCHLORIDE

AP	HOSPIRA	2MG/ML	A090194	001	Sep 23, 2014	Sep NEWA
AP		5MG/ML	A090194	002	Sep 23, 2014	Sep NEWA
AP		7.5MG/ML	A090194	003	Sep 23, 2014	Sep NEWA
AP		10MG/ML	A090194	004	Sep 23, 2014	Sep NEWA
AP	NAVINTA LLC	5MG/ML	A078601	002	Jul 17, 2014	Jul NEWA
AP		10MG/ML	A078601	003	Jul 17, 2014	Jul NEWA
AP	SAGENT STRIDES	2MG/ML	A090318	001	Sep 23, 2014	Sep NEWA
AP		5MG/ML	A090318	002	Sep 23, 2014	Sep NEWA
AP		7.5MG/ML	A090318	003	Sep 23, 2014	Sep NEWA
AP		10MG/ML	A090318	004	Sep 23, 2014	Sep NEWA

>D> SAFFLOWER OIL; SOYBEAN OIL>D> INJECTABLE; INJECTION  
>D> LIPOSYN II 10%

>D>	+	HOSPIRA	5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984	Dec DISC
>A>	@		5%;5% (5GM/100ML)	N018997	001	Aug 27, 1984	Dec DISC
>D>		LIPOSYN II 20%					
>D>	+	HOSPIRA	10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984	Dec DISC
>A>	@		10%;10% (10GM/100ML)	N018991	001	Aug 27, 1984	Dec DISC

SALMETEROL XINAFOATEPOWDER; INHALATION  
SEREVENT

+	GLAXOSMITHKLINE	EQ 0.05MG BASE/INH	N020692	001	Sep 19, 1997	Sep CAHN
---	-----------------	--------------------	---------	-----	--------------	----------

SAXAGLIPTIN HYDROCHLORIDETABLET; ORAL  
ONGLYZA

	ASTRAZENECA AB	EQ 2.5MG BASE	N022350	001	Jul 31, 2009	May CAHN
+		EQ 5MG BASE	N022350	002	Jul 31, 2009	May CAHN

SELEGILINE HYDROCHLORIDECAPSULE; ORAL  
SELEGILINE HYDROCHLORIDE

@	LANNETT HOLDINGS INC	5MG	A075145	001	Sep 15, 2003	Nov CAHN
---	----------------------	-----	---------	-----	--------------	----------

SELENIUM SULFIDELOTION/SHAMPOO; TOPICAL  
SELENIUM SULFIDE

@	G AND W LABS INC	2.5%	A086209	001		Aug CAHN
---	------------------	------	---------	-----	--	----------

SERTRALINE HYDROCHLORIDETABLET; ORAL  
SERTRALINE HYDROCHLORIDE

AB	ACCORD HLTHCARE	EQ 25MG BASE	A202825	001	Nov 07, 2014	Oct NEWA
AB		EQ 50MG BASE	A202825	002	Nov 07, 2014	Oct NEWA
AB		EQ 100MG BASE	A202825	003	Nov 07, 2014	Oct NEWA
	@ WATSON LABS	EQ 25MG BASE	A077663	001	Feb 06, 2007	Oct DISC
	@	EQ 50MG BASE	A077663	002	Feb 06, 2007	Oct DISC
	@	EQ 100MG BASE	A077663	003	Feb 06, 2007	Oct DISC

SILDENAFIL CITRATETABLET; ORAL  
SILDENAFIL CITRATE

AB	HETERO LABS LTD V	EQ 20MG BASE	A203623	001	Nov 26, 2014	Nov NEWA
----	-------------------	--------------	---------	-----	--------------	----------

SIMEPREVIR SODIUMCAPSULE; ORAL  
OLYSIO

+	JANSSSEN PRODS	EQ 150MG BASE	N205123	001	Nov 22, 2013	Jun CAHN
+	JANSSSEN RES AND DEV	EQ 150MG BASE	N205123	001	Nov 22, 2013	Feb CAIN

SIMVASTATINTABLET; ORAL  
SIMVASTATIN

	AB	ACCORD HLTHCARE	5MG	A078155	005	Apr 05, 2013	Nov	NEWA
>A>	AB	HETERO LABS LTD III	5MG	A200895	001	Nov 25, 2014	Dec	NEWA
>A>	AB		10MG	A200895	002	Nov 25, 2014	Dec	NEWA
>A>	AB		20MG	A200895	003	Nov 25, 2014	Dec	NEWA
>A>	AB		40MG	A200895	004	Nov 25, 2014	Dec	NEWA
>A>	AB		80MG	A200895	005	Nov 25, 2014	Dec	NEWA

SIROLIMUSTABLET; ORAL  
RAPAMUNE

AB	PF PRISM CV	1MG	N021110	001	Aug 25, 2000	Oct	CFTG
AB	+	2MG	N021110	002	Aug 22, 2002	Oct	CFTG
	SIROLIMUS						
AB	DR REDDYS LABS LTD	1MG	A201578	001	Oct 27, 2014	Oct	NEWA
AB		2MG	A201578	002	Oct 27, 2014	Oct	NEWA

SODIUM BENZOATE; SODIUM PHENYLACETATESOLUTION; IV (INFUSION)  
AMMONUL

+	MEDICIS	10%; 10% (5GM/50ML; 5GM/50ML)	N020645	001	Feb 17, 2005	Jul	CAHN
---	---------	-------------------------------	---------	-----	--------------	-----	------

SODIUM CHLORIDEINJECTABLE; INJECTION  
SODIUM CHLORIDE 0.9%

@	MEDEFIL INC	18MG/2ML (9MG/ML)	N202832	002	Jan 06, 2012	Jun	DISC
@		22.5MG/2.5ML (9MG/ML)	N202832	003	Jan 06, 2012	Jun	DISC
@		27MG/3ML (9MG/ML)	N202832	004	Jan 06, 2012	Jun	DISC
@		45MG/5ML (9MG/ML)	N202832	005	Jan 06, 2012	Jun	DISC
	SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER						
@	MEDEFIL INC	9MG/ML (9MG/ML)	N202832	001	Jan 06, 2012	Jun	DISC

SODIUM FLUORIDE F-18INJECTABLE; INTRAVENOUS  
SODIUM FLUORIDE F-18

>A>	AP	BIOMEDCL RES FDN	10-200mCi/ML	A204351	001	Jan 09, 2015	Dec	NEWA
	AP	ESSENTIAL ISOTOPES	10-200mCi/ML	A204541	001	Oct 29, 2014	Oct	NEWA
	AP	GLOBAL ISOTOPES LLC	10-200mCi/ML	A204464	001	Oct 21, 2014	Oct	NEWA
	AP	NCM USA BRONX LLC	10-200mCi/ML	A204513	001	Nov 28, 2014	Nov	NEWA
	AP	SHERTECH LABS LLC	10-200mCi/ML	A204315	001	Sep 22, 2014	Sep	NEWA
	AP	THE FEINSTEIN INST	20-600mCi/ML	A204328	001	Nov 19, 2014	Nov	NEWA
	AP	UCSF RODIOPHARM	10-200mCi/ML	A204437	001	Mar 13, 2014	Mar	NEWA

SODIUM IODIDE I-131

CAPSULE; ORAL

SODIUM IODIDE I-131

JUBILANT DRAXIMAGE	0.009-0.1mCi	N021305	006	May 19, 2005	Nov	CPOT
--------------------	--------------	---------	-----	--------------	-----	------

SODIUM POLYSTYRENE SULFONATE

POWDER; ORAL, RECTAL

SODIUM POLYSTYRENE SULFONATE

AA	EPIC PHARMA LLC	453.6GM/BOT	A202333	001	Mar 19, 2014	Mar	NEWA
	NUVO PHARM INC	15GM/BOT	A204071	002	Nov 28, 2014	Nov	NEWA
AA		454GM/BOT	A204071	001	Nov 28, 2014	Nov	NEWA

SOLIFENACIN SUCCINATE

TABLET; ORAL

SOLIFENACIN SUCCINATE

AB	TEVA PHARMS USA	5MG	A091464	001	Apr 02, 2014	Mar	NEWA
AB		10MG	A091464	002	Apr 02, 2014	Mar	NEWA
	VESICARE						
AB	ASTELLAS	5MG	N021518	001	Nov 19, 2004	Mar	CFTG
AB	+	10MG	N021518	002	Nov 19, 2004	Mar	CFTG

SOMATROPIN RECOMBINANT

INJECTABLE; INJECTION  
ACCRETROPIN  
@ EMERGENT

5MG/ML (5MG/ML)

N021538 001 Jan 23, 2008 Feb CAHN

SOTALOL HYDROCHLORIDE

SOLUTION; ORAL  
SOTYLIZE

+ ARBOR PHARMS LLC  
+

5MG/ML (5MG/ML)  
5MG/ML

N205108 001 Oct 22, 2014 Oct NEWA  
N205108 001 Oct 22, 2014 Oct NEWA

TABLET; ORAL  
BETAPACE AF

>D> @ BAYER HLTHCARE  
>D> @

40MG  
60MG

N021151 006 Apr 02, 2003 Dec CAHN  
N021151 007 Apr 02, 2003 Dec CAHN

&gt;D&gt; AB2

@

80MG

N021151 001 Feb 22, 2000 Dec CAHN

&gt;D&gt; AB2

@

100MG

N021151 005 Mar 14, 2003 Dec CAHN

&gt;D&gt; AB2

@

120MG

N021151 002 Feb 22, 2000 Dec CAHN

&gt;D&gt; AB2

+

160MG

N021151 003 Feb 22, 2000 Dec CAHN

&gt;A&gt; @ COVIS PHARMA SARL

40MG

N021151 006 Apr 02, 2003 Dec CAHN

&gt;A&gt; @

60MG

N021151 007 Apr 02, 2003 Dec CAHN

&gt;A&gt; AB2

@

80MG

N021151 001 Feb 22, 2000 Dec CAHN

&gt;A&gt; AB2

@

100MG

N021151 005 Mar 14, 2003 Dec CAHN

&gt;A&gt; AB2

@

120MG

N021151 002 Feb 22, 2000 Dec CAHN

&gt;A&gt; AB2

+

160MG

N021151 003 Feb 22, 2000 Dec CAHN

SOYBEAN OIL

INJECTABLE; INJECTION  
LIPOSYN III 10%

&gt;D&gt; AP + HOSPIRA

10%

N018969 001 Sep 24, 1984 Dec DISC

&gt;A&gt; @

10%

N018969 001 Sep 24, 1984 Dec DISC

&gt;D&gt; LIPOSYN III 20%

&gt;D&gt; AP + HOSPIRA

20%

N018970 001 Sep 25, 1984 Dec DISC

&gt;A&gt; @

20%

N018970 001 Sep 25, 1984 Dec DISC

&gt;D&gt; LIPOSYN III 30%

&gt;D&gt; AP + HOSPIRA

30%

N020181 001 Jan 13, 1998 Dec DISC

&gt;A&gt; @

30%

N020181 001 Jan 13, 1998 Dec DISC

SPIRONOLACTONE

TABLET; ORAL  
SPIRONOLACTONE

AB JUBILANT GENERICS

25MG

A203253 001 Apr 23, 2014 Aug CAHN

AB

JUBILANT LIFE

50MG

A203253 002 Apr 23, 2014 Aug CAHN

AB

JUBILANT LIFE

100MG

A203253 003 Apr 23, 2014 Aug CAHN

AB

JUBILANT LIFE

25MG

A203253 001 Apr 23, 2014 Apr NEWA

AB

JUBILANT LIFE

50MG

A203253 002 Apr 23, 2014 Apr NEWA

AB

JUBILANT LIFE

100MG

A203253 003 Apr 23, 2014 Apr NEWA

AB ORION CORP ORION

25MG

A202187 001 Mar 06, 2014 Feb NEWA

AB

ORION CORP ORION

50MG

A202187 002 Mar 06, 2014 Feb NEWA

AB

ORION CORP ORION

100MG

A202187 003 Mar 06, 2014 Feb NEWA

SUCRALFATE

SUSPENSION; ORAL  
CARAFATE

+ FOREST LABS INC

1GM/10ML

N019183 001 Dec 16, 1993 Apr CAHN

TABLET; ORAL

CARAFATE

AB + FOREST LABS INC

1GM

N018333 001 Apr CAHN

SULFASALAZINE

TABLET; ORAL  
SULFASALAZINE

@ WATSON LABS

500MG

A087197 001 May DISC

SULFISOXAZOLE ACETYL

SUSPENSION; ORAL  
GANTRISIN PEDIATRIC

@ ROCHE

EQ 500MG BASE/5ML

N009182 004 Sep DISC

SYRUP; ORAL  
GANTRISIN

@ ROCHE

EQ 500MG BASE/5ML

N009182 002 Sep DISC

SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERESFOR SUSPENSION; INTRAVENOUS  
LUMASON

+ BRACCO 60.7MG/25MG N203684 001 Oct 15, 2014 Oct NEWA

SUMATRIPTAN SUCCINATEINJECTABLE; SUBCUTANEOUS  
IMITREX STATDOSE

BX + GLAXOSMITHKLINE EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N020080 002 Feb 01, 2006 May CTEC

SUMATRIPTAN SUCCINATE

AP AGILA SPECLTS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A203322 001 Apr 14, 2014 Mar NEWA

AB DR REDDYS LABS INC EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A090495 001 Jan 29, 2014 Jan NEWA

AP PAR STERILE PRODUCTS EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) A077871 001 Jul 09, 2009 Jun CAHN

SUMAVEL DOSEPRO

BX + ENDO VENTURES LTD EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 Aug CAHN

BX + EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) N022239 001 Jul 15, 2009 Aug CAHN

BX + ZOGENIX INC EQ 4MG BASE/0.5ML (EQ 8MG BASE/ML) N022239 002 Nov 26, 2013 May NEWA

SYSTEM; IONTOPHORESIS

ZECUITY

+ TEVA BRANDED PHARM EQ 6.5MG BASE/4HR N202278 001 Jan 17, 2013 May CAHN

SUNITINIB MALATE

CAPSULE; ORAL

SUNITINIB MALATE

AB MYLAN PHARMS INC EQ 12.5MG BASE A201275 001 Jan 30, 2014 Jan NEWA

AB EQ 25MG BASE A201275 002 Jan 30, 2014 Jan NEWA

AB EQ 37.5MG BASE A201275 003 Jan 30, 2014 Jan NEWA

AB EQ 50MG BASE A201275 004 Jan 30, 2014 Jan NEWA

SUTENT

AB CPPI CV EQ 12.5MG BASE N021938 001 Jan 26, 2006 Jan CFTG

AB EQ 25MG BASE N021938 002 Jan 26, 2006 Jan CFTG

AB EQ 37.5MG BASE N021938 004 Mar 31, 2009 Jan CFTG

AB + EQ 50MG BASE N021938 003 Jan 26, 2006 Jan CFTG

SUVOREXANT

TABLET; ORAL

BELSOMRA

MERCK SHARP DOHME

5MG

N204569 001 Aug 13, 2014 Aug NEWA

10MG

N204569 002 Aug 13, 2014 Aug NEWA

15MG

N204569 003 Aug 13, 2014 Aug NEWA

+ 20MG

N204569 004 Aug 13, 2014 Aug NEWA

TACROLIMUS

CAPSULE; ORAL

TACROLIMUS

AB STRIDES ARCOLAB LTD EQ 0.5MG BASE A090687 001 Jul 22, 2014 Jul NEWA

AB EQ 1MG BASE A090687 002 Jul 22, 2014 Jul NEWA

AB EQ 5MG BASE A090687 003 Jul 22, 2014 Jul NEWA

AB STRIDES PHARMA EQ 0.5MG BASE A090687 001 Jul 22, 2014 Aug CAHN

AB EQ 1MG BASE A090687 002 Jul 22, 2014 Aug CAHN

AB EQ 5MG BASE A090687 003 Jul 22, 2014 Aug CAHN

@ WATSON LABS

EQ 5MG BASE

A090402 001 Jul 01, 2010 May DISC

OINTMENT; TOPICAL

PROTOPIC

AB + ASTELLAS 0.03% N050777 001 Dec 08, 2000 Aug CFTG

AB + 0.1% N050777 002 Dec 08, 2000 Aug CFTG

TACROLIMUS

AB FOUGERA PHARMS INC 0.03% A200744 001 Sep 09, 2014 Aug NEWA

AB 0.1% A200744 002 Sep 09, 2014 Aug NEWA

TAFLUPROST

SOLUTION/DROPS; OPHTHALMIC

ZIOPTAN

+ OAK PHARMS INC 0.0015% N202514 001 Feb 10, 2012 Apr CAHN

TASIMELTEONCAPSULE;ORAL  
HETLIOZ

+	VANDA PHARMS INC	20MG	N205677	001	Jan 31, 2014	Jan NEWA
---	------------------	------	---------	-----	--------------	----------

TAVABOROLESOLUTION;TOPICAL  
KERYDIN

+	ANACOR PHARMS INC	5%	N204427	001	Jul 07, 2014	Jul NEWA
---	-------------------	----	---------	-----	--------------	----------

TECHNETIUM TC-99M SODIUM PERTECHNETATE GENERATORSOLUTION;INJECTION, ORAL  
TECHNELITE

@	LANTHEUS MEDCL	0.0083-2.7 CI/GENERATOR	N017771	001		May DISC
---	----------------	-------------------------	---------	-----	--	----------

ULTRA-TECHNEKOW FM

@	MALLINCKRODT	0.25-3 CI/GENERATOR	N017243	002		May DISC
---	--------------	---------------------	---------	-----	--	----------

SOLUTION;INTRAVENOUS  
TECHNELITE

+	LANTHEUS MEDCL	1-20 CI/GENERATOR	N017771	002	Feb 12, 2014	May NEWA
---	----------------	-------------------	---------	-----	--------------	----------

@		0.0083-2.7 CI/GENERATOR	N017771	001		May CDFR
---	--	-------------------------	---------	-----	--	----------

ULTRA-TECHNEKOW FM

+	MALLINCKRODT	1-19 CI/GENERATOR	N017243	003	Feb 18, 2014	May NEWA
---	--------------	-------------------	---------	-----	--------------	----------

@		0.25-3 CI/GENERATOR	N017243	002		May CDFR
---	--	---------------------	---------	-----	--	----------

SOLUTION;INTRAVENOUS, ORAL

TECHNETIUM TC 99M GENERATOR

+	GE HEALTHCARE	68-2703mCi/GENERATOR	N017693	002	Dec 13, 2013	May NEWA
---	---------------	----------------------	---------	-----	--------------	----------

@		830-16600mCi/GENERATOR	N017693	001		May CDFR
---	--	------------------------	---------	-----	--	----------

TEDIZOLID PHOSPHATEPOWDER;IV (INFUSION)  
SIVEXTRO

+	CUBIST PHARMS INC	200MG/VIAL	N205436	001	Jun 20, 2014	Jun NEWA
---	-------------------	------------	---------	-----	--------------	----------

TABLET;ORAL

SIVEXTRO

+	CUBIST PHARMS INC	200MG	N205435	001	Jun 20, 2014	Jun NEWA
---	-------------------	-------	---------	-----	--------------	----------

TELAVANCIN HYDROCHLORIDEPOWDER;IV (INFUSION)  
VIBATIV

	THERAVANCE BIOPHARMA	EQ 250MG BASE/VIAL	N022110	001	Sep 11, 2009	Jun CAHN
--	----------------------	--------------------	---------	-----	--------------	----------

+		EQ 750MG BASE/VIAL	N022110	002	Sep 11, 2009	Jun CAHN
---	--	--------------------	---------	-----	--------------	----------

TELMISARTAN

TABLET;ORAL

TELMISARTAN

AB	ALEMBIC PHARMS LTD	20MG	A202130	001	Jul 07, 2014	Jun NEWA
----	--------------------	------	---------	-----	--------------	----------

AB		40MG	A202130	002	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A202130	003	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	GLENMARK GENERICS	20MG	A090032	001	Jul 07, 2014	Jun NEWA
----	-------------------	------	---------	-----	--------------	----------

AB		40MG	A090032	002	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A090032	003	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	MYLAN PHARMS INC	20MG	A202397	001	Jul 07, 2014	Jun NEWA
----	------------------	------	---------	-----	--------------	----------

AB		40MG	A202397	002	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A202397	003	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	SANDOZ	20MG	A203867	001	Nov 03, 2014	Oct NEWA
----	--------	------	---------	-----	--------------	----------

AB		40MG	A203867	002	Nov 03, 2014	Oct NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A203867	003	Nov 03, 2014	Oct NEWA
----	--	------	---------	-----	--------------	----------

AB	TORRENT PHARMS LTD	20MG	A203171	001	Jul 07, 2014	Jun NEWA
----	--------------------	------	---------	-----	--------------	----------

AB		40MG	A203171	002	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A203171	003	Jul 07, 2014	Jun NEWA
----	--	------	---------	-----	--------------	----------

AB	ZYDUS PHARMS USA INC	20MG	A203325	001	Aug 26, 2014	Aug NEWA
----	----------------------	------	---------	-----	--------------	----------

AB		40MG	A203325	002	Aug 26, 2014	Aug NEWA
----	--	------	---------	-----	--------------	----------

AB		80MG	A203325	003	Aug 26, 2014	Aug NEWA
----	--	------	---------	-----	--------------	----------

TEMAZEPAMCAPSULE;ORAL  
TEMAZEPAM

@	WATSON LABS	15MG	A071446	001	May 21, 1993	May DISC
---	-------------	------	---------	-----	--------------	----------

@		30MG	A071447	001	May 21, 1993	May DISC
---	--	------	---------	-----	--------------	----------

TEMOZOLOMIDECAPSULE;ORAL  
TEMOZOLOMIDE

AB	SUN PHARMA GLOBAL	5MG	A201742	001	Feb 12, 2014	Feb NEWA
AB		20MG	A201742	002	Feb 12, 2014	Feb NEWA
AB		100MG	A201742	003	Feb 12, 2014	Feb NEWA
AB		140MG	A201742	004	Feb 12, 2014	Feb NEWA
AB		180MG	A201742	005	Feb 12, 2014	Feb NEWA
AB		250MG	A201742	006	Feb 12, 2014	Feb NEWA

TERAZOSIN HYDROCHLORIDECAPSULE;ORAL  
TERAZOSIN HYDROCHLORIDE

AB	+ SANDOZ	EQ 2MG BASE	A074823	002	Mar 30, 1998	Apr CRLD
	TABLET;ORAL					
	HYTRIN					
	@ ABBOTT	EQ 1MG BASE	N019057	001	Aug 07, 1987	Apr DISC
	@	EQ 2MG BASE	N019057	002	Aug 07, 1987	Apr DISC
	@	EQ 5MG BASE	N019057	003	Aug 07, 1987	Apr DISC
	@	EQ 10MG BASE	N019057	004	Aug 07, 1987	Apr DISC

TESAMORELIN ACETATEPOWDER;SUBCUTANEOUS  
EGRIFTA

+	THERATECHNOLOGIES	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	Aug CMFD
	@	EQ 1MG BASE/VIAL	N022505	001	Nov 10, 2010	May CAHN
	@	EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	Aug DISC
+		EQ 2MG BASE/VIAL	N022505	002	Nov 29, 2011	May CAHN

TESTOSTERONEFILM, EXTENDED RELEASE;TRANSDERMAL  
ANDRODERM

+	ACTAVIS LABS UT INC	2MG/24HR	N020489	003	Oct 20, 2011	Nov CAHN
	@	2.5MG/24HR	N020489	001	Sep 29, 1995	Nov CAHN
+		4MG/24HR	N020489	004	Oct 20, 2011	Nov CAHN
	@	5MG/24HR	N020489	002	May 02, 1997	Nov CAHN

GEL;TRANSDERMAL  
ANDROGEL

AB	ABBVIE	25MG/2.5GM PACKET	N021015	001	Feb 28, 2000	Jul CTEC
AB	+	50MG/5GM PACKET	N021015	002	Feb 28, 2000	Jul CTEC
	TESTOSTERONE					
AB	PERRIGO ISRAEL	25MG/2.5GM PACKET	N203098	002	Jan 31, 2013	Jul CTEC
AB		50MG/5GM PACKET	N203098	003	Jan 31, 2013	Jul CTEC
BX	TEVA PHARMS	25MG/2.5GM PACKET	N202763	001	Feb 14, 2012	Jul CTEC
BX		50MG/5GM PACKET	N202763	002	Feb 14, 2012	Jul CTEC

VOGELXO

UPSHER SMITH 50MG/5GM PACKET

N204399 002 Jun 04, 2014 Jun NEWA

GEL, METERED;NASAL  
NATESTO

>A>	ENDO VENTURES LTD	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Dec CMFD
>A>	@	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Dec CAHN
>D>	@ TRIMEL BIOPHARMA SRL	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Dec CAHN
	@	5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	Jun DISC
+		5.5MG/0.122GM ACTUATION	N205488	001	May 28, 2014	May NEWA

GEL, METERED;TRANSDERMAL  
ANDROGEL

AB	+	ABBVIE 12.5MG/1.25GM ACTUATION	N021015	003	Sep 26, 2003	Jul CTEC
	TESTOSTERONE					
AB	PERRIGO ISRAEL	12.5MG/1.25GM ACTUATION	N203098	001	Jan 31, 2013	Jul CTEC
	VOGELXO					
BX	UPSHER SMITH	12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Nov CTEC
		12.5MG/1.25GM ACTUATION	N204399	003	Jun 04, 2014	Jun NEWA

TABLET, EXTENDED RELEASE;BUCCAL  
STRIANT

+	AUXILIUM PHARMS LLC	30MG	N021543	001	Jun 19, 2003	Apr CAHN
---	---------------------	------	---------	-----	--------------	----------



TESTOSTERONE UNDECANOATEINJECTABLE; INTRAMUSCULAR  
AVEED

+	ENDO PHARMS INC	750MG/3ML (250MG/ML)	N022219	001	Mar 04, 2014	Mar NEWA
---	-----------------	----------------------	---------	-----	--------------	----------

THEOPHYLLINESOLUTION, ELIXIR; ORAL  
ELIXOPHYLLIN

+	CARACO	80MG/15ML	A085186	001		Jun CDFR
+	SUN PHARM INDS INC	80MG/15ML	A085186	001		Jul CAHN

TABLET, EXTENDED RELEASE; ORAL  
THEOCHRON

	@ CARACO	300MG	A087400	002	Jan 11, 1983	Jan DISC
AB	SUN PHARM INDS INC	100MG	A088320	001	Feb 21, 1985	Jul CAHN
AB		200MG	A088321	001	Feb 21, 1985	Jul CAHN
	@	300MG	A087400	002	Jan 11, 1983	Jul CAHN

THIAMINE HYDROCHLORIDEINJECTABLE; INJECTION  
THIAMINE HYDROCHLORIDE

@	WATSON LABS	100MG/ML	A080571	001		May DISC
@		200MG/ML	A080571	002		May DISC

THIORIDAZINE HYDROCHLORIDECONCENTRATE; ORAL  
THIORIDAZINE HYDROCHLORIDE

@	ANI PHARMS INC	100MG/ML	A089603	001	Nov 09, 1987	Feb CAHN
---	----------------	----------	---------	-----	--------------	----------

TABLET; ORAL

THIORIDAZINE HYDROCHLORIDE

@	ANI PHARMS INC	10MG	A088270	001	Apr 14, 1983	Feb CAHN
@		10MG	A088493	001	May 17, 1985	Feb CAHN
@		15MG	A088271	001	Apr 14, 1983	Feb CAHN
@		25MG	A088272	001	Apr 14, 1983	Feb CAHN
@		50MG	A088194	001	Apr 14, 1983	Feb CAHN
@		100MG	A088273	001	Oct 03, 1983	Feb CAHN
@		100MG	A088456	001	May 17, 1985	Feb CAHN

THIOTEPAINJECTABLE; INJECTION  
THIOTEPA

	EUROHLTH INTL	15MG/VIAL	A075547	001	Apr 02, 2001	Aug CAHN
--	---------------	-----------	---------	-----	--------------	----------

THIOTHIXENECAPSULE; ORAL  
THIOTHIXENE

@	WATSON LABS	2MG	A070601	001	Jun 05, 1987	May DISC
@		5MG	A070602	001	Jun 05, 1987	May DISC

THIOTHIXENE HYDROCHLORIDECONCENTRATE; ORAL  
THIOTHIXENE HYDROCHLORIDE INTENSOL

@	CYCLE PHARMS LTD	EQ 5MG BASE/ML	A073494	001	Jun 30, 1992	Sep CAHN
---	------------------	----------------	---------	-----	--------------	----------

TICLOPIDINE HYDROCHLORIDETABLET; ORAL  
TICLOPIDINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	250MG	A075526	001	Sep 26, 2002	Jul CAHN
----	--------------------	-------	---------	-----	--------------	----------

TIMOLOLSOLUTION/DROPS; OPHTHALMIC  
BETIMOL

+	OAK PHARMS INC	EQ 0.25% BASE	N020439	001	Mar 31, 1995	Apr CAHN
+		EQ 0.5% BASE	N020439	002	Mar 31, 1995	Apr CAHN

TIMOLOL MALEATESOLUTION, GEL FORMING/DROPS; OPHTHALMIC  
TIMOLOL MALEATE

>A>	AB	ALCON RES LTD	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Dec CAHN
>A>	AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Dec CAHN
>D>	AB	FALCON PHARMS	EQ 0.25% BASE	N020963	001	Oct 21, 1998	Dec CAHN
>D>	AB		EQ 0.5% BASE	N020963	002	Oct 21, 1998	Dec CAHN

## SOLUTION/DROPS;OPHTHALMIC

## TIMOLOL MALEATE

>A> AT	ALCON RES LTD	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Dec CAHN
>A> AT		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Dec CAHN
>D> AT	FALCON PHARMS	EQ 0.25% BASE	A074261	001	Apr 28, 1995	Dec CAHN
>D> AT		EQ 0.5% BASE	A074262	001	Apr 28, 1995	Dec CAHN

TIOTROPIUM BROMIDE

## POWDER; INHALATION

## SPIRIVA

+	BOEHRINGER INGELHEIM	EQ 0.018MG BASE/INH	N021395	001	Jan 30, 2004	Sep CAIN
	SPRAY, METERED; INHALATION					
	SPIRIVA RESPIMAT					
+	BOEHRINGER INGELHEIM	EQ 0.0025MG BASE/INH	N021936	001	Sep 24, 2014	Sep NEWA

TIZANIDINE HYDROCHLORIDE

## TABLET; ORAL

## TIZANIDINE HYDROCHLORIDE

AB	SUN PHARM INDS INC	EQ 2MG BASE	A076416	001	Sep 29, 2003	Jul CAHN
AB		EQ 4MG BASE	A076416	002	Sep 29, 2003	Jul CAHN

TOBRAMYCIN

## SOLUTION; INHALATION

## BETHKIS

>A>	CHIESI USA INC	300MG/4ML	N201820	001	Oct 12, 2012	Apr CAHN	
>A>	KITABIS PAK						
>A>	+	PULMOFLOW INC	300MG/5ML	N205433	001	Dec 02, 2014	Dec NEWA
	TOBRAMYCIN						
AN	AKORN INC	300MG/5ML	A201422	001	May 28, 2014	May NEWA	

TOBRAMYCIN SULFATE

## INJECTABLE; INJECTION

## TOBRAMYCIN SULFATE

AP	AKORN	EQ 40MG BASE/ML	A205179	001	Sep 16, 2014	Sep NEWA
	@ WATSON LABS INC	EQ 10MG BASE/ML	A062945	001	Aug 09, 1989	May DISC
AP	XELLIA PHARMS APS	EQ 1.2GM BASE/VIAL	A205685	001	Sep 16, 2014	Sep NEWA

TOPIRAMATE

## CAPSULE, DELAYED RELEASE; ORAL

## QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Mar NEWA
		50MG	N205122	002	Mar 11, 2014	Mar NEWA
		100MG	N205122	003	Mar 11, 2014	Mar NEWA
		150MG	N205122	004	Mar 11, 2014	Mar NEWA
+		200MG	N205122	005	Mar 11, 2014	Mar NEWA

## CAPSULE, EXTENDED RELEASE; ORAL

## QUDEXY XR

	UPSHER SMITH	25MG	N205122	001	Mar 11, 2014	Apr CDFR
		50MG	N205122	002	Mar 11, 2014	Apr CDFR
		100MG	N205122	003	Mar 11, 2014	Apr CDFR
		150MG	N205122	004	Mar 11, 2014	Apr CDFR
+		200MG	N205122	005	Mar 11, 2014	Apr CDFR

## TABLET; ORAL

## TOPIRAMATE

>D> AB	SUN PHARM INDS LTD	25MG	A090278	001	Mar 27, 2009	Dec CAHN
>D> AB		50MG	A090278	002	Mar 27, 2009	Dec CAHN
>D> AB		100MG	A090278	003	Mar 27, 2009	Dec CAHN
>D> AB		200MG	A090278	004	Mar 27, 2009	Dec CAHN
>A> AB	SUN PHARMA GLOBAL	25MG	A090278	001	Mar 27, 2009	Dec CAHN
>A> AB		50MG	A090278	002	Mar 27, 2009	Dec CAHN
>A> AB		100MG	A090278	003	Mar 27, 2009	Dec CAHN
>A> AB		200MG	A090278	004	Mar 27, 2009	Dec CAHN
	@ WATSON LABS	25MG	A077643	001	Mar 27, 2009	May DISC
	@	50MG	A077643	002	Mar 27, 2009	May DISC
	@	100MG	A077643	003	Mar 27, 2009	May DISC
	@	200MG	A077643	004	Mar 27, 2009	May DISC

TOPOTECAN HYDROCHLORIDE

## INJECTABLE; INJECTION

## TOPOTECAN HYDROCHLORIDE

AP	ACTAVIS ELIZABETH	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Aug CAHN
AP	ACTAVIS TOTOWA	EQ 4MG BASE/VIAL	A090620	001	Dec 02, 2010	Oct CAHN
AP	CIPLA LTD	EQ 4MG BASE/VIAL	A091199	001	Dec 01, 2010	Nov CAHN
>D> AP	FRESENIUS KABI ONCOL	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Dec DISC
>A>	@	EQ 4MG BASE/VIAL	A091376	001	Nov 29, 2010	Dec DISC
AP	INNOPHARMA LICENSING	EQ 4MG BASE/VIAL	A201166	001	Aug 08, 2012	Apr CAHN

TORSEMIDE

## INJECTABLE; INJECTION

## TORSEMIDE

AP	+	EUROHLTH INTL	20MG/2ML (10MG/ML)	A078007	001	Jun 11, 2008	Aug CAHN
AP	+		50MG/5ML (10MG/ML)	A078007	002	Jun 11, 2008	Aug CAHN

TRAMADOL HYDROCHLORIDE

## TABLET; ORAL

## TRAMADOL HYDROCHLORIDE

AB	ALLIED PHARMA INC	50MG	A202075	001	Nov 28, 2011	Apr CAHN
AB	AUROBINDO PHARMA LTD	50MG	A203494	001	Mar 31, 2014	Mar NEWA
AB	SUN PHARM INDS INC	50MG	A075964	001	Jun 19, 2002	Jul CAHN
	@ WATSON LABS	50MG	A075962	001	Jun 24, 2002	May DISC

TRANDOLAPRIL

## TABLET; ORAL

## TRANDOLAPRIL

	@ COREPHARMA	1MG	A077256	001	Jun 12, 2007	Jun DISC
	@	2MG	A077256	002	Jun 12, 2007	Jun DISC
	@	4MG	A077256	003	Jun 12, 2007	Jun DISC

TRANEXAMIC ACID

## INJECTABLE; INJECTION

## TRANEXAMIC ACID

AP	ACIC FINE CHEMS	100MG/ML	A202436	001	Feb 11, 2014	Jan NEWA
AP	EMCURE PHARMS LTD	100MG/ML	A203521	001	Aug 12, 2014	Aug NEWA
	@ FRESENIUS KABI USA	100MG/ML	A091596	001	Mar 02, 2012	Oct DISC

## TABLET; ORAL

## TRANEXAMIC ACID

AB	APOTEX INC	650MG	A202286	001	Jan 27, 2014	Jan NEWA
----	------------	-------	---------	-----	--------------	----------

TRAVOPROST

## SOLUTION/DROPS; OPHTHALMIC

## IZBA

+	ALCON LABS INC	0.003%	N204822	001	May 15, 2014	May NEWA
	TRAVOPROST					
+	PAR PHARM	0.004%	A091340	001	Mar 01, 2013	Feb CRLD

TRAZODONE HYDROCHLORIDE

## TABLET; ORAL

## TRAZODONE HYDROCHLORIDE

	@ WATSON LABS	50MG	A070857	001	Oct 10, 1986	May DISC
	@	100MG	A070858	001	Oct 10, 1986	May DISC

TREPROSTINIL

## SOLUTION; INHALATION

## TYVASO

+	UNITED THERAP	0.6MG/ML	N022387	001	Jul 30, 2009	Sep CPOT
---	---------------	----------	---------	-----	--------------	----------

TREPROSTINIL DIOLAMINE

## TABLET, EXTENDED RELEASE; ORAL

## ORENITRAM

	UNITED THERAP	EQ 0.125MG BASE	N203496	001	Dec 20, 2013	Jun CAIN
		EQ 0.25MG BASE	N203496	002	Dec 20, 2013	Jun CAIN
		EQ 1MG BASE	N203496	003	Dec 20, 2013	Jun CAIN
+		EQ 2.5MG BASE	N203496	004	Dec 20, 2013	Jun CAIN

TRETINOIN

CREAM; TOPICAL							
TRETINOIN							
AB	MATAWAN PHARMS	0.025%	A075264	001	Dec 24, 1998	Sep	CAHN
AB1		0.05%	A075265	001	Dec 24, 1998	Sep	CAHN
AB		0.1%	A075213	001	Dec 24, 1998	Sep	CAHN
	+ WATSON LABS INC	0.0375%	A090098	001	Mar 22, 2010	Sep	CAHN
		0.075%	A202209	001	Oct 11, 2012	Sep	CAHN
GEL; TOPICAL							
RETIN-A-MICRO							
	+ VALEANT INTL	0.08%	N020475	003	Jan 28, 2014	Jan	NEWA
TRETINOIN							
AB	MATAWAN PHARMS	0.01%	A075589	001	Jun 11, 2002	Sep	CAHN
AB		0.025%	A075529	001	Feb 22, 2000	Sep	CAHN
SOLUTION; TOPICAL							
RETIN-A							
	+ VALEANT INTL	0.05%	N016921	001		Feb	CTEC
TRETINOIN							
	@ WOCKHARDT	0.05%	A075260	001	Jan 25, 1999	Feb	DISC

TRIAMCINOLONE

TABLET; ORAL							
KENACORT							
	@ DELCOR ASSET CORP	1MG	N011283	003		Sep	CAHN
	@	2MG	N011283	008		Sep	CAHN
	@	4MG	N011283	006		Sep	CAHN
	@	8MG	N011283	010		Sep	CAHN

TRIAMCINOLONE ACETONIDE

CREAM; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	N011601	003		Jul	CAHN
	@	0.1%	N011601	006		Jul	CAHN
	@	0.5%	A083943	001		Sep	CAHN
KENALOG-H							
	@ DELCOR ASSET CORP	0.1%	A086240	001		Sep	CAHN
INJECTABLE; INJECTION							
KENALOG-10							
	APOTHECON	10MG/ML	N012041	001		May	CTEC
KENALOG-40							
	+ APOTHECON	40MG/ML	N014901	001		May	CTEC
TRIAMCINOLONE ACETONIDE							
	@ SANDOZ	10MG/ML	A090166	001	May 27, 2009	May	DISC
	@ SANDOZ CANADA INC	40MG/ML	A090164	001	Jun 01, 2009	May	DISC
LOTION; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	A084343	001		Sep	CAHN
	@	0.025%	N011602	003		Sep	CAHN
	@	0.1%	A084343	002		Sep	CAHN
	@	0.1%	N011602	001		Sep	CAHN
TRIAMCINOLONE ACETONIDE							
	@ G AND W LABS INC	0.1%	A089129	001	Aug 14, 1986	Aug	CAHN
	@ TARO	0.1%	A089129	001	Aug 14, 1986	Mar	DISC
OINTMENT; TOPICAL							
KENALOG							
	@ DELCOR ASSET CORP	0.025%	N011600	003		Jul	CAHN
	@	0.1%	N011600	001		Jul	CAHN
	@	0.5%	A083944	001		Sep	CAHN
PASTE; DENTAL							
KENALOG IN ORABASE							
	@ DELCOR ASSET CORP	0.1%	N012097	001		Sep	CAHN

TRIAMCINOLONE DIACETATE

SYRUP; ORAL							
KENACORT							
	@ DELCOR ASSET CORP	EQ 4MG BASE/5ML	N012515	001		Sep	CAHN

TRIAMTERENECAPSULE;ORAL  
DYRENIUM

COVIS PHARMA SARL

50MG

N013174 001

Sep CAHN

+

100MG

N013174 002

Sep CAHN

TRIAZOLAMTABLET;ORAL  
TRIAZOLAM

@ WATSON LABS

0.125MG

A074445 001 Oct 20, 1995 May DISC

@

0.25MG

A074445 002 Oct 20, 1995 May DISC

TRIHEXYPHENIDYL HYDROCHLORIDE

TABLET;ORAL

TRIHEXYPHENIDYL HYDROCHLORIDE

@ WATSON LABS

2MG

A040184 001 Feb 06, 1998 May DISC

@

5MG

A040184 002 Feb 06, 1998 May DISC

TRIMETHOBENZAMIDE HYDROCHLORIDE

INJECTABLE;INJECTION

TIGAN

AP

+

PAR STERILE PRODUCTS

100MG/ML

N017530 001

May CAHN

UMECLIDINIUM BROMIDEPOWDER;INHALATION  
INCRUSE ELLIPTA

+ GLAXO GRP ENGLAND

EQ 62.5MCG BASE/INH

N205382 001 Apr 30, 2014 Apr NEWA

UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATEPOWDER;INHALATION  
ANORO ELLIPTA

+ GLAXOSMITHKLINE

EQ 0.0625MG BASE/INH;EQ 0.025MG  
BASE/INH

N203975 001 Dec 18, 2013 Apr CAHN

UNOPROSTONE ISOPROPYLSOLUTION/DROPS;OPHTHALMIC  
RESCULA

+ SUCAMPO PHARMS

0.15%

N021214 001 Aug 03, 2000 Aug CRLD

UREA C-13

FOR SOLUTION;ORAL

BREATHTEK UBT FOR H-PYLORI

@ OTSUKA AMERICA

EQ 75MG/POUCH

N020586 002 May 10, 2001 May DISC

URSODIOL

TABLET;ORAL

URSO 250

AB

FOREST LABS INC

250MG

N020675 001 Dec 10, 1997 Apr CAHN

URSO FORTE

AB

+

FOREST LABS INC

500MG

N020675 002 Jul 21, 2004 Apr CAHN

URSODIOL

AB

IMPAX LABS INC

250MG

A200826 001 Dec 23, 2011 Jul CAHN

AB

500MG

A200826 002 Dec 23, 2011 Jul CAHN

VALACYCLOVIR HYDROCHLORIDE

TABLET;ORAL

VALACYCLOVIR HYDROCHLORIDE

AB

APOTEX INC

EQ 1GM BASE

A090500 002 Apr 04, 2014 Mar NEWA

AB

EQ 500MG BASE

A090500 001 Apr 04, 2014 Mar NEWA

AB

CIPLA LTD

EQ 1GM BASE

A077135 002 May 24, 2010 Jan CAHN

AB

EQ 500MG BASE

A077135 001 May 24, 2010 Jan CAHN

AB

JUBILANT GENERICS

EQ 1GM BASE

A201506 002 Apr 03, 2012 Aug CAHN

AB

EQ 500MG BASE

A201506 001 Apr 03, 2012 Aug CAHN

AB

WATSON LABS INC

EQ 1GM BASE

A090370 002 Mar 16, 2011 Apr CAHN

AB

EQ 500MG BASE

A090370 001 Mar 16, 2011 Apr CAHN

VALGANCICLOVIR HYDROCHLORIDE

TABLET; ORAL

VALCYTE

AB	+	HOFFMANN LA ROCHE	EQ 450MG BASE	N021304	001	Mar 29, 2001	Oct CFTG
VALGANCICLOVIR HYDROCHLORIDE							
AB		DR REDDYS LABS LTD	EQ 450MG BASE	A203511	001	Nov 04, 2014	Oct NEWA
AB		ENDO PHARMS INC	EQ 450MG BASE	A200790	001	Nov 04, 2014	Oct NEWA

VALPROIC ACID

SYRUP; ORAL

VALPROIC ACID

AA		ANI PHARMS INC	250MG/5ML	A073178	001	Aug 25, 1992	Jan CAHN
----	--	----------------	-----------	---------	-----	--------------	----------

VALSARTAN

TABLET; ORAL

DIOVAN

AB		NOVARTIS	40MG	N021283	004	Aug 14, 2002	Jun CFTG
AB			80MG	N021283	001	Jul 18, 2001	Jun CFTG
AB			160MG	N021283	002	Jul 18, 2001	Jun CFTG
AB	+		320MG	N021283	003	Jul 18, 2001	Jun CFTG

VALSARTAN

>A>	AB	ALEMBIC PHARMS LTD	40MG	A091367	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A091367	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A091367	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A091367	004	Jan 05, 2015	Dec NEWA
>A>	AB	AUROBINDO PHARMA LTD	40MG	A202223	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A202223	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A202223	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A202223	004	Jan 05, 2015	Dec NEWA
>A>	AB	HETERO LABS LTD V	40MG	A203311	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A203311	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A203311	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A203311	004	Jan 05, 2015	Dec NEWA
>A>	AB	IVAX PHARMS	40MG	A077530	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A077530	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A077530	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A077530	004	Jan 05, 2015	Dec NEWA
>A>	AB	JUBILANT GENERICS	40MG	A203536	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A203536	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A203536	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A203536	004	Jan 05, 2015	Dec NEWA
>A>	AB	LUPIN LTD	40MG	A201677	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A201677	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A201677	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A201677	004	Jan 05, 2015	Dec NEWA
>A>	AB	MYLAN LABS LTD	40MG	A090866	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A090866	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A090866	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A090866	004	Jan 05, 2015	Dec NEWA
	AB	OHM LABS INC	40MG	A077492	001	Jun 26, 2014	Jun NEWA
	AB		80MG	A077492	002	Jun 26, 2014	Jun NEWA
	AB		160MG	A077492	003	Jun 26, 2014	Jun NEWA
	AB		320MG	A077492	004	Jun 26, 2014	Jun NEWA
>A>	AB	TORRENT PHARMS LTD	40MG	A202728	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A202728	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A202728	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A202728	004	Jan 05, 2015	Dec NEWA
>A>	AB	WATSON LABS INC	40MG	A090642	001	Jan 05, 2015	Dec NEWA
>A>	AB		80MG	A090642	002	Jan 05, 2015	Dec NEWA
>A>	AB		160MG	A090642	003	Jan 05, 2015	Dec NEWA
>A>	AB		320MG	A090642	004	Jan 05, 2015	Dec NEWA

VANCOMYCIN HYDROCHLORIDE

CAPSULE; ORAL

VANCOCIN HYDROCHLORIDE

AB		ANI PHARMS INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	Aug CAHN
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	Aug CAHN
AB		SHIRE VIROPHARM INC	EQ 125MG BASE	N050606	001	Apr 15, 1986	May CAHN
AB	+		EQ 250MG BASE	N050606	002	Apr 15, 1986	May CAHN

VANCOMYCIN HYDROCHLORIDE

AB		STRIDES PHARMA	EQ 125MG BASE	A065490	001	Apr 09, 2012	Aug CAHN
AB			EQ 250MG BASE	A065490	002	Apr 09, 2012	Aug CAHN

## FOR SOLUTION;ORAL

## VANCOCIN HYDROCHLORIDE

@ ANI PHARMS INC

EQ 250MG BASE/5ML

A061667 002 Jul 13, 1983

Aug CAHN

@

EQ 500MG BASE/6ML

A061667 001

Aug CAHN

## INJECTABLE;INJECTION

## VANCOCIN HYDROCHLORIDE

@ ANI PHARMS INC

EQ 1GM BASE/VIAL

A060180 002 Mar 21, 1986

Aug CAHN

@

EQ 1GM BASE/VIAL

A062476 002 Mar 21, 1986

Aug CAHN

@

EQ 1GM BASE/VIAL

A062716 002 Mar 13, 1987

Aug CAHN

@

EQ 1GM BASE/VIAL

A062812 002 Nov 17, 1987

Aug CAHN

@

EQ 10GM BASE/VIAL

A062812 003 Nov 17, 1987

Aug CAHN

@

EQ 500MG BASE/VIAL

A060180 001

Aug CAHN

@

EQ 500MG BASE/VIAL

A062476 001 Mar 15, 1984

Aug CAHN

@

EQ 500MG BASE/VIAL

A062716 001 Mar 13, 1987

Aug CAHN

@

EQ 500MG BASE/VIAL

A062812 001 Nov 17, 1987

Aug CAHN

## VANCOMYCIN HYDROCHLORIDE

AP AGILA SPECLTS

EQ 10GM BASE/VIAL

A091554 001 Sep 19, 2011

Feb CAHN

&gt;D&gt; AP HOSPIRA

EQ 750MG BASE/VIAL

A062912 002 Jan 07, 2009

Dec CRLD

&gt;A&gt; AP +

EQ 750MG BASE/VIAL

A062912 002 Jan 07, 2009

Dec CRLD

&gt;D&gt; AP

EQ 750MG BASE/VIAL

A062933 002 May 27, 2009

Dec CRLD

&gt;A&gt; AP +

EQ 750MG BASE/VIAL

A062933 002 May 27, 2009

Dec CRLD

AP MUSTAFA NEVZAT ILAC

EQ 1GM BASE/VIAL

A065401 002 Jun 30, 2008

May CAHN

AP

EQ 500MG BASE/VIAL

A065401 001 Jun 30, 2008

May CAHN

AP SAGENT PHARMS

EQ 10GM BASE/VIAL

A200837 002 Sep 02, 2014

Aug NEWA

VASOPRESSIN

## SOLUTION;IV (INFUSION)

## VASOSTRICT

+ PAR STERILE PRODUCTS 20UNITS/ML (20UNITS/ML)

N204485 001 Apr 17, 2014

Apr NEWA

VECURONIUM BROMIDE

## INJECTABLE;INJECTION

## VECURONIUM BROMIDE

@ WATSON LABS

10MG/VIAL

A074334 001 Aug 31, 1995

May DISC

@

20MG/VIAL

A074334 002 Aug 31, 1995

May DISC

VENLAFAXINE HYDROCHLORIDE

## TABLET;ORAL

## VENLAFAXINE HYDROCHLORIDE

AB SUN PHARM INDS INC

EQ 25MG BASE

A078627 001 Jun 13, 2008

Jul CAHN

AB

EQ 37.5MG BASE

A078627 002 Jun 13, 2008

Jul CAHN

AB

EQ 50MG BASE

A078627 003 Jun 13, 2008

Jul CAHN

AB

EQ 75MG BASE

A078627 004 Jun 13, 2008

Jul CAHN

AB

EQ 100MG BASE

A078627 005 Jun 13, 2008

Jul CAHN

VERAPAMIL HYDROCHLORIDE

## SOLUTION;INTRAVENOUS

## VERAPAMIL HYDROCHLORIDE

AP + HOSPIRA

10MG/4ML (2.5MG/ML)

A070738 001 May 06, 1987

Oct CRLD

AP +

5MG/2ML (2.5MG/ML)

A075136 001 Oct 20, 1998

Oct CRLD

AP +

5MG/2ML (2.5MG/ML)

A070737 001 May 06, 1987

Oct CRLD

AP +

10MG/4ML (2.5MG/ML)

A070737 002 May 06, 1987

Oct NEWA

## TABLET;ORAL

## VERAPAMIL HYDROCHLORIDE

AB MYLAN

80MG

A071483 002 Feb 15, 1989

Apr CMS1

@ WATSON LABS

40MG

A072923 001 Jun 29, 1993

May DISC

@

80MG

A070855 001 Sep 24, 1986

May DISC

@

80MG

A071366 001 Oct 01, 1986

May DISC

@

120MG

A070856 001 Sep 24, 1986

May DISC

@

120MG

A071367 001 Oct 01, 1986

May DISC

## TABLET, EXTENDED RELEASE;ORAL

## VERAPAMIL HYDROCHLORIDE

AB ANI PHARMS INC

120MG

A090529 001 Dec 30, 2011

Jun CAHN

AB

180MG

A090529 002 Dec 30, 2011

Jun CAHN

AB

240MG

A090529 003 Dec 30, 2011

Jun CAHN

AB SUN PHARM INDS INC

120MG

A090529 001 Dec 30, 2011

Jul CAHN

AB

180MG

A090529 002 Dec 30, 2011

Jul CAHN

AB

240MG

A090529 003 Dec 30, 2011

Jul CAHN

VINBLASTINE SULFATE

INJECTABLE; INJECTION  
VINBLASTINE SULFATE

+ EUROHLTH INTL 10MG/VIAL A089395 001 Apr 09, 1987 Aug CAHN

VINORELBINE TARTRATE

INJECTABLE; INJECTION  
VINORELBINE TARTRATE

AP ACTAVIS ELIZABETH EQ 10MG BASE/ML A078011 001 Jul 22, 2009 Aug CAHN  
AP ACTAVIS TOTOWA EQ 10MG BASE/ML A078011 001 Jul 22, 2009 Oct CAHN  
@ EBEWE PHARMA EQ 10MG BASE/ML A078408 001 Feb 13, 2008 Nov DISC

VORAPAXAR SULFATE

TABLET; ORAL  
ZONTIVITY

+ MERCK SHARP DOHME EQ 2.08MG BASE N204886 001 May 08, 2014 Jun CPOT  
+ EQ 2.5MG BASE N204886 001 May 08, 2014 May NEWA

VORICONAZOLE

FOR SUSPENSION; ORAL  
VFEND

AB + PF PRISM CV 200MG/5ML N021630 001 Dec 19, 2003 Sep CAHN

INJECTABLE; IV (INFUSION)  
VFEND

AP + PF PRISM CV 200MG/VIAL N021267 001 May 24, 2002 Sep CAHN

TABLET; ORAL  
VFEND

AB PF PRISM CV 50MG N021266 001 May 24, 2002 Sep CAHN  
AB + 200MG N021266 002 May 24, 2002 Sep CAHN

WARFARIN SODIUM

INJECTABLE; INJECTION  
COUMADIN

@ BRISTOL MYERS SQUIBB 5MG/VIAL N009218 024 Feb 07, 1995 Mar DISC

TABLET; ORAL  
COUMADIN

AB BRISTOL MYERS SQUIBB 1MG N009218 022 Mar 01, 1990 Apr CMFD  
@ 1MG N009218 022 Mar 01, 1990 Mar DISC  
AB 2MG N009218 013 Apr CMFD  
@ 2MG N009218 013 Mar DISC  
AB 2.5MG N009218 018 Apr CMFD  
@ 2.5MG N009218 018 Mar DISC  
AB 3MG N009218 025 Nov 18, 1996 Apr CMFD  
@ 3MG N009218 025 Nov 18, 1996 Mar DISC  
AB 4MG N009218 023 Aug 24, 1993 Apr CMFD  
@ 4MG N009218 023 Aug 24, 1993 Mar DISC  
AB 5MG N009218 007 Apr CMFD  
@ 5MG N009218 007 Mar DISC  
AB 6MG N009218 026 Nov 18, 1996 Apr CMFD  
@ 6MG N009218 026 Nov 18, 1996 Mar DISC  
AB 7.5MG N009218 016 Apr CMFD  
@ 7.5MG N009218 016 Mar DISC  
AB + 10MG N009218 005 Apr CMFD  
@ 10MG N009218 005 Mar DISC

ZICONOTIDE ACETATE

INJECTABLE; INTRATHECAL  
PRIALT

@ JAZZ PHARMS INTL 200MCG/2ML (100MCG/ML) N021060 003 Dec 28, 2004 Feb CAIN

ZIDOVUDINE

INJECTABLE; INJECTION  
ZIDOVUDINE

@ LIAONING CHENGDA 10MG/ML A204538 001 Nov 26, 2013 Mar DISC

ZILEUTON

TABLET; ORAL  
ZYFLO

@ CHIESI USA INC 300MG N020471 001 Dec 09, 1996 Apr CAHN  
+ 600MG N020471 003 Dec 09, 1996 Apr CAHN



TABLET, EXTENDED RELEASE;ORAL  
ZYFLO CR

+	CHIESI USA INC	600MG	N022052	001	May 30, 2007	Apr CAHN
---	----------------	-------	---------	-----	--------------	----------

ZOLEDRONIC ACID

INJECTABLE;IV (INFUSION)  
ZOLEDRONIC ACID

AP	AKORN	EQ 5MG BASE/100ML	A200918	001	Aug 21, 2014	Aug NEWA
AP	AKORN INC	EQ 4MG BASE/5ML	A202548	001	May 22, 2014	May NEWA
AP	SAGENT PHARMS	EQ 4MG BASE/5ML	A091493	001	Nov 24, 2014	Nov NEWA
AP	+ SUN PHARMA GLOBAL	EQ 4MG BASE/VIAL	A090018	001	Mar 04, 2013	Oct CTEC
AP	USV NORTH AMERICA	EQ 4MG BASE/VIAL	A202923	001	Sep 04, 2014	Aug NEWA

ZOLMITRIPTAN

TABLET;ORAL  
ZOLMITRIPTAN

AB	INVAGEN PHARMS	2.5MG	A204284	001	Apr 09, 2014	Mar NEWA
AB		5MG	A204284	002	Apr 09, 2014	Mar NEWA
AB	JUBILANT GENERICS	2.5MG	A202279	001	Nov 20, 2014	Nov NEWA
AB		5MG	A202279	002	Nov 20, 2014	Nov NEWA
AB	SUN PHARMA GLOBAL	2.5MG	A203476	001	Nov 13, 2014	Oct NEWA
AB		5MG	A203476	002	Nov 13, 2014	Oct NEWA
AB	TEVA PHARMS USA	2.5MG	A090861	001	Mar 04, 2014	Feb NEWA
AB		5MG	A090861	002	Mar 04, 2014	Feb NEWA

ZOLPIDEM TARTRATE

TABLET;ORAL  
ZOLPIDEM TARTRATE

AB	SUN PHARM INDS INC	5MG	A077359	001	Apr 23, 2007	Jul CAHN
AB		10MG	A077359	002	Apr 23, 2007	Jul CAHN
	@ VIVIMED LABS	5MG	A076062	001	Apr 23, 2007	Apr CAHN
	@	10MG	A076062	002	Apr 23, 2007	Apr CAHN
	@ WATSON LABS	5MG	A077773	001	Apr 23, 2007	May DISC
	@	10MG	A077773	002	Apr 23, 2007	May DISC

ZONISAMIDE

CAPSULE;ORAL  
ZONISAMIDE

@	ANI PHARMS INC	25MG	A077639	001	Dec 22, 2005	Sep DISC
AB		25MG	A077639	001	Dec 22, 2005	Jan CAHN
	@	25MG	A077641	003	Dec 22, 2005	Jan CAHN
	@	50MG	A077639	002	Dec 22, 2005	Sep DISC
AB		50MG	A077639	002	Dec 22, 2005	Jan CAHN
	@	50MG	A077641	002	Dec 22, 2005	Jan CAHN
	@	100MG	A077639	003	Dec 22, 2005	Sep DISC
AB		100MG	A077639	003	Dec 22, 2005	Jan CAHN
	@	100MG	A077641	001	Dec 22, 2005	Jan CAHN
	@ SANDOZ	25MG	A077644	001	Dec 22, 2005	Feb DISC
	@	50MG	A077644	002	Dec 22, 2005	Feb DISC
	@	100MG	A077644	003	Dec 22, 2005	Feb DISC

CETIRIZINE HYDROCHLORIDE

## SYRUP;ORAL

CHILDREN'S CETIRIZINE HYDROCHLORIDE ALLERGY

SUN PHARM INDS INC 5MG/5ML

A091327 001 Oct 17, 2011 Sep CAHN

CHILDREN'S CETIRIZINE HYDROCHLORIDE HIVES RELIEF

SUN PHARM INDS INC 5MG/5ML

A091327 002 Oct 17, 2011 Sep CAHN

## TABLET;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

IPCA LABS LTD 5MG

A202277 002 Mar 11, 2014 Feb NEWA

10MG

A202277 004 Mar 11, 2014 Feb NEWA

SUN PHARM INDS INC 5MG

A077499 001 Dec 27, 2007 Jul CAHN

10MG

A077499 002 Dec 27, 2007 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES

IPCA LABS LTD 5MG

A202277 001 Mar 11, 2014 Feb NEWA

10MG

A202277 003 Mar 11, 2014 Feb NEWA

SUN PHARM INDS INC 5MG

A077499 003 Dec 27, 2007 Jul CAHN

10MG

A077499 004 Dec 27, 2007 Jul CAHN

## TABLET, CHEWABLE;ORAL

CETIRIZINE HYDROCHLORIDE ALLERGY

@ CARACO 5MG

A077631 004 Jan 11, 2008 Feb DISC

@ 10MG

A077631 003 Jan 11, 2008 Feb DISC

@ SUN PHARM INDS INC 5MG

A077631 004 Jan 11, 2008 Jul CAHN

@ 10MG

A077631 003 Jan 11, 2008 Jul CAHN

CETIRIZINE HYDROCHLORIDE HIVES RELIEF

@ CARACO 5MG

A077631 001 Jan 11, 2008 Feb DISC

@ 10MG

A077631 002 Jan 11, 2008 Feb DISC

@ SUN PHARM INDS INC 5MG

A077631 001 Jan 11, 2008 Jul CAHN

@ 10MG

A077631 002 Jan 11, 2008 Jul CAHN

CIMETIDINE

## TABLET;ORAL

CIMETIDINE

@ WATSON LABS 200MG

A075425 001 Jul 29, 1999 May DISC

CLOTRIMAZOLE

## CREAM, TABLET;TOPICAL, VAGINAL

GYNE-LOTTRIMIN 3 COMBINATION PACK

+ BAYER HEALTHCARE LLC 1%,200MG

N020526 002 Jul 29, 1996 Sep CAHN

## TABLET;VAGINAL

GYNE-LOTTRIMIN 3

+ BAYER HEALTHCARE LLC 200MG

N020525 001 Jul 29, 1996 Sep CAHN

DEXBROMPHENIRAMINE MALEATE; PSEUDOEPHEDRINE SULFATE

## TABLET, EXTENDED RELEASE;ORAL

DEXBROMPHENIRAMINE MALEATE AND PSEUDOEPHEDRINE SULFATE

+ AVANTHI INC 6MG;120MG

A078648 001 Feb 27, 2013 Jan CRLD

DISOPHROL

@ SCHERING PLOUGH 6MG;120MG

N013483 004 Sep 13, 1982 Jan DISC

DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN

## CAPSULE;ORAL

IBUPROFEN AND DIPHENHYDRAMINE HYDROCHLORIDE

STRIDES PHARMA 25MG;EQ 200MG FREE ACID AND  
POTASSIUM SALT

A200888 001 Mar 05, 2012 Aug CAHN

DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM

## TABLET;ORAL

ALEVE PM

+ BAYER HLTHCARE 25MG;220MG

N205352 001 Jan 17, 2014 Jan NEWA

ESOMEPRAZOLE MAGNESIUM

## CAPSULE, DELAYED RELEASE;ORAL

NEXIUM

ASTRAZENECA LP EQ 20MG BASE

N204655 001 Mar 28, 2014 Apr CMS2

EQ 20MG BASE

N204655 001 Mar 28, 2014 Mar NEWA

NEXIUM 24HR

+ ASTRAZENECA LP EQ 20MG BASE

N204655 001 Mar 28, 2014 Apr CTNA

FAMOTIDINETABLET; ORAL  
FAMOTIDINE

@ WATSON LABS	10MG	A075404	001	Nov 28, 2001	May DISC
---------------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE

SUSPENSION; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

ACTAVIS MID ATLANTIC	30MG/5ML	A203330	001	Nov 18, 2014	Nov NEWA
----------------------	----------	---------	-----	--------------	----------

CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES

ACTAVIS MID ATLANTIC	30MG/5ML	A203330	002	Nov 18, 2014	Nov NEWA
----------------------	----------	---------	-----	--------------	----------

TABLET; ORAL

CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	30MG	A202039	001	Nov 19, 2014	Nov NEWA
---------------------	------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE ALLERGY

AUROLIFE PHARMA LLC	60MG	A202039	002	Nov 19, 2014	Nov NEWA
---------------------	------	---------	-----	--------------	----------

	180MG	A202039	003	Nov 19, 2014	Nov NEWA
--	-------	---------	-----	--------------	----------

FEXOFENADINE HYDROCHLORIDE; PSEUDOEPHEDRINE HYDROCHLORIDE

TABLET, EXTENDED RELEASE; ORAL

FEXOFENADINE HYDROCHLORIDE AND PSEUDOEPHEDRINE HYDROCHLORIDE

DR REDDYS LABS LTD	60MG;120MG	A076667	001	Nov 18, 2014	Nov NEWA
--------------------	------------	---------	-----	--------------	----------

FLUTICASONE PROPIONATE

SPRAY, METERED; NASAL

FLONASE ALLERGY RELIEF

+ GLAXOSMITHKLINE CONS	0.05MG/SPRAY	N205434	001	Jul 23, 2014	Jul NEWA
------------------------	--------------	---------	-----	--------------	----------

IBUPROFEN

CAPSULE; ORAL

IBUPROFEN

P AND L DEV LLC	EQ 200MG FREE ACID AND POTASSIUM SALT	A077338	001	Jul 10, 2009	Sep CAHN
-----------------	---------------------------------------	---------	-----	--------------	----------

SUSPENSION; ORAL

CHILDREN'S ELIXSURE

MOBERG PHARMA NORTH	100MG/5ML	N021604	001	Jan 07, 2004	May CAHN
---------------------	-----------	---------	-----	--------------	----------

TABLET; ORAL

IBUPROFEN

AMNEAL PHARMS	200MG	A079233	001	Mar 18, 2014	Mar NEWA
---------------	-------	---------	-----	--------------	----------

@ WATSON LABS	200MG	A070435	001	Mar 05, 1986	May DISC
---------------	-------	---------	-----	--------------	----------

IBUPROFEN; PHENYLEPHRINE HYDROCHLORIDE

TABLET; ORAL

IBUPROFEN AND PHENYLEPHRINE HYDROCHLORIDE

PERRIGO R AND D	200MG;10MG	A203200	001	Jul 03, 2014	Jun NEWA
-----------------	------------	---------	-----	--------------	----------

KETOCONAZOLE

SHAMPOO; TOPICAL

NIZORAL A-D

+ JOHNSON AND JOHNSON	1%	N020310	001	Oct 10, 1997	Nov CAHN
-----------------------	----	---------	-----	--------------	----------

LEVONORGESTREL

TABLET; ORAL

FALLBACK SOLO

LUPIN LTD	1.5MG	A201446	001	Jun 19, 2014	Jun NEWA
-----------	-------	---------	-----	--------------	----------

LEVONORGESTREL

FAMY CARE LTD	1.5MG	A202739	001	Oct 31, 2014	Oct NEWA
---------------	-------	---------	-----	--------------	----------

@ LUPIN LTD	0.75MG	A091328	001	Jan 23, 2013	Sep DISC
-------------	--------	---------	-----	--------------	----------

PERRIGO R AND D	1.5MG	A202334	001	Aug 20, 2014	Aug NEWA
-----------------	-------	---------	-----	--------------	----------

OPCICON ONE-STEP

SUN PHARM INDS LTD	1.5MG	A202635	001	Sep 11, 2014	Sep NEWA
--------------------	-------	---------	-----	--------------	----------

LORATADINE

TABLET; ORAL

CLARITIN

+ BAYER HEALTHCARE LLC	10MG	N019658	002	Nov 27, 2002	Sep CAHN
------------------------	------	---------	-----	--------------	----------

CLARITIN HIVES RELIEF

+ BAYER HEALTHCARE LLC	10MG	N019658	003	Nov 19, 2003	Sep CAHN
------------------------	------	---------	-----	--------------	----------

TABLET, ORALLY DISINTEGRATING;ORAL  
CLARITIN HIVES RELIEF REDITAB

+ BAYER HEALTHCARE LLC	10MG	N020704	003	Nov 19, 2003	Sep CAHN
CLARITIN REDITABS					
+ BAYER HEALTHCARE LLC	10MG	N020704	002	Nov 27, 2002	Sep CAHN

MICONAZOLE NITRATE

## CREAM;TOPICAL, VAGINAL

## MONISTAT 3 COMBINATION PACK

MEDTECH PRODUCTS 2%,4%

N021261 003 Jun 17, 2003 Oct CAHN

## MONISTAT 3 COMBINATION PACK (PREFILLED)

+ MEDTECH PRODUCTS 2%,4%

N021261 001 Feb 02, 2001 Oct CAHN

## CREAM;VAGINAL

## MONISTAT 3

+ MEDTECH PRODUCTS 4%

N020827 001 Mar 30, 1998 Oct CAHN

## MONISTAT 7

+ MEDTECH PRODUCTS 2%

N017450 002 Feb 15, 1991 Oct CAHN

## CREAM, SUPPOSITORY;TOPICAL, VAGINAL

## MONISTAT 1 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,1.2GM

N021308 001 Jun 29, 2001 Oct CAHN

## MONISTAT 7 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,100MG

N020288 002 Apr 26, 1993 Oct CAHN

## MONISTAT-3 COMBINATION PACK

+ MEDTECH PRODUCTS 2%,200MG

N020670 002 Apr 16, 1996 Oct CAHN

## SUPPOSITORY;VAGINAL

## MONISTAT 7

+ MEDTECH PRODUCTS 100MG

N018520 002 Feb 15, 1991 Oct CAHN

MINOXIDIL

## AEROSOL, FOAM;TOPICAL

## WOMEN'S ROGAINE

+ JOHNSON AND JOHNSON 5%

N021812 002 Feb 28, 2014 Feb NEWA

NICOTINE

## FILM, EXTENDED RELEASE;TRANSDERMAL

## HABITROL

>A>	+	DR REDDYS LABS INC	7MG/24HR
>A>	+		14MG/24HR
>A>	+		21MG/24HR
>D>	+	NOVARTIS	7MG/24HR
>D>	+		14MG/24HR
>D>	+		21MG/24HR

N020076	004	Nov 12, 1999	Dec CAHN
N020076	005	Nov 12, 1999	Dec CAHN
N020076	006	Nov 12, 1999	Dec CAHN
N020076	004	Nov 12, 1999	Dec CAHN
N020076	005	Nov 12, 1999	Dec CAHN
N020076	006	Nov 12, 1999	Dec CAHN

NICOTINE POLACRILEX

## GUM, CHEWING;BUCCAL

## NICOTINE POLACRILEX

>A>	ACTAVIS LABS NY INC	EQ 2MG BASE
>A>	@	EQ 2MG BASE
		EQ 2MG BASE
		EQ 2MG BASE
		EQ 2MG BASE
>A>		EQ 4MG BASE
>A>		EQ 4MG BASE
	@	EQ 4MG BASE
		EQ 4MG BASE
>A>		EQ 4MG BASE
>A>		EQ 4MG BASE
>D>	WATSON LABS	EQ 2MG BASE
>D>	@	EQ 2MG BASE
>D>		EQ 4MG BASE
>D>		EQ 4MG BASE
>D>		EQ 4MG BASE
>D>		EQ 4MG BASE

A074507	001	Mar 15, 1999	Dec CAHN
A076568	001	Jul 29, 2004	Dec CAHN
A076569	001	Jul 29, 2004	Nov CAHN
A078699	001	Dec 29, 2008	Nov CAHN
A079216	001	Jul 08, 2009	Nov CAHN
A074707	001	Mar 19, 1999	Dec CAHN
A076568	002	Jul 29, 2004	Dec CAHN
A076569	002	Jul 29, 2004	Nov CAHN
A078697	001	Dec 29, 2008	Nov CAHN
A079038	001	Jul 08, 2009	Dec CAHN
A079219	001	Jul 08, 2009	Dec CAHN
A074507	001	Mar 15, 1999	Dec CAHN
A076568	001	Jul 29, 2004	Dec CAHN
A074707	001	Mar 19, 1999	Dec CAHN
A076568	002	Jul 29, 2004	Dec CAHN
A079038	001	Jul 08, 2009	Dec CAHN
A079219	001	Jul 08, 2009	Dec CAHN

NONOXYNOL-9

## SPONGE;VAGINAL

## TODAY

+ MAYER LABS INC 1GM

N018683 001 Apr 01, 1983 Aug CAHN

OMEPRazole MAGNESIUM

TABLET, DELAYED RELEASE;ORAL  
PRILOSEC OTC

>D>	+	ASTRAZENECA	EQ 20MG BASE	N021229	001	Jun 20, 2003	Dec CAHN
>A>	+	ASTRAZENECA PHARMS	EQ 20MG BASE	N021229	001	Jun 20, 2003	Dec CAHN

OXYBUTYNIN

FILM, EXTENDED RELEASE;TRANSDERMAL  
OXYTROL FOR WOMEN

+	BAYER HEALTHCARE LLC	3.9MG/24HR	N202211	001	Jan 25, 2013	Sep CAHN
---	----------------------	------------	---------	-----	--------------	----------

PERMETHRIN

LOTION;TOPICAL  
NIX

+	MEDTECH PRODUCTS	1%	N019918	001	May 02, 1990	Oct CAHN
---	------------------	----	---------	-----	--------------	----------

RANITIDINE HYDROCHLORIDE

TABLET;ORAL  
RANITIDINE HYDROCHLORIDE  
@ WOCKHARDT

EQ 150MG BASE	A078653	001	Nov 26, 2007	Oct DISC
---------------	---------	-----	--------------	----------

TRIAMCINOLONE ACETONIDE

SPRAY, METERED;NASAL  
NASACORT ALLERGY 24 HOUR

+	SANOFI AVENTIS US	0.055MG/SPRAY	N020468	002	Oct 11, 2013	Jul CRLD
---	-------------------	---------------	---------	-----	--------------	----------

**DRUG PRODUCTS WITH APPROVAL UNDER SECTION 505 OF THE ACT  
ADMINISTERED BY THE CENTER FOR BIOLOGICS EVALUATION AND RESEARCH LIST**

**CUMULATIVE SUPPLEMENT NUMBER 12 DECEMBER 2014**

NO DECEMBER 2014 APPROVALS

## ORPHAN PRODUCT DESIGNATIONS AND APPROVALS LIST

The list of List of Orphan Designations and Approvals is available at:

<http://www.fda.gov/orphan/designat/list.htm>

**DRUG PRODUCTS WHICH MUST DEMONSTRATE *IN VIVO* BIOAVAILABILITY  
ONLY IF PRODUCT FAILS TO ACHIEVE ADEQUATE DISSOLUTION**

NO DECEMBER 2014 ADDITIONS



PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ABACAVIR SULFATE; DOLUTEGRAVIR SODIUM; LAMIVUDINE - TRIUMEQ</u>						
N 205551 001	5905082	May 18, 2016	DS DP		NCE	Aug 12, 2018
	5905082*PED	Nov 18, 2016				
	6294540	May 14, 2018	DS DP U-1572			
	6294540*PED	Nov 14, 2018				
	6417191	Mar 28, 2016	DP U-1572			
	8129385	Oct 05, 2027	DS DP			
<u>ABIRATERONE ACETATE - ZYTIGA</u>						
N 202379 001	8822438	Aug 24, 2027	U-1579			
	8822438	Aug 24, 2027	U-1580			
<u>ACETAMINOPHEN; OXYCODONE HYDROCHLORIDE - XARTEMIS XR</u>						
N 204031 001	6488962	Jun 20, 2020	DP		NP	Mar 11, 2017
	7976870	Jun 01, 2027	U-1498			
	8372432	Mar 11, 2029	DP U-1499			
	8377453	Nov 19, 2029	DP U-1499			
	8394408	Mar 11, 2029	DP			
	8597681	Dec 21, 2030	DP			
	8658631	May 16, 2032	DP			
	8668929	Mar 11, 2029	U-1499			
	8741885	May 16, 2032	DP U-1499			
<u>ACETYLCYSTEINE - ACETADOTE</u>						
N 021539 001	8653061	Aug 24, 2025	U-1373			
	8722738	Apr 06, 2032	U-1373			
<u>ACYCLOVIR - SITAVIG</u>						
N 203791 001	8592434	Jun 16, 2030	DP U-1460			
	8747896	Jun 03, 2027	DP U-1460			
	8791127	Mar 23, 2027	DP U-1460			
<u>ACYCLOVIR; HYDROCORTISONE - XERESE</u>						
N 022436 001	6514980	Jan 24, 2019	DP U-1006		NPP	Jan 22, 2017
	6514980	Jan 24, 2019	DP U-1484			
	7223387	May 13, 2023	DP U-1006			
	7223387	May 13, 2023	DP U-1484			
	RE39264	Aug 02, 2016	DP U-1006			
	RE39264	Aug 02, 2016	DP U-1484			
<u>ADAPALENE - ADAPALENE</u>						
A 200298 001					PC	Oct 25, 2014
<u>ADAPALENE - DIFFERIN</u>						
N 021753 001	8703820	Mar 12, 2023	U-1078			
<u>ADAPALENE - DIFFERIN</u>						
N 022502 001	8709392	Sep 15, 2026	DP U-1078			
<u>ADAPALENE; BENZOYL PEROXIDE - EPIDUO</u>						
N 022320 001	8809305	Dec 23, 2022	U-1078			
<u>ADENOSINE - ADENOSINE</u>						
A 077425 001					PC	Mar 22, 2014
<u>ALBUTEROL SULFATE - VENTOLIN HFA</u>						
N 020983 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>ALBUTEROL SULFATE - PROAIR HFA</u>						
N 021457 001	8834849	Jun 04, 2017	DP			
<u>ALCAFTADINE - LASTACAF</u>						
N 022134 001	8664215	Oct 05, 2029	U-1493			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 001	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE - TEKTURN</u>						
N 021985 002	8617595	Feb 19, 2026	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 001	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 002	8613949	Dec 21, 2029	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 003	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE - TEKAMLO</u>						
N 022545 004	8613949	Dec 21, 2029	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 001	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 002	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 003	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 004	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE - AMTURNIDE</u>						
N 200045 005	8618174	Nov 15, 2021	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 001	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 002	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 003	8618172	Jul 13, 2028	DP			
<u>ALISKIREN HEMIFUMARATE; HYDROCHLOROTHIAZIDE - TEKTRUNA HCT</u>						
N 022107 004	8618172	Jul 13, 2028	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 001	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 002	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE - NESINA</u>						
N 022271 003	8697125	Jan 22, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 001 >A>	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; METFORMIN HYDROCHLORIDE - KAZANO</u>						
N 203414 002 >A>	8900638	May 24, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 001	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 002	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 003	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 004	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 005	8637079	Jan 23, 2029	DP			
<u>ALOGLIPTIN BENZOATE; PIOGLITAZONE HYDROCHLORIDE - OSENI</u>						
N 022426 006	8637079	Jan 23, 2029	DP			
<u>ALVIMOPAN - ENTEREG</u>						
N 021775 001	8112290	Jul 31, 2030	U-1443			
	8645160	Jun 18, 2029	U-1485			
<u>AMINOLEVULINIC ACID HYDROCHLORIDE - LEVULAN</u>						
N 020965 001	8758418	May 01, 2018	U-289			
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 001					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 002					PC	Mar 29, 2015
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090011 004					PC	Mar 29, 2015

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>AMLODIPINE BESYLATE; VALSARTAN - AMLODIPINE BESYLATE AND VALSARTAN</u>						
A 090144	001				PC	Mar 29, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	001				PC	May 30, 2015
					>A> PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	002				>A> PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	003				PC	May 30, 2015
					>A> PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	004				>A> PC	May 30, 2015
					PC	May 30, 2015
<u>AMLODIPINE; HYDROCHLOROTHIAZIDE; VALSARTAN - AMLODIPINE, VALSARTAN AND HYDROCHLOROTHIAZIDE</u>						
A 200435	005				PC	May 30, 2015
					>A> PC	May 30, 2015
<u>APIXABAN - ELIQUIS</u>						
N 202155	001	6413980	Dec 22, 2019	DS DP U-1200	I-661	Aug 21, 2017
		6413980	Dec 22, 2019	DS DP U-1301	I-681	Mar 03, 2017
		6413980	Dec 22, 2019	DS DP U-1302	I-690	Aug 21, 2017
		6413980	Dec 22, 2019	DS DP U-1501	I-691	Aug 21, 2017
		6967208	Feb 03, 2023	DS DP U-1167		
		6967208	Feb 03, 2023	DS DP U-1200		
		6967208	Feb 03, 2023	DS DP U-1301		
		6967208	Feb 03, 2023	DS DP U-1302		
		6967208	Feb 03, 2023	DS DP U-1323		
		6967208	Feb 03, 2023	DS DP U-1501		
		6967208	Feb 03, 2023	DS DP U-1502		
<u>APIXABAN - ELIQUIS</u>						
N 202155	002				I-661	Aug 21, 2017
					I-690	Aug 21, 2017
					I-691	Aug 21, 2017
<u>APREMILAST - OTEZLA</u>						
N 205437	001	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		
<u>APREMILAST - OTEZLA</u>						
N 205437	002	6020358	Oct 30, 2018	DS DP U-1504	I-694	Sep 23, 2017
		6962940	Mar 19, 2023	U-1504	NCE	Mar 21, 2019
		7208516	Mar 19, 2023	U-1505		
		7427638	Nov 17, 2024	DS DP		
		7659302	Mar 19, 2023	U-1505		
		7659302	Mar 19, 2023	U-1595		
		7893101	Dec 09, 2023	DS DP		
		8455536	Mar 19, 2023	U-1505		
		8455536	Mar 19, 2023	U-1595		
		8802717	Mar 19, 2023	U-1561		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>APREMILAST - OTEZLA</u>						
N 205437 003	6020358	Oct 30, 2018	DS DP U-1504		I-694	Sep 23, 2017
	6962940	Mar 19, 2023	U-1504		NCE	Mar 21, 2019
	7208516	Mar 19, 2023	U-1505			
	7427638	Nov 17, 2024	DS DP			
	7659302	Mar 19, 2023	U-1505			
	7659302	Mar 19, 2023	U-1595			
	7893101	Dec 09, 2023	DS DP			
	8455536	Mar 19, 2023	U-1505			
	8455536	Mar 19, 2023	U-1595			
	8802717	Mar 19, 2023	U-1561			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 001	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 002	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 003	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 004	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 005	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021436 006	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021713 001	8642600	Jan 28, 2022	U-1492		M-137	Jun 09, 2017
	8642600*PED	Jul 28, 2022				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 002	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			
<u>ARIPIPRAZOLE - ABILIFY</u>						
N 021729 003	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
	8759350	Mar 02, 2027	U-1529			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 004	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021729 005	8642600	Jan 28, 2022	U-1492		>A> I-700	Dec 12, 2017
	8642600*PED	Jul 28, 2022			M-137	Jun 09, 2017
	8642760	Sep 25, 2022	DS			
	8642760*PED	Mar 25, 2023				
<u>ARIPRAZOLE - ABILIFY</u>						
N 021866 001					>A> I-700	Dec 12, 2017
					M-137	Jun 09, 2017
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 001	8722679	Oct 19, 2024	DP		>A> M-150	Dec 05, 2017
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 002	8722679	Oct 19, 2024	DP		>A> M-150	Dec 05, 2017
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 003	5006528	Apr 20, 2015	DS DP U-1530		>A> M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ARIPRAZOLE - ABILIFY MAINTENA KIT</u>						
N 202971 004	5006528	Apr 20, 2015	DS DP U-1530		>A> M-150	Dec 05, 2017
	7807680	Oct 19, 2024	DP		NDF	Feb 28, 2016
	8030313	Oct 19, 2024	U-543			
	8338427	Mar 15, 2025	DP U-1530			
	8338428	Aug 06, 2023	DP U-1530			
	8399469	Dec 29, 2023	DS			
	8722679	Oct 19, 2024	DP			
	8759351	Aug 06, 2023	DP U-1530			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 001	8022228	Apr 06, 2026	DS DP			
<u>ASENAPINE MALEATE - SAPHRIS</u>						
N 022117 002	8022228	Apr 06, 2026	DS DP			
<u>ASPIRIN - ASPIRIN</u>						
N 203697 001	>A> 8865187	Mar 23, 2022	DP			
<u>ATAZANAVIR SULFATE - REYATAZ</u>						
N 206352 001	5849911	Jun 20, 2017	DS DP U-167		NP	Jun 02, 2017
	6087383	Dec 21, 2018	DS DP			
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 001	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 002	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 003	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ATORVASTATIN CALCIUM; EZETIMIBE - LIPTRUZET</u>						
N 200153 004	5686104	Nov 11, 2014	DP U-1400			
	5686104*PED	May 11, 2015				
	5969156	Jul 08, 2016	DS			
	5969156*PED	Jan 08, 2017				
<u>AVANAFIL - STENDRA</u>						
N 202276 001					D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 002					D-140	Sep 17, 2017
<u>AVANAFIL - STENDRA</u>						
N 202276 003					D-140	Sep 17, 2017
<u>AXITINIB - INLYTA</u>						
N 202324 001	8791140	Aug 05, 2030	DS			
<u>AXITINIB - INLYTA</u>						
N 202324 002	8791140	Aug 05, 2030	DS			
<u>BAZEDOXIFENE ACETATE; ESTROGENS, CONJUGATED - DUAVEE</u>						
N 022247 001	8815934	May 06, 2019	DP		NP	Oct 03, 2016
<u>BECLOMETHASONE DIPROPIONATE - OVAR 80</u>						
N 020911 001	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - OVAR 40</u>						
N 020911 002	5683677	Nov 04, 2014	DP			
	5776432	Jul 07, 2015	DP U-645			
	6446627	Dec 18, 2017	DP			
<u>BECLOMETHASONE DIPROPIONATE - ONASI</u>						
N 202813 002	>A> 5776432	Jul 07, 2015	DP		>A> NP	Mar 23, 2015
	>A> 7780038	Jan 24, 2027	DP		>A> NS	Dec 17, 2017
<u>BEDAQUILINE FUMARATE - SIRTURO</u>						
N 204384 001	8546428	Mar 19, 2029	DS DP U-1321			
<u>BELINOSTAT - BELEODAO</u>						
N 206256 001	6888027	Sep 27, 2021	DS DP U-1544		NCE	Jul 03, 2019
	8835501	Oct 27, 2027	DP		ODE	Jul 03, 2021
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 001	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 002	8669279	Mar 26, 2029	DP U-1402			
	8669279*PED	Sep 26, 2029				
	8791270	Jan 12, 2026	DP U-1542			
	8791270*PED	Jul 12, 2026				
	8883836	Mar 26, 2029	DP U-1402			
	8883836*PED	Sep 26, 2029				
	8895756	Jan 12, 2026	DP			
	8895756*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 003	>A> 8791270	Jan 12, 2026	DP U-1542			
	>A> 8791270*PED	Jul 12, 2026				
<u>BENDAMUSTINE HYDROCHLORIDE - TREANDA</u>						
N 022249 004	>A> 8791270	Jan 12, 2026	DP U-1542			
	>A> 8791270*PED	Jul 12, 2026				
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ACANYA</u>						
N 050819 001	>A> 5733886	Mar 31, 2015	DP			
	8663699	Jun 03, 2029	U-124			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BENZOYL PEROXIDE; CLINDAMYCIN PHOSPHATE - ONEXTON</u>						
N 050819 002 >A>	5733886	Mar 31, 2015	DP			
	8288434	Aug 05, 2029	DP U-124			
	8288434	Aug 05, 2029	DP U-134			
	8288434	Aug 05, 2029	DP U-818			
	8288434	Aug 05, 2029	DP U-916			
	8288434	Aug 05, 2029	DP U-921			
	8288434	Aug 05, 2029	DP U-1033			
<u>BEPOTASTINE BESILATE - BEPREVE</u>						
N 022288 001	8784789	Sep 05, 2024	DP			
	8877168	Jul 30, 2023	DP			
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - CALCIPOTRIENE AND BETAMETHASONE DIPROPIONATE</u>						
A 201615 001					PC	Sep 27, 2014
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 021852 001					>A> NPP	Dec 23, 2017
<u>BETAMETHASONE DIPROPIONATE; CALCIPOTRIENE HYDRATE - TACLONEX</u>						
N 022185 001					NPP	Aug 29, 2017
<u>BIMATOPROST - LUMIGAN</u>						
N 022184 001	8772338	Mar 16, 2025	DP U-1528			
<u>BIMATOPROST - LATISSE</u>						
N 022369 001	8263054	Jan 15, 2023	U-1277		M-140	Sep 04, 2017
	8632760	Jan 15, 2023	U-1487			
	8758733	Jan 15, 2023	U-1487			
	>A> 8906962	Jan 31, 2021	U-1217			
	>A> 8926953	Jan 15, 2023	U-1217			
<u>BORTEZOMIB - VELCADE</u>						
N 021602 001	5780454	May 03, 2017	DS DP		D-141	Oct 08, 2017
	6713446	Jan 25, 2022	DS DP		D-142	Oct 08, 2017
	6958319	Jan 25, 2022	DS DP		I-695	Oct 08, 2017
					M-139	Aug 08, 2017
					ODE	Jun 20, 2015
					ODE	Oct 08, 2021
<u>BRIMONIDINE TARTRATE - ALPHAGAN P</u>						
N 021770 001	8858961	Sep 02, 2023	DP			
	8858961*PED	Mar 02, 2024				
<u>BRIMONIDINE TARTRATE - MIRVASO</u>						
N 204708 001	8859551	May 25, 2024	U-1428			
<u>BRIMONIDINE TARTRATE; TIMOLOL MALEATE - COMBIGAN</u>						
N 021398 001	8748425	Apr 19, 2022	DP U-1524			
<u>BROMFENAC SODIUM - PROLENSA</u>						
N 203168 001	8669290	Jan 16, 2024	DP			
	8754131	Jan 16, 2024	DP			
	8871813	Jan 16, 2024	DP			
	>A> 8927606	Jan 16, 2024	U-100			
	>A> 8927606	Jan 16, 2024	U-810			
	>A> 8927606	Jan 16, 2024	U-1095			
<u>BROMOCRIPTINE MESYLATE - CYCLOSET</u>						
N 020866 001	8613947	Apr 30, 2032	DP U-976			
<u>BUDESONIDE - UCERIS</u>						
N 203634 001	8784888	Jun 09, 2020	DP			
	8895064	Sep 07, 2031	DP			
<u>BUDESONIDE - UCERIS</u>						
N 205613 001					NP	Oct 07, 2017
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 001	8616196	Apr 07, 2029	DP			
	>A> 8875699	Nov 10, 2024	DP			
<u>BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE - SYMBICORT</u>						
N 021929 002	8616196	Apr 07, 2029	DP			
	>A> 8875699	Nov 10, 2024	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 001	8834921	Sep 18, 2018	DP U-1587			
<u>BUPIVACAINE - EXPAREL</u>						
N 022496 002	8834921	Sep 18, 2018	DP U-1587			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 001	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 002	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 003	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 004	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE - BUTRANS</u>						
N 021306 005	6264980	Dec 18, 2015	DP			
	6344211	Dec 18, 2015	U-1072			
	6344211	Dec 18, 2015	U-1556			
	RE41408	Sep 29, 2017	U-1072			
	RE41408	Sep 29, 2017	U-1556			
	RE41489	Sep 29, 2017	U-1072			
	RE41489	Sep 29, 2017	U-1556			
	RE41571	Sep 29, 2017	U-1072			
	RE41571	Sep 29, 2017	U-1556			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 001	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 002	8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 003	>A> 8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1425			
	>A> 8658198	Dec 03, 2027	DP U-1494			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - ZUBSOLV</u>						
N 204242 004	>A> 8454996	Sep 24, 2019	U-1421			
	>A> 8470361	Oct 14, 2029	DP U-1425			
	>A> 8658198	Dec 03, 2027	DP U-1494			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 001	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 002	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPRENORPHINE HYDROCHLORIDE; NALOXONE HYDROCHLORIDE - BUNAVAIL</u>						
N 205637 003	6159498	Oct 18, 2016	DP		NP	Jun 06, 2017
	7579019	Jan 22, 2020	U-1521			
	8147866	Jul 23, 2027	DP U-1521			
	8703177	Aug 20, 2032	DP			
<u>BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - CONTRAVE</u>						
N 200063 001	7375111	Mar 26, 2025	DP		NC	Sep 10, 2017
	7462626	Jul 20, 2024	U-1583			
	8088786	Feb 03, 2029	DP			
	8318788	Nov 08, 2027	U-1584			
	8722085	Nov 08, 2027	U-1585			
	8815889	Jul 20, 2024	U-1586			
<u>CABAZITAXEL - JEVTANA KIT</u>						
N 201023 001	5847170	Mar 26, 2021	DS DP			
	>A> 8927592	Oct 27, 2030	U-1630			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 001	8877776	Oct 08, 2030	DS DP U-1617			
<u>CABOZANTINIB S-MALATE - COMETRIO</u>						
N 203756 002	8877776	Oct 08, 2030	DS DP U-1617			
<u>CALCIPOTRIENE - SORILUX</u>						
N 022563 001	8263580	Sep 27, 2028	DP U-1280			
	8269128	May 26, 2026	DP U-1280			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 001	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 002	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 003	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - INVOKAMET</u>						
N 204353 004	7943582	Feb 26, 2029	DS DP U-493		NC	Aug 08, 2017
	7943788	Jul 14, 2027	DS DP		NCE	Mar 29, 2018
	8222219	Jul 30, 2024	U-493			
	8513202	Dec 03, 2027	DS DP U-493			
	8785403	Jul 30, 2024	DP			
<u>CEFTOLOZANE SULFATE; TAZOBACTAM SODIUM - ZERBAXA</u>						
N 206829 001	>A> 7129232	Oct 21, 2024	DS DP U-36		>A> NCE	Dec 19, 2019
	>A> 8476425	Sep 27, 2032	DS		>A> GAIN	Dec 19, 2024
	>A> 8685957	Sep 27, 2032	DS U-36			
	>A> 8906898	May 28, 2034	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>CERITINIB - ZYKADIA</u>						
N 205755 001	7153964	Feb 26, 2021	DS DP		NCE	Apr 29, 2019
	7893074	Apr 25, 2026	DS DP		ODE	Apr 29, 2021
	7964592	Jan 13, 2027	DS DP			
	8039474	Jun 29, 2030	DS DP			
	8039479	Jun 29, 2030	DS DP			
	8377921	Nov 20, 2027		U-1179		
	8703787	Feb 02, 2032		U-1179		
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 001					>A> ODE	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 002					>A> ODE	Nov 21, 2021
<u>CINACALCET HYDROCHLORIDE - SENSIPAR</u>						
N 021688 003					>A> ODE	Nov 21, 2021
<u>CIPROFLOXACIN; DEXAMETHASONE - CIPRODEX</u>						
N 021537 001	8846650	Jun 04, 2025	DP U-1578			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 001	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 002	8658676	Oct 10, 2031	DP			
<u>CLEVIDIPINE - CLEVIPREX</u>						
N 022156 003	5739152	Apr 14, 2015	DP U-893			
	5856346	Jan 05, 2021	DS DP U-893			
	8658676	Oct 10, 2031	DP			
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 003					M-149	Nov 20, 2017
<u>CLONIDINE HYDROCHLORIDE - KAPVAY</u>						
N 022331 004					M-149	Nov 20, 2017
<u>COBICISTAT - TYBOST</u>						
N 203094 001	8148374	Sep 03, 2029	DS DP U-1279		NP	Sep 24, 2017
<u>COBICISTAT; ELVITEGRAVIR; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - STRIBILD</u>						
N 203100 001	8633219	Oct 11, 2031	DP U-257		NP	Aug 27, 2015
	8716264	Jan 13, 2024	DP U-257			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 001	8785632	Mar 01, 2025	DS			
<u>CRIZOTINIB - XALKORI</u>						
N 202570 002	8785632	Mar 01, 2025	DS			
<u>CYANOCOBALAMIN - NASCOBAL</u>						
N 021642 001	8003353	Jun 11, 2024		U-817		
<u>CYCLOSPORINE - RESTASIS</u>						
N 050790 001	8633162	Aug 27, 2024		U-1479		
	8642556	Aug 27, 2024	DP			
	8648048	Aug 27, 2024		U-1483		
	8685930	Aug 27, 2024	DP			
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 001					ODE	Apr 30, 2020
<u>CYSTEAMINE BITARTRATE - PROCYSBI</u>						
N 203389 002					ODE	Apr 30, 2020
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 001					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABIGATRAN ETEXILATE MESYLATE - PRADAXA</u>						
N 022512 002					I-682	Apr 04, 2017
					I-683	Apr 04, 2017
<u>DABRAFINIB MESYLATE - TAFINLAR</u>						
N 202806 001					I-678	Jan 08, 2017
					ODE	Jan 09, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DABRAFENIB MESYLATE - TAFINLAR</u>						
N 202806	002				I-678 ODE	Jan 08, 2017 Jan 09, 2021
<u>DALBAVANCIN HYDROCHLORIDE - DALVANCE</u>						
N 021883	001	6900175	Dec 25, 2023	U-1517		
		7115564	Nov 14, 2023	DP	NCE	May 23, 2019
		7119061	Nov 14, 2023	DP	GAIN	May 23, 2024
		8143212	Nov 14, 2023	U-1517		
<u>DALFAMPRIDINE - AMPYRA</u>						
N 022250	001	8663685	Jan 18, 2025	U-1030		
<u>DANTROLENE SODIUM - RYANODEX</u>						
N 205579	001	7758890	Jul 01, 2025	DP		
		8110225	Dec 24, 2022	DP		
		8604072	Dec 24, 2022	DP		
		8685460	Feb 15, 2023	U-1546		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	001	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
<u>DAPAGLIFLOZIN - FARXIGA</u>						
N 202293	002	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7851502	Aug 19, 2028	DP		
		7919598	Dec 16, 2029	DS		
		8221786	Mar 21, 2028	DP		
		8361972	Mar 21, 2028	U-493		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
		8716251	Mar 21, 2028	DP		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	001	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	002	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649	003	6414126	Oct 04, 2020	DS DP U-493	NCE	Jan 08, 2019
		6515117	Oct 04, 2020	DS DP U-493		
		6936590	Oct 04, 2020	U-493		
		7919598	Dec 16, 2029	DS		
		8501698	Jun 20, 2027	DP U-493		
		8685934	May 26, 2030	U-1522		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DAPAGLIFLOZIN; METFORMIN HYDROCHLORIDE - XIGDUO XR</u>						
N 205649 004	6414126	Oct 04, 2020	DS DP U-493		NCE	Jan 08, 2019
	6515117	Oct 04, 2020	DS DP U-493			
	6936590	Oct 04, 2020	U-493			
	7919598	Dec 16, 2029	DS			
	8501698	Jun 20, 2027	DP U-493			
	8685934	May 26, 2030	U-1522			
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 001	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 002	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 003	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 004	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 005	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DARUNAVIR ETHANOLATE - PREZISTA</u>						
N 021976 006	8597876	Jun 23, 2019	U-1305			
	8597876*PED	Dec 23, 2019				
<u>DASABUVIR SODIUM ; OMBITASVIR; PARITAPREVRIR; RITONAVIR - VIEKIRA PAK (COPACKAGED)</u>						
N 206619 001					>A> NCE	Dec 19, 2019
<u>DASATINIB - SPRYCEL</u>						
N 021986 001	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 002	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 003	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 004	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 005	8680103	Feb 04, 2025	DP			
<u>DASATINIB - SPRYCEL</u>						
N 021986 006	8680103	Feb 04, 2025	DP			
<u>DESOXIMETASONE - TOPICORT</u>						
N 204141 001	8277780	Sep 01, 2028	DP U-1408			
	8715624	May 26, 2026	DP U-1408			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 001	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DESVENLAFAXINE SUCCINATE - PRISTIQ</u>						
N 021992 002	6673838	Mar 01, 2022	DS U-860			
	6673838	Mar 01, 2022	DS U-1364			
<u>DEXAMETHASONE - OZURDEX</u>						
N 022315 001					I-686	Jun 29, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 001	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8784885	Oct 15, 2023	DP U-1552			
	8784885	Oct 15, 2023	DP U-1553			
	8784885	Oct 15, 2023	DP U-1554			
	8871273	Jan 11, 2028	DP			
<u>DEXLANSOPRAZOLE - DEXILANT</u>						
N 022287 002	6664276	Jan 30, 2023	DS DP U-949			
	6664276	Jan 30, 2023	DS DP U-950			
	6664276	Jan 30, 2023	DS DP U-951			
	6664276	Jan 30, 2023	DS DP U-1507			
	6664276*PED	Jul 30, 2023				
	8722084	Oct 15, 2023	DP			
	8722084*PED	Apr 15, 2024				
	8871273	Jan 11, 2028	DP			
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 001					M-61 PED	Jun 17, 2016 Dec 17, 2016
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 002	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMEDETOMIDINE HYDROCHLORIDE - PRECEDEX</u>						
N 021038 003	8648106	Jan 04, 2032	DP		M-61 PED	Jun 17, 2016 Dec 17, 2016
	8648106*PED	Jul 04, 2032				
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 001					>A> PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 002					>A> PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 003					>A> PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078908 004					>A> PC	May 09, 2015
<u>DEXMETHYLPHENIDATE HYDROCHLORIDE - DEXMETHYLPHENIDATE HYDROCHLORIDE</u>						
A 078992 003					PC	May 18, 2014
<u>DEXTROMETHORPHAN HYDROBROMIDE; QUINIDINE SULFATE - NUEDEXTA</u>						
N 021879 001	RE38115	Jan 26, 2016	DP	Y		
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 001	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC - ZORVOLEX</u>						
N 204592 002	8679544	Apr 23, 2030	DP		I-692	Aug 22, 2017
<u>DICLOFENAC EPOLAMINE - FLECTOR</u>						
N 021234 001	5607690	Apr 13, 2019	DP			
<u>DICLOFENAC POTASSIUM - ZIPSOR</u>						
N 022202 001	6287594	Jan 15, 2019	DP			
	8623920	Feb 24, 2029	U-1482			
<u>DICLOFENAC SODIUM - DICLOFENAC SODIUM</u>						
A 202027 001					PC	Nov 23, 2014
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 020947 001	8741956	Jul 10, 2029	U-1435			
<u>DICLOFENAC SODIUM - DYLOJECT</u>						
N 022396 001					>A> NP	Dec 23, 2017

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DICLOFENAC SODIUM - PENNSAID</u>						
N 204623 001	8217078	Jul 10, 2029	U-1477		NP	Jan 16, 2017
	8252838	Apr 21, 2028	DP U-1489			
	8546450	Aug 09, 2030	U-1435			
	8546450	Aug 09, 2030	U-1436			
	8563613	Oct 17, 2027	DP U-1488			
	8618164	Jul 10, 2029	U-1477			
	8741956	Jul 10, 2029	U-1435			
	8871809	Oct 17, 2027	U-1614			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 001	8759393	Oct 29, 2019	DP			
<u>DIMETHYL FUMARATE - TECFIDERA</u>						
N 204063 002	8759393	Oct 29, 2019	DP			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; IBUPROFEN - ADVIL PM</u>						
N 021393 001	8883849	Jan 17, 2022	U-1618			
<u>DIPHENHYDRAMINE HYDROCHLORIDE; NAPROXEN SODIUM - ALEVE PM</u>						
N 205352 001					NC	Jan 17, 2017
<u>DOXYCYCLINE - ORACEA</u>						
N 050805 001	8709478	Apr 07, 2024	U-1063			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 001	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 002	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 003	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 004	8715724	Feb 03, 2028	DP			
<u>DOXYCYCLINE HYCLATE - DORYX</u>						
N 050795 005	8715724	Feb 03, 2028	DP			
<u>DROSPIRENONE; ESTRADIOL - ANGELIQ</u>						
N 021355 001 >A>	8906890	Oct 22, 2031	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - BEYAZ</u>						
N 022532 001	8617597	Feb 08, 2030	DP			
<u>DROSPIRENONE; ETHINYL ESTRADIOL; LEVOMEFOLATE CALCIUM - SAFYRAL</u>						
N 022574 001	8617597	Feb 08, 2030	DP			
<u>DROXIDOPA - NORTHERA</u>						
N 203202 001					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 002					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DROXIDOPA - NORTHERA</u>						
N 203202 003					NCE ODE	Feb 18, 2019 Feb 18, 2021
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090745 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 001					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090774 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 001					PC	Jun 09, 2014

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 002					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - DULOXETINE HYDROCHLORIDE</u>						
A 090778 003					PC	Jun 09, 2014
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 001					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 002					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>DULOXETINE HYDROCHLORIDE - CYMBALTA</u>						
N 021427 004					NPP	Oct 16, 2017
					NPP	Oct 16, 2017
<u>EFAVIRENZ; EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - ATRIPLA</u>						
N 021937 001	8716264	Jan 13, 2024	DP U-257			
<u>EFINACONAZOLE - JUBLIA</u>						
N 203567 001	7214506	Oct 05, 2021	U-281		NCE	Jun 06, 2019
	8039494	Jul 08, 2030	U-281			
	8486978	Oct 24, 2030	DP			
<u>ELIGLUSTAT TARTRATE - CERDELGA</u>						
N 205494 001	6916802	Apr 29, 2022	U-1571		NCE	Aug 19, 2019
	7196205	Apr 29, 2022	DS		ODE	Aug 19, 2021
	7615573	Apr 29, 2022	U-1571			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 001	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052993	Aug 01, 2027	DP U-930			
	8052993	Aug 01, 2027	DP U-1306			
	8052993	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 002	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052994	Aug 01, 2027	DP U-930			
	8052994	Aug 01, 2027	DP U-1306			
	8052994	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 003	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8062665	Aug 01, 2027	DP U-930			
	8062665	Aug 01, 2027	DP U-1306			
	8062665	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 004	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8071129	Aug 01, 2027	DP U-930			
	8071129	Aug 01, 2027	DP U-1306			
	8071129	Aug 01, 2027	DP U-1575			
	8828430	Aug 01, 2027	DP U-1306			
	8828430	Aug 01, 2027	DP U-1619			
<u>ELTROMBOPAG OLAMINE - PROMACTA</u>						
N 022291 005	6280959	Oct 30, 2018	DS DP U-930		ODE	Aug 26, 2021
	6280959	Oct 30, 2018	DS DP U-1306			
	6280959	Oct 30, 2018	DS DP U-1575			
	7160870	Nov 20, 2022	DS DP U-930			
	7160870	Nov 20, 2022	DS DP U-1306			
	7160870	Nov 20, 2022	DS DP U-1575			
	7332481	May 24, 2021	U-930			
	7332481	May 24, 2021	U-1306			
	7332481	May 24, 2021	U-1575			
	7473686	May 24, 2021	DS DP U-930			
	7473686	May 24, 2021	DS DP U-1306			
	7473686	May 24, 2021	DS DP U-1575			
	7547719	Jul 13, 2025	DS DP U-930			
	7547719	Jul 13, 2025	DS DP U-1306			
	7547719	Jul 13, 2025	DS DP U-1575			
	7790704	May 24, 2021	U-930			
	7790704	May 24, 2021	U-1306			
	7790704	May 24, 2021	U-1575			
	7795293	May 21, 2023	U-930			
	7795293	May 21, 2023	U-1306			
	7795293	May 21, 2023	U-1575			
	8052995	Aug 01, 2027	DP U-1306			
	8052995	Aug 01, 2027	DP U-1575			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 001	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>ELVITEGRAVIR - VITEKTA</u>						
N 203093 002	7176220	Nov 20, 2023	DS DP U-257		NP	Sep 24, 2017
	7635704	Oct 26, 2026	DS DP U-257			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 001	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			
<u>EMPAGLIFLOZIN - JARDIANCE</u>						
N 204629 002	7579449	Nov 05, 2025	DS		NCE	Aug 01, 2019
	7713938	Apr 15, 2027	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EMTRICITABINE; RILPIVIRINE HYDROCHLORIDE; TENOFOVIR DISOPROXIL FUMARATE - COMPLERA</u>						
N 202123 001	8716264	Jan 13, 2024	DP U-257			
	8841310	Dec 09, 2025	DP U-257			
<u>EMTRICITABINE; TENOFOVIR DISOPROXIL FUMARATE - TRUVADA</u>						
N 021752 001	8716264	Jan 13, 2024	DP U-257			
<u>ENALAPRIL MALEATE - EPANED KIT</u>						
N 204308 001	8778366	Nov 06, 2032	U-3			
	8778366	Nov 06, 2032	U-185			
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 001					PC	Feb 21, 2015
<u>ENTECAVIR - ENTECAVIR</u>						
A 202122 002					PC	Feb 21, 2015
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021797 002					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENTECAVIR - BARACLUDE</u>						
N 021798 001					NPP PED	Mar 20, 2017 Sep 20, 2017
<u>ENZALUTAMIDE - XTANDI</u>						
N 203415 001	8183274	May 15, 2026	U-1281		I-693	Sep 10, 2017
	8183274	May 15, 2026	U-1588			
<u>EPINEPHRINE - EPIPEN</u>						
N 019430 001	8870827	Sep 11, 2025	DP			
<u>EPINEPHRINE - EPIPEN JR.</u>						
N 019430 002	8870827	Sep 11, 2025	DP			
<u>ESOMEPRAZOLE MAGNESIUM - NEXIUM 24HR</u>						
N 204655 001	5690960	Nov 25, 2014	DP U-1509		RTO	Mar 28, 2017
	5714504	Feb 03, 2015	DP U-1509			
	5877192	May 27, 2014	U-1509			
	5900424	May 04, 2016	DS U-1509			
	6369085	May 25, 2018	DS DP U-1509			
	6428810	Nov 03, 2019	DP U-1509			
	6875872	May 27, 2014	DS			
	7411070	May 25, 2018	DS			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 001	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE MAGNESIUM; NAPROXEN - VIMOVO</u>						
N 022511 002	8852636	May 31, 2022	DP U-1052			
	8858996	May 31, 2022	DP U-1052			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 001	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESOMEPRAZOLE SODIUM - NEXIUM IV</u>						
N 021689 002	5877192	May 27, 2014	U-643		D-138	Mar 04, 2017
	5877192	May 27, 2014	U-1495		I-679	Mar 04, 2017
	5877192*PED	Nov 27, 2014				
	6143771	May 27, 2015	DP U-643			
	6143771	May 27, 2015	DP U-1495			
<u>ESTRADIOL - EVAMIST</u>						
N 022014 001	6978945	Jul 31, 2022	DP			
<u>ETHINYL ESTRADIOL; NORETHINDRONE ACETATE - MINASTRIN 24 FE</u>						
N 203667 001	6667050	Apr 06, 2019	DP U-1			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ETHIODIZED OIL - LIPIODOL</u>						
N 009190 001					ODE	Apr 04, 2021
<u>ETONOGESTREL - NEXPLANON</u>						
N 021529 002	8722037	Sep 28, 2027	DP			
	8888745	Aug 28, 2026	DP			
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 001 >A>	7741338	Dec 06, 2019	DP			
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 002 >A>	7741338	Dec 06, 2019	DP			
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 003 >A>	7741338	Dec 06, 2019	DP			
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR</u>						
N 022334 004 >A>	7741338	Dec 06, 2019	DP			
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 001	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 002	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EVEROLIMUS - AFINITOR DISPERZ</u>						
N 203985 003	8617598	Sep 27, 2022	DP			
	8617598*PED	Mar 27, 2023				
	8778962	Feb 18, 2022	U-1541			
	8778962*PED	Aug 18, 2022				
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 001 >A>	6858576	Jan 06, 2017	U-656		M-148	Nov 24, 2017
	>A> 6858576	Jan 06, 2017	U-1108			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 6956026	Jan 07, 2018	U-1074			
	>A> 6956026	Jan 07, 2018	U-1623			
	>A> 7741269	Jan 07, 2018	U-653			
	>A> 7741269	Jan 07, 2018	U-1074			
	>A> 7741269	Jan 07, 2018	U-1108			
<u>EXENATIDE SYNTHETIC - BYETTA</u>						
N 021773 002 >A>	6858576	Jan 06, 2017	U-656		M-148	Nov 24, 2017
	>A> 6858576	Jan 06, 2017	U-1108			
	>A> 6872700	Jan 14, 2020	U-654			
	>A> 6956026	Jan 07, 2018	U-687			
	>A> 6956026	Jan 07, 2018	U-1074			
	>A> 6956026	Jan 07, 2018	U-1623			
	>A> 7741269	Jan 07, 2018	U-653			
	>A> 7741269	Jan 07, 2018	U-1074			
	>A> 7741269	Jan 07, 2018	U-1108			
<u>EXENATIDE SYNTHETIC - BYDUREON</u>						
N 022200 001	8216180	Jan 12, 2028	DP			
	8439864	Mar 25, 2028	DP			
	>A> 8906851	Aug 18, 2026	U-1313			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>EZETIMIBE - ZETIA</u>						
N 021445 001	7612058	Oct 30, 2025	U-1027			
	7612058	Oct 30, 2025	U-1173			
	7612058*PED	Apr 30, 2026				
<u>FENTANYL - SUBSYS</u>						
N 202788 001	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 002	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 003	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 004	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 005	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 006	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL - SUBSYS</u>						
N 202788 007	8486972	Apr 27, 2030	DP			
	8486973	Apr 27, 2030	U-55			
	8835459	Jan 25, 2027	DP			
	8835460	Jan 25, 2027	DP U-55			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 001	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 002	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 003	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 004	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - FENTORA</u>						
N 021947 005	8728441	Mar 26, 2019	U-1514			
	8753611	Mar 26, 2019	U-1514			
	8765100	Mar 26, 2019	DP			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 001 >A>	8889176	Jan 16, 2024	U-767			
<u>FENTANYL CITRATE - LAZANDA</u>						
N 022569 002 >A>	8889176	Jan 16, 2024	U-767			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FERRIC CARBOXYMALTOSE - INJECTAFER</u>						
N 203565 001	>A> 8895612	Jan 08, 2027	DP U-1620			
<u>FERRIC CITRATE - FERRIC CITRATE</u>						
N 205874 001	5753706	Feb 03, 2017	DP U-1577			
	7767851	Feb 18, 2024	DS DP			
	8093423	Apr 21, 2026	U-1577			
	8299298	Feb 18, 2024	DP			
	8338642	Feb 18, 2024	DS DP U-1577			
	8609896	Feb 18, 2024	DP			
	8754257	Feb 18, 2024	DP			
	8754258	Feb 18, 2024	DP			
	8846976	Feb 18, 2024	U-1577			
<u>FERUMOXYTOL - FERAHEME</u>						
N 022180 001	6599498	Jun 30, 2023	DS DP			
	>A> 8926947	Mar 08, 2020	DS DP			
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE ALLERGY</u>						
A 203330 001					>A> PC	Jun 20, 2015
<u>FEXOFENADINE HYDROCHLORIDE - CHILDREN'S FEXOFENADINE HYDROCHLORIDE HIVES</u>						
A 203330 002					>A> PC	Jun 20, 2015
<u>FIDAXOMICIN - DIFICID</u>						
N 201699 001	8859510	Jul 31, 2027	U-319			
<u>FINAFLORACIN - XTORO</u>						
N 206307 001					>A> NCE	Dec 17, 2019
					>A> PED	Jun 17, 2020
<u>FLORBETABEN F-18 - NEURACEO</u>						
N 204677 001	7807135	Mar 18, 2029	DS DP U-1497		NCE	Mar 21, 2019
<u>FLUOCINOLONE ACETONIDE - ILUVIEN</u>						
N 201923 001	6217895	Mar 22, 2019	DP U-1597		NP	Sep 26, 2017
	6375972	Apr 26, 2020	DP U-1597			
	6548078	Mar 22, 2019	DP U-1597			
	8252307	Jun 27, 2019	DP			
	8871241	Aug 12, 2027	DP			
<u>FLUOCINOLONE ACETONIDE; HYDROQUINONE; TRETINOIN - TRI-LUMA</u>						
N 021112 001	8653053	Oct 25, 2022	DP			
<u>FLUOCINONIDE - FLUOCINONIDE</u>						
A 090256 001					PC	Jul 13, 2014
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 001					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 002					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 003					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 004					M-142	Oct 10, 2017
<u>FLUOXETINE HYDROCHLORIDE; OLANZAPINE - SYMBYAX</u>						
N 021520 005					M-142	Oct 10, 2017
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 001	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTEMETAMOL F-18 - VIZAMYL</u>						
N 203137 002	7270800	Jan 24, 2023	DS DP U-336		NCE	Oct 25, 2018
	7351401	Jan 24, 2023	DS DP U-336			
	8691185	Jan 24, 2023	U-336			
<u>FLUTICASONE FUROATE - VERAMYST</u>						
N 022051 001	8147461	Oct 15, 2028	DP			
	8347879	Jul 15, 2028	DP			
	8752543	Apr 05, 2026	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 001	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE - ARNUITY ELLIPTA</u>						
N 205625 002	5873360	Feb 23, 2016	DP		NP	Aug 20, 2017
	7101866	Aug 03, 2021	DS DP U-1559			
	7629335	Aug 03, 2021	DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8201556	Feb 05, 2029	DP			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>FLUTICASONE FUROATE; VILANTEROL TRIFENATATE - BREO ELLIPTA</u>						
N 204275 001	8746242	Oct 11, 2030	DP		NP	May 10, 2016
	RE44874	Mar 23, 2023	DS DP U-1548			
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 001	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 002	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLOVENT HFA</u>						
N 021433 003	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE - FLONASE ALLERGY RELIEF</u>						
N 205434 001					M-147	Jul 23, 2017
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 001	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 002	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FLUTICASONE PROPIONATE; SALMETEROL XINAFOATE - ADVAIR HFA</u>						
N 021254 003	6743413	Jun 01, 2021	U-1591			
	6743413*PED	Dec 01, 2021				
	7500444	Feb 26, 2026	DP			
	7500444*PED	Aug 26, 2026				
<u>FORMOTEROL FUMARATE - PERFOROMIST</u>						
N 022007 001	8623922	Jun 22, 2021	DP			
<u>GABAPENTIN - GRALISE</u>						
N 022544 001					ODE	Jan 28, 2018
<u>GABAPENTIN - GRALISE</u>						
N 022544 002					ODE	Jan 28, 2018
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 001	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>GABAPENTIN ENACARBIL - HORIZANT</u>						
N 022399 002	8686034	Jan 24, 2025	U-1231		ODE	Jun 06, 2019
	8686034	Jan 24, 2025	U-1247			
	8795725	Jun 10, 2029	DP U-1231			
	8795725	Jun 10, 2029	DP U-1247			
<u>GADOBUTROL - GADAVIST</u>						
N 201277 001					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 002					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 003					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 004					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 005					I-688	Jun 11, 2017
<u>GADOBUTROL - GADAVIST</u>						
N 201277 006					I-688 NCE	Jun 11, 2017 Mar 14, 2016
<u>GLATIRAMER ACETATE - COPAXONE</u>						
N 020622 003	6054430	May 24, 2014	DS		NP	Jan 28, 2017
	6342476	May 24, 2014	U-441			
	6362161	May 24, 2014	DS			
	7199098	May 24, 2014	DS			
	8232250	Aug 19, 2030	U-441			
	8367605	May 24, 2014	DS			
	8399413	Aug 19, 2030	U-441			
<u>GLYCEROL PHENYLBUTYRATE - RAVICTI</u>						
N 203284 001	8642012	Sep 22, 2030	U-1383			
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 001	5854290	Sep 21, 2015	U-494	Y	>A> D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP		PED	Aug 25, 2014
	6287599*PED	Jun 20, 2021			>A> PED	May 19, 2018
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 002	5854290	Sep 21, 2015	U-494	Y	>A> D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP		PED	Aug 25, 2014
	6287599*PED	Jun 20, 2021			>A> PED	May 19, 2018
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 003	5854290	Sep 21, 2015	U-494	Y	>A> D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP		PED	Aug 25, 2014
	6287599*PED	Jun 20, 2021			>A> PED	May 19, 2018
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>GUANFACINE HYDROCHLORIDE - INTUNIV</u>						
N 022037 004	5854290	Sep 21, 2015	U-494	Y	>A> D-145	Nov 19, 2017
	5854290*PED	Mar 21, 2016			I-635	Feb 25, 2014
	6287599	Dec 20, 2020	DP		PED	Aug 25, 2014
	6287599*PED	Jun 20, 2021			>A> PED	May 19, 2018
	6811794	Jul 04, 2022	DP U-494			
	6811794*PED	Jan 04, 2023				
<u>HEXAMINOLEVULINATE HYDROCHLORIDE - CYSVIEW KIT</u>						
N 022555 001	7348361	Nov 06, 2020	DP U-1087			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 001	6228398	Nov 01, 2019	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 002	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 003	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 004	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 005	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - ZOHYDRO ER</u>						
N 202880 006	6228398	Nov 01, 2019	DP			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 001	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 002	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 003	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 004	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 005	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 006	8808740	Dec 21, 2031	DP U-1556			
<u>HYDROCODONE BITARTRATE - HYSINGLA</u>						
N 206627 007	8808740	Dec 21, 2031	DP U-1556			
<u>IBRUTINIB - IMBRUVICA</u>						
N 205552 001	8476284	Dec 28, 2026	U-1456		I-680	Feb 12, 2017
	8476284	Dec 28, 2026	U-1491		I-689	Jul 28, 2017
	8497277	Dec 28, 2026	U-1456		ODE	Feb 12, 2021
	8497277	Dec 28, 2026	U-1491		ODE	Jul 28, 2021
	8697711	Dec 28, 2026	DS DP			
	8703780	Dec 28, 2026	U-1491			
	8735403	Dec 28, 2026	DS DP			
	8754090	Jun 03, 2031	U-1456			
	8754091	Dec 28, 2026	DP			
<u>IBUPROFEN - CALDOLOR</u>						
N 022348 002	8735452	Sep 30, 2029	U-981			
	8871810	Aug 27, 2030	U-1599			
<u>ICATIBANT ACETATE - FIRAZYR</u>						
N 022150 001	5648333	Jul 15, 2015	DS DP U-1187			
<u>ICOSAPENT ETHYL - VASCEPA</u>						
N 202057 001					NP	Jul 26, 2015
<u>IDELALISIB - ZYDELIG</u>						
N 205858 001	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			
<u>IDELALISIB - ZYDELIG</u>						
N 205858 002	6800620	Apr 24, 2021	DS U-1560		NCE	Jul 23, 2019
	6949535	Apr 24, 2021	DS U-1560			
	8138195	Apr 24, 2021	DS DP			
	8492389	Apr 24, 2021	DS DP			
	8637533	Apr 24, 2021	DS DP			
	8865730	Mar 05, 2033	DS DP U-1615			
	RE44599	Jul 21, 2025	U-1558			
	RE44638	Aug 05, 2025	DS DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>ILOPERIDONE - FANAPT</u>						
N 022192 001 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 002 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 003 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 004 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 005 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 006 >A>	8586610	Nov 02, 2027	U-1625			
<u>ILOPERIDONE - FANAPT</u>						
N 022192 007 >A>	8586610	Nov 02, 2027	U-1625			
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 001	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021335 002	RE43932	Jan 16, 2019	DS DP			
	RE43932*PED	Jul 16, 2019				
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 001					ODE	Dec 19, 2015
<u>IMATINIB MESYLATE - GLEEVEC</u>						
N 021588 002					ODE	Dec 19, 2015
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 001	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INDOMETHACIN - TIVORBEX</u>						
N 204768 002	8734847	Apr 23, 2030	DP		NP	Feb 24, 2017
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 001	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INGENOL MEBUTATE - PICATO</u>						
N 202833 002	8716271	Dec 18, 2026	U-1440			
	8735375	Dec 18, 2026	U-1440			
<u>INSULIN ASPART RECOMBINANT - NOVOLOG FLEXTOUCH</u>						
N 020986 005	5618913	Jun 07, 2014	DS DP			
	5618913*PED	Dec 07, 2014				
	5866538	Jun 20, 2017	DP			
	5866538*PED	Dec 20, 2017				
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN DETEMIR RECOMBINANT - LEVEMIR FLEXTOUCH</u>						
N 021536 005	5750497	Jun 16, 2019	DS DP U-668			
	5866538	Jun 20, 2017	DP			
	6899699	Jan 02, 2022	DP			
	7686786	Aug 03, 2026	DP			
	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
<u>INSULIN GLARGINE RECOMBINANT - LANTUS SOLOSTAR</u>						
N 021081 002	8679069	Apr 12, 2025	DP			
<u>INSULIN GLULISINE RECOMBINANT - APIDRA SOLOSTAR</u>						
N 021629 003	8679069	Apr 12, 2025	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 001	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	7943572	Aug 10, 2026	U-1539			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8424518	Oct 17, 2031	DP			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8623817	Sep 18, 2029	U-1537			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
>A>	8889099	Jun 29, 2020	DP U-1621			
<u>INSULIN RECOMBINANT HUMAN - AFREZZA</u>						
N 022472 002	6071497	May 15, 2015	DP U-1533		NP	Jun 27, 2017
	6428771	May 15, 2015	DP U-1533			
	6444226	Jun 29, 2020	DP U-1534			
	6652885	Jun 29, 2020	U-1535			
	6663898	Sep 30, 2014	DP			
	6906030	Sep 30, 2014	DP			
	7276534	Sep 30, 2014	DP U-1536			
	7305986	Jan 16, 2023	DP			
	7464706	Mar 02, 2023	DP			
	7648960	Jun 29, 2020	U-1535			
	7943178	Jun 29, 2020	DP U-1535			
	8119593	Aug 11, 2029	U-1537			
	8133514	Sep 30, 2014	DP			
	8146588	Apr 24, 2023	DP			
	8156936	Jan 16, 2023	DP			
	8215300	Nov 24, 2022	DP			
	8227409	Mar 08, 2031	DP U-1538			
	8258095	Aug 11, 2029	U-1537			
	8389470	Jun 29, 2020	DP			
	8394414	May 15, 2015	DP U-1533			
	8485180	Mar 25, 2030	DP			
	8499757	Feb 19, 2032	DP			
	8551528	Jun 11, 2030	DP			
	8636001	Jul 12, 2032	DP			
	8729019	Jun 06, 2028	DP			
	8734845	Jun 11, 2030	DP			
	8778403	Jun 11, 2030	DP U-1538			
>A>	8889099	Jun 29, 2020	DP U-1621			
<u>IOFLUPANE I-123 - DATSCAN</u>						
N 022454 001	5310912	Feb 25, 2015	DS			
<u>IVACAFTOR - KALYDECO</u>						
N 203188 001	8754224	Dec 28, 2026	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>IVERMECTIN - SKLICE</u>						
N 202736 001	8791153	Oct 12, 2027	DP			
<u>IVERMECTIN - SOOLANTRA</u>						
N 206255 001					>A> NP	Dec 19, 2017
<u>KETOCONAZOLE - XOLEGEL</u>						
N 021946 001	8735393	Dec 04, 2018	DP			
<u>KETOROLAC TROMETHAMINE - ACULAR LS</u>						
N 021528 001	8648107	May 28, 2024	DP			
	>A> 8906950	May 28, 2024	U-1626			
<u>KETOROLAC TROMETHAMINE; PHENYLEPHRINE HYDROCHLORIDE - Omidria</u>						
N 205388 001	8173707	Jul 30, 2023	U-1518		NP	May 30, 2017
	8586633	Jul 30, 2023	DP			
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 002	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 003	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022253 004	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022254 001	RE38551	Mar 17, 2022	DS DP U-1565		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1568		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LACOSAMIDE - VIMPAT</u>						
N 022255 001	RE38551	Mar 17, 2022	DS DP U-1566		D-143	Aug 29, 2017
	RE38551	Mar 17, 2022	DS DP U-1567		D-144	Aug 29, 2017
					I-696	Aug 29, 2017
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 001	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 002	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 003	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 004	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 005	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL XR</u>						
N 022115 006	8637512	Jun 14, 2028	DP			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 001	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 002	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 003	8840925	Jul 02, 2028	DP U-1596			
<u>LAMOTRIGINE - LAMICTAL ODT</u>						
N 022251 004	8840925	Jul 02, 2028	DP U-1596			
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074 001					>A> I-701	Dec 19, 2017
					>A> ODE	Dec 16, 2021

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	002				>A> I-701	Dec 19, 2017
					>A> ODE	Dec 16, 2021
<u>LANREOTIDE ACETATE - SOMATULINE DEPOT</u>						
N 022074	003				>A> I-701	Dec 19, 2017
					>A> ODE	Dec 16, 2021
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	001	5968976	Oct 26, 2018	DP U-1592		
		7465465	Aug 26, 2024	DP		
<u>LANTHANUM CARBONATE - FOSRENOL</u>						
N 204734	002	5968976	Oct 26, 2018	DP U-1592		
		7465465	Aug 26, 2024	DP		
<u>LAPATINIB DITOSYLATE - TYKERB</u>						
N 022059	001	8821927	Jun 12, 2029	DS DP		
<u>LEDIPASVIR; SOFOSBUVIR - HARVONI</u>						
N 205834	001	7964580	Mar 26, 2029	DS DP U-1470	NCE	Oct 10, 2019
		8088368	May 12, 2030	DS DP		
		8273341	May 12, 2030	U-1470		
		8334270	Mar 21, 2028	DS DP U-1470		
		8580765	Mar 21, 2028	DS DP U-1470		
		8618076	Dec 11, 2030	DS DP U-1470		
		8633309	Mar 26, 2029	DS DP U-1470		
		8735372	Mar 21, 2028	U-1470		
		8822430	May 12, 2030	DS DP U-1470		
		8841278	May 12, 2030	DP U-1470		
	>A>	8889159	Mar 26, 2029	DP U-1470		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	001	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	002	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	003	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	004	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	005	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LENALIDOMIDE - REVLIMID</u>						
N 021880	006	8626531	Oct 23, 2020	U-1210		
		8648095	May 15, 2023	U-1216		
		8741929	Mar 08, 2028	U-1414		
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	001	6036976	Dec 13, 2016	DP		
<u>LEUPROLIDE ACETATE; NORETHINDRONE ACETATE - LUPANETA PACK</u>						
N 203696	002	6036976	Dec 13, 2016	DP		
<u>LEVALBUTEROL TARTRATE - XOPENEX HFA</u>						
N 021730	001	8765153	Dec 08, 2023	DP		
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035	001	8802142	Jun 07, 2031	DP		
		8802142*PED	Dec 07, 2031			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 002	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 003	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVETIRACETAM - KEPPRA</u>						
N 021035 004	8802142	Jun 07, 2031	DP			
	8802142*PED	Dec 07, 2031				
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 001	8865937	May 23, 2032	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 002	8865937	May 23, 2032	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 003	8865937	May 23, 2032	DS DP			
<u>LEVOMILNACIPRAN HYDROCHLORIDE - FETZIMA</u>						
N 204168 004	8865937	May 23, 2032	DS DP			
<u>LIDOCAINE HYDROCHLORIDE - AKTEN</u>						
N 022221 001	8759401	Jul 24, 2026	DP U-1523			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 001	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINACLOTIDE - LINZESS</u>						
N 202811 002	8748573	Jun 20, 2031	U-1515			
	8748573	Jun 20, 2031	U-1516			
	8802628	Jul 24, 2031	DP			
<u>LINAGLIPTIN - TRADJENTA</u>						
N 201280 001	8673927	Aug 23, 2027	U-1503			
	8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 001	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 002	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
<u>LINAGLIPTIN; METFORMIN HYDROCHLORIDE - JENTADUETO</u>						
N 201281 003	8673927	Aug 23, 2027	U-1503		M-146	Jul 30, 2017
	8846695	Jun 04, 2030	U-1503			
	>A> 8883805	Nov 26, 2025	DP			
<u>LIRAGLUTIDE RECOMBINANT - SAXENDA</u>						
N 206321 001					>A> NCE >A> NP	Jan 25, 2015 Jan 25, 2017
<u>LISDEXAMFETAMINE DIMESYLATE - VYVANSE</u>						
N 021977 007					I-645	Jan 31, 2015
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 001	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 002	8618135	Mar 07, 2025	U-1316			
<u>LOMITAPIDE MESYLATE - JUXTAPID</u>						
N 203858 003	8618135	Mar 07, 2025	U-1316			
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 001	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>LOPINAVIR; RITONAVIR - KALETRA</u>						
N 021906 002	8691878	Aug 25, 2024	U-1513			
	8691878*PED	Feb 25, 2025				
<u>LORCASERIN HYDROCHLORIDE - BELVIO</u>						
N 022529 001	8697686	Dec 20, 2025	DS DP			
<u>LOXAPINE - ADASUVE</u>						
N 022549 001	7052679	Oct 26, 2021	DP			
	7537009	Oct 28, 2024	DP			
	8074644	Jul 25, 2022	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 001	8748481	Sep 01, 2025	U-1520			
	8779187	Jul 23, 2027	DP			
<u>LUBIPROSTONE - AMITIZA</u>						
N 021908 002	8748481	Sep 01, 2025	U-1519			
	8779187	Jan 23, 2027	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 001	8729085	May 26, 2026	DP			
	8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 002	8729085	May 26, 2026	DP			
	8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 003	8729085	May 26, 2026	DP			
	8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 004	8729085	May 26, 2026	DP			
	8883794	May 26, 2026	DP			
<u>LURASIDONE HYDROCHLORIDE - LATUDA</u>						
N 200603 005	5532372	Jul 02, 2018	DS			
	8729085	May 26, 2026	DP			
	8883794	May 26, 2026	DP			
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021487 002	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA</u>						
N 021627 001	5061703	Apr 11, 2015	U-539			
	5061703*PED	Oct 11, 2015				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 001	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 002	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 003	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
<u>MEMANTINE HYDROCHLORIDE - NAMENDA XR</u>						
N 022525 004	5061703	Apr 11, 2015	U-539		M-138	Jul 03, 2017
	5061703*PED	Oct 11, 2015			PED	Jan 03, 2018
	8039009	Mar 24, 2029	U-539			
	8039009*PED	Sep 24, 2029				
	8168209	Nov 22, 2025	DP			
	8168209*PED	May 22, 2026				
	8173708	Nov 22, 2025	U-539			
	8173708*PED	May 22, 2026				
	8283379	Nov 22, 2025	U-539			
	8283379*PED	May 22, 2026				
	8329752	Nov 22, 2025	DP			
	8329752*PED	May 22, 2026				
	8362085	Nov 22, 2025	U-539			
	8362085*PED	May 22, 2026				
	8598233	Nov 22, 2025	DP			
	8598233*PED	May 22, 2026				
<u>MENOTROPINS (FSH;LH) - MENOPUR</u>						
N 021663 001					D-139	Feb 19, 2017
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 001	8809615	Jan 03, 2030	DP			
<u>MENTHOL; METHYL SALICYLATE - SALONPAS</u>						
N 022029 002	8809615	Jan 03, 2030	DP			
<u>MERCAPTOPYRINE - PURIXAN</u>						
N 205919 001					ODE	Apr 28, 2021
<u>MESALAMINE - APRISO</u>						
N 022301 001	8865688	May 01, 2030	U-1310			
	>A> 8911778	Apr 20, 2018	DP U-1310			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 001	8668931	Sep 19, 2023	DP			
<u>METFORMIN HYDROCHLORIDE; PIOGLITAZONE HYDROCHLORIDE - ACTOPLUS MET XR</u>						
N 022024 002	8668931	Sep 19, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 001	8628799	Jul 13, 2025	DP		M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 002					M-134	May 24, 2016
<u>METFORMIN HYDROCHLORIDE; SAXAGLIPTIN HYDROCHLORIDE - KOMBIGLYZE XR</u>						
N 200678 003					M-134	May 24, 2016
<u>METHOTREXATE - OTREXUP</u>						
N 204824 001	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 002	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 003	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 004	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - OTREXUP</u>						
N 204824 005	6746429	Apr 12, 2020	DP			
	8021335	Oct 04, 2026	DP			
	8480631	Mar 19, 2030	DP U-1442			
	8562564	Jan 24, 2026	DP			
	8579865	Mar 19, 2030	DP U-1442			
	RE44846	Aug 10, 2019	DP			
	RE44847	Aug 10, 2019	DP U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 001	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 002	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 003	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 004	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 005	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 006	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 007	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 008	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 009	8664231	Jun 01, 2029	U-1442			
<u>METHOTREXATE - RASUVO</u>						
N 205776 010	8664231	Jun 01, 2029	U-1442			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 001	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 002	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLNALTREXONE BROMIDE - RELISTOR</u>						
N 021964 003	8822490	Sep 30, 2029	DP U-1185			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 001	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 002	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 003	8632802	Oct 07, 2025	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>METHYLPHENIDATE - DAYTRANA</u>						
N 021514 004	8632802	Oct 07, 2025	DP			
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 001	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 002	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 003	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - CONCERTA</u>						
N 021121 004	8629179	Jul 31, 2017	DP			
	8629179*PED	Jan 31, 2018				
<u>METHYLPHENIDATE HYDROCHLORIDE - QUILLIVANT XR</u>						
N 202100 001	8778390	Feb 15, 2031	DP U-1543			
<u>METRONIDAZOLE - METRONIDAZOLE</u>						
N 205223 001					NP	Mar 24, 2017
<u>MILTEFOSINE - IMPAVIDO</u>						
N 204684 001					NCE ODE	Mar 19, 2019 Mar 19, 2021
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 006	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 007	8722650	Jun 24, 2025	U-1078			
<u>MINOCYCLINE HYDROCHLORIDE - SOLODYN</u>						
N 050808 008	8722650	Jun 24, 2025	U-1078			
<u>MINOXIDIL - WOMEN'S ROGAINE</u>						
N 021812 002					NP	Feb 28, 2017
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 001	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MIRABEGRON - MYRBETRIO</u>						
N 202611 002	8835474	Nov 04, 2023	U-1527			
	RE44872	Dec 18, 2023	U-1527			
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 001	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MOMETASONE FUROATE - ASMANEX HFA</u>						
N 205641 002	5889015	Jan 27, 2014	U-645			
	5889015*PED	Jul 27, 2014				
	6057307	Jan 27, 2014	DP U-645			
	6057307*PED	Jul 27, 2014				
	6068832	Aug 27, 2017	DP U-645			
	6365581	Jan 27, 2014	U-645			
	6365581*PED	Jul 27, 2014				
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 001	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 002	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 003	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 004	6066339	Nov 25, 2017	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 005	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE - AVINZA</u>						
N 021260 006	6066339	Nov 25, 2017	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 001	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 002	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 003	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 004	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 005	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MORPHINE SULFATE; NALTREXONE HYDROCHLORIDE - EMBEDA</u>						
N 022321 006	7682633	Jun 19, 2027	U-1510			
	8158156	Jun 19, 2027	U-1510			
	8685443	Jul 03, 2025	U-1508			
	8685444	Jul 03, 2025	DP			
	8846104	Jun 19, 2027	DP			
	8877247	Jun 19, 2027	DP			
<u>MYCOPHENOLIC ACID - MYCOPHENOLIC ACID</u>						
A 091248 001					PC	Jul 07, 2014
<u>NAFTIFINE HYDROCHLORIDE - NAFTIN</u>						
N 204286 001	8778365	Jan 31, 2033	DP			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 001	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			
<u>NALOXEGOL OXALATE - MOVANTIK</u>						
N 204760 002	7662365	Oct 18, 2022	DS DP		NCE	Sep 16, 2019
	7786133	Dec 19, 2027	DP			
	8067431	Dec 16, 2024	U-1185			
	8617530	Oct 18, 2022	U-1185			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NALOXONE HYDROCHLORIDE - EVZIO</u>						
N 205787 001	7731686	Jun 10, 2026	DP			
	7731690	Jan 15, 2025	DP			
	7749194	Oct 30, 2028	DP			
	7918823	Nov 23, 2024	DP			
	7947017	Mar 12, 2028	DP			
	8016788	Mar 21, 2025	DP			
	8021344	Nov 02, 2029	DP			
	8206360	Feb 27, 2027	DP			
	8226610	Apr 10, 2029	DP			
	8231573	Nov 25, 2028	DP			
	8313466	Nov 23, 2024	DP			
	8361029	Nov 23, 2024	DP			
	8425462	Nov 23, 2024	DP			
	8608698	Nov 23, 2024	DP			
	8627816	Feb 04, 2032	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 001	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 002	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NALOXONE HYDROCHLORIDE; OXYCODONE HYDROCHLORIDE - TARGINIQ</u>						
N 205777 003	6277384	Dec 22, 2018	DP			
	6696066	Dec 22, 2018	DP			
	7674799	Mar 30, 2025	DP			
	7674800	Mar 30, 2025	DS			
	7683072	Mar 30, 2025	DS			
	8673355	Dec 22, 2018	DP			
	8822487	Dec 22, 2018	DP			
	8846090	Apr 04, 2023	DP			
	8846091	Apr 04, 2023	DP			
<u>NETUPITANT; PALONOSETRON HYDROCHLORIDE - AKYNZEO</u>						
N 205718 001	5202333	Apr 13, 2015	DS DP U-528		NCE	Oct 10, 2019
	6297375	Feb 22, 2020	DS			
	8623826	Nov 18, 2030	U-528			
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 203411 001					PC	Oct 12, 2014
<u>NEVIRAPINE - NEVIRAPINE</u>						
A 205258 001					PC	Oct 12, 2014
<u>NIACIN - NIACIN</u>						
A 076250 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 001					PC	Mar 19, 2014
<u>NIACIN - NIACIN</u>						
A 076378 002					PC	Mar 19, 2014
<u>NICOTINE - NICODERM CO</u>						
N 020165 004	8663680	Feb 13, 2020	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>NICOTINE - NICODERM CO</u>						
N 020165 005	8663680	Feb 13, 2020	DP			
<u>NICOTINE - NICODERM CO</u>						
N 020165 006	8663680	Feb 13, 2020	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 001	8293756	Sep 25, 2027	DP			
<u>NILOTINIB HYDROCHLORIDE MONOHYDRATE - TASIGNA</u>						
N 022068 002	8293756	Sep 25, 2027	DP			
<u>NINTEDANIB - OFEV</u>						
N 205832 001	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NINTEDANIB - OFEV</u>						
N 205832 002	6762180	Dec 10, 2020	DS DP		NCE	Oct 15, 2019
	7119093	Feb 21, 2024	DS DP		ODE	Oct 15, 2021
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 002	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>NITRIC OXIDE - INOMAX</u>						
N 020845 003	8776794	Jan 06, 2031	DP U-1226		M-132	Dec 21, 2013
	8776794*PED	Jul 06, 2031			PED	Jun 21, 2014
	8776795	Jan 06, 2031	DP U-1226			
	8776795*PED	Jul 06, 2031				
	8795741	Jun 30, 2029	U-1286			
	8795741*PED	Dec 30, 2029				
	8846112	Jun 30, 2029	U-1286			
	8846112*PED	Dec 30, 2029				
<u>OLAPARIB - OLAPARIB</u>						
N 206162 001					>A> NCE	Dec 19, 2019
<u>OLIVE OIL; SOYBEAN OIL - CLINOLIPID 20%</u>						
N 204508 001	5840757	Nov 24, 2015	DP		NP	Oct 03, 2016
<u>OLODATEROL HYDROCHLORIDE - STRIVERDI RESPIMAT</u>						
N 203108 001	5964416	Oct 04, 2016	DP		NCE	Jul 31, 2019
	6149054	Dec 19, 2016	DP			
	6176442	Oct 04, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP U-1547			
	7056916	Dec 07, 2023	DS DP			
	7104470	Oct 04, 2016	DP			
	7220742	May 12, 2025	DS DP U-1547			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP U-1547			
	7491719	Nov 10, 2023	DS DP			
	7727984	Nov 10, 2023	DS			
	7786111	Nov 10, 2023	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	8034809	May 12, 2025	U-1547			
	8044046	Nov 10, 2023	U-1547			
<u>OLOPATADINE HYDROCHLORIDE - PATADAY</u>						
N 021545 001	5641805	Jun 06, 2015	U-765	Y		
	5641805*PED	Dec 06, 2015				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OMACETAXINE MEPESUCCINATE - SYNRIBO</u>						
N 203585 001	RE45128	Mar 16, 2019	DS DP U-1576			
<u>OMEGA-3-CARBOXYLIC ACIDS - EPANOVA</u>						
N 205060 001	5792795	May 13, 2016	DP			
	5948818	May 13, 2016	DP			
	7960370	Feb 07, 2025	DP			
	8383678	Feb 07, 2025	DP U-1511			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 001	RE45198	Jul 16, 2016	U-588			
<u>OMEPRazole; SODIUM BICARBONATE - ZEGERID</u>						
N 021636 002	RE45198	Jul 16, 2016	U-588			
<u>ORITAVANCIN DIPHOSPHATE - ORBACTIV</u>						
N 206334 001	5840684	Nov 24, 2015	DS DP U-1569		NCE	Aug 06, 2019
	5998581	Nov 12, 2017	DS		GAIN	Aug 06, 2024
	8420592	Aug 29, 2029	U-1570			
<u>OSPemifene - OSPHENA</u>						
N 203505 001	8642079	Mar 01, 2028	DP			
	8772353	Feb 13, 2024	U-1369			
	8772353	Feb 13, 2024	U-1370			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 001	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 002	8821930	Apr 13, 2027	DP			
<u>OXCARBAZEPINE - OXTELLAR XR</u>						
N 202810 003	8821930	Apr 13, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 001	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 002	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 003	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 004	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
	8894987	Mar 29, 2030	DP			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 005	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 006	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXYCONTIN</u>						
N 022272 007	8309060	Nov 20, 2023	DP U-1556			
	8808741	Aug 24, 2027	U-1556			
>A>	8894988	Aug 24, 2027	DP			
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 001	8637540	Nov 26, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>OXYCODONE HYDROCHLORIDE - OXECTA</u>						
N 202080 002	8637540	Nov 26, 2023	DP			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 001	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 002	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 003	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 004	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 005	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 006	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>OXYMORPHONE HYDROCHLORIDE - OPANA ER</u>						
N 201655 007	8808737	Jun 21, 2027	U-1598			
	8871779	Nov 22, 2029	DS			
<u>PACLITAXEL - ABRAXANE</u>						
N 021660 001	8853260	Aug 14, 2020	DP			
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 001					I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 002					I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 003					I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 004					I-698	Nov 12, 2017
<u>PALIPERIDONE PALMITATE - INVEGA SUSTENNA</u>						
N 022264 005					I-698	Nov 12, 2017
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 001	5202333	Apr 13, 2015	DS DP U-528		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
	8729094	Jan 30, 2024	DP U-528			
	8729094*PED	Jul 30, 2024				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PALONOSETRON HYDROCHLORIDE - ALOXI</u>						
N 021372 002	5202333	Apr 13, 2015	DS DP U-901		I-684	May 27, 2017
	5202333*PED	Oct 13, 2015			M-136	May 27, 2017
	7947724	Jan 30, 2024	DP		PED	Nov 27, 2017
	7947724*PED	Jul 30, 2024			PED	Nov 27, 2017
	7947725	Jan 30, 2024	DP			
	7947725*PED	Jul 30, 2024				
	7960424	Jan 30, 2024	DP			
	7960424*PED	Jul 30, 2024				
	8518981	Jan 30, 2024	DP			
	8518981*PED	Jul 30, 2024				
	8598218	Jan 30, 2024	DP			
	8598218*PED	Jul 30, 2024				
	8598219	Jan 30, 2024	DP			
	8598219*PED	Jul 30, 2024				
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 001	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 002	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 003	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 004	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 005	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 006	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANCRELIPASE (AMYLASE;LIPASE;PROTEASE) - ZENPEP</u>						
N 022210 007	8221747	Feb 20, 2028	DP			
	8562978	Feb 20, 2028	DP			
	8562979	Feb 20, 2028	DP U-1274			
	8562980	Feb 20, 2028	DP U-1274			
	8562981	Feb 20, 2028	U-1274			
<u>PANTOPRAZOLE SODIUM - PROTONIX IV</u>						
N 020988 001	8754108	Nov 17, 2021	DP			
	8754108*PED	May 17, 2022				
<u>PARICALCITOL - ZEMPLAR</u>						
N 020819 003	>A> 5597815	Jul 13, 2015	U-1195			
	>A> 5597815*PED	Jan 13, 2016				
	>A> 6136799	Apr 08, 2018				
	>A> 6136799*PED	Oct 08, 2018				
	>A> 6361758	Apr 08, 2018	DP			
	>A> 6361758*PED	Oct 08, 2018				
<u>PAROXETINE MESYLATE - BRISDELLE</u>						
N 204516 001	8658663	Apr 06, 2029	DS DP U-904			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 001	>A> 6225284	Jun 28, 2016	DS DP U-1628		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> NP	Dec 15, 2017
	>A> 7759308	Oct 25, 2026	DP		>A> ODE	Dec 15, 2021
	>A> 8822637	Aug 06, 2023	U-1629			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 002	>A> 6225284	Jun 28, 2016	DS DP U-1628		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> NP	Dec 15, 2017
	>A> 7759308	Oct 25, 2026	DP		>A> ODE	Dec 15, 2021
	>A> 8822637	Aug 06, 2023	U-1629			
<u>PASIREOTIDE PAMOATE - SIGNIFOR LAR</u>						
N 203255 003	>A> 6225284	Jun 28, 2016	DS DP U-1628		>A> NCE	Dec 14, 2017
	>A> 7473761	Jul 29, 2025	DS DP		>A> NP	Dec 15, 2017
	>A> 7759308	Oct 25, 2026	DP		>A> ODE	Dec 15, 2021
	>A> 8822637	Aug 06, 2023	U-1629			
<u>PEGVISOMANT - SOMAVERT</u>						
N 201106 004	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PEGVISOMANT - SOMAVERT</u>						
N 021106 005	5849535	Mar 25, 2017	DS			
	6057292	Sep 21, 2015	U-507			
<u>PERAMIVIR - RAPIVAB</u>						
N 206426 001	>A> 6503745	Nov 05, 2019	DS		>A> NCE	Dec 19, 2019
	>A> 6562861	Dec 17, 2018	DS			
	>A> 8778997	May 07, 2027	U-1627			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 001	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 002	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 003	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 004	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 005	8772497	May 16, 2026	DS			
<u>PERAMPANEL - FYCOMPA</u>						
N 202834 006	8772497	May 16, 2026	DS			
<u>PERFLUTREN - DEFINITY</u>						
N 021064 001	8658205	Apr 20, 2019	DP			
	8685441	Jan 13, 2019	U-665			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 001	6071537	Jun 23, 2017	U-1262			
	>A> 8895057	Jun 09, 2028	U-1262			
	>A> 8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 002	6071537	Jun 23, 2017	U-1262			
	>A> 8895057	Jun 09, 2028	U-1262			
	>A> 8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 003	6071537	Jun 23, 2017	U-1262			
	>A> 8895057	Jun 09, 2028	U-1262			
	>A> 8895058	Jun 09, 2028	DP			
<u>PHENTERMINE HYDROCHLORIDE; TOPIRAMATE - QSYMIA</u>						
N 022580 004	6071537	Jun 23, 2017	U-1262			
	>A> 8895057	Jun 09, 2028	U-1262			
	>A> 8895058	Jun 09, 2028	DP			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 001	8859623	Nov 14, 2033	U-1594			
<u>PHENYLEPHRINE HYDROCHLORIDE - PHENYLEPHRINE HYDROCHLORIDE</u>						
N 203510 002	8859623	Nov 14, 2033	U-1594			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PIRFENIDONE - ESBRIET</u>						
N 022535 001	7566729	Apr 22, 2029	U-1600		NCE	Oct 16, 2019
	7635707	Apr 22, 2029	U-1609		ODE	Oct 15, 2021
	7696326	Dec 18, 2027	U-1601			
	7767225	Sep 22, 2026	DP U-1602			
	7767700	Dec 18, 2027	U-1601			
	7816383	Jan 08, 2030	U-1603			
	7910610	Jan 08, 2030	U-1604			
	7988994	Sep 22, 2026	DP U-1602			
	8013002	Jan 08, 2030	U-1603			
	8084475	Jan 08, 2030	U-1605			
	8318780	Jan 08, 2030	U-1606			
	8383150	Sep 22, 2026	DP U-1607			
	8420674	Dec 18, 2027	DP U-1608			
	8592462	Apr 22, 2029	U-1609			
	8609701	Apr 22, 2029	U-1610			
	8648098	Jan 08, 2030	U-1611			
	8753679	Sep 22, 2026	DP U-1602			
	8754109	Jan 08, 2030	U-1612			
	8778947	Aug 30, 2033	U-1613			
<u>POLIDOCANOL - VARITHENA</u>						
N 205098 001	8734833	May 26, 2020	DS DP			
	RE40640	Oct 14, 2015	DS DP U-1462			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 001	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 002	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 003	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POMALIDOMIDE - POMALYST</u>						
N 204026 004	8626531	Oct 23, 2020	U-1361			
	8673939	May 15, 2023	U-1360			
	8735428	May 15, 2023	U-1360			
	8828427	Jun 21, 2031	DS DP			
<u>POSACONAZOLE - NOXAFIL</u>						
N 205596 001	5661151	Jul 19, 2019	DS DP U-1454			
	5703079	Aug 26, 2014	DS DP U-1454			
	8410077	Mar 13, 2029	DP			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 001	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 002	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 003	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 004	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 005	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 006	8679533	Sep 08, 2029	DP U-219			
<u>PRAMIPEXOLE DIHYDROCHLORIDE - MIRAPEX ER</u>						
N 022421 007	8679533	Sep 08, 2029	DP U-219			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 001	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PRASUGREL HYDROCHLORIDE - EFFIENT</u>						
N 022307 002	8404703	Jan 02, 2023	U-1381			
	8569325	Jan 02, 2023	U-1381			
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 001					>A> PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 002					>A> PC	Jun 06, 2015
<u>PREDNISOLONE SODIUM PHOSPHATE - PREDNISOLONE SODIUM PHOSPHATE</u>						
A 202179 003					>A> PC	Jun 06, 2015
<u>PROPRANOLOL HYDROCHLORIDE - HEMANGEOL</u>						
N 205410 001	8338489	Oct 16, 2028	U-1496		NP ODE	Mar 14, 2017 Mar 14, 2021
<u>RALOXIFENE HYDROCHLORIDE - RALOXIFENE HYDROCHLORIDE</u>						
A 078193 001					PC	Sep 24, 2014
<u>RALTEGRAVIR POTASSIUM - ISENTRESS</u>						
N 205786 001	7169780	Oct 03, 2023	DS DP			
	7217713	Oct 21, 2022	U-257			
	7435734	Oct 21, 2022	U-257			
	7754731	Mar 11, 2029	DS DP U-257			
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 001					I-685	May 29, 2017
<u>RASAGILINE MESYLATE - AZILECT</u>						
N 021641 002					I-685	May 29, 2017
<u>REGORAFENIB - STIVARGA</u>						
N 203085 001	8637553	Jul 08, 2029	DS DP			
	8680124	Jul 20, 2028	U-1506			
<u>RIFAXIMIN - XIFAXAN</u>						
N 021361 001	8518949	Feb 27, 2026	DP			
	8741904	Feb 27, 2026	DS U-1526			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RIFAXIMIN - XIFAXAN</u>						
N 022554 001	8642573	Oct 02, 2029	U-1481			
	8741904	Feb 27, 2026	DS U-1526			
	8829017	Jul 24, 2029	U-1562			
	8835452	Jun 19, 2024	DS DP			
	8853231	Jun 19, 2024	DP			
<u>RITONAVIR - NORVIR</u>						
N 022417 001	8691878	Aug 25, 2024	U-688			
	8691878*PED	Feb 25, 2025				
<u>ROFLUMILAST - DALIRESP</u>						
N 022522 001	8618142	Mar 08, 2024	DP			
<u>ROPIVACAINE HYDROCHLORIDE - NAROPIN</u>						
N 020533 001	7828787	Oct 18, 2025	DP			
	7857802	Nov 28, 2026	DP			
	8118802	May 18, 2023	DP			
	8162915	May 23, 2024	DP			
<u>RUFINAMIDE - BANZEL</u>						
N 021911 001	>A> 6740669	Nov 14, 2022	DS DP		>A> NCE	Nov 14, 2013
	>A> 6740669*PED	May 14, 2023			>A> ODE	Nov 14, 2015
	>A> 7750028	Oct 19, 2018	U-106		>A> PED	May 14, 2014
	>A> 7750028*PED	Apr 19, 2019			>A> PED	May 14, 2016
	>A> 8076362	Jun 08, 2018	DP			
	>A> 8076362*PED	Dec 08, 2018				

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>RUFINAMIDE - BANZEL</u>						
N 021911 002	>A> 6740669	Nov 14, 2022	DS DP		>A> NCE	Nov 14, 2013
	>A> 6740669*PED	May 14, 2023			>A> ODE	Nov 14, 2015
	>A> 7750028	Oct 19, 2018	U-106		>A> PED	May 14, 2014
	>A> 7750028*PED	Apr 19, 2019			>A> PED	May 14, 2016
	>A> 8076362	Jun 08, 2018	DP			
	>A> 8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 021911 003	>A> 6740669	Nov 14, 2022	DS DP		>A> NCE	Nov 14, 2013
	>A> 6740669*PED	May 14, 2023			>A> ODE	Nov 14, 2015
	>A> 7750028	Oct 19, 2018	U-106		>A> PED	May 14, 2014
	>A> 7750028*PED	Apr 19, 2019			>A> PED	May 14, 2016
	>A> 8076362	Jun 08, 2018	DP			
	>A> 8076362*PED	Dec 08, 2018				
<u>RUFINAMIDE - BANZEL</u>						
N 201367 001	>A> 6740669	Nov 14, 2022	DS DP		>A> NCE	Nov 14, 2013
	>A> 6740669*PED	May 14, 2023			>A> ODE	Nov 14, 2015
	>A> 7750028	Oct 19, 2018	U-106		>A> PED	May 14, 2014
	>A> 7750028*PED	Apr 19, 2019			>A> PED	May 14, 2016
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 001	>A> 7598257	Dec 24, 2027	DS DP U-1201		>A> I-699	Dec 04, 2017
	>A> 7598257	Dec 24, 2027	DS DP U-1622		>A> ODE	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 002	>A> 7598257	Dec 24, 2027	DS DP U-1201		>A> I-699	Dec 04, 2017
	>A> 7598257	Dec 24, 2027	DS DP U-1622		>A> ODE	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 003	>A> 7598257	Dec 24, 2027	DS DP U-1201		>A> I-699	Dec 04, 2017
	>A> 7598257	Dec 24, 2027	DS DP U-1622		>A> ODE	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 004	>A> 7598257	Dec 24, 2027	DS DP U-1201		>A> I-699	Dec 04, 2017
	>A> 7598257	Dec 24, 2027	DS DP U-1622		>A> ODE	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			
<u>RUXOLITINIB PHOSPHATE - JAKAFI</u>						
N 202192 005	>A> 7598257	Dec 24, 2027	DS DP U-1201		>A> I-699	Dec 04, 2017
	>A> 7598257	Dec 24, 2027	DS DP U-1622		>A> ODE	Dec 04, 2021
	8722693	Jun 12, 2028	DS DP			
	8822481	Jun 12, 2028	U-1573			
	>A> 8829013	Jun 12, 2028	U-1201			
	>A> 8829013	Jun 12, 2028	U-1622			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 022181 001	7566462	Nov 16, 2025	DP		NPP	Apr 23, 2017
	7566462*PED	May 16, 2026			ODE	Dec 13, 2014
	7566714	Nov 17, 2024	U-989		PED	Jun 13, 2015
	7566714*PED	May 17, 2025			PED	Oct 23, 2017
	7612073	Nov 17, 2024	U-1010			
	7612073*PED	May 17, 2025				
	7727987	Nov 17, 2024	DP			
	7727987*PED	May 17, 2025				
	7947681	Nov 17, 2024	U-1156	Y		
	7947681*PED	May 17, 2025				
	8003126	Nov 16, 2025				
	8003126*PED	May 17, 2015				
	8067416	Nov 17, 2024	U-989			
	8067416*PED	May 17, 2025				
	8318745	Nov 17, 2024	DP			
	8318745*PED	May 17, 2025				
	RE43797	Nov 17, 2024	U-1156			
	RE43797*PED	May 17, 2025				
<u>SAPROPTERIN DIHYDROCHLORIDE - KUVAN</u>						
N 205065 001	7566714	Nov 17, 2024	U-1589			
	7612073	Nov 17, 2024	U-1010			
	8067416	Nov 17, 2024	U-1589			
	RE43797	Nov 17, 2024	U-1590			
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 001					M-134	May 24, 2016
<u>SAXAGLIPTIN HYDROCHLORIDE - ONGLYZA</u>						
N 022350 002					M-134	May 24, 2016
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 021845 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 022473 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SILDENAFIL CITRATE - REVATIO</u>						
N 203109 001					D-137	Jan 31, 2017
					M-133	Jan 31, 2017
<u>SIMEPREVIR SODIUM - OLYSIO</u>						
N 205123 001	8741926	Jul 28, 2026	DS U-1467		I-697	Nov 05, 2017
	8754106	Jul 28, 2026	DS U-1467			
<u>SIROLIMUS - SIROLIMUS</u>						
A 201676 003					PC	Jul 15, 2014
<u>SODIUM OXYBATE - XYREM</u>						
N 021196 001	8731963	Dec 17, 2022	U-1110			
	8772306	Mar 15, 2033	U-1532			
	8859619	Dec 22, 2019	DP			
<u>SOFOSBUVIR - SOVALDI</u>						
N 204671 001	8618076	Dec 11, 2030	DS DP U-1470			
	8633309	Mar 26, 2029	DS DP U-1470			
	8889159	Mar 26, 2029	DP U-1470			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN NORDIFLEX</u>						
N 021148 007	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 008	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 009	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>SOMATROPIN RECOMBINANT - NORDITROPIN FLEXPRO</u>						
N 021148 010	8672898	Jan 02, 2022	DP			
	8684969	Oct 20, 2025	DP			
	8841252	Dec 26, 2017	DP			
<u>SORAFENIB TOSYLATE - NEXAVAR</u>						
N 021923 001	8618141	Feb 11, 2023	U-1480			
	>A> 8877933	Dec 24, 2027	DS DP	U-1624		
<u>SULFUR HEXAFLUORIDE LIPID-TYPE A MICROSPHERES - LUMASON</u>						
N 203684 001					NCE	Oct 10, 2019
<u>SUMATRIPTAN SUCCINATE - SUMAVEL DOSEPRO</u>						
N 022239 001	6174304	Dec 13, 2015	DP			
	6251091	Dec 09, 2016	DP			
	6280410	Mar 27, 2017	DP			
	6681810	Dec 13, 2015	DP			
	8241243	Aug 10, 2023	DP			
	8491524	Nov 21, 2022	DP			
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 001	7951797	Nov 20, 2029	DS DP	U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 002	7951797	Nov 20, 2029	DS DP	U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 003	7951797	Nov 20, 2029	DS DP	U-620	NCE	Aug 13, 2019
<u>SUVOREXANT - BELSOMRA</u>						
N 204569 004	7951797	Nov 20, 2029	DS DP	U-620	NCE	Aug 13, 2019
<u>TALIGLUCERASE ALFA - ELELYSO</u>						
N 022458 001	8741620	Feb 24, 2024	DS DP		NPP	Aug 27, 2017
	8790641	Oct 18, 2025	U-1564			
	8790641	Oct 18, 2025	U-1574			
<u>TASIMELTEON - HETLIOZ</u>						
N 205677 001	5856529	Dec 09, 2017	DS DP	U-1486	NCE	Jan 31, 2019
	8785492	Jan 25, 2033	U-1486		ODE	Jan 31, 2021
<u>TAVABOROLE - KERYDIN</u>						
N 204427 001	7582621	May 26, 2027	U-718		NCE	Jul 07, 2019
	7767657	May 22, 2027	DP			
<u>TAZAROTENE - FABIOR</u>						
N 202428 001	8808716	Feb 24, 2030	DP			
<u>TECHNETIUM TC-99M TILMANOCEPT - LYMPHOSEEK KIT</u>						
N 202207 001					I-687 ODE	Jun 13, 2017 Jun 13, 2021
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205435 001	7816379	Feb 23, 2028	DS DP	U-282	NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP	U-282	GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP	U-282		
<u>TEDIZOLID PHOSPHATE - SIVEXTRO</u>						
N 205436 001	7816379	Feb 23, 2028	DS DP	U-282	NCE	Jun 20, 2019
	8420676	Feb 23, 2028	DS DP	U-282	GAIN	Jun 20, 2024
	8426389	Dec 31, 2030	DS DP	U-282		
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 001					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 002					PC	Jul 07, 2014
<u>TELMISARTAN - TELMISARTAN</u>						
A 078710 003					PC	Jul 07, 2014
<u>TEMOZOLOMIDE - TEMODAR</u>						
N 022277 001	8623868	Feb 21, 2023	DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TEMSIROLIMUS - TORISEL</u>						
N 022088 001	5362718	Feb 15, 2019	DS DP	Y		
	5362718*PED	Aug 15, 2019				
	8722700	Jul 25, 2023	DP			
	8722700*PED	Jan 25, 2024				
	8791097	May 10, 2032		U-1550		
	8791097	May 10, 2032		U-1551		
	RE44768	Feb 15, 2019	DS DP			
	RE44768*PED	Aug 15, 2019				
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 001	8802735	Sep 14, 2030	DP			
<u>TERIFLUNOMIDE - AUBAGIO</u>						
N 202992 002	8802735	Sep 14, 2030	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 001	7517334	Mar 25, 2025	DP			
<u>TERIPARATIDE RECOMBINANT HUMAN - FORTEO</u>						
N 021318 002	7517334	Mar 25, 2025	DP			
<u>TESAMORELIN ACETATE - EGRIFTA</u>						
N 022505 001	5861379	May 26, 2020	DS DP U-1100			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 001	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 002	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - ANDROGEL</u>						
N 022309 003	6503894	Aug 30, 2020		U-1103		
	8729057	Oct 12, 2026	DP			
	8741881	Oct 12, 2026		U-1103		
	8754070	Oct 12, 2026	DP			
	8759329	Oct 12, 2026	DP			
<u>TESTOSTERONE - AXIRON</u>						
N 022504 001	8784878	Jul 13, 2023	DP U-1545			
	8807861	Feb 26, 2027	DP U-1563			
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 002	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - VOGELXO</u>						
N 204399 003	8785426	Feb 11, 2034	DP U-1531		NP	Jun 04, 2017
<u>TESTOSTERONE - NATESTO</u>						
N 205488 001	8574622	Feb 04, 2024	DP		NP	May 28, 2017
	8784869	Feb 04, 2024	DP			
	8784882	Feb 04, 2024	DP U-1557			
	8877230	Feb 04, 2024		U-1616		
<u>TESTOSTERONE UNDECANOATE - AVEED</u>						
N 022219 001	7718640	Mar 14, 2027	DP		NP	Mar 05, 2017
	8338395	Feb 27, 2026		U-1500		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 001	8626531	Oct 23, 2020		U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 002	8626531	Oct 23, 2020		U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 003	8626531	Oct 23, 2020		U-1465		
<u>THALIDOMIDE - THALOMID</u>						
N 020785 004	8626531	Oct 23, 2020		U-1465		

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TICAGRELOR - BRILINTA</u>						
N 022433 001	8425934	Apr 17, 2030	DP			
<u>TIMOLOL MALEATE - ISTALOL</u>						
N 021516 001	6645963	Nov 16, 2018	DP			
<u>TIOTROPIUM BROMIDE - SPIRIVA RESPIMAT</u>						
N 021936 001	5964416	Oct 04, 2016	DP		NP	Sep 24, 2017
	6149054	Dec 16, 2016	DP			
	6176242	May 31, 2016	DP			
	6453795	Dec 05, 2016	DP			
	6726124	Oct 04, 2016	DP			
	6846413	Aug 28, 2018	DP			
	6977042	Aug 28, 2018	DP			
	6988496	Feb 23, 2020	DP			
	7104470	Oct 04, 2016	DP			
	7246615	May 31, 2016	DP			
	7284474	Aug 26, 2024	DP			
	7396341	Oct 10, 2026	DP			
	7802568	Feb 26, 2019	DP			
	7837235	Mar 13, 2028	DP			
	7896264	May 26, 2025	DP			
	7988001	Aug 04, 2021	DP			
	RE39820	Jan 30, 2018	DS DP U-1593			
<u>TOBRAMYCIN - TOBI PODHALER</u>						
N 201688 001	8715623	Dec 19, 2022	DP U-909			
<u>TOFACITINIB CITRATE - XELJANZ</u>						
N 203214 001					M-135	Feb 21, 2017
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 001	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 002	5753677	May 19, 2020	U-978			
<u>TOLVAPTAN - SAMSCA</u>						
N 022275 003	5753677	May 19, 2020	U-978			
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 001					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 002					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 003					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 004					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 005					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020505 006					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 001					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX</u>						
N 020844 002					NPP	Mar 28, 2017
<u>TOPIRAMATE - TOPAMAX SPRINKLE</u>						
N 020844 003					NPP	Mar 28, 2017
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 001	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	>A> 8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 002	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	>A> 8889191	Nov 16, 2027	U-106			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 003	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	>A> 8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - TROKENDI XR</u>						
N 201635 004	8663683	Nov 16, 2027	DP U-106			
	8877248	Nov 16, 2027	DP U-106			
	>A> 8889191	Nov 16, 2027	U-106			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 001	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 002	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 003	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 004	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TOPIRAMATE - OUDEXY XR</u>						
N 205122 005	8652527	Mar 19, 2033	DP			
	8889190	Mar 19, 2033	DP			
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 001	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 002	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRAMETINIB DIMETHYL SULFOXIDE - MEKINIST</u>						
N 204114 003	8835443	Sep 13, 2025	U-1581		I-678	Jan 08, 2017
	8835443	Sep 13, 2025	U-1582		ODE	Jan 08, 2021
<u>TRANEXAMIC ACID - LYSTEDA</u>						
N 022430 001	8791160	Mar 04, 2025	DP U-1182			
	8809394	Mar 04, 2025	DP U-1182			
<u>TRAVOPROST - IZBA</u>						
N 204822 001	8722735	Oct 10, 2029	DP		NP	May 15, 2017
	8754123	May 19, 2029	DP			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 001	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 002	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 003	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - REMODULIN</u>						
N 021272 004	8653137	Sep 05, 2028	U-1437			
	8658694	Sep 05, 2028	U-1437			
<u>TREPROSTINIL - TYVASO</u>						
N 022387 001					M-145	May 20, 2017
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 001	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 002	8747897	Oct 08, 2029	DP			
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 003	8747897	Oct 08, 2029	DP			



## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>TREPROSTINIL DIOLAMINE - ORENITRAM</u>						
N 203496 004	8747897	Oct 08, 2029	DP			
<u>ULIPRISTAL ACETATE - ELLA</u>						
N 022474 001	8735380	Feb 20, 2029	DP			
<u>UMECLIDINIUM BROMIDE - INCRUSE ELLIPTA</u>						
N 205382 001	5873360	Feb 23, 2016	DP			
	7488827	Apr 27, 2025	DS DP			
	7498440	Apr 27, 2025	DS DP			
	8113199	Oct 23, 2027	DP			
	8161968	Feb 05, 2028	DP			
	8183257	Jul 27, 2025	U-1476			
	8201556	Feb 05, 2029	DP			
	8309572	Apr 27, 2025	U-1476			
	8534281	Aug 10, 2029	DP			
	8746242	Oct 11, 2030	DP			
<u>UMECLIDINIUM BROMIDE; VILANTEROL TRIFENATATE - ANORO ELLIPTA</u>						
N 203975 001	8746242	Oct 11, 2030	DP		NP	Dec 18, 2016
	RE44874	Mar 23, 2023	DS DP U-1476			
<u>UROFOLLITROPIN - BRAVELLE</u>						
N 021289 001					D-139	Feb 19, 2017
<u>VALSARTAN - VALSARTAN</u>						
A 077492 001					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 002					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 003					PC	Jan 03, 2015
<u>VALSARTAN - VALSARTAN</u>						
A 077492 004					PC	Jan 03, 2015
<u>VANDETANIB - CAPRELSA</u>						
N 022405 001	8642608	Feb 06, 2022	U-1490			
<u>VANDETANIB - CAPRELSA</u>						
N 022405 002	8642608	Feb 06, 2022	U-1490			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 001	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 002	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 003	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - LEVITRA</u>						
N 021400 004	8841446	Jul 03, 2023	DP			
<u>VARDENAFIL HYDROCHLORIDE - STAXYN</u>						
N 200179 001	8613950	Dec 23, 2028	DP			
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 001					M-143 M-144	Oct 15, 2017 Oct 15, 2017
<u>VARENICLINE TARTRATE - CHANTIX</u>						
N 021928 002					M-143 M-144	Oct 15, 2017 Oct 15, 2017
<u>VEMURAFENIB - ZELBORAF</u>						
N 202429 001	8741920	Jul 27, 2030	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 001	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 002	8673921	Jun 05, 2022	DS DP			
<u>VILAZODONE HYDROCHLORIDE - VIIBRYD</u>						
N 022567 003	8673921	Jun 05, 2022	DS DP			

## PATENT AND EXCLUSIVITY DRUG PRODUCT LIST - CUMULATIVE SUPPLEMENT 12 - December 2014

See List footnote for information regarding List content

APPL/PROD NO	PATENT NO	PATENT EXPIRATION DATE	PATENT CODES	PATENT DELIST REQUESTED	EXCLUSIVITY CODE (S)	EXCLUSIVITY EXPIRATION DATE
<u>VORAPAXAR SULFATE - ZONTIVITY</u>						
N 204886 001	7235567	Jun 13, 2021	DS DP		NCE	May 08, 2019
	7304078	Apr 06, 2024	DS DP U-1512			
<u>VORINOSTAT - ZOLINZA</u>						
N 021991 001	8450372	Mar 18, 2028	U-892			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 001	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 002	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 003	8722684	Nov 11, 2030	DS DP			
<u>VORTIOXETINE HYDROBROMIDE - BRINTELLIX</u>						
N 204447 004	8722684	Nov 11, 2030	DS DP			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 001	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 002	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 003	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZICONOTIDE ACETATE - PRIALT</u>						
N 021060 004	8653033	Oct 01, 2024	U-48			
	8653033	Oct 01, 2024	U-55			
	8765680	Oct 01, 2024	U-48			
	8765680	Oct 01, 2024	U-55			
<u>ZOLMITRIPTAN - ZOMIG</u>						
N 021450 003	6750237	Nov 28, 2020	DP			
	6750237*PED	May 28, 2021				
	7220767	Nov 28, 2020	DP			
	7220767*PED	May 28, 2021				

## Footnote:

1. Patents are published upon receipt by the Orange book Staff and may not reflect the official receipt date as described in 21 CFR 314.53(d)(5).

2. Patents listed prior to August 18, 2003 are flagged with method of use claims only as applicable and submitted by the sponsor. They may not be flagged with respect to other claims which may apply.

## PATENT AND EXCLUSIVITY TERMS

Due to space limitations in the patent and exclusivity columns, abbreviations and references have been developed. Refer to the APPROVED DRUG PRODUCTS WITH THERAPEUTIC EQUIVALENCE EVALUATIONS, 34<sup>th</sup> Edition for a full listing of patent and exclusivity terms (Abbreviations, Dosing Schedule, Indications, and Patent Use Codes).

The current complete list of patent terms is available at  
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/pattermsall.cfm>

The current complete list of exclusivity terms is available at  
<http://www.accessdata.fda.gov/scripts/cder/ob/docs/excltermsall.cfm>